{
  "doc": {
    "source": "/home/taylor/medical-question-solver/source_pdfs/2025_Final_Part2.pdf",
    "pages_total": 27,
    "pages_parsed": 27,
    "parsing_warnings": [],
    "label_maps": {}
  },
  "defaults": {
    "depth": "expanded"
  },
  "questions": [
    {
      "question_no": "1",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "사물을 손가락으로 가리킬 수 있다"
      },
      "why": [
        "* **Diagnosis:** Normal developmental milestones for a 12-month-old infant.",
        "* **Clinical Scenario:** A 12-month-old infant is being evaluated for age-appropriate developmental skills.",
        "* **Developmental Milestones at 12 Months:** At this age, infants are expected to achieve specific milestones across several domains.",
        "* **Fine Motor Skills:** A key fine motor skill that develops around 9-12 months is the ability to point with the index finger. This is a crucial step in developing joint attention and communication.",
        "* **Gross Motor Skills:** Typically, a 12-month-old can pull to a stand, cruise (walk while holding onto furniture), and may take their first independent steps. They are not yet able to run well.",
        "* **Language Skills:** Language at 12 months usually consists of saying \"mama\" and \"dada\" (specifically for parents) and one or two other single words. They do not yet combine words into sentences.",
        "* **Cognitive/Social Skills:** They can imitate gestures, play simple games like pat-a-cake, and indicate their wants through non-verbal cues like pointing.",
        "* **Conclusion:** Pointing to objects with a finger is a hallmark developmental achievement for a 12-month-old infant, reflecting progress in fine motor control and social communication."
      ],
      "others": [
        {
          "label": "①",
          "text": "잘 뛴다",
          "reason": "Running well is a gross motor milestone typically achieved between 18 and 24 months of age, not at 12 months."
        },
        {
          "label": "②",
          "text": "동그라미를 그릴 수 있다",
          "reason": "Copying a circle is a fine motor skill that develops around 3 years of age."
        },
        {
          "label": "③",
          "text": "두 단어를 연결해서 문장을 표현할 수 있다",
          "reason": "Using two-word sentences is a language milestone typically seen between 18 and 24 months of age."
        },
        {
          "label": "⑤",
          "text": "한발로 설 수 있다",
          "reason": "Standing on one foot for a few seconds is a gross motor skill that typically develops around 3 years of age."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "사물을 손가락으로 가리킬 수 있다"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** This question assesses knowledge of normal developmental milestones for a 12-month-old infant.",
        "* **Gross Motor Milestones (12 months):** Infants should be able to pull to a stand, cruise (walk while holding furniture), and may take their first independent steps. They cannot yet run well.",
        "* **Fine Motor Milestones (12 months):** A well-developed pincer grasp (thumb and index finger) is present. A key emerging skill is pointing with the index finger to indicate wants or direct attention.",
        "* **Language Milestones (12 months):** Infants typically say \"mama\" and \"dada\" with specific meaning (referring to parents), use 1-2 other single words, imitate sounds, and respond to simple commands like \"come here.\"",
        "* **Social/Cognitive Milestones (12 months):** Infants demonstrate joint attention (looking where others point), imitate gestures (e.g., waving bye-bye, pat-a-cake), and understand object permanence.",
        "* **Significance of Pointing:** The ability to point is a crucial milestone for social communication, indicating the development of joint attention and the desire to share experiences, which is a precursor to language.",
        "* **Discriminators (Incorrect Options):**\n  - **Running well:** Typically achieved between 18-24 months.\n  - **Copying a circle:** A fine motor skill that develops around 3 years of age.\n  - **Two-word sentences:** A language milestone seen between 18-24 months.\n  - **Standing on one foot:** A gross motor skill that develops around 3 years of age.",
        "* **Developmental Red Flags (12 months):** Concerns should be raised if an infant does not babble, does not respond to their name, does not pull to a stand, or loses previously acquired skills."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "2",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "사람유두종바이러스백신"
      },
      "why": [
        "* **Topic:** Routine vaccinations for the elderly population (typically defined as age ≥ 65).",
        "* **Rationale for Elderly Vaccinations:** Older adults are at increased risk for severe morbidity and mortality from certain vaccine-preventable diseases due to immunosenescence and a higher prevalence of comorbidities.",
        "* **Indicated Vaccines in the Elderly:** Standard recommendations for older adults include annual influenza vaccine, pneumococcal vaccines, herpes zoster (shingles) vaccine, and tetanus/diphtheria/pertussis (Td/Tdap) boosters.",
        "* **Human Papillomavirus (HPV) Vaccine:** The HPV vaccine is primarily recommended to prevent HPV-related cancers (e.g., cervical, oropharyngeal).",
        "* **HPV Vaccine Target Population:** Routine HPV vaccination is recommended for adolescents at age 11-12. Catch-up vaccination is recommended for all individuals through age 26.",
        "* **HPV Vaccine in Older Adults:** For adults aged 27-45, HPV vaccination is not routinely recommended but can be considered based on shared clinical decision-making if they were not adequately vaccinated previously. It is not recommended for adults older than 45, including the elderly, as it is presumed most have already been exposed to HPV and the vaccine would offer little to no benefit.",
        "* **Conclusion:** The HPV vaccine is not a necessary or routinely recommended vaccination for the general elderly population."
      ],
      "others": [
        {
          "label": "①",
          "text": "폐렴구균백신",
          "reason": "Pneumococcal vaccination (both PCV20 or PCV15 followed by PPSV23) is strongly recommended for all adults aged 65 and older to prevent invasive pneumococcal disease."
        },
        {
          "label": "②",
          "text": "대상포진백신",
          "reason": "The recombinant zoster (shingles) vaccine is recommended for all adults aged 50 and older to prevent herpes zoster and its complications, such as postherpetic neuralgia."
        },
        {
          "label": "③",
          "text": "인플루엔자백신",
          "reason": "Annual influenza vaccination is recommended for all persons aged 6 months and older, and is especially important for the elderly who are at high risk for severe complications."
        },
        {
          "label": "⑤",
          "text": "파상풍, 디프테리아 및 백일해 백신",
          "reason": "Adults, including the elderly, should receive a Td booster every 10 years. At least one of these boosters should be Tdap to provide protection against pertussis."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "사람유두종바이러스백신"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Rationale:** Older adults (≥65 years) require specific vaccinations due to immunosenescence and a higher risk of severe outcomes from vaccine-preventable diseases.",
        "* **Routinely Recommended Vaccines (≥65 years):** The core recommended vaccines are for influenza, pneumococcus, herpes zoster (shingles), and tetanus/diphtheria/pertussis.",
        "* **Influenza Vaccine:** Recommended annually for all adults. High-dose or adjuvanted formulations are preferred for those ≥65 years to elicit a stronger immune response.",
        "* **Pneumococcal Vaccine:** All adults ≥65 should receive either PCV20 alone, or PCV15 followed by PPSV23 at least one year later, to protect against invasive pneumococcal disease.",
        "* **Herpes Zoster (Shingles) Vaccine:** The recombinant zoster vaccine (Shingrix) is recommended as a two-dose series for all immunocompetent adults aged ≥50 years to prevent shingles and postherpetic neuralgia.",
        "* **Tetanus, Diphtheria, Pertussis (Td/Tdap) Vaccine:** Adults should receive a Td booster every 10 years. One of these doses should be substituted with Tdap to provide protection against pertussis (whooping cough).",
        "* **Human Papillomavirus (HPV) Vaccine:** This vaccine is **not** routinely recommended for adults over age 26, and certainly not for the general elderly population.",
        "* **HPV Vaccine Indications:** Routine vaccination is recommended at age 11-12 to prevent HPV-related cancers. Catch-up vaccination is recommended through age 26. For adults aged 27-45, it may be considered based on shared clinical decision-making, but it is not routinely given as most individuals have already been exposed to HPV."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "3",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "IV-1"
      },
      "why": [
        "* **Diagnosis:** Identifying a *de novo* mutation in a pedigree for an X-linked recessive disorder (Hemophilia A).",
        "* **Pedigree Analysis:** The pedigree shows a pattern consistent with X-linked recessive inheritance. Affected males (filled squares) inherit the condition from their carrier mothers (circles with dots).",
        "* **Tracing the Familial Mutation:** The mutation originates with individual I-2. She is a carrier and passes the mutated X chromosome to her daughter II-2 (carrier) and son II-3 (affected).",
        "* **Line of Inheritance:** This same familial mutation is then passed from carrier II-2 to her daughter III-4 (carrier) and son III-5 (affected). Subsequently, carrier III-4 passes it to her son IV-7 (affected).",
        "* **Shared Mutation:** Therefore, individuals I-2, II-2, III-4, and IV-7 all carry the same familial mutation that has been passed down through the generations.",
        "* **Identifying the Outlier:** We must examine individual IV-1. The pedigree shows she is a carrier.",
        "* **Parents of IV-1:** Her parents are III-1 (unaffected male) and III-2 (unaffected female). An unaffected male (III-1) has a normal X chromosome. An unaffected female (III-2) from outside the family is presumed to have two normal X chromosomes.",
        "* **De Novo Mutation:** For IV-1 to be a carrier, she must have a mutated X chromosome. Since her father's X is normal, and her mother is not a carrier, the mutation must have arisen spontaneously. This is called a *de novo* mutation. It could have occurred in the germline of one of her parents or during her own early embryonic development.",
        "* **Conclusion:** Because IV-1's mutation is a new, spontaneous event, its origin and potentially its specific type are different from the familial mutation shared by all the other individuals in the pedigree who are carriers or affected."
      ],
      "others": [
        {
          "label": "①",
          "text": "1-2",
          "reason": "This individual is the original carrier in the family. Her mutation is the familial one that is passed down to subsequent generations."
        },
        {
          "label": "②",
          "text": "11-2",
          "reason": "This individual is a carrier who inherited the mutated X chromosome directly from her mother, I-2. Thus, she carries the same familial mutation."
        },
        {
          "label": "③",
          "text": "III-4",
          "reason": "This individual is a carrier who inherited the mutated X chromosome from her mother, II-2. She carries the same familial mutation as her mother and grandmother."
        },
        {
          "label": "⑤",
          "text": "IV-7",
          "reason": "This individual is an affected male who inherited the mutated X chromosome from his carrier mother, III-4. He has the same familial mutation that has been present in the family for generations."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 0.95,
      "rethink": {
        "mismatch": true,
        "first_guess": {
          "label": "④",
          "text": "IV-1"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "override_key",
        "note": "The pedigree clearly shows IV-1 is a carrier with unaffected parents, indicating a de novo mutation. IV-7 is in the direct line of inheritance of the familial mutation. Therefore, IV-1 is the individual with a different mutation. The provided key appears to be incorrect.",
        "override_key": true
      },
      "teaching_points": [
        "* **Clinical picture:** This pedigree depicts a family with Hemophilia A, an X-linked recessive disorder.",
        "* **X-Linked Recessive Inheritance:** Key features include affecting males almost exclusively, transmission from asymptomatic carrier mothers to sons (50% probability), and no male-to-male transmission.",
        "* **Pedigree Analysis:** A square represents a male, a circle a female. Shaded shapes indicate affected individuals, and a dot within a circle indicates a carrier female.",
        "* **Tracing the Familial Mutation:** The original mutation is in individual I-2 (carrier). She passes it to her daughter II-2 (carrier) and son II-3 (affected). II-2 then passes it to her daughter III-4 (carrier) and son III-5 (affected). Finally, III-4 passes it to her son IV-7 (affected).",
        "* **Definition of De Novo Mutation:** A *de novo* mutation is a genetic alteration that is present for the first time in one family member as a result of a mutation in a germ cell (egg or sperm) of one of the parents or a mutation that arises in the fertilized egg itself during early embryogenesis.",
        "* **Identifying the De Novo Mutation:** Individual IV-1 is a carrier (circle with a dot). However, her parents, III-1 (unaffected male) and III-2 (unaffected female from outside the family), are not carriers. Her father can only pass a normal X chromosome. Her mother is presumed to have two normal X chromosomes.",
        "* **Conclusion:** For IV-1 to be a carrier, the mutation must have occurred spontaneously. Therefore, her mutation is a *de novo* event and is different from the familial mutation inherited by all other carriers and affected individuals in the pedigree.",
        "* **Genetic Counseling:** Identifying a *de novo* mutation is crucial for genetic counseling, as it implies a very low recurrence risk for the parents' future children, but a 50% risk for the offspring of the individual with the new mutation."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "4",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "작업장 내 보호구 착용의 적절성 여부와 필요시 근무 변경이 필요하다."
      },
      "why": [
        "* **Diagnosis:** Occupational lung disease, most likely occupational asthma, possibly with features of hypersensitivity pneumonitis.",
        "* **Clinical Presentation:** The patient is a 52-year-old shipyard painter with progressive dyspnea. The key diagnostic clue is the temporal relationship between symptoms and work: symptoms worsen during the work week and improve on weekends and holidays. This pattern is pathognomonic for an occupational exposure-related illness.",
        "* **Exposure History:** Working as a painter, especially in shipbuilding, involves exposure to various chemicals, most notably isocyanates, which are a leading cause of occupational asthma.",
        "* **Image Findings:**\n  - **CXR:** Shows diffuse, fine reticulonodular opacities, suggesting an interstitial process, which can be seen in hypersensitivity pneumonitis, also caused by isocyanates.\n  - **PFT:** The spirometry reveals a severe mixed obstructive-restrictive pattern. FVC is reduced (57% predicted), indicating restriction. FEV1 is disproportionately low and the FEV1/FVC ratio is very low (45%), indicating severe obstruction. There is a significant bronchodilator response, further supporting an asthma component.",
        "* **Integrated Diagnosis:** The combination of work-related symptoms, exposure history, obstructive physiology, and interstitial changes on imaging points strongly to an occupational lung disease caused by his painting work.",
        "* **Treatment Principle:** The cornerstone of managing any occupational disease is to eliminate or minimize the causative exposure. This is critical to prevent further lung function decline and potentially irreversible damage.",
        "* **Management Step:** Therefore, the most appropriate and immediate consideration is to evaluate the patient's workplace environment. This includes assessing the adequacy of personal protective equipment (e.g., respirators) and considering a change in job duties to remove him from the exposure.",
        "* **Conclusion:** The statement about checking protective equipment and considering a work change is the most accurate and crucial aspect of this patient's management plan."
      ],
      "others": [
        {
          "label": "①",
          "text": "이 환자의 증상은 노출 후 수 년 지나야 발병하므로, 현재 직업과는 무관할 것이다.",
          "reason": "This is incorrect. The latency period for occupational asthma can be variable, and symptoms can develop within months to a year of starting a new exposure, as in this patient's case."
        },
        {
          "label": "②",
          "text": "장시간 노출된 경우에도, 노출 중단되면 완전히 회복된다.",
          "reason": "This is incorrect. While early removal from exposure can lead to improvement, prolonged or high-intensity exposure often causes persistent asthma and irreversible lung function decline."
        },
        {
          "label": "③",
          "text": "제한성 환기 장애 소견으로 간질성 폐질환 감별을 요한다.",
          "reason": "While there is a restrictive component and the CXR is concerning, the PFTs show a severe obstructive defect as well. Focusing only on the restrictive part ignores the full picture and the most important aspect, which is the occupational etiology and its management."
        },
        {
          "label": "④",
          "text": "이 환자의 원인은 성인에게 해당 질환의 가장 흔한 원인이다.",
          "reason": "This statement is ambiguous and likely incorrect. While isocyanates are the most common cause of *occupational* asthma, the most common cause of asthma in adults overall is atopy."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "작업장 내 보호구 착용의 적절성 여부와 필요시 근무 변경이 필요하다."
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Occupational asthma is characterized by respiratory symptoms (dyspnea, wheezing, cough) that have a clear temporal relationship with work exposure, typically worsening through the work week and improving on weekends or holidays.",
        "* **Workup:** The most important diagnostic tool is a detailed occupational history. Pulmonary function tests (PFTs) are essential. Spirometry performed before and after a work shift can demonstrate a significant drop in FEV1.",
        "* **PFT Findings:** This patient's PFTs show a severe mixed obstructive-restrictive pattern. The low FEV1/FVC ratio (45%) indicates obstruction, while the low FVC (57% predicted) indicates restriction. A significant bronchodilator response supports an asthma component.",
        "* **Imaging:** Chest X-ray in occupational asthma is often normal. The presence of reticulonodular opacities, as in this case, suggests a concomitant process like hypersensitivity pneumonitis, which can also be caused by isocyanates.",
        "* **Common Etiologies:** Isocyanates, found in spray paints and foams, are a leading cause of occupational asthma. Other causes include wood dust, flour, and animal dander.",
        "* **Management (algorithmic):** The cornerstone of management is the complete and early cessation of exposure to the sensitizing agent. This is the only intervention that can halt disease progression and prevent irreversible lung damage.",
        "* **Management Steps:** The most appropriate next step is to assess the workplace environment, including the adequacy of personal protective equipment (PPE) like respirators, and to strongly consider a job modification or change to remove the patient from further exposure.",
        "* **Pharmacotherapy:** Inhaled corticosteroids and bronchodilators are used to manage symptoms but are secondary to exposure avoidance. They do not alter the underlying disease process if exposure continues.",
        "* **Prognosis:** Prognosis is better with early diagnosis and removal from exposure. Continued exposure leads to persistent asthma and irreversible decline in lung function, even after leaving the job."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "5",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "고환에서 발생한 종양 중 가장 흔하다."
      },
      "why": [
        "* **Diagnosis:** Classic Seminoma of the testis.",
        "* **Image Findings:**\n  - **Gross Pathology:** The image shows a well-demarcated, solid, homogenous, tan-to-yellow, lobulated mass replacing the normal testicular tissue. The absence of significant hemorrhage or necrosis is characteristic of seminoma.\n  - **Microscopic Pathology:** The histology shows sheets of large, uniform, polygonal cells with distinct borders, clear or eosinophilic cytoplasm, and large central nuclei with prominent nucleoli. Fibrous septa containing a prominent lymphocytic infiltrate divide the tumor cells into nests. This appearance is often described as 'fried-egg' like.",
        "* **Epidemiology:** Seminomas are the most common type of pure testicular germ cell tumor, accounting for approximately 50% of all cases. Testicular germ cell tumors are the most common solid malignancy in men aged 15-35.",
        "* **Pathophysiology:** Most adult testicular germ cell tumors, including seminoma, are believed to arise from a precursor lesion known as germ cell neoplasia in situ (GCNIS).",
        "* **Clinical Behavior:** Seminomas are generally less aggressive than non-seminomatous germ cell tumors (NSGCTs). They tend to remain localized for longer and are highly sensitive to both radiation therapy and chemotherapy.",
        "* **Tumor Markers:** Pure seminomas do not produce alpha-fetoprotein (AFP). A subset may contain syncytiotrophoblastic giant cells, leading to a mild elevation of beta-human chorionic gonadotropin (β-hCG).",
        "* **Conclusion:** Based on its prevalence, the statement that this tumor (seminoma) is the most common type of testicular tumor is correct."
      ],
      "others": [
        {
          "label": "②",
          "text": "주로 소아에서 발생한다.",
          "reason": "This is incorrect. Seminomas peak in incidence in the third and fourth decades of life. The most common testicular tumors in infants and young children are yolk sac tumors and teratomas."
        },
        {
          "label": "③",
          "text": "공격적인 생물학적 행동(aggressive behavior)을 보이고 출혈 괴사가 흔하다.",
          "reason": "This describes non-seminomatous tumors like embryonal carcinoma or choriocarcinoma. Classic seminomas are typically indolent, with a homogenous gross appearance lacking hemorrhage and necrosis."
        },
        {
          "label": "④",
          "text": "혈중 alpha-fetoprotein이 상승되어 있다.",
          "reason": "This is incorrect. Pure seminomas do not produce AFP. An elevated AFP level in a patient with a testicular tumor indicates the presence of a non-seminomatous component, such as a yolk sac tumor."
        },
        {
          "label": "⑤",
          "text": "제자리종자세포종양(germ cell neoplasia in situ)에서 기원하지 않는 종양이다.",
          "reason": "This is incorrect. The vast majority of post-pubertal testicular germ cell tumors, including seminoma, arise from the precursor lesion germ cell neoplasia in situ (GCNIS). An exception is the spermatocytic tumor."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "고환에서 발생한 종양 중 가장 흔하다."
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Testicular seminoma typically presents as a painless, firm mass in the testis of a man between 25 and 45 years old.",
        "* **Epidemiology:** Seminomas are the most common type of pure testicular germ cell tumor (GCT), accounting for about 50% of cases. GCTs are the most common solid malignancy in men aged 15-35.",
        "* **Pathology (Gross):** The tumor is typically a well-demarcated, solid, homogenous, tan-to-yellow or white, lobulated mass. Hemorrhage and necrosis are characteristically absent, unlike in non-seminomatous GCTs.",
        "* **Pathology (Microscopic):** Histology shows sheets of large, uniform polygonal cells with clear cytoplasm, distinct cell borders, and large central nuclei with prominent nucleoli (a 'fried-egg' appearance). Fibrous septa containing a prominent lymphocytic infiltrate are characteristic.",
        "* **Pathogenesis:** Most post-pubertal GCTs, including seminoma, arise from a precursor lesion called germ cell neoplasia in situ (GCNIS).",
        "* **Workup:** Initial evaluation includes a scrotal ultrasound, followed by measurement of serum tumor markers (AFP, β-hCG, LDH) and staging CT scans.",
        "* **Tumor Markers:** Pure seminomas do not produce alpha-fetoprotein (AFP). An elevated AFP level indicates a non-seminomatous component. Beta-hCG may be mildly elevated in about 15% of cases.",
        "* **Management:** The initial step is radical inguinal orchiectomy. Subsequent treatment depends on the stage but often involves active surveillance, chemotherapy, or radiation therapy.",
        "* **Prognosis:** Seminomas are highly sensitive to both radiation and chemotherapy, leading to an excellent prognosis, even in advanced stages.",
        "* **Differential/Discriminators:** Non-seminomatous GCTs (e.g., embryonal carcinoma, yolk sac tumor) are typically more aggressive, show hemorrhage and necrosis on gross examination, and are often associated with elevated AFP."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "6",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "환자D: 유전자 검사 결과 - pathogenic POLE muta tion"
      },
      "why": [
        "* **Topic:** Prognostic factors in endometrial carcinoma, specifically focusing on the molecular classification.",
        "* **Patient A's Profile:** This patient has a very low-risk tumor with multiple favorable prognostic features:\n  - **Histology:** Endometrioid type (typically low-grade).\n  - **Stage:** No myometrial or lymph node invasion (Stage IA).\n  - **Molecular:** p53 wild-type and POLE wild-type. This places her in the 'No Specific Molecular Profile' (NSMP) category.",
        "* **Molecular Classification of Endometrial Cancer:** Modern classification (e.g., ProMisE) categorizes endometrial cancers into four prognostic groups:\n  1. **POLE ultramutated:** Best prognosis.\n  2. **Mismatch repair deficient (MMRd/MSI-H):** Intermediate prognosis.\n  3. **No specific molecular profile (NSMP):** Intermediate prognosis (Patient A fits here).\n  4. **p53 abnormal (p53abn):** Worst prognosis.",
        "* **Prognostic Hierarchy:** The presence of a pathogenic mutation in the DNA polymerase epsilon (POLE) gene defines the 'ultramutated' subgroup. These tumors, despite sometimes having high-grade histology, have an exceptionally favorable prognosis.",
        "* **Comparison:** The question asks for a finding that confers a *better* prognosis than Patient A's. Patient A already has an excellent prognosis within the NSMP group. However, the POLE-mutated category has an even better prognosis than the best-case NSMP scenario.",
        "* **Conclusion:** A pathogenic POLE mutation is the single most powerful favorable prognostic marker in endometrial cancer, indicating a better outcome than that of Patient A."
      ],
      "others": [
        {
          "label": "①",
          "text": "환자B: 진단명 - Serous carcinoma",
          "reason": "Serous carcinoma is a high-grade, aggressive histologic subtype of endometrial cancer and is associated with a much poorer prognosis than low-risk endometrioid carcinoma."
        },
        {
          "label": "②",
          "text": "환자C: 면역조직화학염색 결과 - p53 overexpressio n",
          "reason": "p53 overexpression is an aberrant pattern indicating a TP53 mutation. This defines the 'p53 abnormal' molecular subgroup, which has the worst prognosis."
        },
        {
          "label": "④",
          "text": "환자E: 종양의 pelvic lymph node 전이 존재",
          "reason": "The presence of lymph node metastasis indicates advanced disease (at least Stage IIIC) and is a strong indicator of a poor prognosis."
        },
        {
          "label": "⑤",
          "text": "환자F: 자궁 근층1/2 이상 침윤",
          "reason": "Deep myometrial invasion (>50%) is an adverse prognostic factor, upstaging the tumor to at least Stage IB and increasing the risk of recurrence."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "환자D: 유전자 검사 결과 - pathogenic POLE muta tion"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Endometrial carcinoma most commonly presents with postmenopausal bleeding or abnormal uterine bleeding in premenopausal women.",
        "* **Prognostic Factors:** Prognosis is determined by a combination of traditional pathologic features and modern molecular classification.",
        "* **Traditional Factors:** Key factors include FIGO stage, histologic type (e.g., endometrioid vs. serous), tumor grade, depth of myometrial invasion, and lymphovascular space invasion (LVSI).",
        "* **Molecular Classification:** Endometrial cancers are stratified into four prognostically distinct groups:\n  - 1. **POLE ultramutated:** Best prognosis.\n  - 2. **Mismatch repair-deficient (MMRd):** Intermediate prognosis.\n  - 3. **No specific molecular profile (NSMP):** Intermediate prognosis.\n  - 4. **p53 abnormal (p53abn):** Worst prognosis.",
        "* **POLE ultramutated:** These tumors have pathogenic mutations in the proofreading domain of DNA polymerase epsilon, leading to a very high tumor mutation burden. Despite sometimes having high-grade histology, they have an exceptionally favorable prognosis.",
        "* **p53 abnormal (p53abn):** These tumors have mutations in the *TP53* gene, often identified by aberrant p53 expression on immunohistochemistry. This group includes most serous carcinomas and has the most aggressive behavior and worst prognosis.",
        "* **Prognostic Hierarchy:** The molecular classification provides prognostic information independent of traditional factors. A POLE mutation confers the best prognosis, while a p53 mutation confers the worst.",
        "* **Patient A Profile:** Patient A has a low-risk, stage IA endometrioid carcinoma with no adverse features and falls into the NSMP group, which has an excellent prognosis.",
        "* **Conclusion:** A pathogenic POLE mutation (Patient D) is the single most powerful favorable prognostic marker and indicates an even better prognosis than the already excellent outlook for Patient A.",
        "* **Poor Prognostic Factors (Distractors):** Serous histology, p53 overexpression, pelvic lymph node metastasis, and deep myometrial invasion are all associated with a significantly worse prognosis."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "7",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "cholecalcitriol"
      },
      "why": [
        "* **Diagnosis:** Nutritional rickets secondary to vitamin D deficiency due to malabsorption from severe cholestatic liver disease.",
        "* **Clinical Presentation:** A 10-month-old infant presents with signs of severe liver disease (jaundice, abdominal distension) and bone disease (inability to stand, crying with weight-bearing, a regression of motor skills).",
        "* **Lab Findings:**\n  - **Liver Disease:** Elevated AST/ALT (hepatitis), mixed hyperbilirubinemia, and markedly elevated alkaline phosphatase (severe cholestasis).\n  - **Rickets:** The classic biochemical triad of hypocalcemia (7.7 mg/dL), hypophosphatemia (2.4 mg/dL), and elevated alkaline phosphatase (1,235 IU/L) confirms rickets. The elevated ALP is from both bone and liver.\n  - **Anemia:** Mild microcytic, hypochromic anemia with low iron suggests concurrent iron deficiency.",
        "* **Pathophysiology:** Severe cholestatic liver disease impairs the secretion of bile, leading to malabsorption of fat and fat-soluble vitamins, including vitamin D. The liver is also responsible for the first step in vitamin D activation: converting cholecalciferol (D3) or ergocalciferol (D2) to 25-hydroxyvitamin D.",
        "* **Treatment Principle:** The patient's liver is failing, so it cannot be relied upon to perform the 25-hydroxylation step to activate vitamin D precursors. Therefore, the treatment must bypass this impaired metabolic step.",
        "* **Pharmacology:**\n  - **Ergocalciferol (D2) / Cholecalciferol (D3):** These are inactive precursors requiring hydroxylation in both the liver and kidney.\n  - **Calcitriol (1,25-dihydroxycholecalciferol):** This is the fully active form of vitamin D. It does not require hepatic or renal activation and can directly act on the intestines to increase calcium and phosphate absorption.",
        "* **Conclusion:** In a patient with rickets caused by severe liver disease, administering the active form of vitamin D, calcitriol, is the most effective and appropriate treatment."
      ],
      "others": [
        {
          "label": "①",
          "text": "erogocalciferol",
          "reason": "Ergocalciferol (Vitamin D2) is an inactive precursor that requires 25-hydroxylation in the liver, a step that is likely impaired in this patient with severe liver disease."
        },
        {
          "label": "②",
          "text": "cholecalciferol",
          "reason": "Cholecalciferol (Vitamin D3) is also an inactive precursor that requires hepatic 25-hydroxylation, making it an ineffective choice for this patient."
        },
        {
          "label": "④",
          "text": "ferrous sulfate",
          "reason": "While the patient has concurrent iron-deficiency anemia, the most acute and debilitating problem is the severe rickets causing bone pain and inability to stand. Treating the rickets is the immediate priority."
        },
        {
          "label": "⑤",
          "text": "ferric sulfate",
          "reason": "Similar to ferrous sulfate, this treats iron deficiency but does not address the primary and most symptomatic problem of severe rickets from vitamin D deficiency."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "cholecalcitriol"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** The infant presents with signs of severe cholestatic liver disease (jaundice, hepatomegaly) and nutritional rickets (bone pain, motor regression, inability to stand).",
        "* **Diagnosis:** The biochemical triad of hypocalcemia, hypophosphatemia, and markedly elevated alkaline phosphatase confirms rickets. The severe liver disease is the underlying cause.",
        "* **Pathophysiology of Vitamin D Metabolism:** Vitamin D requires two hydroxylation steps for activation:\n  - **Step 1 (Liver):** Conversion of dietary/cutaneous vitamin D (cholecalciferol/ergocalciferol) to 25-hydroxyvitamin D (calcidiol).\n  - **Step 2 (Kidney):** Conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (calcitriol), the biologically active form.",
        "* **Pathophysiology in Liver Disease:** Severe cholestatic liver disease causes rickets through two main mechanisms:\n  - **Malabsorption:** Impaired bile flow leads to malabsorption of fat-soluble vitamins, including vitamin D.\n  - **Impaired Activation:** Damaged hepatocytes cannot efficiently perform the initial 25-hydroxylation step.",
        "* **Treatment Principle:** The therapeutic goal is to bypass the defective metabolic steps. Since the liver cannot activate precursor vitamin D, the active form must be supplied directly.",
        "* **Pharmacology:**\n  - **Cholecalciferol (D3) / Ergocalciferol (D2):** Inactive precursors requiring hepatic activation. They are ineffective in this setting.\n  - **Calcitriol (1,25-dihydroxycholecalciferol):** This is the fully active form of vitamin D. It does not require activation by the liver or kidneys and is the treatment of choice for rickets secondary to severe liver or kidney disease.",
        "* **Management:** In addition to calcitriol, the patient requires calcium and phosphate supplementation to heal the bones. The underlying liver disease must also be managed.",
        "* **Differential/Discriminators:** While nutritional vitamin D deficiency is the most common cause of rickets overall, the presence of severe jaundice and liver enzyme elevation points directly to hepatic rickets."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "8",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "유리지방산이 간에서 중성지방으로 합성된다."
      },
      "why": [
        "* **Diagnosis:** Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly Non-alcoholic Fatty Liver Disease (NAFLD), in the context of pediatric metabolic syndrome.",
        "* **Clinical Picture:** The 10-year-old boy presents with obesity (BMI 26), acanthosis nigricans (a cutaneous marker of insulin resistance), and elevated liver enzymes.",
        "* **Lab Findings:** The labs confirm metabolic dysregulation:\n  - **Hyperglycemia:** Fasting glucose of 103 mg/dL indicates impaired fasting glucose.\n  - **Hepatitis:** Elevated AST/ALT (60/90 IU/L) with ALT > AST is typical for MASLD.\n  - **Dyslipidemia:** High total cholesterol (230 mg/dL), high LDL (130 mg/dL), and low HDL (38 mg/dL).",
        "* **Pathophysiology of MASLD:** The central mechanism is insulin resistance.",
        "* **Insulin Resistance and Lipolysis:** In a state of insulin resistance, insulin fails to suppress hormone-sensitive lipase in adipose tissue. This leads to increased breakdown of stored triglycerides and a massive efflux of free fatty acids (FFAs) into the circulation.",
        "* **Hepatic Fat Accumulation:** The liver takes up these excess FFAs from the blood. When the rate of FFA uptake and de novo lipogenesis exceeds the liver's capacity to either oxidize them for energy or export them as very-low-density lipoproteins (VLDL), the FFAs are re-esterified into triglycerides. These triglycerides accumulate within hepatocytes as lipid droplets, causing hepatic steatosis (fatty liver).",
        "* **Conclusion:** The statement that free fatty acids are synthesized into triglycerides in the liver accurately describes the core process leading to the fat accumulation seen in MASLD."
      ],
      "others": [
        {
          "label": "①",
          "text": "간의 포도당 신생합성이 억제된다.",
          "reason": "This is incorrect. Insulin normally suppresses hepatic gluconeogenesis. In insulin resistance, this suppression fails, leading to *increased* or disinhibited gluconeogenesis and contributing to hyperglycemia."
        },
        {
          "label": "②",
          "text": "미토콘드리아 ROS 생성을 억제한다.",
          "reason": "This is incorrect. The overload of fatty acids in the liver leads to mitochondrial stress and dysfunction, resulting in *increased* production of reactive oxygen species (ROS) and oxidative stress."
        },
        {
          "label": "③",
          "text": "Kupffer 세포 염증 반응이 억제된다.",
          "reason": "This is incorrect. Lipotoxicity and signals from the gut microbiome can *activate* Kupffer cells (liver macrophages), promoting an inflammatory response that drives the progression from simple steatosis to steatohepatitis (MASH)."
        },
        {
          "label": "④",
          "text": "아디포넥틴 증가가 지방 축적을 촉진한다.",
          "reason": "This is incorrect. Adiponectin is a protective adipokine that enhances insulin sensitivity. Its levels are typically *decreased* in obesity and MASLD, and this decrease contributes to the disease process."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "유리지방산이 간에서 중성지방으로 합성된다."
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD, formerly NAFLD) is the hepatic manifestation of metabolic syndrome. This patient shows obesity, acanthosis nigricans (a sign of insulin resistance), dyslipidemia, and elevated liver enzymes.",
        "* **Lab Findings:** A characteristic finding is elevated aminotransferases with an ALT to AST ratio > 1. Dyslipidemia (high LDL, low HDL) and impaired fasting glucose are common.",
        "* **Pathophysiology (Insulin Resistance):** Insulin resistance is the central pathogenic mechanism.",
        "* **Free Fatty Acid (FFA) Flux:** In an insulin-resistant state, insulin fails to suppress hormone-sensitive lipase in adipose tissue. This leads to uncontrolled lipolysis and an increased flow of FFAs from adipose tissue to the liver.",
        "* **Hepatic Steatosis:** The liver takes up these excess FFAs. When FFA uptake and *de novo* lipogenesis exceed the liver's capacity for fatty acid oxidation or export as VLDL, the FFAs are esterified into triglycerides, which accumulate in hepatocytes, causing steatosis.",
        "* **Progression to MASH:** The accumulation of toxic lipid species (lipotoxicity) leads to mitochondrial dysfunction, increased reactive oxygen species (ROS) production, and endoplasmic reticulum stress. This triggers an inflammatory response, involving activation of Kupffer cells, leading to hepatocyte injury, inflammation, and fibrosis (Metabolic Dysfunction-Associated Steatohepatitis, or MASH).",
        "* **Role of Adiponectin:** Adiponectin is an anti-inflammatory and insulin-sensitizing hormone produced by adipose tissue. In obesity and MASLD, adiponectin levels are paradoxically *decreased*, contributing to insulin resistance and inflammation.",
        "* **Hepatic Glucose Production:** Insulin normally suppresses glucose production (gluconeogenesis) in the liver. In insulin resistance, this suppression is lost, leading to *increased* hepatic glucose output and contributing to hyperglycemia."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "9",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "터너 증후군(Turner Syndrome)"
      },
      "why": [
        "* **Diagnosis:** Turner Syndrome.",
        "* **Clinical Presentation:** The patient presents with the classic features of Turner Syndrome: primary amenorrhea (no menarche by age 16), significant short stature (143 cm), and lack of secondary sexual development (Tanner stage 1 for breasts and pubic hair).",
        "* **Pathophysiology:** Turner Syndrome is caused by the complete or partial absence of one X chromosome. The lack of a second X chromosome leads to gonadal dysgenesis, where the ovaries are replaced by non-functional fibrous tissue ('streak ovaries').",
        "* **Hormonal Profile:** This ovarian failure results in an inability to produce estrogen. The lack of estrogen prevents the development of breasts and the onset of menstruation. The absence of negative feedback from estrogen and inhibin on the hypothalamic-pituitary axis leads to a compensatory, marked increase in gonadotropins.",
        "* **Lab Findings:** The laboratory results are pathognomonic for hypergonadotropic hypogonadism (primary ovarian failure):\n  - **LH:** 45.2 mIU/mL (High; ref 2.0-15.0)\n  - **FSH:** 86.5 mIU/mL (Very High; ref 2.0-15.0)\n  - **Estradiol:** 17 pg/mL (Low; ref 20-200)",
        "* **Diagnostic Criteria:** The diagnosis is definitively confirmed by the karyotype analysis.",
        "* **Karyotype:** The result of 45,X confirms the diagnosis of Turner Syndrome.",
        "* **Differential / Discriminators:** The absence of cyclic pain rules out an obstructive cause like imperforate hymen. The absence of anosmia makes Kallmann syndrome (hypogonadotropic hypogonadism) less likely, and the high gonadotropins rule it out completely."
      ],
      "others": [
        {
          "label": "①",
          "text": "뮐러관 무발생증 (Mullerian Agenesis)",
          "reason": "Patients with Mullerian agenesis have normal ovarian function, resulting in normal secondary sexual development (Tanner stage 4-5 breasts) and a 46,XX karyotype. This patient has no sexual development."
        },
        {
          "label": "③",
          "text": "처녀막 막힘증 (Imperforate hymen)",
          "reason": "This is an outflow tract obstruction. Patients have normal puberty and secondary sexual development but present with primary amenorrhea and cyclic pelvic pain due to retained menstrual blood (hematocolpos)."
        },
        {
          "label": "④",
          "text": "안드로겐 무감응 증후군 (Androgen insensitivity syn drome)",
          "reason": "Patients are 46,XY with female external genitalia. They have breast development due to aromatization of androgens, but scant pubic hair. This patient has no breast development."
        },
        {
          "label": "⑤",
          "text": "다낭성 난소증후군 (Polycystic ovary syndrome)",
          "reason": "PCOS typically presents with oligomenorrhea or secondary amenorrhea after puberty has already occurred, along with signs of hyperandrogenism. It does not cause a complete lack of pubertal development and short stature."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "터너 증후군(Turner Syndrome)"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Turner Syndrome is characterized by the classic triad of short stature, primary amenorrhea (lack of menarche), and absent secondary sexual characteristics (e.g., breast development).",
        "* **Associated Physical Stigmata:** Patients may also have a webbed neck, shield chest with widely spaced nipples, low posterior hairline, and cubitus valgus (increased carrying angle of the elbow).",
        "* **Pathophysiology:** The underlying cause is complete or partial absence of one X chromosome, leading to a 45,X karyotype or mosaicism. This results in gonadal dysgenesis, where the ovaries are replaced by non-functional fibrous tissue ('streak ovaries').",
        "* **Endocrine Profile:** The streak ovaries cannot produce estrogen. The lack of estrogen prevents pubertal development. The absence of negative feedback from estrogen and inhibin on the pituitary results in a compensatory, marked elevation of gonadotropins (FSH and LH).",
        "* **Diagnosis:** The hormonal profile is one of **hypergonadotropic hypogonadism** (high FSH/LH, low estradiol), indicating primary ovarian failure. The diagnosis is confirmed by karyotype analysis.",
        "* **Workup for Primary Amenorrhea:** The first step is to assess for breast development. If absent, an FSH level should be checked. High FSH points to ovarian failure (hypergonadotropic), while low/normal FSH points to a central (hypothalamic-pituitary) cause.",
        "* **Associated Medical Conditions:** Patients with Turner Syndrome are at increased risk for coarctation of the aorta, bicuspid aortic valve, horseshoe kidney, autoimmune hypothyroidism, and hearing loss.",
        "* **Management:** Treatment is multidisciplinary and includes growth hormone therapy to improve height, estrogen replacement therapy to induce puberty and maintain bone health, and regular screening for associated comorbidities.",
        "* **Differential/Discriminators:** Mullerian agenesis presents with primary amenorrhea but has normal puberty and a 46,XX karyotype. Central causes (e.g., Kallmann syndrome) present with low/normal FSH and LH."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "10",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "자궁내막긁어냄술(Endometrial curettage)을 시행"
      },
      "why": [
        "* **Diagnosis:** Abnormal Uterine Bleeding (AUB) with suspected endometrial hyperplasia or carcinoma.",
        "* **Clinical Presentation:** A 34-year-old nulliparous woman presents with menorrhagia and frequent bleeding. Her history of irregular menses (oligomenorrhea, 3-4 cycles/year) indicates chronic anovulation.",
        "* **Pathophysiology:** Chronic anovulation leads to continuous estrogen production without the opposing effect of progesterone (which is normally produced after ovulation). This unopposed estrogen stimulation causes excessive proliferation of the endometrium.",
        "* **Risk Factors:** This patient's chronic anovulation is a major risk factor for developing endometrial hyperplasia, which can be a precursor to endometrial cancer.",
        "* **Image Findings:**\n  - **Transvaginal Ultrasound:** The image shows a markedly thickened endometrium, measured at 2.08 cm (20.8 mm). This finding, especially immediately after a menstrual period when the endometrium should be at its thinnest, is highly abnormal and suspicious for pathology.",
        "* **Diagnostic Thresholds:** In a premenopausal woman with AUB, an endometrial thickness >12-16 mm is often considered abnormal, though there is no universally accepted cutoff. A thickness of 20.8 mm is unequivocally concerning.",
        "* **Diagnostic Algorithm:** The standard of care for a premenopausal woman with AUB and risk factors for endometrial cancer, coupled with a thickened endometrium on ultrasound, is to obtain a tissue sample for histologic evaluation.",
        "* **Next Step in Management:** Endometrial sampling is required to rule out hyperplasia or carcinoma. This can be done via an office endometrial biopsy or a formal dilation and curettage (D&C). Therefore, endometrial curettage is the correct next step."
      ],
      "others": [
        {
          "label": "①",
          "text": "경과관찰",
          "reason": "Observation is inappropriate and unsafe given the high suspicion for endometrial hyperplasia or cancer based on the clinical history and ultrasound findings."
        },
        {
          "label": "②",
          "text": "경구 클로미펜 투여",
          "reason": "Clomiphene is an ovulation induction agent used for infertility. It is not indicated for the evaluation of AUB and may be harmful if an underlying malignancy is present."
        },
        {
          "label": "③",
          "text": "경구 에스트로겐 투여",
          "reason": "Administering estrogen is contraindicated as the underlying problem is already one of unopposed estrogen stimulation. This would worsen the endometrial proliferation."
        },
        {
          "label": "④",
          "text": "자궁절제술(Hysterectomy)",
          "reason": "Hysterectomy is a definitive treatment, not a diagnostic procedure. A tissue diagnosis must be obtained via biopsy or curettage before considering major surgery."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "자궁내막긁어냄술(Endometrial curettage)을 시행"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A premenopausal woman with a history of chronic anovulation (oligomenorrhea) presenting with abnormal uterine bleeding (AUB), specifically menorrhagia.",
        "* **Pathophysiology:** Chronic anovulation leads to a state of unopposed estrogen. Without ovulation, no progesterone is produced to counteract estrogen's proliferative effect on the endometrium. This leads to endometrial overgrowth (hyperplasia), which can be a precursor to cancer.",
        "* **Risk Factors for Endometrial Hyperplasia/Cancer:** Conditions causing unopposed estrogen, including chronic anovulation (PCOS), obesity, nulliparity, and tamoxifen use.",
        "* **Workup:** The initial investigation for AUB is a transvaginal ultrasound to evaluate the endometrium and rule out structural causes.",
        "* **Ultrasound Findings:** A markedly thickened endometrium (20.8 mm) is highly suspicious for hyperplasia or carcinoma, especially in a patient with risk factors and when measured shortly after menses.",
        "* **Criteria/Thresholds:** While there is no strict cutoff in premenopausal women, an endometrial thickness >12-16 mm is generally considered abnormal and warrants further investigation. A thickness >20 mm is highly concerning.",
        "* **Management (algorithmic):** In a premenopausal woman with AUB, risk factors, and a thickened endometrium on ultrasound, **endometrial tissue sampling is mandatory** to rule out malignancy.",
        "* **Methods of Sampling:**\n  - **Office Endometrial Biopsy (e.g., Pipelle):** The first-line, least invasive method.\n  - **Dilation and Curettage (D&C):** A more invasive procedure, often performed with hysteroscopy for direct visualization, which provides a larger tissue sample and can be both diagnostic and therapeutic.",
        "* **Pitfalls:** Attributing AUB in a patient with risk factors to 'hormonal imbalance' without obtaining an ultrasound and, if indicated, a tissue sample. Delaying diagnosis can allow progression from simple hyperplasia to atypical hyperplasia or invasive carcinoma."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "11",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "뇌 자기공명영상(brain MRI)"
      },
      "why": [
        "* **Diagnosis:** The patient presents with secondary amenorrhea, defined as the absence of menses for three or more months in a woman with previously regular cycles.",
        "* **Clinical Presentation:** A 32-year-old woman with a history of regular 29-day cycles now reports 3 months of amenorrhea, preceded by 6 months of cycle irregularity. Her BMI is normal (20), and she denies significant weight loss or stress.",
        "* **Diagnostic Algorithm / First step:** The initial workup for secondary amenorrhea is a stepwise process. The very first step is to rule out pregnancy, which was done with a negative urine hCG test.",
        "* **Diagnostic Algorithm / Second step:** After excluding pregnancy, the next step is to evaluate for common endocrine causes. This involves measuring serum levels of TSH, prolactin, and gonadotropins (FSH, LH).",
        "* **Rationale for TSH:** Thyroid dysfunction (both hypothyroidism and hyperthyroidism) is a frequent cause of menstrual disturbances, including amenorrhea. Therefore, checking TSH is a standard part of the initial evaluation.",
        "* **Rationale for Prolactin (PRL):** Hyperprolactinemia, often caused by a pituitary microadenoma, can suppress the hypothalamic-pituitary-ovarian axis, leading to amenorrhea. A serum prolactin level is essential.",
        "* **Rationale for FSH:** The FSH level helps differentiate the level of the defect. High FSH suggests primary ovarian insufficiency (ovarian failure), while low or inappropriately normal FSH points towards a hypothalamic or pituitary cause (central dysfunction).",
        "* **Rationale for Pelvic Ultrasound:** An ultrasound is valuable for assessing the anatomy of the uterus and ovaries. It can identify structural abnormalities, signs of polycystic ovary syndrome (PCOS), or assess endometrial thickness, which can provide clues about the patient's estrogen status.",
        "* **Rationale for Excluding Brain MRI (initially):** A brain MRI is a second-line investigation. It is not performed as part of the initial screening for all patients with secondary amenorrhea. It is indicated only if initial tests suggest a central nervous system pathology, such as a significantly elevated prolactin level (suspicion for prolactinoma) or evidence of hypogonadotropic hypogonadism (low FSH/LH) without another explanation.",
        "* **Conclusion:** TSH, prolactin, FSH, and pelvic ultrasound are all appropriate and necessary components of the initial workup for this patient's secondary amenorrhea. A brain MRI is premature and not indicated at this stage."
      ],
      "others": [
        {
          "label": "①",
          "text": "혈중 갑상선 자극 호르몬 수치(serum TSH)",
          "reason": "This is an essential initial test. Thyroid disorders are a common and reversible cause of menstrual irregularity and secondary amenorrhea."
        },
        {
          "label": "②",
          "text": "혈중 프로락틴 수치(serum PRL)",
          "reason": "This is an essential initial test. Hyperprolactinemia is a key differential diagnosis for secondary amenorrhea, as it inhibits gonadotropin release."
        },
        {
          "label": "③",
          "text": "혈중 난포 자극 호르몬 수치(serum FSH)",
          "reason": "This is an essential initial test. It helps to distinguish between ovarian failure (high FSH) and central causes like hypothalamic-pituitary dysfunction (low/normal FSH)."
        },
        {
          "label": "④",
          "text": "골반 초음파 검사(pelvic ultrasound)",
          "reason": "This is a necessary part of the workup to evaluate for anatomical abnormalities of the uterus and ovaries (e.g., PCOS morphology, uterine outflow obstruction) that could cause amenorrhea."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "뇌 자기공명영상(brain MRI)"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Definition:** Secondary amenorrhea is the cessation of menses for ≥3 months in a woman with previously regular cycles or ≥6 months in a woman with previously irregular cycles.",
        "* **Workup (algorithmic):** The evaluation is a stepwise process to identify the underlying cause.",
        "* **Step 1: Exclude Pregnancy.** This is always the first and most important step, typically with a urine or serum hCG test.",
        "* **Step 2: Initial Hormonal Screen.** After pregnancy is ruled out, a basic panel of blood tests should be ordered to screen for common endocrine causes. This panel must include:\n  - **TSH:** To rule out thyroid dysfunction (both hypo- and hyperthyroidism).\n  - **Prolactin (PRL):** To rule out hyperprolactinemia, often from a pituitary adenoma.\n  - **FSH:** To differentiate between ovarian and central causes.",
        "* **Step 3: Anatomic and Estrogen Status Assessment.** A pelvic ultrasound is a standard part of the initial workup to assess the uterus, endometrium, and ovaries for abnormalities (e.g., PCOS morphology, Asherman syndrome).",
        "**Interpreting FSH levels:**\n  - **High FSH:** Indicates primary ovarian insufficiency (hypergonadotropic hypogonadism).\n  - **Low or Inappropriately Normal FSH:** Suggests a central cause, such as hypothalamic amenorrhea or a pituitary lesion (hypogonadotropic hypogonadism).",
        "* **Role of Brain MRI:** A brain MRI is **not** a first-line investigation for all cases of secondary amenorrhea. It is a targeted, second-line test.",
        "* **Indications for Brain MRI:** It is specifically indicated if the initial workup suggests a central nervous system pathology, such as:\n  - Markedly elevated prolactin level (suspicion for prolactinoma).\n  - Hypogonadotropic hypogonadism (low FSH/LH) without an obvious cause like functional hypothalamic amenorrhea.\n  - Other signs of pituitary dysfunction or a CNS tumor.",
        "* **Conclusion:** TSH, prolactin, FSH, and pelvic ultrasound are all essential components of the initial workup. Brain MRI is reserved for specific indications found during the initial evaluation."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "12",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "BCR::ABL 융합 유전자"
      },
      "why": [
        "* **Diagnosis:** Chronic Myeloid Leukemia (CML), chronic phase.",
        "* **Clinical Presentation:** The patient is a 45-year-old man found to have leukocytosis on a routine health check-up, which is a common presentation for chronic phase CML.",
        "* **Lab Findings:** The complete blood count (CBC) is classic for CML.\n  - **Marked Leukocytosis:** WBC count is very high at 98,000/uL.\n  - **Granulocytic Left Shift:** The differential shows the full spectrum of myeloid maturation, from myeloblasts (1%) and promyelocytes (5%) to mature neutrophils. This orderly proliferation is characteristic of CML, distinguishing it from an acute leukemia or a leukemoid reaction.\n  - **Basophilia:** The basophil count is elevated at 6%, a hallmark feature of CML.\n  - **Thrombocytosis:** The platelet count is high at 680,000/uL, which is also frequently seen in CML.\n  - **Anemia:** Mild normocytic anemia (Hb 11.9 g/dL) is common due to bone marrow crowding.",
        "* **Pathophysiology:** CML is a myeloproliferative neoplasm characterized by a specific chromosomal translocation known as the Philadelphia chromosome.",
        "* **Molecular Genetics:** The Philadelphia chromosome results from a reciprocal translocation between the long arms of chromosome 9 and 22, denoted as t(9;22)(q34;q11).",
        "* **Key Genetic Marker:** This translocation juxtaposes the ABL proto-oncogene from chromosome 9 with the BCR gene on chromosome 22, creating the BCR::ABL fusion gene.",
        "* **Mechanism:** The BCR::ABL fusion gene encodes a constitutively active tyrosine kinase protein that drives uncontrolled proliferation of myeloid cells, leading to the clinical and laboratory features of CML.",
        "* **Diagnostic Confirmation:** The presence of the BCR::ABL fusion gene (or its transcript) is the definitive diagnostic marker for CML and can be detected by cytogenetics (karyotyping), fluorescence in situ hybridization (FISH), or reverse transcription-polymerase chain reaction (RT-PCR).",
        "* **Differential / Discriminators:** While other myeloproliferative neoplasms can cause leukocytosis and thrombocytosis, the combination of marked left-shifted granulocytosis and basophilia is highly specific for CML."
      ],
      "others": [
        {
          "label": "①",
          "text": "JAK2V618F 돌연변이",
          "reason": "This mutation is primarily associated with other myeloproliferative neoplasms like polycythemia vera (~95%), essential thrombocythemia (~50-60%), and primary myelofibrosis (~50-60%), not CML. The classic CML picture with a full left shift and basophilia points away from these diagnoses."
        },
        {
          "label": "②",
          "text": "CALR 유전자 돌연변이",
          "reason": "CALR mutations are found in JAK2-negative essential thrombocythemia and primary myelofibrosis. They are mutually exclusive with the BCR::ABL fusion gene and are not associated with CML."
        },
        {
          "label": "④",
          "text": "PML::RARA 융합 유전자",
          "reason": "This fusion gene, resulting from t(15;17), is the hallmark of Acute Promyelocytic Leukemia (APL). APL presents with a proliferation of abnormal promyelocytes and is often associated with pancytopenia and disseminated intravascular coagulation (DIC), a very different clinical picture."
        },
        {
          "label": "⑤",
          "text": "MPL유전자 돌연변이",
          "reason": "MPL mutations are found in a small subset of patients with essential thrombocythemia and primary myelofibrosis, particularly those negative for JAK2 and CALR mutations. They are not a feature of CML."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "BCR::ABL 융합 유전자"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm that often presents in the chronic phase with incidental findings on a CBC or with nonspecific symptoms like fatigue or splenomegaly.",
        "* **Hallmark Lab Findings:** The peripheral blood smear is classic for CML:\n  - **Marked Leukocytosis:** WBC count is typically >100,000/µL.\n  - **Granulocytic Left Shift:** The differential shows the full spectrum of myeloid maturation, from a small percentage of myeloblasts to mature neutrophils.\n  - **Basophilia:** Absolute basophilia is a nearly universal and highly characteristic finding.\n  - **Thrombocytosis:** An elevated platelet count is common.",
        "* **Pathophysiology:** CML is defined by a specific genetic abnormality, the Philadelphia chromosome.",
        "* **Genetics:** The Philadelphia chromosome is the result of a reciprocal translocation between the long arms of chromosome 9 and chromosome 22, denoted as **t(9;22)(q34;q11)**.",
        "* **Molecular Consequence:** This translocation creates the **BCR::ABL1 fusion gene**. The protein product of this gene is a constitutively active tyrosine kinase.",
        "* **Mechanism of Disease:** The BCR::ABL1 tyrosine kinase drives uncontrolled proliferation of hematopoietic stem cells and their progeny, leading to the massive expansion of the myeloid lineage seen in CML.",
        "* **Diagnosis:** The diagnosis is confirmed by detecting the Philadelphia chromosome via karyotyping or, more commonly, by detecting the BCR::ABL1 fusion gene or its mRNA transcript using fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR).",
        "* **Differential/Discriminators:** Other myeloproliferative neoplasms (MPNs) are in the differential but have different genetic drivers:\n  - **Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis:** Associated with mutations in *JAK2*, *CALR*, or *MPL*.\n  - **Acute Promyelocytic Leukemia (APL):** Characterized by the t(15;17) translocation and the *PML::RARA* fusion gene.",
        "* **Treatment:** The disease has been revolutionized by the use of tyrosine kinase inhibitors (TKIs) like imatinib, which specifically target the BCR::ABL1 protein."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "13",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "임상적인 증상이 없는 경우 (no disease related sy mptoms)"
      },
      "why": [
        "* **Diagnosis:** The question asks for a condition that is NOT an indication for treating Chronic Lymphocytic Leukemia (CLL).",
        "* **Treatment Principle / Guidelines:** The management of early-stage, asymptomatic CLL is active surveillance, often termed \"watch and wait.\" Treatment is deferred until the patient develops specific signs of disease progression or symptoms, as early intervention has not been shown to improve overall survival and can cause unnecessary toxicity.",
        "* **Indications for Treatment (iwCLL criteria):** Treatment is initiated for patients with active disease, which is defined by one or more of the following:\n  - **Constitutional Symptoms:** Significant disease-related symptoms such as weight loss ≥10% within 6 months, significant fatigue, fevers >38°C for ≥2 weeks without infection, or drenching night sweats for >1 month without infection.\n  - **End-Organ Dysfunction:** Evidence of progressive marrow failure shown by developing or worsening anemia (hemoglobin < 10 g/dL) or thrombocytopenia (platelets < 100,000/uL).\n  - **Organomegaly:** Massive (>6 cm below costal margin), progressive, or symptomatic splenomegaly.\n  - **Lymphadenopathy:** Massive (nodes ≥10 cm), progressive, or symptomatic lymphadenopathy.\n  - **Rapid Disease Progression:** Progressive lymphocytosis with an increase of >50% over a 2-month period, or a lymphocyte doubling time of less than 6 months.\n  - **Autoimmune Complications:** Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapies.",
        "* **Analysis of the Correct Option:** The absence of disease-related symptoms is the definition of asymptomatic CLL. This is the primary reason to *withhold* treatment and continue observation, not to initiate it.",
        "* **Analysis of Distractors:** All other options represent criteria for active disease that warrant starting therapy.\n  - **Threatened end-organ function:** This is a clear indication, as organ damage must be prevented.\n  - **Progressive thrombocytopenia/anemia:** These signify bone marrow failure, a major indication for treatment.\n  - **Steroid-refractory autoimmune cytopenias:** This indicates that the autoimmune complication of CLL is severe and not controlled by first-line therapy, necessitating CLL-directed treatment."
      ],
      "others": [
        {
          "label": "②",
          "text": "장기 부전 동반 (threatened end-organ function)",
          "reason": "This is a clear indication for treatment. Organ dysfunction due to leukemic infiltration (e.g., renal failure, biliary obstruction) requires immediate therapy to prevent irreversible damage."
        },
        {
          "label": "③",
          "text": "진행하는 혈소판 감소증(progressive thrombocytop enia)",
          "reason": "This is a major indication for treatment, as it signifies progressive bone marrow failure and puts the patient at high risk of bleeding."
        },
        {
          "label": "④",
          "text": "진행하는 빈혈(progressive anemia)",
          "reason": "This is a major indication for treatment, as it signifies progressive bone marrow failure and leads to significant symptoms like fatigue and dyspnea."
        },
        {
          "label": "⑤",
          "text": "스테로이드에 반응하지 않는 자가면역성 혈구감소증(ste roid refractory autoimmune cytopenias)",
          "reason": "This is an indication for treatment. When autoimmune complications of CLL do not respond to standard immunosuppression, treatment directed at the underlying CLL clone is required."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "임상적인 증상이 없는 경우 (no disease related sy mptoms)"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Chronic Lymphocytic Leukemia (CLL) is a low-grade B-cell lymphoma characterized by a progressive accumulation of mature-appearing lymphocytes. Many patients are asymptomatic at diagnosis.",
        "* **Management Principle:** The standard of care for early-stage, asymptomatic CLL is active surveillance, also known as **\"watch and wait.\"**",
        "* **Rationale for Observation:** Multiple randomized controlled trials have shown that initiating treatment early in asymptomatic patients does not improve overall survival and exposes them to unnecessary treatment-related toxicity.",
        "* **Indications for Treatment:** Therapy is initiated only when a patient develops \"active disease,\" as defined by the International Workshop on CLL (iwCLL) criteria.",
        "* **iwCLL Criteria for Active Disease:**\n  - **Constitutional Symptoms:** Significant fatigue, unintentional weight loss (≥10% in 6 months), fevers (≥38°C) or drenching night sweats without infection.\n  - **Progressive Marrow Failure:** Development or worsening of anemia (hemoglobin <10 g/dL) or thrombocytopenia (platelets <100,000/µL).\n  - **Bulky Disease:** Massive (>6 cm below costal margin), progressive, or symptomatic splenomegaly; or massive (≥10 cm), progressive, or symptomatic lymphadenopathy.\n  - **Rapid Progression:** Lymphocyte doubling time of less than 6 months.",
        "* **Autoimmune Complications:** Autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP) that is refractory to standard immunosuppressive therapy (e.g., corticosteroids) is also an indication for CLL-directed treatment.",
        "* **Conclusion:** The absence of any disease-related symptoms is the definition of asymptomatic disease and is the primary reason to **withhold** therapy, not to start it.",
        "* **Pitfalls:** Treating CLL based solely on a high lymphocyte count in an asymptomatic patient is a common error. The absolute count is not an indication for treatment; the rate of rise (doubling time) is."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "14",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "유전진단에서 질병의 원인으로 규명된 변이는pathogen ic variant으로 표기한다."
      },
      "why": [
        "* **Topic:** This question assesses knowledge of molecular diagnostics for hereditary hematologic disorders and standard genetic nomenclature.",
        "* **Correct Statement Analysis:** The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have established a five-tier system for classifying genetic variants based on evidence of their role in disease.",
        "* **Variant Classification:** The five categories are:\n  - **Pathogenic:** Sufficient evidence to be considered disease-causing.\n  - **Likely Pathogenic:** Strong evidence suggests it is disease-causing, but not definitively proven.\n  - **Variant of Uncertain Significance (VUS):** Insufficient or conflicting evidence to classify as benign or pathogenic.\n  - **Likely Benign:** Strong evidence suggests it is not disease-causing.\n  - **Benign:** Sufficient evidence to be considered not disease-causing.",
        "* **Conclusion:** Therefore, the statement that a variant identified as the cause of a disease is designated a 'pathogenic variant' is correct according to international standards.",
        "* **Distractor Analysis (Why others are incorrect):**",
        "* **Factor V Leiden:** This is the most common inherited thrombophilia in Caucasian populations but is extremely rare in East Asian populations, including Koreans. The prevalence is <0.1% in Korea, so it is not a major cause of thrombosis.",
        "* **Beta-thalassemia:** The vast majority of beta-thalassemia cases are caused by point mutations (e.g., missense, nonsense, splice-site mutations) or small insertions/deletions within or around the beta-globin (HBB) gene. Large gene deletions are a much less common cause for beta-thalassemia, whereas they are a common cause for alpha-thalassemia.",
        "* **von Willebrand disease (vWD):** The molecular diagnosis of vWD involves identifying mutations in the VWF gene. These are most commonly sequence variants (missense, nonsense) or small deletions/insertions found by gene sequencing. Gene rearrangements are not a typical mechanism for vWD.",
        "* **HGVS Nomenclature:** The notation `c.113+1G>A` describes a splice-site mutation according to Human Genome Variation Society (HGVS) nomenclature. 'c.113' refers to the last nucleotide of the preceding exon. The '+1' indicates the first nucleotide of the following intron. Thus, the variant is a G to A change at the first position of the intron, which disrupts the canonical splice donor site. It does not mean the 113th coding base itself has changed."
      ],
      "others": [
        {
          "label": "①",
          "text": "FV Leiden은 한국인의 혈전증에서 다발하는 주요 원인이다.",
          "reason": "This is incorrect. Factor V Leiden is the most common inherited risk factor for thrombosis in Caucasians but is exceedingly rare in the Korean and other East Asian populations."
        },
        {
          "label": "②",
          "text": "베타지중해빈혈증의 대부분은 유전자의 대결실에 의해 발생한다.",
          "reason": "This is incorrect. Most cases of beta-thalassemia are caused by point mutations or small indels in the HBB gene, not large deletions. Large deletions are more characteristic of alpha-thalassemia."
        },
        {
          "label": "③",
          "text": "von Willebrand disease의 분자진단은VWF 유전자의 재배열을 검사한다.",
          "reason": "This is incorrect. The molecular diagnosis of von Willebrand disease primarily involves sequencing the VWF gene to find point mutations or small indels. Gene rearrangements are not a common cause."
        },
        {
          "label": "⑤",
          "text": "c.113+1G〉A는113번째 염기가G〉A 로 바뀌었다는 뜻이다.",
          "reason": "This is incorrect. According to HGVS nomenclature, 'c.113+1G>A' indicates a change from G to A at the first nucleotide of the intron immediately following coding nucleotide 113, representing a splice-site mutation."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "유전진단에서 질병의 원인으로 규명된 변이는pathogen ic variant으로 표기한다."
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Variant Classification:** The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) provide a standardized five-tier system for classifying the clinical significance of genetic variants.",
        "* **ACMG/AMP Tiers:**\n  - **Pathogenic:** Sufficient evidence to be considered disease-causing.\n  - **Likely Pathogenic:** Strong evidence suggests it is disease-causing.\n  - **Variant of Uncertain Significance (VUS):** Insufficient or conflicting evidence.\n  - **Likely Benign:** Strong evidence suggests it is not disease-causing.\n  - **Benign:** Sufficient evidence to be considered not disease-causing.",
        "* **HGVS Nomenclature:** The Human Genome Variation Society (HGVS) provides the standard nomenclature for describing genetic variants. The notation `c.113+1G>A` describes a splice-site mutation, not a change in the coding sequence itself. It indicates a G-to-A substitution at the first nucleotide of the intron following coding nucleotide 113, disrupting the canonical splice donor site.",
        "* **Inherited Thrombophilia:** Factor V Leiden is the most common inherited cause of thrombophilia in Caucasian populations but is extremely rare (<0.1%) in East Asian populations, including Koreans.",
        "* **Beta-Thalassemia:** The vast majority of cases are caused by point mutations (e.g., missense, nonsense, splice-site) or small insertions/deletions within the beta-globin (*HBB*) gene. Large gene deletions are an uncommon cause.",
        "* **Alpha-Thalassemia:** In contrast to beta-thalassemia, alpha-thalassemia is most commonly caused by large deletions involving one or more of the alpha-globin genes.",
        "* **von Willebrand Disease (vWD):** The molecular diagnosis of vWD involves identifying mutations in the *VWF* gene. These are typically sequence variants (missense, nonsense) or small deletions/insertions identified by gene sequencing. Large gene rearrangements are not a common mechanism."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "15",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "소포림프종"
      },
      "why": [
        "* **Diagnosis:** Follicular Lymphoma.",
        "* **Clinical Presentation:** The patient is a 52-year-old woman with a long history of an indolent, slowly progressive, widespread lymphadenopathy. The absence of B symptoms (fever, night sweats, weight loss) and normal lab values (CBC, LDH) are classic for a low-grade lymphoma, such as follicular lymphoma.",
        "* **Image Findings:** The provided images are from a lymph node biopsy.\n  - **H&E Stain:** The image shows effacement of the normal lymph node architecture by multiple, crowded, back-to-back nodules (follicles) of varying sizes. This nodular or follicular growth pattern is the key morphologic feature.\n  - **Immunohistochemistry (CD10):** The neoplastic follicles are strongly positive for CD10. CD10 is a germinal center B-cell marker, confirming the origin of the tumor cells from the follicular germinal center.\n  - **Immunohistochemistry (Bcl-2):** The neoplastic follicles show strong, diffuse expression of Bcl-2. This is the crucial diagnostic finding. Normal, reactive germinal centers are Bcl-2 negative, as Bcl-2 expression is downregulated to allow for apoptosis of B-cells with low-affinity receptors. In follicular lymphoma, the characteristic t(14;18) translocation leads to the overexpression of the anti-apoptotic protein Bcl-2, preventing cell death and promoting clonal expansion.",
        "* **Pathophysiology:** Follicular lymphoma is characterized by the t(14;18)(q32;q21) chromosomal translocation. This translocation places the BCL2 gene from chromosome 18 under the control of the immunoglobulin heavy chain (IGH) gene promoter on chromosome 14, resulting in constitutive overexpression of Bcl-2 protein.",
        "* **Diagnostic Criteria:** The diagnosis is established by the combination of a follicular growth pattern of centrocytes and centroblasts, which express pan-B-cell markers (like CD20), germinal center markers (CD10, BCL6), and aberrant expression of Bcl-2.",
        "* **Differential / Discriminators:**\n  - **Reactive follicular hyperplasia:** Follicles would be variable in size and shape, preserve the mantle zone, and be Bcl-2 negative.\n  - **Mantle cell lymphoma:** Can have a nodular pattern but cells are typically CD5 positive, Cyclin D1 positive, and CD10 negative.\n  - **Hodgkin lymphoma:** Would show classic Reed-Sternberg cells in a mixed inflammatory background, not neoplastic follicles."
      ],
      "others": [
        {
          "label": "①",
          "text": "감염단핵구증",
          "reason": "Infectious mononucleosis presents with acute symptoms like fever and pharyngitis and histologically shows a paracortical expansion with a mixed population of immunoblasts, not monotonous Bcl-2 positive follicles."
        },
        {
          "label": "②",
          "text": "결핵성림프절염",
          "reason": "Tuberculous lymphadenitis is characterized by caseating granulomas with epithelioid histiocytes and Langhans giant cells, a completely different histology."
        },
        {
          "label": "③",
          "text": "호지킨림프종",
          "reason": "Hodgkin lymphoma is defined by the presence of Reed-Sternberg cells and their variants within a reactive inflammatory cell background, not a follicular architecture of neoplastic B-cells."
        },
        {
          "label": "⑤",
          "text": "외투세포림프종",
          "reason": "Mantle cell lymphoma is composed of monotonous small lymphocytes that are characteristically positive for CD5 and Cyclin D1. While it can be Bcl-2 positive, it is typically CD10 negative, and the morphology is distinct."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "소포림프종"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Follicular lymphoma is a type of non-Hodgkin lymphoma that typically presents in older adults as painless, slowly progressive, widespread lymphadenopathy. It is usually an indolent (low-grade) disease.",
        "* **Pathology (Architecture):** The key histologic feature is the effacement of the normal lymph node architecture by a nodular or follicular proliferation of neoplastic B-cells.",
        "* **Pathology (Immunophenotype):** The tumor cells are of germinal center B-cell origin. They express pan-B-cell markers (e.g., CD20), germinal center markers (**CD10**, BCL6), and, crucially, show aberrant overexpression of **Bcl-2**.",
        "* **Diagnostic Hallmark:** The combination of a follicular growth pattern with aberrant Bcl-2 expression within the germinal centers is diagnostic. Normal, reactive germinal centers are Bcl-2 negative because Bcl-2 is downregulated to allow for apoptosis.",
        "* **Pathophysiology:** The underlying genetic lesion is the **t(14;18)(q32;q21)** chromosomal translocation. This translocation juxtaposes the *BCL2* gene on chromosome 18 with the immunoglobulin heavy chain (*IGH*) gene locus on chromosome 14.",
        "* **Mechanism:** This rearrangement leads to the constitutive overexpression of the Bcl-2 protein, which is an anti-apoptotic protein. This prevents programmed cell death, leading to the accumulation of neoplastic B-cells.",
        "* **Management:** For asymptomatic patients with low tumor burden, the standard approach is often observation (\"watch and wait\"). Treatment for symptomatic or bulky disease typically involves an anti-CD20 monoclonal antibody (rituximab) with or without chemotherapy.",
        "* **Differential/Discriminators:** The main differential is reactive follicular hyperplasia. In reactive hyperplasia, follicles are variable in size, maintain their mantle zones, contain tangible body macrophages, and are Bcl-2 negative."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "16",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "직장 MRI"
      },
      "why": [
        "* **Diagnosis:** The patient has a rectal adenocarcinoma, confirmed by colonoscopy and biopsy.",
        "* **Clinical Staging:** The patient has a tumor located 10 cm from the anal verge, which classifies it as rectal cancer (typically defined as within 12-15 cm). The chest and abdominal CT scans have ruled out distant metastases (M0 disease). The crucial next step is to determine the local stage (TNM staging: Tumor depth, Node involvement, Metastasis).",
        "* **Treatment Principle:** The treatment strategy for non-metastatic rectal cancer depends heavily on the local stage. For early-stage tumors (e.g., T1-T2, N0), upfront surgery may be sufficient. For locally advanced tumors (e.g., T3-T4 or any N+), the standard of care is neoadjuvant chemoradiotherapy (nCRT) followed by surgery (total mesorectal excision).",
        "* **Role of Imaging:** Accurate local staging is paramount to select the appropriate treatment pathway. Pelvic MRI with a dedicated rectal protocol is the gold standard for this purpose.",
        "* **Advantages of Rectal MRI:**\n  - **T-staging:** It can precisely delineate the depth of tumor invasion through the rectal wall layers.\n  - **Mesorectal Fascia (MRF):** It is superior in assessing the distance between the tumor and the mesorectal fascia. A threatened or involved MRF is a strong indication for neoadjuvant therapy.\n  - **N-staging:** It can identify suspicious regional lymph nodes based on size and morphology.\n  - **Extramural Venous Invasion (EMVI):** It can detect EMVI, another high-risk feature.",
        "* **Conclusion:** To make the critical decision between upfront surgery and neoadjuvant therapy, a rectal MRI is the essential next investigation for accurate local staging.",
        "* **Image Findings:**\n  - **Photo 1 (Endoscopy):** Shows a large, ulcerated, partially circumferential mass typical of an advanced adenocarcinoma.\n  - **Photo 2 (Histology):** Confirms adenocarcinoma with irregular, crowded malignant glands infiltrating the stroma."
      ],
      "others": [
        {
          "label": "①",
          "text": "Microsatellite instability (MSI)",
          "reason": "MSI testing is important for prognosis and predicting response to immunotherapy, but it does not determine the initial local staging or the need for neoadjuvant therapy. It is typically performed on the surgical specimen."
        },
        {
          "label": "②",
          "text": "KRAS mutation",
          "reason": "KRAS mutation status is a predictive biomarker for response to anti-EGFR therapy in the setting of metastatic colorectal cancer. It is not relevant for staging or initial treatment planning of localized rectal cancer."
        },
        {
          "label": "③",
          "text": "전신 PET-CT",
          "reason": "While PET-CT can be used to clarify equivocal findings for distant metastases, it is not the primary modality for local T and N staging of rectal cancer. Pelvic MRI provides superior soft tissue resolution for this purpose."
        },
        {
          "label": "⑤",
          "text": "혈액 CEA",
          "reason": "Carcinoembryonic antigen (CEA) is a tumor marker used for establishing a baseline before treatment and for surveillance after treatment. It does not provide the anatomical staging information needed to decide on the primary treatment modality."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "직장 MRI"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Diagnosis and Initial Workup:** Rectal cancer is diagnosed via colonoscopy and biopsy. Once confirmed, staging is required to guide treatment. The initial staging workup includes a CT scan of the chest, abdomen, and pelvis to assess for distant metastatic disease (M-stage).",
        "* **Importance of Local Staging:** For non-metastatic rectal cancer, accurate local staging (T-stage and N-stage) is critical to determine whether the patient should receive upfront surgery or neoadjuvant (preoperative) therapy.",
        "* **Gold Standard for Local Staging:** High-resolution **pelvic MRI** is the gold standard imaging modality for local staging of rectal cancer.",
        "* **Information from Rectal MRI:** MRI provides crucial anatomical details, including:\n  - **T-stage:** The depth of tumor invasion into or through the rectal wall.\n  - **Nodal Status (N-stage):** The presence and characteristics of regional lymph nodes.\n  - **Mesorectal Fascia (MRF):** The distance from the tumor to the MRF, which is the circumferential resection margin. A threatened or involved margin is a strong indication for neoadjuvant therapy.\n  - **Extramural Venous Invasion (EMVI):** A key prognostic factor.",
        "* **Treatment Algorithm:**\n  - **Early Stage (e.g., T1-2, N0):** Often treated with upfront surgery (Total Mesorectal Excision - TME).\n  - **Locally Advanced Stage (e.g., T3-4 or any N+):** Standard of care is neoadjuvant chemoradiotherapy followed by TME. This approach significantly reduces the risk of local recurrence.",
        "* **Role of Other Tests:**\n  - **CEA:** A baseline tumor marker used for monitoring treatment response and surveillance.\n  - **PET-CT:** Not the primary tool for local staging but can be useful for clarifying equivocal metastatic findings.\n  - **MSI/KRAS:** Molecular markers that are important for prognosis and guiding therapy in the advanced/metastatic setting, but not for initial local staging."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "17",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "Chimeric antigen receptor T cell therapy"
      },
      "why": [
        "* **Diagnosis:** The question describes a specific type of immunotherapy for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).",
        "* **Key Components Described:** The stem provides a precise, step-by-step definition of Chimeric Antigen Receptor (CAR) T-cell therapy.\n  - **Target Cell:** Patient's own T cells ('자가 T세포').\n  - **Genetic Modification:** A '유전자 재조합 수용체 유전자' (recombinant receptor gene) is inserted using a '바이러스 벡터' (viral vector).\n  - **Receptor Structure:** The receptor is a 'chimeric' construct, combining two parts: an '인지하는 부분' (recognition part) that targets 'CD19 단백질' (CD19 protein) on leukemia cells, and a '활성 신호를 전달하는 부분' (activation signal-transducing part).\n  - **Mechanism of Action:** These engineered T cells are infused back into the patient to find and kill leukemia cells.",
        "* **Terminology:** This entire process defines CAR T-cell therapy. The 'chimeric antigen receptor' (CAR) is the synthetic receptor, and the therapy involves using T cells expressing this receptor.",
        "* **Clinical Context:** CAR T-cell therapy targeting CD19 (e.g., tisagenlecleucel) is a standard of care for pediatric and young adult patients with relapsed or refractory B-ALL, exactly the scenario described.",
        "* **Differential / Discriminators:** The key distinguishing feature is the ex vivo genetic engineering of the patient's own T cells to express a synthetic receptor, which is unique to CAR T-cell therapy among the options provided."
      ],
      "others": [
        {
          "label": "①",
          "text": "Bi-specific antibody",
          "reason": "This therapy uses a single antibody molecule to simultaneously bind a tumor antigen (like CD19) and an activating receptor on an immune cell (like CD3 on T cells), bringing them together. It does not involve genetically modifying T cells."
        },
        {
          "label": "②",
          "text": "Antibody drug conjugate",
          "reason": "This involves an antibody linked to a potent chemotherapy drug. The antibody targets a protein on the cancer cell (like CD22), delivering the toxin directly. It is a form of targeted chemotherapy, not a cellular immunotherapy."
        },
        {
          "label": "③",
          "text": "Immune checkpoint blockade therapy",
          "reason": "This therapy uses antibodies to block inhibitory pathways (like PD-1/PD-L1) to 'release the brakes' on the patient's existing anti-tumor immune response. It does not involve creating genetically engineered T cells."
        },
        {
          "label": "⑤",
          "text": "Donor lymphocyte infusion",
          "reason": "This involves infusing unmodified T cells from a prior allogeneic stem cell donor to induce a graft-versus-leukemia effect. It uses normal donor cells, not genetically engineered patient cells."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "Chimeric antigen receptor T cell therapy"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Definition:** Chimeric Antigen Receptor (CAR) T-cell therapy is a highly specialized form of immunotherapy where a patient's own T-cells are genetically engineered to recognize and kill cancer cells.",
        "* **Mechanism of Action (Step-by-Step):**\n  - 1. **Leukapheresis:** T-cells are collected from the patient's blood.\n  - 2. **Genetic Modification:** The T-cells are modified *ex vivo* using a viral vector (e.g., lentivirus) to insert a gene for a synthetic CAR.\n  - 3. **CAR Structure:** The CAR is a fusion protein with an extracellular antigen-recognition domain (derived from an antibody, e.g., anti-CD19) and intracellular signaling domains that activate the T-cell.\n  - 4. **Expansion:** The engineered CAR T-cells are grown to large numbers in the laboratory.\n  - 5. **Infusion:** The patient receives lymphodepleting chemotherapy, followed by infusion of the CAR T-cell product.",
        "* **Function:** Once infused, the CAR T-cells act as 'living drugs,' seeking out cells with the target antigen (e.g., CD19 on B-cell leukemia cells) and launching a potent cytotoxic attack.",
        "* **Indications:** This therapy has shown remarkable efficacy in relapsed/refractory hematologic malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma.",
        "* **Major Toxicities:**\n  - **Cytokine Release Syndrome (CRS):** A systemic inflammatory response from massive T-cell activation, causing fever, hypotension, and hypoxia. Managed with tocilizumab (an IL-6 receptor antagonist).\n  - **Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS):** Neurologic toxicity that can range from confusion and aphasia to seizures and cerebral edema. Managed with corticosteroids.",
        "* **Differential/Discriminators:**\n  - **Bi-specific Antibodies:** Off-the-shelf proteins that link a patient's existing T-cells to tumor cells; no genetic modification is involved.\n  - **Antibody-Drug Conjugates (ADCs):** Monoclonal antibodies linked to a chemotherapy payload.",
        "* **Immune Checkpoint Blockade:** Antibodies that block inhibitory pathways (e.g., PD-1) to unleash a pre-existing anti-tumor immune response."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "18",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "Rasburicase"
      },
      "why": [
        "* **Diagnosis:** The patient has Burkitt lymphoma, a highly aggressive B-cell lymphoma with a very high proliferation rate (Ki-67 95%). This tumor type is associated with a high risk of Tumor Lysis Syndrome (TLS).",
        "* **Clinical Picture:** The patient has a large tumor burden (extensive abdominal disease) and is presenting with signs of spontaneous TLS even before chemotherapy has started.",
        "* **Tumor Lysis Syndrome (TLS):** This is an oncologic emergency caused by the rapid breakdown of cancer cells, which releases large amounts of potassium, phosphate, and nucleic acids into the circulation.",
        "* **Pathophysiology of Hyperuricemia:** Nucleic acids are metabolized to uric acid, which is poorly soluble and can precipitate in the renal tubules, causing obstructive uropathy and acute kidney injury (AKI).",
        "* **Lab Findings:** The patient's labs show established laboratory TLS.\n  - **Uric Acid:** 14.5 mg/dL (severely elevated; normal for a child is typically < 5.5 mg/dL).\n  - **Renal Function:** BUN 25 mg/dL and Creatinine 1.2 mg/dL are elevated for a 5-year-old, indicating AKI, likely secondary to the hyperuricemia.\n  - **Other Electrolytes:** Phosphorus (3.8 mg/dL) and potassium (4.6 mmol/L) are currently within the normal range for a child but are expected to rise dramatically once chemotherapy is initiated.",
        "* **Treatment Principle:** The immediate priority is to manage the existing hyperuricemia and prevent further renal damage. This must be done before or concurrently with the initiation of chemotherapy.",
        "* **Management of Hyperuricemia:** Rasburicase is a recombinant urate oxidase enzyme. It rapidly converts existing uric acid into allantoin, a highly soluble compound that is easily excreted by the kidneys. It is the treatment of choice for patients with established TLS and severe hyperuricemia.",
        "* **Why not Allopurinol?:** Allopurinol is a xanthine oxidase inhibitor that prevents the formation of *new* uric acid. It would be too slow and ineffective for this patient's established, severe hyperuricemia. Rasburicase is needed to break down the existing uric acid load.",
        "* **Image Findings:** The abdominal CT shows a large, infiltrative mass, confirming the high tumor burden that predisposes to TLS."
      ],
      "others": [
        {
          "label": "①",
          "text": "Ibuprofen",
          "reason": "This is contraindicated. NSAIDs like ibuprofen can impair renal blood flow and worsen acute kidney injury, which is already present in this patient with tumor lysis syndrome."
        },
        {
          "label": "②",
          "text": "20% Albumin",
          "reason": "The primary fluid management for TLS is aggressive intravenous hydration with an isotonic crystalloid (like normal saline) to maintain high urine output. Albumin is not a first-line therapy for this condition."
        },
        {
          "label": "④",
          "text": "Glucarpidase",
          "reason": "This is an enzyme used to rapidly clear toxic levels of methotrexate, a chemotherapy agent. It has no role in the management of tumor lysis syndrome or hyperuricemia."
        },
        {
          "label": "⑤",
          "text": "Immunoglobulin",
          "reason": "Intravenous immunoglobulin (IVIG) is used for various immunodeficiency or autoimmune conditions. It has no role in the treatment of Burkitt lymphoma or tumor lysis syndrome."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "Rasburicase"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Definition:** Tumor Lysis Syndrome (TLS) is an oncologic emergency resulting from the rapid destruction of malignant cells and the release of their intracellular contents into the bloodstream.",
        "* **High-Risk Tumors:** TLS is most common in hematologic malignancies with a high proliferative rate, large tumor burden, and high sensitivity to therapy, such as Burkitt lymphoma and acute lymphoblastic leukemia (ALL).",
        "* **Pathophysiology:** The massive release of intracellular contents leads to a tetrad of metabolic abnormalities:\n  - **Hyperuricemia:** From the breakdown of nucleic acids to uric acid.\n  - **Hyperkalemia:** From the release of intracellular potassium.\n  - **Hyperphosphatemia:** From the release of intracellular phosphate.\n  - **Hypocalcemia:** Secondary to precipitation of calcium with the excess phosphate.",
        "* **Clinical Consequences:** The primary consequence is acute kidney injury (AKI) due to the precipitation of uric acid and calcium phosphate crystals in the renal tubules. Hyperkalemia can cause life-threatening cardiac arrhythmias.",
        "* **Management of Hyperuricemia:** The choice of agent depends on the clinical scenario.\n  - **Allopurinol:** A xanthine oxidase inhibitor that prevents the *formation* of new uric acid. It is used for prophylaxis in low- to intermediate-risk patients but does not affect pre-existing uric acid levels.\n  - **Rasburicase:** A recombinant urate oxidase enzyme that rapidly converts existing uric acid into the highly soluble compound allantoin. It is the treatment of choice for established TLS and for prophylaxis in high-risk patients.",
        "* **Vignette Analysis:** This patient has Burkitt lymphoma (high-risk) and presents with pre-existing, severe hyperuricemia (14.5 mg/dL) and AKI. This constitutes established TLS, making rasburicase the most appropriate and urgent therapy.",
        "* **General Management:** Key principles include aggressive intravenous hydration to promote diuresis, frequent monitoring of electrolytes and renal function, and management of other electrolyte abnormalities (e.g., hyperkalemia).",
        "* **Pitfalls:** Using NSAIDs (like ibuprofen) is contraindicated as they can worsen renal function. Allopurinol is inadequate for treating established, severe hyperuricemia."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "19",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "연명의료계획서"
      },
      "why": [
        "* **Topic:** This question concerns the legal documentation for end-of-life decisions under the Korean \"Act on Decisions on Life-Sustaining Treatment\".",
        "* **Clinical Scenario:** A 52-year-old man with terminal metastatic lung cancer is discussing his end-of-life wishes with his physician. Together, they are completing a formal document to record his decision to forgo life-sustaining treatment.",
        "* **Key Legal Documents in Korea:**\n  - **사전연명의료의향서 (Advance Directive on Life-Sustaining Treatment):** This is a document completed by any competent adult (age 19+) *in advance* of a terminal illness. It expresses general wishes and is registered with a national agency.\n  - **연명의료계획서 (Physician Orders for Life-Sustaining Treatment - POLST):** This document is created specifically for a patient who has *already been diagnosed* as being in a terminal or end-of-life stage. It is a result of a direct conversation between the patient (or their surrogate) and the physician, and it translates the patient's wishes into actionable medical orders. This perfectly matches the scenario described.",
        "* **Analysis of the Scenario:** The patient is currently in a terminal state, and the document is being created jointly by the patient and his attending physician. This process and the resulting document are specifically defined as the '연명의료계획서' (POLST).",
        "* **Distinguishing from Other Options:**\n  - An 'Advance Directive' would have been filled out before he was diagnosed as terminal.\n  - An 'Implementation Form' is used to document the *execution* of the decision, not the decision-making process itself.\n  - 'Advance Care Planning' is the broader conversation, while the POLST is the specific legal document that results from it in this context."
      ],
      "others": [
        {
          "label": "①",
          "text": "연명의료중단등 결정 이행서",
          "reason": "This is the 'Implementation Form,' which is filled out by medical staff when they actually carry out the act of withholding or withdrawing treatment. It is not the document where the patient's decision is initially recorded with the physician."
        },
        {
          "label": "②",
          "text": "연명의료중단등 결정에 대한 환자의사 확인서",
          "reason": "This 'Patient's Intention Confirmation Form' is used to document the wishes of a terminal patient who lacks a prior directive but can still communicate. While similar in purpose, the '연명의료계획서' (POLST) is the specific term for the comprehensive plan created collaboratively between physician and patient."
        },
        {
          "label": "③",
          "text": "사전연명의료의향서",
          "reason": "This is an 'Advance Directive' completed by a competent adult at any time, *before* they are in a terminal state. The scenario describes a document being created *after* the patient has been declared terminal."
        },
        {
          "label": "⑤",
          "text": "사전돌봄계획서",
          "reason": "This term, 'Advance Care Planning,' refers to the overall process of communication and discussion about future medical care. The '연명의료계획서' (POLST) is the specific, formal medical order document that is an outcome of this planning process for a terminally ill patient."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "연명의료계획서"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Legal Framework:** The Korean \"Act on Decisions on Life-Sustaining Treatment\" provides the legal basis for patients to document their end-of-life wishes.",
        "* **Advance Care Planning (ACP):** This is the broad process of communication between patients, families, and healthcare providers about future medical care and end-of-life preferences.",
        "* **Key Legal Documents:** The Act defines two primary documents for recording these wishes.",
        "* **1. 사전연명의료의향서 (Advance Directive):**\n  - **Who:** Any competent adult (age 19+) can complete this.\n  - **When:** Completed *in advance* of being diagnosed with a terminal illness.\n  - **What:** A general statement of intent to forgo life-sustaining treatment in the future.",
        "* **2. 연명의료계획서 (Physician Orders for Life-Sustaining Treatment - POLST):**\n  - **Who:** Created collaboratively by a physician and a patient.\n  - **When:** Completed *after* the patient has been diagnosed as being in a terminal or end-of-life stage.\n  - **What:** A specific set of actionable medical orders reflecting the patient's current wishes for their current condition.",
        "* **Vignette Analysis:** The scenario describes a patient with terminal cancer creating a document *with his physician* to outline his wishes. This process and the resulting document precisely match the definition of the 연명의료계획서 (POLST).",
        "* **Distinction is Key:** The crucial difference is the timing and context. An Advance Directive is for a future, hypothetical state of health. A POLST is for a current, diagnosed terminal condition and functions as a direct medical order.",
        "* **Scope of the Act:** The law applies to specific life-sustaining treatments (CPR, mechanical ventilation, dialysis, chemotherapy) and does not permit the withdrawal of basic care like nutrition, hydration, and pain management."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "20",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "60세"
      },
      "why": [
        "* **Topic:** The question asks to identify what is NOT a risk factor for psychological distress in cancer patients.",
        "* **Definition of Distress:** In oncology, distress is a multifactorial unpleasant emotional experience of a psychological, social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment.",
        "* **Known Risk Factors for Distress:** Numerous factors are associated with a higher risk of distress in cancer patients. These include:\n  - **Demographics:** Female gender and younger age are consistently identified as risk factors.\n  - **Psychiatric History:** A personal or family history of psychiatric disorders, such as depression, anxiety, or panic disorder, is a strong predictor of distress.\n  - **Disease and Treatment Factors:** Poorly controlled physical symptoms (especially pain), advanced disease stage, and functional impairment increase distress.\n  - **Timing in Cancer Trajectory:** Certain time points are particularly stressful, including diagnosis, recurrence, transition to palliative care, and the period immediately following the completion of active treatment.",
        "* **Analysis of Options:**\n  - **Female gender:** This is a well-established risk factor.\n  - **History of panic disorder:** A pre-existing psychiatric condition is a major risk factor.\n  - **Immediately after completion of treatment:** This is a known high-risk period due to fear of recurrence, loss of the medical 'safety net', and long-term side effects.\n  - **Uncontrolled pain:** This is a major physical contributor to psychological distress.",
        "* **Analysis of Age:** Contrary to what might be assumed, *younger* age at diagnosis is associated with higher levels of distress. Younger patients often face greater disruption to their lives (career, family, finances) and may have fewer coping mechanisms. Older age (e.g., 60 years or older) is often associated with better emotional regulation and is generally not considered a risk factor; in some studies, it is a protective factor against severe distress. Therefore, being 60 years old is the option that is not a risk factor."
      ],
      "others": [
        {
          "label": "②",
          "text": "여성",
          "reason": "This is a known risk factor. Studies consistently show that female cancer patients report higher levels of psychological distress compared to male patients."
        },
        {
          "label": "③",
          "text": "공황장애 기왕력",
          "reason": "This is a significant risk factor. A pre-existing history of any psychiatric illness, including panic disorder, strongly predisposes a patient to experiencing heightened distress during their cancer journey."
        },
        {
          "label": "④",
          "text": "치료 종료 직후",
          "reason": "This is a well-recognized high-risk period. Patients often experience increased anxiety about recurrence and feel a sense of abandonment as frequent contact with the oncology team decreases."
        },
        {
          "label": "⑤",
          "text": "조절되지 않는 통증 동반",
          "reason": "This is a major risk factor. Uncontrolled physical symptoms, particularly pain, are strongly correlated with high levels of psychological and emotional distress."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "60세"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Definition:** Distress in cancer patients is a significant emotional, psychological, social, or spiritual experience that can interfere with the ability to cope with the disease and its treatment.",
        "* **Screening:** Routine screening for distress is a standard of care in oncology, often using tools like the NCCN Distress Thermometer.",
        "* **Risk Factors for Distress:** Several factors are consistently associated with a higher risk of significant distress.",
        "* **Demographic and Social Factors:**\n  - **Age:** *Younger* age is a significant risk factor. Older age (e.g., >60) is often associated with better coping and is not considered a risk factor.\n  - **Gender:** Female gender is associated with higher reported distress.\n  - **Social Support:** Being single, divorced, or lacking a strong support system increases risk.",
        "* **Psychiatric History:** A personal or family history of any psychiatric disorder, such as depression, anxiety, or panic disorder, is one of the strongest predictors of distress during cancer treatment.",
        "* **Medical Factors:**\n  - **Symptom Burden:** Poorly controlled physical symptoms, especially pain and fatigue, are major contributors to distress.\n  - **Disease Status:** Advanced stage of disease, poor prognosis, and functional impairment increase risk.",
        "* **Timing in the Cancer Trajectory:** Certain periods are particularly high-risk for distress, including:\n  - The time of initial diagnosis.\n  - Disease recurrence or progression.\n  - The period immediately following the completion of active treatment (due to fear of recurrence and loss of frequent medical contact).",
        "* **Conclusion:** Among the options, being 60 years old is the only one that is not a risk factor for distress. All other options—female gender, history of panic disorder, the post-treatment period, and uncontrolled pain—are well-established risk factors."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "21",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "골절위험도 평가 (FRAX)"
      },
      "why": [
        "* **Diagnosis:** Osteopenia, based on Dual-energy X-ray Absorptiometry (DXA) results.",
        "* **Clinical Presentation:** A 59-year-old woman undergoing bone mineral density (BMD) testing. The stem does not provide clinical symptoms, focusing on the interpretation of the DXA scan for treatment decisions.",
        "* **Image Findings:** The provided DXA report shows T-scores consistent with osteopenia.\n  - **Lumbar Spine (L1-L4):** T-score = -2.4.\n  - **Left Femoral Neck:** T-score = -2.3.\n  - **Left Total Hip:** T-score = -2.2.\n  - **Right Femoral Neck:** T-score = -2.2.\n  - **Right Total Hip:** T-score = -1.9.",
        "* **Diagnostic Criteria / Thresholds:** According to WHO criteria:\n  - **Normal:** T-score ≥ -1.0.\n  - **Osteopenia:** T-score between -1.0 and -2.5.\n  - **Osteoporosis:** T-score ≤ -2.5.\n  - This patient's lowest T-score at a major site (lumbar spine) is -2.4, which falls into the osteopenia category.",
        "* **Treatment Principle / Guidelines:** For postmenopausal women with osteopenia, the decision to initiate pharmacologic therapy is not based on the T-score alone. It depends on the calculated future risk of fracture.",
        "* **Diagnostic Algorithm / Next step:** The Fracture Risk Assessment Tool (FRAX) is used for patients with osteopenia to estimate the 10-year probability of a major osteoporotic fracture (hip, clinical vertebral, humerus, or wrist) and the 10-year probability of a hip fracture.",
        "* **Treatment Thresholds:** In the United States, treatment is generally recommended for patients with osteopenia if the 10-year FRAX probability is:\n  - ≥ 20% for a major osteoporotic fracture, OR\n  - ≥ 3% for a hip fracture.",
        "* **Conclusion:** Since the patient has osteopenia, calculating her fracture risk with FRAX is the essential next step to determine if the risk is high enough to warrant starting medication."
      ],
      "others": [
        {
          "label": "①",
          "text": "혈중 C-telopeptide of type I collagen (CTX)",
          "reason": "This is a bone turnover marker. While it can be used to monitor treatment response, it is not the primary tool used to decide whether to initiate treatment for osteopenia."
        },
        {
          "label": "②",
          "text": "혈중 25-hydroxyvitamin D (25OHD)",
          "reason": "Measuring vitamin D levels is important before starting osteoporosis therapy to ensure sufficiency and correct any deficiency, but it does not determine the need for treatment itself. The fracture risk assessment is the key decision-making step."
        },
        {
          "label": "③",
          "text": "척추 정량 전산단층화촬영 (QCT)",
          "reason": "Quantitative CT is another method to measure bone density, but DXA is the gold standard. Performing a QCT after a definitive DXA scan is redundant and not the standard next step in the diagnostic or treatment algorithm."
        },
        {
          "label": "⑤",
          "text": "골 스캔(bone scan)",
          "reason": "A bone scan (scintigraphy) is used to detect areas of increased bone turnover, such as in fractures, metastatic disease, or infection. It is not used to assess bone density or decide on treatment for osteopenia."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "골절위험도 평가 (FRAX)"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Osteoporosis is a silent disease until a fracture occurs. Risk factors include advanced age, female sex, postmenopausal status, low body weight, smoking, and certain medications (e.g., glucocorticoids).",
        "* **Workup:** Dual-energy X-ray absorptiometry (DXA) is the gold standard for measuring bone mineral density (BMD) and diagnosing osteoporosis.",
        "* **Criteria/Thresholds:** The World Health Organization (WHO) defines bone density based on T-scores:\n  - **Normal:** T-score ≥ -1.0\n  - **Osteopenia (low bone mass):** T-score between -1.0 and -2.5\n  - **Osteoporosis:** T-score ≤ -2.5",
        "* **Diagnostic Sites:** The diagnosis is based on the lowest T-score from one of three sites: the lumbar spine (L1-L4 average), the total hip, or the femoral neck.",
        "* **Management (Osteopenia):** For patients with osteopenia, the decision to treat is based on fracture risk, not the T-score alone. The Fracture Risk Assessment Tool (FRAX) is used for this purpose.",
        "* **FRAX Tool:** FRAX calculates the 10-year probability of a major osteoporotic fracture (hip, spine, humerus, wrist) and a hip fracture. It incorporates BMD and clinical risk factors.",
        "* **Treatment Thresholds (FRAX):** In the U.S., pharmacologic therapy is recommended for patients with osteopenia if the 10-year FRAX risk is:\n  - ≥ 20% for a major osteoporotic fracture, OR\n  - ≥ 3% for a hip fracture.",
        "* **Initial Management (All):** All patients with low bone mass should be counseled on lifestyle modifications, including adequate calcium and vitamin D intake, weight-bearing exercise, and smoking cessation.",
        "* **Differential/Discriminators:** A fragility fracture (e.g., from a fall from standing height) establishes a clinical diagnosis of osteoporosis, regardless of the T-score, and is an indication for treatment.",
        "* **Monitoring/Follow-up:** Bone turnover markers (e.g., CTX) are not used for initial diagnosis but can be helpful to monitor the response to antiresorptive therapy.",
        "* **Workup (Pre-treatment):** Measuring serum 25-hydroxyvitamin D is important to ensure sufficiency before starting osteoporosis medications, but it does not determine the need for treatment.",
        "* **Pitfalls (general):**\n  - Initiating drug therapy for all patients with osteopenia without first assessing fracture risk using FRAX.\n  - Using non-standard sites like the Ward's triangle from a DXA report for diagnosis."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "22",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "Pulsatile GnRH infusion pump를 적용한다."
      },
      "why": [
        "* **Diagnosis:** Secondary hypogonadism (hypogonadotropic hypogonadism) and infertility, secondary to pituitary adenoma resection.",
        "* **Pathophysiology:** The patient's pituitary gland is unable to produce LH and FSH due to surgical removal of an adenoma. This leads to insufficient stimulation of the testes, resulting in low testosterone production and impaired spermatogenesis. Exogenous testosterone replacement further suppresses any residual pituitary function and directly inhibits spermatogenesis at the testicular level.",
        "* **Clinical Presentation:** A 29-year-old man with a history of pituitary surgery on multiple hormone replacements (glucocorticoids, thyroid hormone, testosterone) who desires fertility. Testicular volume is reduced (12 cc; normal is >15 cc).",
        "* **Lab Findings:**\n  - **LH:** < 0.1 mIU/mL (Normal: 1-10) → Markedly suppressed, consistent with pituitary failure and exogenous testosterone use.\n  - **FSH:** < 0.2 mIU/mL (Normal: 1-9) → Markedly suppressed, consistent with pituitary failure and exogenous testosterone use.\n  - **Testosterone:** 120 ng/dL (Normal: 300-1,000) → Low, indicating inadequate replacement or timing of measurement, but the key issue for fertility is the lack of gonadotropins.",
        "* **Treatment Principle for Fertility:** The goal is to stimulate spermatogenesis. This requires stopping suppressive exogenous testosterone and providing gonadotropin stimulation directly to the testes.",
        "* **Management Sequence:**\n  1. **Stop exogenous testosterone:** This is the essential first step to remove the inhibitory feedback.\n  2. **Initiate hCG therapy:** Human chorionic gonadotropin (hCG) mimics LH, stimulating Leydig cells to produce intratesticular testosterone, which is crucial for spermatogenesis.\n  3. **Add FSH/hMG:** If semen analysis shows persistent azoospermia after 3-6 months of hCG therapy, recombinant FSH or human menopausal gonadotropin (hMG, contains FSH and LH) is added to stimulate Sertoli cells and promote sperm maturation.",
        "* **Rationale for Incorrect Option:** Pulsatile GnRH therapy works by stimulating a functional pituitary gland to release its own LH and FSH. In this patient, the pituitary is non-functional due to surgery, as evidenced by his need for multiple hormone replacements and undetectable gonadotropins. Therefore, GnRH would have no effect.",
        "* **Semen Analysis:** Performing a semen analysis at the beginning is a reasonable step to establish a baseline, though azoospermia is highly expected given the history."
      ],
      "others": [
        {
          "label": "①",
          "text": "정자생성여부를 확인하기 위해 정액검사를 우선 시행한다.",
          "reason": "This is a correct and logical step. A baseline semen analysis is performed to confirm the expected azoospermia or severe oligospermia before starting treatment."
        },
        {
          "label": "②",
          "text": "테스토스테론 제제 복용을 먼저 중단하다.",
          "reason": "This is a correct and essential step. Exogenous testosterone suppresses spermatogenesis and must be discontinued to allow gonadotropin therapy to be effective."
        },
        {
          "label": "③",
          "text": "LH역할을 하는hCG를 투여한다.",
          "reason": "This is a correct step in the treatment process. After stopping testosterone, hCG is used to mimic LH and stimulate endogenous testosterone production within the testes."
        },
        {
          "label": "⑤",
          "text": "hCG투여 후에도 무정자증이 지속되면FSH를 추가로투여한다.",
          "reason": "This is a correct subsequent step. If hCG alone is insufficient to restore spermatogenesis, adding FSH is the standard next step to stimulate the Sertoli cells."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "Pulsatile GnRH infusion pump를 적용한다."
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Secondary (hypogonadotropic) hypogonadism is characterized by low testosterone with inappropriately low or normal levels of gonadotropins (LH and FSH). This indicates a problem at the pituitary or hypothalamus.",
        "* **Pathophysiology:** In this patient, pituitary surgery has caused panhypopituitarism, leading to a lack of LH and FSH production and subsequent testicular failure.",
        "* **Workup:** Diagnosis requires measurement of morning total testosterone, LH, and FSH. If secondary hypogonadism is confirmed, further workup includes prolactin levels and pituitary MRI.",
        "* **Management (Testosterone Replacement):** For men not seeking fertility, testosterone replacement therapy is the standard of care to restore normal androgen levels and prevent symptoms of hypogonadism.",
        "* **Management (Fertility):** The goal is to stimulate spermatogenesis within the testes. Exogenous testosterone must be stopped as it suppresses intratesticular testosterone production and spermatogenesis via negative feedback on the HPG axis.",
        "* **Treatment (Algorithmic for Fertility):**\n  1. **Stop exogenous testosterone.**\n  2. **Initiate hCG (human chorionic gonadotropin) injections.** hCG mimics LH, stimulating Leydig cells to produce high levels of intratesticular testosterone.\n  3. **Add hMG or recombinant FSH.** If semen analysis shows persistent azoospermia after 3-6 months of hCG alone, human menopausal gonadotropin (hMG) or recombinant FSH is added to stimulate Sertoli cells and promote sperm maturation.",
        "* **Monitoring/Follow-up:** Semen analysis is performed at baseline and every 3-6 months to monitor the response to gonadotropin therapy.",
        "* **Differential/Discriminators:** Pulsatile GnRH therapy is used to induce puberty or fertility in patients with hypothalamic dysfunction but a *functional* pituitary gland. It is ineffective in patients with pituitary failure.",
        "* **Pitfalls (general):**\n  - Attempting to induce fertility while a patient remains on exogenous testosterone.\n  - Prescribing pulsatile GnRH for a patient with known pituitary destruction or removal."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "23",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "성인의 경우 일차성 뇌종양보다는 다른 장기의carcino ma가 전이된 이차성 종양이 더 흔하다."
      },
      "why": [
        "* **Diagnosis:** This question assesses fundamental knowledge of neuro-oncology epidemiology and molecular pathology.",
        "* **Key Concept (Epidemiology):** In the adult population, metastatic brain tumors (secondary tumors) are far more common than primary brain tumors. The most common sources of brain metastases are lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer.",
        "* **Key Concept (Molecular Pathology):** The 2021 WHO Classification of CNS Tumors integrates molecular markers with histology for diagnosis and grading, which has significant prognostic implications.",
        "* **IDH Mutation in Gliomas:** The presence of an isocitrate dehydrogenase (IDH) gene mutation is a strong positive prognostic factor in diffuse gliomas. IDH-mutant gliomas have a significantly better prognosis than IDH-wildtype gliomas of the same histological grade.",
        "* **Oligodendroglioma Definition:** The diagnosis of oligodendroglioma requires the presence of *both* an IDH mutation and co-deletion of chromosome arms 1p and 19q. IDH-wildtype tumors are not classified as oligodendrogliomas.",
        "* **Metastasis of Gliomas:** Primary CNS tumors, including high-grade gliomas like glioblastoma, very rarely metastasize outside the central nervous system. The vast majority of tumor progression and recurrence occurs within the brain.",
        "* **Pilocytic Astrocytoma:** This is a WHO Grade 1 tumor and is the most common primary brain tumor in children. It is typically located in the cerebellum and has a very good prognosis after surgical resection.",
        "* **Conclusion:** The only correct statement is that brain metastases are more common than primary brain tumors in adults."
      ],
      "others": [
        {
          "label": "①",
          "text": "성인 신경교종(glioma)에서IDH 유전자의 변이가 있는 경우가IDH 유전자의 변이가 없는 경우 보다 예후가 좋지 않다.",
          "reason": "This is incorrect. The presence of an IDH mutation is a favorable prognostic marker in adult gliomas, associated with a better prognosis compared to IDH-wildtype tumors."
        },
        {
          "label": "②",
          "text": "Oligodendroglioma는 대부분이 IDH-willtype이며 1p 19q co-deletion이 중요한 진단적 기준이 된다.",
          "reason": "This is incorrect. By definition, oligodendrogliomas must be IDH-mutant and have the 1p/19q co-deletion. IDH-wildtype tumors cannot be oligodendrogliomas."
        },
        {
          "label": "③",
          "text": "등급이 높은 악성 신경교종은 폐, 간 등 다른 장기로 전이되는 일이 흔하다.",
          "reason": "This is incorrect. Extracranial metastasis from high-grade gliomas is an extremely rare event."
        },
        {
          "label": "⑤",
          "text": "Pilocytic astrocytoma는 소아보다는 주로 성인에서 호발한다.",
          "reason": "This is incorrect. Pilocytic astrocytoma is the most common primary brain tumor in the pediatric population, not adults."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "성인의 경우 일차성 뇌종양보다는 다른 장기의carcino ma가 전이된 이차성 종양이 더 흔하다."
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Brain tumors present with symptoms related to their location and mass effect, such as headache, seizures, focal neurologic deficits, or cognitive changes.",
        "* **Epidemiology (Adults):** Metastatic (secondary) brain tumors are approximately 10 times more common than primary brain tumors in adults. The most frequent primary sources are lung, breast, melanoma, renal, and colorectal cancers.",
        "* **Epidemiology (Children):** In contrast to adults, primary brain tumors are more common than metastases in children. Pilocytic astrocytoma (WHO Grade 1) is the most common primary brain tumor in the pediatric population.",
        "* **Molecular Pathology (Gliomas):** The 2021 WHO classification of CNS tumors integrates molecular markers with histology. Isocitrate dehydrogenase (IDH) mutation status is a critical diagnostic and prognostic marker in diffuse gliomas.",
        "* **Prognosis (IDH):** The presence of an IDH mutation confers a significantly better prognosis in gliomas compared to IDH-wildtype tumors of the same histologic grade.",
        "* **Criteria/Thresholds (Oligodendroglioma):** The definitive diagnosis of oligodendroglioma requires the presence of *both* an IDH mutation and co-deletion of chromosome arms 1p and 19q. Tumors that are IDH-wildtype cannot be classified as oligodendrogliomas.",
        "* **Tumor Behavior:** High-grade primary CNS tumors, such as glioblastoma, very rarely metastasize outside of the central nervous system. Recurrence is almost always intracranial.",
        "* **Pitfalls (general):**\n  - Assuming a solitary brain mass in an adult is more likely to be primary than metastatic.\n  - Diagnosing oligodendroglioma without confirming both IDH mutation and 1p/19q co-deletion."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "24",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "도파민성 신경세포내의 a-synuclein 침착이 특징적인 소견이다."
      },
      "why": [
        "* **Diagnosis:** Parkinson's disease.",
        "* **Clinical Presentation:** The patient is a 65-year-old male with classic parkinsonian motor symptoms: rigidity, stooped posture, and slowness of voluntary movement (bradykinesia).",
        "* **Image Findings:** The image displays a gross pathology specimen of the midbrain. \n  - **Normal (left):** Shows the darkly pigmented substantia nigra, colored by neuromelanin in dopaminergic neurons.\n  - **Patient (right):** Shows marked pallor (depigmentation) of the substantia nigra, indicating a significant loss of these neuromelanin-containing dopaminergic neurons.",
        "* **Pathophysiology:** Parkinson's disease is a neurodegenerative disorder primarily characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. This leads to a dopamine deficiency in the basal ganglia, causing the characteristic motor symptoms.",
        "* **Microscopic Findings:** The pathological hallmark of Parkinson's disease is the presence of Lewy bodies, which are abnormal eosinophilic, round, intracytoplasmic inclusions within the remaining neurons. The primary protein component of Lewy bodies is aggregated alpha-synuclein (α-synuclein).",
        "* **Differential / Discriminators:** Other neurodegenerative diseases have different protein aggregates.\n  - **Tauopathies:** (e.g., Alzheimer's, PSP, CBD) are characterized by inclusions of hyperphosphorylated tau protein.\n  - **Acute injury:** (e.g., stroke) would show 'red neurons' (eosinophilic neurons with pyknotic nuclei), not chronic degenerative changes.",
        "* **Cellular Response to Injury:** In chronic neurodegeneration, there is reactive gliosis (proliferation of astrocytes and microglia), not a decrease in astrocytes or neuronal division. Neurons are post-mitotic and cannot divide.",
        "* **Conclusion:** The combination of parkinsonian symptoms, gross depigmentation of the substantia nigra, and the underlying pathology of dopaminergic neuron loss points to alpha-synuclein deposition as the characteristic microscopic finding."
      ],
      "others": [
        {
          "label": "①",
          "text": "신경세포(neuron)에 봉합체(inclusion)로 보이는 타우(t au) 단백질의 침착이 특징적이다.",
          "reason": "This describes the pathology of tauopathies like Alzheimer's disease or progressive supranuclear palsy, not Parkinson's disease, which is a synucleinopathy."
        },
        {
          "label": "②",
          "text": "Red neuron이 관찰된다.",
          "reason": "Red neurons are a marker of acute neuronal injury (e.g., ischemia/hypoxia) and are not a feature of a chronic neurodegenerative process like Parkinson's disease."
        },
        {
          "label": "③",
          "text": "별아교세포(Astrocyte) 수의 감소가 관찰된다.",
          "reason": "This is incorrect. Neurodegeneration leads to reactive astrogliosis, which is an increase, not a decrease, in the number and size of astrocytes."
        },
        {
          "label": "⑤",
          "text": "신경세포의 반응성(reactive) 분열 및 증가가 관찰된다.",
          "reason": "This is incorrect. Neurons are post-mitotic cells and do not undergo division or proliferation in response to injury."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "도파민성 신경세포내의 a-synuclein 침착이 특징적인 소견이다."
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Parkinson's disease is a progressive neurodegenerative disorder defined by cardinal motor features: resting tremor, bradykinesia (slowness of movement), rigidity, and postural instability.",
        "* **Pathophysiology (Gross):** The core pathology is the selective loss of dopaminergic neurons in the substantia nigra pars compacta. This leads to a visible loss of pigment (pallor) in this midbrain structure on gross examination.",
        "* **Pathophysiology (Microscopic):** The pathognomonic microscopic finding is the Lewy body, an eosinophilic, round, intracytoplasmic inclusion found within the remaining dopaminergic neurons.",
        "* **Biochemistry:** Lewy bodies are composed primarily of aggregated alpha-synuclein protein. Therefore, Parkinson's disease is classified as a synucleinopathy.",
        "* **Differential/Discriminators (Proteinopathies):** It is crucial to distinguish between different neurodegenerative protein aggregates:\n  - **Synucleinopathies:** Parkinson's disease, Dementia with Lewy Bodies, Multiple System Atrophy.\n  - **Tauopathies:** Alzheimer's disease, Progressive Supranuclear Palsy, Corticobasal Degeneration (characterized by neurofibrillary tangles of hyperphosphorylated tau protein).",
        "* **Cellular Response:** Chronic neurodegeneration triggers reactive gliosis, which is a proliferation and hypertrophy of glial cells like astrocytes and microglia, not a decrease in their number.",
        "* **Acute vs. Chronic Injury:** 'Red neurons' are a histological marker of acute, irreversible neuronal injury (e.g., from hypoxia or ischemia) and are not a feature of a chronic degenerative process like Parkinson's disease.",
        "* **Pitfalls (general):** Neurons are post-mitotic cells and do not undergo division or proliferation in response to injury. Confusing the hallmark protein inclusions of different neurodegenerative diseases is a common error."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "25",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "목을 가누고 직립하게 되면서2차만곡이 생긴다."
      },
      "why": [
        "* **Topic:** Normal development of the human vertebral column.",
        "* **Spinal Curvatures:** The adult spine has four curvatures in the sagittal plane that help with shock absorption, balance, and movement.",
        "* **Primary Curvatures:** The thoracic and sacral curvatures are primary curvatures. They are kyphotic (curved backward) and are present in the fetus, giving the fetal spine a C-shape. These curves accommodate the thoracic and pelvic organs.",
        "* **Secondary Curvatures:** The cervical and lumbar curvatures are secondary curvatures. They are lordotic (curved forward) and develop after birth in response to new postural and gravitational forces.",
        "* **Development of Cervical Lordosis:** This curve develops when an infant begins to lift and control their head (around 3-4 months). The posterior cervical muscles contract to hold the head erect, creating the forward curve.",
        "* **Development of Lumbar Lordosis:** This curve develops when a child learns to sit, stand, and walk (around 9-12 months). It is necessary to shift the center of gravity over the legs for upright posture and bipedal locomotion.",
        "* **Conclusion:** The statement that secondary curvatures develop as an infant learns to hold up the head and stand upright is a correct and fundamental concept of spinal development."
      ],
      "others": [
        {
          "label": "①",
          "text": "요추에는 갈비대가 붙게된다.",
          "reason": "This is incorrect. Ribs articulate exclusively with the thoracic vertebrae, not the lumbar vertebrae."
        },
        {
          "label": "③",
          "text": "엄마 뱃속 태아도 성인척추와 같은 만곡을 보인다.",
          "reason": "This is incorrect. The fetal spine has a single, C-shaped primary kyphotic curve, unlike the S-shaped curve with four curvatures seen in adults."
        },
        {
          "label": "④",
          "text": "척추는 분절운동을 할 수 없는 구조다.",
          "reason": "This is incorrect. The spine is a highly mobile structure composed of multiple segments (vertebrae and discs) that allow for a wide range of motion."
        },
        {
          "label": "⑤",
          "text": "추체간 디스크연골은 닳지 않는 특성을 보인다.",
          "reason": "This is incorrect. Intervertebral discs are subject to age-related degenerative changes ('wear and tear'), which can lead to conditions like degenerative disc disease and disc herniation."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "목을 가누고 직립하게 되면서2차만곡이 생긴다."
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** The adult human spine has four distinct curvatures in the sagittal plane that provide balance, flexibility, and shock absorption.",
        "* **Primary Curvatures:** The thoracic and sacral curves are primary curvatures. They are kyphotic (curved posteriorly) and are present in the fetus, giving the spine an overall C-shape.",
        "* **Secondary Curvatures:** The cervical and lumbar curves are secondary curvatures. They are lordotic (curved anteriorly) and develop after birth in response to motor development and gravitational forces.",
        "* **Development (Cervical Lordosis):** The cervical curve develops at approximately 3-4 months of age as an infant begins to lift and control the head.",
        "* **Development (Lumbar Lordosis):** The lumbar curve develops at approximately 9-12 months of age as a child learns to sit, stand, and walk, which is necessary for maintaining an upright posture.",
        "* **Anatomy:** Ribs articulate exclusively with the thoracic vertebrae at the costovertebral and costotransverse joints; they do not attach to lumbar vertebrae.",
        "* **Function:** The spine is a segmented column of vertebrae and intervertebral discs that allows for a wide range of segmental motion (flexion, extension, rotation).",
        "* **Pathophysiology:** Intervertebral discs are subject to age-related degenerative changes ('wear and tear'), which can lead to loss of height, disc herniation, and pain.",
        "* **Pitfalls (general):** Assuming the adult S-shaped spinal curve is present at birth; the fetal spine has a single C-shaped kyphotic curve."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "26",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "소염진통제 복용과 안정가료"
      },
      "why": [
        "* **Diagnosis:** Acute lumbar disc herniation with radiculopathy.",
        "* **Clinical Presentation:** A 31-year-old woman with a 2-week history of low back pain and a 1-week history of radiating leg pain (sciatica). Crucially, her neurological examination is normal, indicating no significant motor weakness, sensory loss, or bowel/bladder dysfunction.",
        "* **Image Findings:** The sagittal T2-weighted lumbar MRI clearly shows a large, posterocentral disc herniation at the L5-S1 level. The herniated material is compressing the thecal sac and likely the descending S1 nerve roots.",
        "* **Treatment Principle / Guidelines:** For acute lumbar radiculopathy without 'red flag' signs (e.g., cauda equina syndrome, progressive major neurologic deficit), the initial treatment is always conservative.",
        "* **Management (First-Line):** Conservative management is effective in over 90% of patients. It consists of:\n  - **Activity Modification:** Avoiding activities that worsen pain (e.g., heavy lifting, prolonged sitting) but encouraging gentle movement and staying active as tolerated. Strict bed rest is not recommended.\n  - **Pharmacotherapy:** Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line medication to reduce inflammation and pain.\n  - **Physical Therapy:** Can be initiated to improve core strength, flexibility, and posture.",
        "* **Indications for Surgery:** Surgical intervention (e.g., discectomy) is reserved for specific situations:\n  - Cauda equina syndrome (a surgical emergency).\n  - Progressive or severe neurologic deficit.\n  - Intractable, disabling pain that has failed an adequate trial (typically at least 6 weeks) of comprehensive conservative therapy.",
        "* **Conclusion:** Given the patient's acute symptoms and normal neurological exam, the most appropriate initial treatment is conservative, consisting of NSAIDs and relative rest/activity modification."
      ],
      "others": [
        {
          "label": "①",
          "text": "강도 높은 요추 운동",
          "reason": "High-intensity exercises are contraindicated in the acute phase of a disc herniation as they can increase intradiscal pressure and worsen nerve root compression and pain."
        },
        {
          "label": "③",
          "text": "마약성진통제",
          "reason": "Opioids are not a first-line treatment for this condition. They should be reserved for short-term use in cases of severe pain that is unresponsive to NSAIDs and other conservative measures."
        },
        {
          "label": "④",
          "text": "추간판제거술",
          "reason": "Surgical discectomy is not indicated at this stage. The patient has no neurological deficits and has not yet undergone a trial of conservative therapy, which is the standard first-line approach."
        },
        {
          "label": "⑤",
          "text": "요추 고정유합술",
          "reason": "Lumbar fusion is a major surgery indicated for spinal instability, severe degenerative disease, or deformity. It is not an appropriate treatment for a simple, acute disc herniation."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "소염진통제 복용과 안정가료"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Acute lumbar disc herniation typically presents with low back pain followed by radiating neuropathic pain (radiculopathy or sciatica) into the buttock and leg in a specific dermatomal distribution.",
        "* **Workup:** MRI of the lumbar spine is the imaging modality of choice to visualize the disc herniation, nerve root compression, and other soft tissue structures.",
        "* **Management (First-Line):** For patients with acute radiculopathy and no 'red flag' signs, the initial treatment is conservative management for at least 6 weeks, as over 90% of cases resolve without surgery.",
        "* **Conservative Treatment:** This includes:\n  - **Activity Modification:** Avoiding aggravating activities while staying as active as tolerated. Strict bed rest is not recommended.\n  - **Pharmacotherapy:** Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line medication.\n  - **Physical Therapy:** Focuses on core strengthening, flexibility, and proper body mechanics.",
        "* **Red Flag Signs:** These warrant urgent evaluation and possible surgical consultation:\n  - **Cauda equina syndrome:** Bowel/bladder incontinence, saddle anesthesia, bilateral leg weakness.\n  - **Progressive or severe motor deficit.**\n  - **Suspected spinal infection or tumor.**",
        "* **Indications for Surgery:** Surgical discectomy is indicated for patients with red flag signs or those with persistent, disabling pain that has failed an adequate trial of comprehensive conservative therapy.",
        "* **Treatment (Second-Line):** Epidural steroid injections may be considered for short-term pain relief if conservative measures fail, but they do not alter the natural history.",
        "* **Pitfalls (general):**\n  - Recommending immediate surgery for an acute disc herniation without neurological deficits.\n  - Prescribing high-intensity exercise or prolonged bed rest in the acute phase."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "27",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "Buprenorphine"
      },
      "why": [
        "* **Diagnosis:** Opioid Use Disorder (OUD) with acute opioid withdrawal.",
        "* **Clinical Presentation:** A 35-year-old man with a history of chronic morphine use presents with classic opioid withdrawal symptoms: insomnia, anxiety, diaphoresis (sweating), and myalgias (muscle aches). He is seeking treatment for dependence.",
        "* **Treatment Principle:** The standard of care for managing moderate to severe opioid withdrawal and for long-term treatment of OUD is Medication-Assisted Treatment (MAT). The goal is to alleviate withdrawal symptoms, reduce cravings, and prevent relapse.",
        "* **Pharmacotherapy Options for OUD:**\n  - **Buprenorphine:** A partial mu-opioid agonist. It binds strongly to opioid receptors, reducing withdrawal symptoms and cravings without causing significant euphoria. Its partial agonism provides a ceiling effect on respiratory depression, making it safer than full agonists.\n  - **Methadone:** A long-acting full mu-opioid agonist. It is very effective but has a higher risk of overdose and requires administration in a highly regulated clinic setting.\n  - **Naltrexone:** A long-acting opioid antagonist. It blocks the effects of opioids and is used for relapse prevention. It must *not* be given to a patient currently using opioids or in withdrawal, as it will precipitate a severe, acute withdrawal syndrome.",
        "* **Management of Acute Withdrawal:** Buprenorphine is a first-line agent for managing acute withdrawal. It is typically initiated when the patient is in mild-to-moderate withdrawal (to avoid precipitating withdrawal).",
        "* **Conclusion:** For a patient actively experiencing opioid withdrawal symptoms, buprenorphine is an appropriate and standard first-line medication to alleviate symptoms and initiate maintenance therapy."
      ],
      "others": [
        {
          "label": "②",
          "text": "Cocaine",
          "reason": "Cocaine is a stimulant and a drug of abuse. It has no therapeutic role in the treatment of opioid withdrawal or OUD."
        },
        {
          "label": "③",
          "text": "Naltrexone",
          "reason": "This is contraindicated in this patient. Naltrexone is an opioid antagonist that would block opioid receptors and precipitate a severe and dangerous withdrawal syndrome in a patient who is currently opioid-dependent and experiencing withdrawal."
        },
        {
          "label": "④",
          "text": "Cannabidiol",
          "reason": "Cannabidiol (CBD) is not an approved or evidence-based primary treatment for opioid withdrawal. While it may have some adjunctive symptomatic benefits, it is not a substitute for standard MAT."
        },
        {
          "label": "⑤",
          "text": "Fentanyl",
          "reason": "Fentanyl is a potent synthetic opioid and a common drug of abuse. Prescribing it would be inappropriate and would perpetuate the patient's opioid dependence."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": true,
        "first_guess": {
          "label": "①",
          "text": "Buprenorphine"
        },
        "provided_key": {
          "label": "3",
          "text": "Naltrexone"
        },
        "final_decision": "override_key",
        "note": "The provided key, Naltrexone, is incorrect and dangerous for a patient in active opioid withdrawal as it would precipitate a severe withdrawal syndrome. Buprenorphine is the standard of care for managing withdrawal and initiating maintenance therapy.",
        "override_key": true
      },
      "teaching_points": [
        "* **Clinical picture:** Opioid withdrawal syndrome is characterized by symptoms such as anxiety, insomnia, myalgias, diaphoresis, rhinorrhea, lacrimation, piloerection, nausea, vomiting, and diarrhea.",
        "* **Management Principle:** Medication-Assisted Treatment (MAT) is the standard of care for Opioid Use Disorder (OUD), both for managing acute withdrawal and for long-term maintenance.",
        "* **Pharmacotherapy Options (MAT):** The three primary medications are buprenorphine, methadone, and naltrexone.",
        "* **Buprenorphine:** A partial mu-opioid agonist. It effectively reduces withdrawal symptoms and cravings while having a ceiling effect on respiratory depression, making it safer than full agonists. It can be prescribed in an office-based setting.",
        "* **Methadone:** A long-acting full mu-opioid agonist. It is highly effective for withdrawal and maintenance but carries a higher risk of overdose and must be dispensed through a federally regulated opioid treatment program.",
        "* **Naltrexone:** A long-acting opioid antagonist. It blocks the effects of opioids and is used for relapse prevention in highly motivated patients. It must only be started after a patient is fully detoxified.",
        "* **Management (Acute Withdrawal):** Buprenorphine is a first-line agent. It should be initiated only when the patient is in mild-to-moderate withdrawal, as administering it too early can precipitate a withdrawal syndrome.",
        "* **Pitfalls (general):** Administering an opioid antagonist like naltrexone to a patient who is currently physically dependent on opioids will precipitate a severe and dangerous acute withdrawal syndrome. This is a critical contraindication."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "28",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "정중신경감각유발전위검사(Median nerve sensory e voked potential)"
      },
      "why": [
        "* **Diagnosis:** Coma and anoxic-ischemic brain injury following cardiac arrest (specifically, pulseless electrical activity - PEA).",
        "* **Clinical Presentation:** A 48-year-old man who is comatose after resuscitation from cardiac arrest. His neurological exam shows absent brainstem reflexes (pupillary, corneal, cough, vestibulo-ocular), indicating severe brain injury. He is undergoing targeted temperature management (TTM).",
        "* **Clinical Question:** The question asks for a test that is helpful for prognostication on day 3.",
        "* **Prognostication in Anoxic Brain Injury:** Guidelines recommend a multimodal approach to predict neurological outcome in comatose survivors of cardiac arrest, usually performed after rewarming from TTM (≥72 hours post-arrest). This avoids the confounding effects of sedation and hypothermia.",
        "* **Role of Evoked Potentials:** Somatosensory Evoked Potentials (SSEPs) are a key component of this multimodal assessment. They test the integrity of the entire sensory pathway from the peripheral nerve to the cerebral cortex.",
        "* **Median Nerve SSEP:** This test involves stimulating the median nerve at the wrist and recording the electrical responses over the brachial plexus, cervical spine, brainstem, and contralateral sensory cortex.",
        "* **Prognostic Value:** The critical waveform is the N20 response, which is generated by the primary somatosensory cortex. The bilateral absence of the N20 cortical potential is an extremely strong and highly specific predictor of a poor neurological outcome (i.e., death or persistent vegetative state). It has a very low false-positive rate for predicting a poor outcome.",
        "* **Conclusion:** Among the options, median nerve SSEP is the most robust and widely recommended electrophysiological test for prognostication in this clinical scenario."
      ],
      "others": [
        {
          "label": "①",
          "text": "신경전도검사 (Nerve conduction study)",
          "reason": "Nerve conduction studies assess the function of peripheral nerves. They provide no information about the brain and are therefore not useful for prognostication of anoxic brain injury."
        },
        {
          "label": "②",
          "text": "시유발전위검사 (Visual evoked potential)",
          "reason": "Visual evoked potentials (VEPs) assess the visual pathway. While they can be abnormal after anoxic injury, they are less standardized and not as reliable or specific for prognostication as SSEPs."
        },
        {
          "label": "③",
          "text": "뇌간청각유발전위검사(Braistem auditory evoked p otential)",
          "reason": "Brainstem auditory evoked potentials (BAEPs) assess the integrity of the auditory pathway through the brainstem. While they can help confirm brainstem death, they are not as useful for predicting overall poor outcomes like a vegetative state, as brainstem function can be preserved despite severe cortical damage."
        },
        {
          "label": "⑤",
          "text": "후경골신경감각유발전위검사 (Posterior tibial nerve s ensory evoked potential)",
          "reason": "While SSEPs can be performed on lower extremity nerves, the median nerve SSEP is the standard, most studied, and most validated evoked potential test for prognostication after cardiac arrest."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "정중신경감각유발전위검사(Median nerve sensory e voked potential)"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Coma following cardiac arrest is a common and severe form of anoxic-ischemic brain injury, with a high mortality and morbidity rate.",
        "* **Management:** Patients are often treated with targeted temperature management (TTM) to improve neurologic outcomes. Sedatives and paralytics are used during TTM, confounding the neurologic exam.",
        "* **Prognostication Principle:** A multimodal approach is essential for accurate prognostication. Neurological assessment should be performed at least 72 hours after the cardiac arrest and after the patient has been rewarmed to a normal temperature and is free from sedative effects.",
        "* **Prognostic Tools:** Key components of the multimodal assessment include the clinical neurological exam, electroencephalography (EEG), somatosensory evoked potentials (SSEP), brain imaging (CT/MRI), and serum biomarkers (e.g., neuron-specific enolase).",
        "* **Somatosensory Evoked Potentials (SSEP):** This test assesses the integrity of the entire somatosensory pathway from the peripheral nerve to the cerebral cortex.",
        "* **Median Nerve SSEP:** The standard SSEP test for this purpose involves stimulating the median nerve at the wrist and recording the N20 cortical response over the contralateral sensory cortex.",
        "* **Criteria/Thresholds:** The bilateral absence of the N20 cortical potential is an extremely strong and highly specific predictor of a poor neurological outcome (death or persistent vegetative state), with a very low false-positive rate.",
        "* **Differential/Discriminators:** Other electrophysiological tests are less useful for this specific prognostic question. Nerve conduction studies (NCS) test peripheral nerves. Brainstem auditory evoked potentials (BAEPs) test the brainstem but not the cortex. Visual evoked potentials (VEPs) are less reliable.",
        "* **Pitfalls (general):**\n  - Making a definitive prognostic determination based on a single modality.\n  - Performing a prognostic assessment too early (e.g., within the first 24-72 hours) or while the patient is still hypothermic or sedated."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "29",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "비유발성 발작이 반복되는 질환을 뇌전증이라고 정의한다."
      },
      "why": [
        "* **Topic:** Definition and diagnosis of epilepsy.",
        "* **Definition of Epilepsy:** Epilepsy is a disease of the brain characterized by an enduring predisposition to generate epileptic seizures. The core concept is the recurrence of *unprovoked* seizures.",
        "* **ILAE Operational Definition (2014):** Epilepsy is considered to be present under any of the following conditions:\n  1. At least two unprovoked (or reflex) seizures occurring more than 24 hours apart.\n  2. One unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures (at least 60%) over the next 10 years.\n  3. Diagnosis of an epilepsy syndrome.",
        "* **Unprovoked vs. Provoked Seizures:** Unprovoked seizures occur without a clear proximate cause. Provoked (or acute symptomatic) seizures are caused by a transient factor, such as high fever, metabolic disturbance (e.g., hypoglycemia), or acute head trauma. Provoked seizures do not constitute epilepsy.",
        "* **Conclusion:** The statement that epilepsy is defined as a disease of recurrent unprovoked seizures is the most accurate and fundamental definition among the choices.",
        "* **Pitfalls (general):** A single seizure is not epilepsy unless the risk of recurrence is high. A normal EEG does not rule out epilepsy, as interictal recordings are often normal."
      ],
      "others": [
        {
          "label": "①",
          "text": "뇌전증 발작의 종류 중 전신 발작은 모두 경련성 발작 (convulsive seizure)이다.",
          "reason": "This is incorrect. Generalized seizures can be non-convulsive. The classic example is a generalized absence seizure ('petit mal'), which involves a brief loss of awareness without motor convulsions."
        },
        {
          "label": "③",
          "text": "국소 발작의 증상은 발작 시작, 전파 부위에 따라 다르지 않다.",
          "reason": "This is incorrect. The symptoms of a focal seizure are entirely determined by the location of seizure onset and its pattern of spread in the brain. For example, a seizure in the occipital lobe causes visual phenomena."
        },
        {
          "label": "④",
          "text": "뇌파 검사를 시행하면 모든 환자에서 발작파가 검출되므로 뇌파 검사가 정상이면 뇌전증을 진단할 수 없다.",
          "reason": "This is incorrect. The sensitivity of a single routine interictal EEG for detecting epileptiform abnormalities is only about 30-50%. A normal EEG does not exclude a diagnosis of epilepsy, which is primarily a clinical diagnosis based on history."
        },
        {
          "label": "⑤",
          "text": "뇌전증의 발생율은 성인기가 가장 높고 영/유아기, 노년기에 상대적으로 낮다.",
          "reason": "This is incorrect. The incidence of epilepsy follows a U-shaped or bimodal curve with age, with the highest rates occurring in early childhood (infancy) and in the elderly population."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "비유발성 발작이 반복되는 질환을 뇌전증이라고 정의한다."
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Definition (Seizure):** A transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.",
        "* **Definition (Epilepsy):** Epilepsy is a disease characterized by an enduring predisposition to generate seizures. The practical definition (ILAE 2014) requires one of the following:\n  1. At least two *unprovoked* seizures occurring >24 hours apart.\n  2. One unprovoked seizure and a high probability (>60%) of further seizures.\n  3. Diagnosis of a specific epilepsy syndrome.",
        "* **Provoked vs. Unprovoked:** A key distinction is between unprovoked seizures (no immediate trigger) and provoked or acute symptomatic seizures (caused by a transient factor like fever, hypoglycemia, or alcohol withdrawal). Provoked seizures do not constitute epilepsy.",
        "* **Seizure Classification (Focal):** Focal seizures originate in one hemisphere. Their symptoms are determined by the brain region involved (e.g., occipital lobe seizures cause visual phenomena).",
        "* **Seizure Classification (Generalized):** Generalized seizures involve both hemispheres from onset. They can be motor (e.g., tonic-clonic, previously 'grand mal') or non-motor (e.g., absence, previously 'petit mal').",
        "* **Workup:** Diagnosis is primarily clinical, based on a detailed history from the patient and witnesses. An electroencephalogram (EEG) is the most important diagnostic test.",
        "* **EEG Limitations:** A single routine interictal EEG has a sensitivity of only 30-50% for detecting epileptiform abnormalities. Therefore, a normal EEG does not rule out epilepsy.",
        "* **Epidemiology:** The incidence of epilepsy follows a U-shaped curve with age, with peaks in early childhood and in the elderly population.",
        "* **Pitfalls (general):**\n  - Diagnosing epilepsy after a single seizure without evidence of high recurrence risk.\n  - Ruling out epilepsy based solely on a normal routine EEG."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "30",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "hemispatial neglect"
      },
      "why": [
        "* **Topic:** Cerebral hemisphere lateralization of function.",
        "* **Left Hemisphere Functions (Dominant):** In most right-handed individuals, the left hemisphere is dominant for:\n  - **Language:** Speech production (Broca's area), language comprehension (Wernicke's area), reading, and writing (agraphia).\n  - **Praxis:** Performing skilled, complex motor tasks.\n  - **Calculation (Acalculia):** Mathematical abilities.\n  - **Sequential/Analytical Processing:** Logical reasoning and analysis of details.",
        "* **Right Hemisphere Functions (Non-dominant):** The right hemisphere is typically dominant for:\n  - **Visuospatial Abilities:** Spatial orientation, facial recognition, map reading.\n  - **Attention:** Directing and maintaining attention, particularly spatial attention.\n  - **Emotion:** Processing and expressing emotion, understanding prosody (emotional tone of voice).\n  - **Holistic/Gestalt Processing:** Perceiving the 'big picture'.",
        "* **Hemispatial Neglect:** This is a profound deficit in attention to and awareness of the contralateral side of space. It is most commonly and severely seen with damage to the non-dominant (usually right) parietal lobe, resulting in neglect of the left side of space.",
        "* **Gerstmann Syndrome:** Acalculia, agraphia, and finger agnosia (along with right-left disorientation) are components of Gerstmann syndrome, which is classically associated with a lesion in the dominant (left) angular gyrus of the parietal lobe.",
        "* **Conduction Aphasia:** This language disorder, characterized by impaired repetition, results from damage to the arcuate fasciculus connecting language centers within the dominant (left) hemisphere.",
        "* **Conclusion:** Acalculia, agraphia, finger agnosia, and conduction aphasia are all associated with left hemisphere damage. Hemispatial neglect is the classic sign of right hemisphere damage."
      ],
      "others": [
        {
          "label": "①",
          "text": "acaculia",
          "reason": "Acalculia (difficulty with calculation) is a classic sign of dominant (usually left) parietal lobe dysfunction, often as part of Gerstmann syndrome."
        },
        {
          "label": "②",
          "text": "agraphia",
          "reason": "Agraphia (inability to write) is a language-related deficit associated with the dominant (left) hemisphere, also a component of Gerstmann syndrome."
        },
        {
          "label": "③",
          "text": "finger agnosia",
          "reason": "Finger agnosia (inability to identify fingers) is another component of Gerstmann syndrome, linked to the dominant (left) parietal lobe."
        },
        {
          "label": "⑤",
          "text": "conduction aphasia",
          "reason": "Conduction aphasia is a specific type of aphasia caused by a lesion in the arcuate fasciculus within the dominant (left) hemisphere."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "hemispatial neglect"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Cerebral Lateralization:** The two cerebral hemispheres are specialized for different cognitive functions. In most individuals, the left hemisphere is dominant for language.",
        "* **Left (Dominant) Hemisphere Functions:** This hemisphere is primarily responsible for:\n  - **Language:** Speech production (Broca's area), comprehension (Wernicke's area), reading, and writing.\n  - **Praxis:** Performing complex, learned motor sequences.\n  - **Calculation:** Mathematical abilities.\n  - **Analytical and sequential processing.**",
        "* **Right (Non-dominant) Hemisphere Functions:** This hemisphere is primarily responsible for:\n  - **Visuospatial skills:** Spatial orientation, facial recognition, map reading.\n  - **Attention:** Particularly directing spatial attention.\n  - **Emotion:** Processing and expressing emotion, interpreting tone of voice (prosody).\n  - **Holistic and gestalt processing.**",
        "* **Hemispatial Neglect:** A profound deficit in attention to and awareness of the contralateral side of space. It is a classic sign of a lesion in the non-dominant (usually right) parietal lobe, resulting in neglect of the left visual field.",
        "* **Gerstmann Syndrome:** A constellation of deficits (acalculia, agraphia, finger agnosia, and right-left disorientation) classically associated with a lesion in the angular gyrus of the dominant (left) parietal lobe.",
        "* **Aphasia:** All major aphasia syndromes (Broca's, Wernicke's, conduction, global) are caused by lesions within the dominant (left) hemisphere.",
        "* **Conduction Aphasia:** Specifically caused by damage to the arcuate fasciculus, which connects Broca's and Wernicke's areas, leading to impaired repetition with relatively preserved fluency and comprehension.",
        "* **Pitfalls (general):** Confusing the functions of the dominant and non-dominant hemispheres, especially regarding language (left) versus spatial attention (right)."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "31",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "뇌 CT (Brain CT)"
      },
      "why": [
        "* **Diagnosis:** The question asks for the most appropriate initial diagnostic method for a patient with suspected ischemic stroke in the emergency department.",
        "* **Diagnostic Algorithm:** The immediate priority in evaluating a patient with acute stroke symptoms is to differentiate between ischemic and hemorrhagic stroke. This distinction is critical because the treatments are fundamentally different and thrombolytic therapy, the primary treatment for acute ischemic stroke, is contraindicated in hemorrhagic stroke.",
        "* **First Step:** A non-contrast computed tomography (CT) scan of the brain is the most crucial initial imaging study in the acute setting.",
        "* **Rationale for Brain CT:** The primary role of the non-contrast CT is to rapidly and reliably exclude intracranial hemorrhage. It is fast, widely available, and highly sensitive for acute blood.",
        "* **CT Findings in Stroke:**\n  - **Hemorrhagic Stroke:** A non-contrast CT will immediately show hyperdense (bright) areas corresponding to acute bleeding.\n  - **Ischemic Stroke:** In the hyperacute phase (first few hours), the CT scan may appear normal. Early signs of ischemia, such as loss of gray-white matter differentiation, sulcal effacement, or a hyperdense MCA sign, may develop later but are often subtle or absent initially.",
        "* **Clinical Significance:** By ruling out hemorrhage, the non-contrast CT scan clears the patient for potential treatment with intravenous thrombolysis (e.g., alteplase) if they are within the therapeutic window and have no other contraindications.",
        "* **Guidelines:** All major stroke guidelines (e.g., American Heart Association/American Stroke Association) mandate a non-contrast brain CT as the first imaging step before any acute stroke therapy is initiated.",
        "* **Differential / Discriminators:** While other imaging modalities like MRI (especially DWI sequence) are more sensitive for detecting early ischemia, CT is faster and superior for the primary goal of excluding hemorrhage in the emergency setting."
      ],
      "others": [
        {
          "label": "①",
          "text": "디지털 감산 혈관조영술(digital subtraction angiogra phy)",
          "reason": "Digital subtraction angiography (DSA) is an invasive procedure used to visualize blood vessels. It is not the initial diagnostic test but may be used later for endovascular treatment (thrombectomy) or to investigate underlying vascular abnormalities like aneurysms or dissections."
        },
        {
          "label": "②",
          "text": "모야모야병 진단을 위한 RNF213 유전자 다형성(poly morphism) 확인",
          "reason": "Genetic testing for Moyamoya disease is irrelevant in the acute emergency management of a suspected stroke. This is a specialized test performed in a non-acute setting when there is a high suspicion of this specific vasculopathy."
        },
        {
          "label": "④",
          "text": "뇌척수액 검사(CSF tapping)",
          "reason": "A lumbar puncture is not indicated for the initial diagnosis of ischemic stroke. It is primarily used to diagnose subarachnoid hemorrhage (if CT is negative but suspicion is high) or central nervous system infections like meningitis."
        },
        {
          "label": "⑤",
          "text": "신경전도검사(nerve conduction study)",
          "reason": "Nerve conduction studies evaluate peripheral nerve function and are used to diagnose conditions like peripheral neuropathy or myasthenia gravis. They have no role in the diagnosis of an acute central nervous system event like a stroke."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "뇌 CT (Brain CT)"
        },
        "provided_key": {
          "label": "3",
          "text": "뇌 CT (Brain CT)"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Acute stroke presents with the sudden onset of a focal neurologic deficit (e.g., hemiparesis, aphasia, visual field cut).",
        "* **Initial Priority:** The most critical initial step in the emergency department is to rapidly differentiate between ischemic stroke and hemorrhagic stroke, as their treatments are opposite.",
        "* **Workup (First Step):** A non-contrast head computed tomography (CT) scan is the mandatory first-line imaging study for all patients with suspected acute stroke.",
        "* **Rationale for CT:** CT is fast, widely available, and extremely sensitive for detecting acute intracranial hemorrhage, which is a contraindication to thrombolytic therapy.",
        "* **CT Findings (Hemorrhagic):** Acute blood appears hyperdense (bright) on a non-contrast CT, allowing for immediate diagnosis of hemorrhagic stroke.",
        "* **CT Findings (Ischemic):** In the hyperacute phase (the first few hours), the non-contrast CT may be normal. The primary purpose of the scan is to rule out hemorrhage, thereby 'ruling in' ischemic stroke as the diagnosis of exclusion and clearing the patient for thrombolysis.",
        "* **Management Algorithm:** If the non-contrast CT shows no hemorrhage and the patient is within the therapeutic window (typically <4.5 hours from symptom onset) and has no other contraindications, intravenous thrombolysis (e.g., alteplase) should be administered.",
        "* **Role of Advanced Imaging:** While brain MRI (especially DWI) is more sensitive for detecting early ischemia, CT is faster for the crucial initial decision. CT angiography (CTA) is often performed concurrently to look for a large vessel occlusion (LVO) that may be amenable to mechanical thrombectomy.",
        "* **Pitfalls (general):**\n  - Delaying the initial non-contrast CT scan ('time is brain').\n  - Administering thrombolytics before obtaining a head CT to rule out hemorrhage."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "32",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "축삭형(axonal) 변이는 예후가 더 나쁘다."
      },
      "why": [
        "* **Diagnosis:** Guillain-Barré Syndrome (GBS).",
        "* **Clinical Presentation:** The patient presents with a classic picture of GBS: a subacute, ascending, symmetric sensorimotor polyneuropathy (bilateral hand/foot numbness, leg weakness) preceded by an infection (severe diarrhea, likely Campylobacter jejuni).",
        "* **Key Findings:**\n  - **Neurological Exam:** Hyporeflexia/areflexia (decreased deep tendon reflexes) is a hallmark finding.\n  - **NCS:** Confirms a sensorimotor polyneuropathy.\n  - **CSF Analysis:** Shows albuminocytologic dissociation (elevated protein with normal white blood cell count), which is highly characteristic of GBS.",
        "* **Pathophysiology:** GBS is an acute, immune-mediated polyradiculoneuropathy. Molecular mimicry following an infection leads to the production of antibodies that cross-react with components of peripheral nerves (myelin or axons).",
        "* **Prognosis and Variants:** GBS has several variants. The two main categories are demyelinating (Acute Inflammatory Demyelinating Polyneuropathy, AIDP) and axonal (Acute Motor Axonal Neuropathy, AMAN; Acute Motor-Sensory Axonal Neuropathy, AMSAN).",
        "* **Prognostic Factors:** Recovery from demyelination (remyelination) is generally faster and more complete than recovery from axonal damage (axonal regeneration). Therefore, the axonal variants (AMAN, AMSAN) are associated with a more severe clinical course, slower recovery, and a worse overall prognosis with more residual deficits.",
        "* **Treatment Principle:** The mainstay of treatment is immunotherapy with either intravenous immunoglobulin (IVIG) or plasma exchange (PLEX) to remove the pathogenic antibodies. Corticosteroids are not effective and should not be used.",
        "* **Clinical Course:** Symptoms typically progress and nadir (reach their peak severity) within 2 to 4 weeks of onset. Progression beyond 8 weeks suggests a chronic process like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)."
      ],
      "others": [
        {
          "label": "①",
          "text": "발병 이후 8주 이상 증상이 악화될 수 있다.",
          "reason": "This statement is incorrect. By definition, GBS symptoms peak within 4 weeks. If symptoms continue to progress for more than 8 weeks, the diagnosis is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), not GBS."
        },
        {
          "label": "②",
          "text": "신경뿌리(nerve root)를 침범하는 경우는 거의 없다.",
          "reason": "This is incorrect. GBS is a poly*radiculo*neuropathy, meaning inflammation of the nerve roots is a characteristic feature. This radiculopathy contributes to the pain and is responsible for the elevated CSF protein."
        },
        {
          "label": "③",
          "text": "탈수초형(demyelinating)에서는 항갱글리오시드 항체가 흔히 양성이다.",
          "reason": "This is incorrect. While anti-ganglioside antibodies can be found in GBS, they are more strongly and frequently associated with the axonal variants (e.g., anti-GM1 in AMAN) rather than the classic demyelinating form (AIDP)."
        },
        {
          "label": "⑤",
          "text": "일차 치료제로 스테로이드가 사용된다.",
          "reason": "This is incorrect. Multiple large randomized controlled trials have shown that corticosteroids are ineffective in treating GBS and may even be harmful. The standard first-line treatments are IVIG or plasma exchange."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "축삭형(axonal) 변이는 예후가 더 나쁘다."
        },
        "provided_key": {
          "label": "4",
          "text": "축삭형(axonal) 변이는 예후가 더 나쁘다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Guillain-Barré Syndrome (GBS) is an acute, ascending, and symmetric polyradiculoneuropathy. It typically presents with progressive weakness and sensory changes, often preceded by an infection (e.g., *Campylobacter jejuni* gastroenteritis).",
        "* **Hallmark Signs:** Areflexia or marked hyporeflexia is a cardinal feature. Autonomic dysfunction (e.g., tachycardia, blood pressure lability) and respiratory muscle weakness can be life-threatening.",
        "* **Workup (CSF):** Cerebrospinal fluid analysis characteristically shows albuminocytologic dissociation: a high protein level with a normal white blood cell count. This finding may not be present in the first week.",
        "* **Workup (Electrophysiology):** Nerve conduction studies (NCS) are the most specific diagnostic test, typically showing features of demyelination (e.g., slowed conduction velocities, prolonged distal latencies).",
        "* **Pathophysiology:** GBS is an immune-mediated disorder where antibodies attack components of the peripheral nerves and nerve roots (radiculopathy), often triggered by molecular mimicry after an infection.",
        "* **Variants and Prognosis:** The two main subtypes are demyelinating (AIDP) and axonal (AMAN, AMSAN). Axonal variants involve direct damage to the axon and are associated with a more rapid onset, more severe deficits, and a poorer prognosis for recovery compared to demyelinating variants.",
        "* **Clinical Course:** By definition, symptoms reach their peak severity (nadir) within 4 weeks of onset. If symptoms continue to progress for more than 8 weeks, the diagnosis is chronic inflammatory demyelinating polyneuropathy (CIDP).",
        "* **Management:** Treatment consists of supportive care (especially monitoring for respiratory failure) and immunotherapy with either intravenous immunoglobulin (IVIG) or plasma exchange (PLEX).",
        "* **Pitfalls (general):** Corticosteroids have been proven to be ineffective in GBS and should not be used. Anti-ganglioside antibodies are more strongly associated with axonal variants than with the classic demyelinating form."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "33",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "소뇌 병변에 의한 intention tremor는 목표 지점에 가까워질수록 심해진다."
      },
      "why": [
        "* **Diagnosis:** The question asks to identify the correct description of a type of tremor among various movement disorders.",
        "* **Tremor Definition:** Tremor is a rhythmic, involuntary, oscillatory movement of a body part. It is classified based on its activation condition: rest tremor or action tremor (which includes postural, kinetic, and intention tremors).",
        "* **Intention Tremor:** This is a specific type of kinetic tremor that is amplified as the patient approaches a target with their limb (e.g., during a finger-to-nose test).",
        "* **Pathophysiology:** Intention tremor is a classic sign of a lesion in the cerebellum or its pathways (e.g., dentate nucleus, superior cerebellar peduncle). The cerebellum is crucial for coordinating movement, and its dysfunction leads to an inability to smoothly brake or correct movements as they near their endpoint, resulting in the characteristic terminal oscillation.",
        "* **Clinical Correlation:** This type of tremor is often seen in conditions like multiple sclerosis, stroke affecting the cerebellum, or cerebellar tumors.",
        "* **Differential / Discriminators:** It is important to distinguish intention tremor from other types:\n  - **Resting Tremor:** Occurs when the limb is fully supported against gravity. It decreases with action. Classic for Parkinson's disease.\n  - **Postural Tremor:** Occurs when holding a position against gravity (e.g., holding arms outstretched). Common in essential tremor.\n  - **Kinetic Tremor:** Occurs throughout a voluntary movement. Intention tremor is a subtype of kinetic tremor where the amplitude is greatest at the end of the movement."
      ],
      "others": [
        {
          "label": "①",
          "text": "불규칙적이며 방향과 분포가 일정하지 않은 운동을 보인다.",
          "reason": "This describes chorea, which is characterized by irregular, non-rhythmic, flowing movements. Tremor, by contrast, is rhythmic and oscillatory."
        },
        {
          "label": "②",
          "text": "주로 지속적인 근육 수축에 의한 비정상적인 자세가 특징이다.",
          "reason": "This is the definition of dystonia, a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both."
        },
        {
          "label": "③",
          "text": "파킨슨병에서는 의지적 움직임을 시작할 때 가장 심한 진전이 나타난다.",
          "reason": "This is incorrect. The characteristic tremor of Parkinson's disease is a resting tremor, which is most prominent at rest and typically improves or disappears with voluntary movement."
        },
        {
          "label": "⑤",
          "text": "자발운동시 여러 관절이 부드럽게 함께 움직이지 않고 끊어지는 모습이 나타난다.",
          "reason": "This describes dyssynergia or decomposition of movement, which is another sign of cerebellar dysfunction, but it is not the definition of tremor itself. It refers to the breakdown of smooth multi-joint movements into a series of individual component movements."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "소뇌 병변에 의한 intention tremor는 목표 지점에 가까워질수록 심해진다."
        },
        "provided_key": {
          "label": "4",
          "text": "소뇌 병변에 의한 intention tremor는 목표 지점에 가까워질수록 심해진다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Definition:** Tremor is a rhythmic, involuntary, oscillatory movement of a body part.",
        "* **Classification:** Tremors are primarily classified based on the state in which they occur: at rest (resting tremor) or during voluntary muscle contraction (action tremor).",
        "* **Resting Tremor:** This tremor is present when the limb is fully supported and at rest. It is characteristically suppressed or diminished by voluntary action. It is the hallmark tremor of Parkinson's disease.",
        "* **Action Tremor:** This category includes postural, kinetic, and intention tremors.\n  - **Postural Tremor:** Occurs when holding a position against gravity (e.g., arms outstretched). It is the classic tremor of Essential Tremor.\n  - **Kinetic Tremor:** Occurs throughout a voluntary movement.",
        "* **Intention Tremor:** A specific type of kinetic tremor where the amplitude markedly increases as the limb approaches its target (e.g., during the finger-to-nose test).",
        "* **Pathophysiology (Intention Tremor):** Intention tremor is a pathognomonic sign of a lesion affecting the cerebellum or its pathways. The cerebellum's role in coordinating and fine-tuning movement is disrupted, leading to an 'overshoot' oscillation.",
        "* **Differential (Other Movement Disorders):** It is crucial to distinguish tremor from other hyperkinetic movements:\n  - **Chorea:** Irregular, non-rhythmic, flowing, 'dance-like' movements.\n  - **Dystonia:** Sustained or intermittent muscle contractions causing abnormal postures.\n  - **Dyssynergia:** Decomposition of smooth, multi-joint movements into a sequence of individual parts, another sign of cerebellar dysfunction.",
        "* **Pitfalls (general):** Misclassifying the type of tremor, which is key to the differential diagnosis. For example, incorrectly stating that Parkinson's tremor is worst with action."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "34",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "우측 동안(눈돌림)신경의 후교통동맥 동맥류에 의한 압박성 마비"
      },
      "why": [
        "* **Diagnosis:** Right oculomotor nerve (CN III) palsy due to a compressive posterior communicating artery (PCOM) aneurysm.",
        "* **Clinical Presentation:** A 20-year-old woman with acute onset of binocular vertical diplopia.",
        "* **Image Findings (Figure 1: 9-Gaze Photography):** The images demonstrate a classic right CN III palsy.\n  - **Right Ptosis:** The right upper eyelid is drooping.\n  - **Mydriasis:** The right pupil is dilated compared to the left.\n  - **Ophthalmoplegia:** The right eye is deviated 'down and out' in the primary position. There is a marked deficit in adduction (looking left), elevation (looking up), and depression (looking down). Abduction (looking right) is preserved (innervated by CN VI), as is intorsion/depression in adduction (innervated by CN IV).",
        "* **Image Findings (Figure 2: Brain MRA):** The magnetic resonance angiography shows a saccular aneurysm arising from the junction of the internal carotid artery and the posterior communicating artery (PCOM) on the right side.",
        "* **Pathophysiology:** The oculomotor nerve (CN III) runs in close proximity to the PCOM. An aneurysm arising from the PCOM can expand and compress the nerve. The parasympathetic fibers that control pupillary constriction run on the superomedial surface of the nerve, making them particularly vulnerable to external compression. This explains the classic presentation of a 'pupil-involving' CN III palsy (with mydriasis) in the setting of a PCOM aneurysm.",
        "* **Etiology:** In a young patient presenting with an acute, painful, pupil-involving CN III palsy, a PCOM aneurysm is the most likely and most dangerous cause and must be ruled out immediately. Ischemic (microvascular) CN III palsy typically occurs in older patients with vascular risk factors and classically 'spares the pupil'.",
        "* **Conclusion:** The combination of the clinical signs of a right pupil-involving CN III palsy and the MRA finding of a right PCOM aneurysm confirms the diagnosis."
      ],
      "others": [
        {
          "label": "①",
          "text": "우측 활차(도르레)신경의 미세혈관폐색에 의한 허혈성 마비",
          "reason": "This is incorrect. The findings are of a CN III palsy (ptosis, mydriasis, impaired adduction/elevation/depression), not a CN IV (trochlear) palsy, which would cause vertical diplopia worsening on contralateral gaze and ipsilateral head tilt. Also, an ischemic cause is less likely in a 20-year-old, and the MRA shows an aneurysm."
        },
        {
          "label": "③",
          "text": "좌측 활차(도르레)신경의 후교통동맥 동맥류에 의한 압박성 마비",
          "reason": "This is incorrect. The clinical signs are on the right side, not the left, and indicate a CN III palsy, not a CN IV palsy."
        },
        {
          "label": "④",
          "text": "좌측 동안(눈돌림)신경의 후교통동맥 동맥류에 의한 압박성 마비",
          "reason": "This is incorrect. The clinical signs of ptosis, mydriasis, and ophthalmoplegia are clearly affecting the right eye, not the left."
        },
        {
          "label": "⑤",
          "text": "우측 외전(갓돌림)신경의 미세혈관폐색에 의한 허혈성 마비",
          "reason": "This is incorrect. This describes a CN VI (abducens) palsy, which would cause an inability to abduct the eye, resulting in horizontal diplopia. The patient's findings are consistent with a CN III palsy."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "우측 동안(눈돌림)신경의 후교통동맥 동맥류에 의한 압박성 마비"
        },
        "provided_key": {
          "label": "2",
          "text": "우측 동안(눈돌림)신경의 후교통동맥 동맥류에 의한 압박성 마비"
        },
        "final_decision": "agree_with_key",
        "note": ""
      },
      "teaching_points": [
        "* **Anatomy (CN III):** The oculomotor nerve (CN III) innervates four of the six extraocular muscles (superior, medial, and inferior recti; inferior oblique), the levator palpebrae superioris (eyelid elevation), and carries parasympathetic fibers for pupillary constriction.",
        "* **Clinical picture (Complete CN III Palsy):** A complete palsy results in ptosis (drooping eyelid), a dilated and nonreactive pupil (mydriasis), and the eye being deviated 'down and out' due to the unopposed action of the lateral rectus (CN VI) and superior oblique (CN IV).",
        "* **Pathophysiology ('Rule of the Pupil'):** The parasympathetic fibers that control the pupil run along the superomedial surface of CN III, making them vulnerable to external compression.",
        "* **Compressive vs. Ischemic Palsy:**\n  - **Pupil-Involving Palsy:** Caused by compression (e.g., an aneurysm). The dilated pupil is a key sign. This is a neurological emergency.\n  - **Pupil-Sparing Palsy:** Caused by microvascular ischemia (e.g., in diabetes). The ischemic core of the nerve is affected, sparing the superficial pupillary fibers.",
        "* **Workup:** An acute, pupil-involving CN III palsy must be considered a posterior communicating artery (PCOM) aneurysm until proven otherwise. Urgent neurovascular imaging (CT or MR angiography) is mandatory.",
        "* **Image Findings:** In this case, the MRA confirms a saccular aneurysm at the junction of the internal carotid artery and the PCOM, which is the classic location for an aneurysm causing a compressive CN III palsy.",
        "* **Differential (Other CN Palsies):**\n  - **CN IV (Trochlear) Palsy:** Causes vertical diplopia, often with a compensatory head tilt.\n  - **CN VI (Abducens) Palsy:** Causes horizontal diplopia due to failure of abduction.",
        "* **Pitfalls (general):** Failing to recognize the urgency of a pupil-involving CN III palsy and delaying neurovascular imaging."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "35",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "Acinar predominant adenocarcinoma"
      },
      "why": [
        "* **Diagnosis:** Acinar predominant adenocarcinoma of the lung.",
        "* **Clinical Presentation:** A 56-year-old woman with a 3.5 cm lung mass, resected surgically.",
        "* **Microscopic Findings:** The provided histology slide shows malignant glandular cells forming distinct acinar or tubular structures. These glands are crowded, back-to-back, and infiltrate the surrounding stroma. The cells exhibit nuclear atypia, including enlarged nuclei, irregular nuclear contours, and prominent nucleoli. This architectural pattern is the defining feature of acinar adenocarcinoma.",
        "* **Lung Adenocarcinoma Classification:** The current WHO classification of lung adenocarcinoma is based on the predominant histological pattern. The main patterns are:\n  - **Lepidic:** Growth along pre-existing alveolar walls.\n  - **Acinar:** Glandular, cribriform, or tubular structures.\n  - **Papillary:** Growth on fibrovascular cores.\n  - **Micropapillary:** Small tufts of cells without fibrovascular cores.\n  - **Solid:** Sheets of tumor cells with intracellular mucin.",
        "* **Prognostic Significance:** The predominant pattern has prognostic value. Lepidic predominant tumors have the best prognosis, while micropapillary and solid predominant tumors have the worst. Acinar and papillary patterns have an intermediate prognosis.",
        "* **Image Interpretation:** The image clearly demonstrates well-formed glandular structures, making 'acinar' the correct descriptor for the predominant pattern.",
        "* **Differential / Discriminators:** The other patterns are excluded based on the visual evidence. There are no sheets of cells (solid), no growth along alveolar septa (lepidic), no prominent papillary fronds (papillary), and no small, detached tufts (micropapillary)."
      ],
      "others": [
        {
          "label": "①",
          "text": "Solid predominant adenocarcinoma",
          "reason": "This pattern is characterized by sheets of tumor cells with little to no gland formation, which is not the architecture seen in the image."
        },
        {
          "label": "③",
          "text": "Lepidic predominant adenocarcinoma",
          "reason": "This pattern involves tumor cells growing along intact alveolar walls without stromal invasion. The image shows invasive, crowded glands, not a lepidic growth pattern."
        },
        {
          "label": "④",
          "text": "Papillary predominant adenocarcinoma",
          "reason": "This pattern features finger-like projections with fibrovascular cores. The image shows enclosed glandular structures (acini), not papillary fronds."
        },
        {
          "label": "⑤",
          "text": "Micropapillary predominant adenocarcinoma",
          "reason": "This pattern consists of small, tufted clusters of tumor cells without fibrovascular cores. The image shows larger, well-formed glands, which is inconsistent with a micropapillary pattern."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "Acinar predominant adenocarcinoma"
        },
        "provided_key": {
          "label": "2",
          "text": "Acinar predominant adenocarcinoma"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Lung adenocarcinoma is the most common subtype of non-small cell lung cancer, particularly in women and non-smokers. It typically arises in the periphery of the lung.",
        "* **Histologic Classification:** The WHO classification of lung adenocarcinoma is based on the predominant architectural pattern seen on microscopy, which has significant prognostic implications.",
        "* **Major Histologic Patterns:**\n  - **Lepidic:** Non-invasive growth along pre-existing alveolar walls (best prognosis).\n  - **Acinar:** Invasive tumor composed of well-formed glands or tubules (intermediate prognosis).\n  - **Papillary:** Invasive tumor with finger-like projections with fibrovascular cores (intermediate prognosis).\n  - **Micropapillary:** Small, tufted clusters of tumor cells without fibrovascular cores (poor prognosis).\n  - **Solid:** Sheets of invasive tumor cells with little to no gland formation (poor prognosis).",
        "* **Image Interpretation:** The provided micrograph clearly shows malignant cells forming distinct, back-to-back glandular structures, which is the defining feature of the acinar pattern.",
        "* **Prognosis:** The prognosis is determined by the predominant pattern, but the presence of any amount of a high-grade pattern (micropapillary or solid) worsens the outcome.",
        "* **Workup:** Diagnosis is made by biopsy. Once adenocarcinoma is diagnosed, molecular testing for targetable driver mutations (e.g., EGFR, ALK, ROS1) is standard of care to guide therapy.",
        "* **Pitfalls (general):** Confusing the different histologic patterns, as this can lead to an inaccurate assessment of prognosis."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "36",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "Mycobacterium Polymerase chain reaction (PCR) 검사"
      },
      "why": [
        "* **Diagnosis:** Pulmonary tuberculosis (TB).",
        "* **Clinical Presentation:** A 55-year-old woman with a persistent cough for several months, leading to the discovery and resection of a lung lesion.",
        "* **Microscopic Findings:** The histology images are classic for a tuberculous granuloma.\n  - **Image A (Low Power):** Shows a well-defined granuloma with a large area of central, amorphous, eosinophilic material consistent with caseous necrosis.\n  - **Image B (High Power):** Confirms the caseous necrosis and shows the surrounding inflammatory infiltrate, which includes epithelioid histiocytes (macrophages) and likely multinucleated giant cells (not perfectly in view but implied by the context).",
        "* **Pathophysiology:** Caseating granuloma formation is the hallmark pathological response to infection with *Mycobacterium tuberculosis*. The host's cell-mediated immune response walls off the bacteria, but the intense inflammation leads to tissue destruction and the characteristic 'cheesy' necrosis.",
        "* **Diagnostic Workup:** When a caseating granuloma is identified on histology, the next step is to confirm the presence of *M. tuberculosis*.",
        "* **Diagnostic Test of Choice:** While traditional acid-fast bacilli (AFB) staining is often performed, Mycobacterium PCR is a more sensitive and specific method for detecting mycobacterial DNA directly from the tissue sample. It provides rapid confirmation of the diagnosis.",
        "* **Conclusion:** Given the pathognomonic histological findings of a caseating granuloma, a Mycobacterium PCR test is the most appropriate and definitive diagnostic test to perform on the resected tissue."
      ],
      "others": [
        {
          "label": "①",
          "text": "Gram 염색",
          "reason": "Gram stain is used to identify common bacteria by their cell wall characteristics. *Mycobacterium tuberculosis* has a lipid-rich cell wall and does not stain with Gram stain; it requires an acid-fast stain."
        },
        {
          "label": "②",
          "text": "EBV in-situ hybridization 검사",
          "reason": "This test is used to detect Epstein-Barr virus, which is associated with certain lymphomas and nasopharyngeal carcinoma, not caseating granulomas."
        },
        {
          "label": "③",
          "text": "Immunohistochemistry Cytokeratin 염색",
          "reason": "Cytokeratin is an immunohistochemical marker for cells of epithelial origin. It is used to diagnose carcinomas and would be negative in a granuloma."
        },
        {
          "label": "④",
          "text": "Grocott's methenamine silver (GMS) 염색",
          "reason": "GMS stain is a special stain used to highlight the cell walls of fungi. While fungal infections can also cause granulomas (usually non-caseating or suppurative), the classic caseating appearance strongly points towards TB, making a test for mycobacteria the priority."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "Mycobacterium Polymerase chain reaction (PCR) 검사"
        },
        "provided_key": {
          "label": "5",
          "text": "Mycobacterium Polymerase chain reaction (PCR) 검사"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Pulmonary tuberculosis (TB) can present with chronic constitutional symptoms (fever, night sweats, weight loss) and respiratory symptoms (cough, hemoptysis, dyspnea).",
        "* **Pathology Hallmark:** The histologic hallmark of infection with *Mycobacterium tuberculosis* is the caseating granuloma.",
        "* **Granuloma Morphology:** A granuloma is an organized collection of immune cells. In TB, it classically consists of a central area of amorphous, eosinophilic caseous necrosis, surrounded by epithelioid histiocytes, Langhans multinucleated giant cells, and a peripheral cuff of lymphocytes.",
        "* **Workup (Histology):** When a caseating granuloma is identified on a tissue biopsy, the immediate next step is to confirm the presence of mycobacteria.",
        "* **Confirmatory Tests:**\n  - **Acid-Fast Bacilli (AFB) Stain:** A special stain (e.g., Ziehl-Neelsen) that identifies mycobacteria based on their lipid-rich cell wall. Sensitivity can be low.\n  - **Mycobacterium PCR:** A nucleic acid amplification test (NAAT) that is highly sensitive and specific for detecting mycobacterial DNA directly from tissue or fluid. It provides rapid confirmation.\n  - **Culture:** The gold standard for diagnosis and drug susceptibility testing, but it is slow, taking several weeks to grow.",
        "* **Differential (Granulomas):** Other causes of granulomatous inflammation include fungal infections (e.g., histoplasmosis, coccidioidomycosis) and sarcoidosis (which typically forms non-caseating granulomas).",
        "* **Special Stains:** Grocott's methenamine silver (GMS) stain is used to identify fungi, while Gram stain is for typical bacteria. Neither is appropriate for mycobacteria.",
        "* **Pitfalls (general):** Assuming a negative AFB stain rules out TB, especially when histology is highly suggestive. The more sensitive PCR or culture is needed."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "37",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "병리학적 진단에 중요한 소견은 종양 세포가 생성하는ㅇ steoid 이다."
      },
      "why": [
        "* **Diagnosis:** Osteosarcoma.",
        "* **Clinical Presentation:** An 8-year-old girl with a painful mass in the proximal humerus, a common location for osteosarcoma in children.",
        "* **Image Findings (Gross and Microscopic):**\n  - **Gross Pathology:** The image shows a large, destructive intramedullary tumor arising in the metaphysis. It is fleshy and tan-white with areas of hemorrhage, and it has breached the cortex to form a soft tissue mass. This is characteristic of a high-grade sarcoma.\n  - **Microscopic Pathology:** The high-power view reveals highly malignant, pleomorphic spindle cells with hyperchromatic nuclei and atypical mitoses. The crucial diagnostic feature is that these malignant cells are directly producing an eosinophilic, lace-like extracellular matrix, which is osteoid.",
        "* **Pathophysiology:** Osteosarcoma is a primary malignant tumor of bone in which the cancerous cells produce bone matrix (osteoid). This is the defining characteristic that separates it from other bone sarcomas like Ewing sarcoma or chondrosarcoma.",
        "* **Diagnostic Criteria:** The definitive diagnosis of osteosarcoma rests on the histological demonstration of malignant tumor cells producing osteoid. This is the most important and fundamental concept regarding its pathology.",
        "* **Genetics:** Osteosarcoma is strongly associated with mutations in tumor suppressor genes, particularly *RB1* (retinoblastoma gene) and *TP53* (Li-Fraumeni syndrome).",
        "* **Location and Age:** It typically occurs in the metaphysis of long bones (distal femur, proximal tibia, proximal humerus) during the adolescent growth spurt, a period of high osteoblastic activity.",
        "* **Prognosis:** The response to neoadjuvant chemotherapy is a critical prognostic factor. A good response, typically defined as >90% tumor necrosis on the resected specimen, is associated with a much better outcome."
      ],
      "others": [
        {
          "label": "①",
          "text": "p53, RB1 유전자 변이는 해당 종양의 발생과는 무관하다.",
          "reason": "This is incorrect. Mutations in the *TP53* and *RB1* tumor suppressor genes are strongly linked to the pathogenesis of osteosarcoma, particularly in familial cancer syndromes like Li-Fraumeni and hereditary retinoblastoma."
        },
        {
          "label": "②",
          "text": "소아에서 발생하는 경우 골 생성 및 흡수가 적은 성숙 뼈에서 발생한다",
          "reason": "This is incorrect. Osteosarcoma typically arises in areas of high bone turnover and growth, such as the metaphyses of long bones during the adolescent growth spurt, not in mature, quiescent bone."
        },
        {
          "label": "④",
          "text": "항암 치료 후 종양의95% 이상이 괴사되는 경우(viable tumor 〈5%) 예후가 나쁘다.",
          "reason": "This is incorrect. A high degree of tumor necrosis (>90-95%) after neoadjuvant chemotherapy is a strong indicator of a good response to treatment and is associated with a favorable prognosis."
        },
        {
          "label": "⑤",
          "text": "발생기전에 연관된 마커인RANKL을 표적으로하는mono clonal Ab (Denosumab)가 치료의 중요한 옵션이다.",
          "reason": "This is incorrect. Denosumab is a RANKL inhibitor used primarily for giant cell tumor of bone, where RANKL-mediated osteoclastogenesis is central to the pathology. It is not a standard therapy for osteosarcoma."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "The text in option ③ has a typo 'ㅇ steoid', which is assumed to mean 'osteoid'.",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "병리학적 진단에 중요한 소견은 종양 세포가 생성하는ㅇ steoid 이다."
        },
        "provided_key": {
          "label": "3",
          "text": "병리학적 진단에 중요한 소견은 종양 세포가 생성하는ㅇ steoid 이다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. It typically presents with localized pain and swelling, often around the knee (distal femur/proximal tibia) or shoulder (proximal humerus).",
        "* **Pathology Hallmark:** The definitive diagnostic feature of osteosarcoma is the production of osteoid (unmineralized bone matrix) directly by malignant neoplastic cells.",
        "* **Histology:** Characterized by pleomorphic, anaplastic spindle or epithelioid cells with hyperchromatic nuclei and atypical mitoses, associated with a lace-like, eosinophilic (pink) osteoid matrix.",
        "* **Genetics:** Pathogenesis is strongly linked to mutations in key tumor suppressor genes, including *RB1* (patients with hereditary retinoblastoma have a markedly increased risk) and *TP53* (Li-Fraumeni syndrome).",
        "* **Location:** Arises in the metaphysis of long bones during periods of rapid growth, consistent with its origin from primitive bone-forming mesenchymal cells.",
        "* **Management:** The standard treatment paradigm involves neoadjuvant (pre-operative) chemotherapy, followed by wide surgical resection, and then adjuvant (post-operative) chemotherapy.",
        "* **Prognosis:** The single most important prognostic factor is the histologic response to neoadjuvant chemotherapy. A good response, defined as >90% tumor necrosis in the resected specimen, is associated with a significantly better outcome.",
        "* **Differential/Discriminators:** Other bone sarcomas like Ewing sarcoma (small round blue cells, no osteoid) and chondrosarcoma (malignant cartilage production) are distinguished by their histology.",
        "* **Pitfalls (general):** Denosumab, a RANKL inhibitor, is a key treatment for giant cell tumor of bone, not osteosarcoma."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "38",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "대퇴골두 골괴사"
      },
      "why": [
        "* **Diagnosis:** Avascular necrosis (AVN), also known as osteonecrosis, of the femoral head.",
        "* **Clinical Presentation:** A 54-year-old man with a major risk factor (chronic heavy alcohol use) presents with a 3-month history of progressive right groin pain and limp, with recent onset of left-sided pain, suggesting a bilateral process.",
        "* **Physical Exam:** A positive Patrick (FABER) test is sensitive for intra-articular hip pathology, including AVN. The negative impingement test makes femoroacetabular impingement less likely.",
        "* **Risk Factors:** Chronic alcohol abuse and corticosteroid use are the two most common non-traumatic causes of osteonecrosis. Alcohol is thought to cause fat emboli, intravascular coagulation, and increased intraosseous pressure, leading to ischemia of the femoral head.",
        "* **Image Findings (X-ray - Photo 1):** The AP pelvis X-ray shows subtle signs. There may be some increased density (sclerosis) in the femoral heads and early subchondral lucency (crescent sign), but X-rays can be normal in early stages. The joint space is preserved, which argues against advanced osteoarthritis.",
        "* **Image Findings (MRI - Photo 2):** The coronal T1-weighted MRI is definitive. It shows a classic serpiginous, low-signal intensity line in the subchondral region of both femoral heads. This line demarcates the necrotic bone from the viable bone and is pathognomonic for osteonecrosis.",
        "* **Pathophysiology:** AVN is a condition resulting from the temporary or permanent loss of blood supply to the bone. In the hip, the anterolateral aspect of the femoral head has a tenuous blood supply, making it particularly vulnerable. Ischemia leads to the death of bone cells and marrow, followed by mechanical failure and eventual collapse of the femoral head.",
        "* **Conclusion:** The combination of significant risk factors, clinical symptoms, and pathognomonic MRI findings makes osteonecrosis of the femoral head the clear diagnosis."
      ],
      "others": [
        {
          "label": "①",
          "text": "대퇴골 전자간 골절",
          "reason": "This is an acute intertrochanteric fracture, which would present with acute pain after trauma and a clear fracture line on X-ray. The patient's presentation is chronic and non-traumatic."
        },
        {
          "label": "②",
          "text": "대퇴 비구 충돌 증후군",
          "reason": "Femoroacetabular impingement (FAI) is a mechanical disorder related to abnormal hip morphology. While it causes groin pain, the MRI findings are not consistent with FAI and are instead classic for AVN."
        },
        {
          "label": "④",
          "text": "고관절의 퇴행성 관절염",
          "reason": "Osteoarthritis would typically show significant joint space narrowing, osteophytes, and subchondral cysts. The X-ray shows relatively preserved joint space, and the MRI findings are specific to AVN, not primary OA."
        },
        {
          "label": "⑤",
          "text": "비구 이형성증",
          "reason": "Acetabular dysplasia is a developmental condition characterized by a shallow acetabulum. The imaging does not show evidence of dysplasia."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "대퇴골두 골괴사"
        },
        "provided_key": {
          "label": "3",
          "text": "대퇴골두 골괴사"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Avascular necrosis (AVN), or osteonecrosis, of the femoral head typically presents with insidious onset of groin pain, which is initially activity-related but progresses to pain at rest. It is frequently bilateral.",
        "* **Pathophysiology:** Caused by the disruption of blood supply to the femoral head, leading to ischemia and death of bone cells. This weakens the bone, leading to subchondral fracture and eventual collapse of the articular surface.",
        "* **Risk Factors:** The most common non-traumatic risk factors are chronic systemic corticosteroid use and excessive alcohol consumption. Other causes include trauma, sickle cell disease, and coagulopathies.",
        "* **Workup (Imaging):**\n  - **X-ray:** May be normal in early stages. Later findings include sclerosis, the 'crescent sign' (a subchondral lucency indicating fracture), and eventual femoral head collapse.\n  - **MRI:** The most sensitive and specific imaging modality for early diagnosis, able to detect AVN long before X-ray changes are apparent.",
        "* **MRI Findings:** The pathognomonic finding on a T1-weighted MRI is a serpiginous, low-signal intensity line in the subchondral region of the femoral head, which demarcates the necrotic bone segment.",
        "* **Physical Exam:** Findings include pain with range of motion, particularly on internal rotation. The Patrick (FABER) test is often positive, indicating intra-articular hip pathology.",
        "* **Differential/Discriminators:** Differentiated from primary osteoarthritis by the preservation of joint space in early stages and the characteristic MRI findings. Femoroacetabular impingement (FAI) is a diagnosis of abnormal morphology, not ischemic bone death.",
        "* **Pitfalls (general):** Relying on a normal X-ray to rule out AVN in a high-risk patient with hip pain; an MRI is required for definitive exclusion."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "39",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "해당 질환 후기에는 프로테오글리칸(proteogycan)의 성분이 미성숙 연골과 유사해진다."
      },
      "why": [
        "* **Diagnosis:** Bilateral knee osteoarthritis (OA).",
        "* **Clinical Presentation:** The patient is a 75-year-old woman with chronic, worsening bilateral knee pain over 5 years. The pain is associated with swelling and medial joint line tenderness. The lack of systemic symptoms and normal inflammatory markers (ESR, CRP) points away from an inflammatory arthritis like rheumatoid arthritis.",
        "* **Image Findings:** The weight-bearing knee X-ray is classic for osteoarthritis, showing:\n  - **Asymmetric joint space narrowing:** Predominantly affecting the medial compartments.\n  - **Osteophyte formation:** Bony spurs at the joint margins.\n  - **Subchondral sclerosis:** Increased bone density below the cartilage in the medial compartments.",
        "* **Pathophysiology of Osteoarthritis:** OA is a degenerative joint disease involving the breakdown of articular cartilage, subchondral bone remodeling, and synovial inflammation. It is a disease of the entire joint organ.",
        "* **Cartilage Changes in OA:**\n  - **Early OA:** The cartilage swells due to an increase in water content as the proteoglycan network is disrupted.\n  - **Progressive OA:** There is a progressive loss of proteoglycans and degradation of the type II collagen network. Chondrocyte apoptosis occurs.\n  - **Late/Reparative Phase:** The remaining chondrocytes attempt to repair the damaged matrix. This repair is ineffective and results in the synthesis of abnormal matrix components. The proteoglycans produced are smaller and less aggregated, and there is a shift from producing type II collagen to type I collagen. This altered matrix composition is functionally inferior and resembles that of fibrocartilage or immature cartilage.",
        "* **Conclusion:** The statement that in late-stage OA, the composition of proteoglycans resembles that of immature cartilage is a correct description of the pathophysiology."
      ],
      "others": [
        {
          "label": "①",
          "text": "골다공증이 해당 질환 발생의 위험인자이다.",
          "reason": "This is incorrect. Studies have shown an inverse relationship between osteoporosis and osteoarthritis. Higher bone mineral density is actually considered a risk factor for the development of OA."
        },
        {
          "label": "②",
          "text": "해당 질환이 진행할수록 연골세포 수는 증가하게 된다.",
          "reason": "This is incorrect. Osteoarthritis is characterized by the progressive loss of chondrocytes (cartilage cells) through apoptosis and mechanical destruction."
        },
        {
          "label": "③",
          "text": "해당 질환이 진행할수록 2형 콜라겐(type 2 collagen)의 농도가 증가하게 된다.",
          "reason": "This is incorrect. The hallmark of OA is the degradation and net loss of type II collagen, which is the primary structural protein in healthy articular cartilage."
        },
        {
          "label": "④",
          "text": "해당 질환 초기에는 관절 연골의 수분 함량이 줄어들게 된다.",
          "reason": "This is incorrect. In the early stages of OA, disruption of the proteoglycan matrix leads to an *increase* in water content and swelling of the cartilage. Water content decreases only in the very late stages when proteoglycans are severely depleted."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "해당 질환 후기에는 프로테오글리칸(proteogycan)의 성분이 미성숙 연골과 유사해진다."
        },
        "provided_key": {
          "label": "5",
          "text": "해당 질환 후기에는 프로테오글리칸(proteogycan)의 성분이 미성숙 연골과 유사해진다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Osteoarthritis (OA) is the most common form of arthritis, characterized by joint pain that worsens with use and improves with rest, morning stiffness lasting <30 minutes, and crepitus.",
        "* **Radiographic Hallmarks:** The four cardinal features of OA on X-ray are:\n  1. Asymmetric joint space narrowing\n  2. Osteophyte formation (bone spurs)\n  3. Subchondral sclerosis (increased bone density)\n  4. Subchondral cysts",
        "* **Pathophysiology:** OA is a degenerative disease of the entire joint, involving progressive loss of articular cartilage, subchondral bone remodeling, and synovial inflammation.",
        "* **Cartilage Changes (Early):** The cartilage matrix is disrupted, leading to a net loss of proteoglycans. This allows an influx of water, causing the cartilage to swell and soften.",
        "* **Cartilage Changes (Progressive):** There is ongoing degradation of the type II collagen network and depletion of proteoglycans. Chondrocyte (cartilage cell) numbers decrease due to apoptosis.",
        "* **Cartilage Changes (Late):** The remaining chondrocytes attempt an ineffective repair process. They synthesize smaller, less functional proteoglycans and shift from producing type II collagen to type I collagen. This results in a mechanically inferior fibrocartilage-like matrix, similar in composition to immature cartilage.",
        "* **Risk Factors:** Major risk factors include advanced age, obesity, female gender, and prior joint trauma.",
        "* **Pitfalls (general):** There is an inverse relationship between OA and osteoporosis; higher bone mineral density is a risk factor for OA. In early OA, cartilage water content *increases*, not decreases."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "40",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "L1-2의 평균 골밀도 T-score가 -2.6이므로 골다공증으로 진단할 수 있다."
      },
      "why": [
        "* **Diagnosis:** Osteoporosis.",
        "* **Diagnostic Criteria (WHO):** Osteoporosis in postmenopausal women is diagnosed based on bone mineral density (BMD) using a dual-energy X-ray absorptiometry (DXA) scan. A T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck indicates osteoporosis. The diagnosis is based on the lowest T-score from these three sites.",
        "* **Image Findings (DXA Report):**\n  - **Lumbar Spine:** The L1-L4 average T-score is -2.4 (osteopenia). However, individual vertebral values are provided. L1 has a T-score of -2.7, and L2 has a T-score of -2.5. The average of L1-L2 is -2.6.\n  - **Femur:** The femoral neck T-score is -2.3 (osteopenia), and the total hip T-score is -2.0 (osteopenia). The Ward's triangle T-score is -3.0, but this site is not used for formal diagnosis.",
        "* **Interpretation Rules:**\n  1.  **Use the lowest score:** The diagnosis is based on the worst T-score from the lumbar spine, total hip, or femoral neck.\n  2.  **Lumbar Spine ROI:** The standard region of interest (ROI) is the average of L1-L4. However, if a vertebra is structurally abnormal (e.g., fracture, severe arthritis), it should be excluded. At least two evaluable vertebrae are needed for a valid lumbar spine assessment.\n  3.  **Using Sub-regions:** Even if the L1-L4 average is above -2.5, if any of the three primary diagnostic sites (lumbar spine, total hip, femoral neck) has a T-score ≤ -2.5, the diagnosis is osteoporosis. In this case, the L1 vertebra alone (-2.7) or the L1-L2 average (-2.6) meets the criteria.",
        "* **Conclusion:** The T-score for the L1-L2 vertebral segment is -2.6. Since this value is less than or equal to -2.5, it meets the WHO criteria for a diagnosis of osteoporosis. The overall diagnosis for the patient is osteoporosis based on the lumbar spine findings."
      ],
      "others": [
        {
          "label": "①",
          "text": "대퇴골의 ward 부위의 골밀도 T-score가 -3.0이므로 대퇴골 부위에서 골다공증으로 진단할 수 있다.",
          "reason": "This is incorrect. The Ward's triangle region is no longer recommended for diagnostic purposes by the International Society for Clinical Densitometry (ISCD) because of its high variability and poor precision. Diagnosis should be based on the femoral neck or total hip T-scores."
        },
        {
          "label": "②",
          "text": "요추 골밀도에서 골절이 발생한 분절은 골밀도 분석에 반드시 포함하여야 한다.",
          "reason": "This is incorrect. Vertebrae with focal structural abnormalities, such as compression fractures, should be *excluded* from the analysis as they can artifactually increase the measured BMD."
        },
        {
          "label": "④",
          "text": "골밀도 검사에서 중심골의 골밀도가 골감소증이면, 원위 요골 골절이 발생하더라도 약물 치료는 필요 없다.",
          "reason": "This is incorrect. A fragility fracture (a fracture from a fall from standing height or less), such as a distal radius fracture, in a postmenopausal woman establishes a clinical diagnosis of severe osteoporosis, regardless of the T-score. It is a strong indication for initiating pharmacologic therapy."
        },
        {
          "label": "⑤",
          "text": "요추에서 골밀도 T-score가 골다공증이지만, 대퇴골의 골밀도 T-score가 골감소증이므로 골감소증으로 진단한다.",
          "reason": "This is incorrect. The diagnosis of osteoporosis is made if *any* of the qualifying sites (lumbar spine, total hip, femoral neck) meets the T-score criterion of ≤ -2.5. The final diagnosis is based on the lowest value, not an average or the better of the two sites."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "L1-2의 평균 골밀도 T-score가 -2.6이므로 골다공증으로 진단할 수 있다."
        },
        "provided_key": {
          "label": "3",
          "text": "L1-2의 평균 골밀도 T-score가 -2.6이므로 골다공증으로 진단할 수 있다."
        },
        "final_decision": "agree_with_key",
        "note": ""
      },
      "teaching_points": [
        "* **Workup:** Dual-energy X-ray absorptiometry (DXA) is the standard method for diagnosing osteoporosis based on bone mineral density (BMD).",
        "* **Criteria/Thresholds (WHO):** In postmenopausal women and men aged 50 and older, osteoporosis is diagnosed if the T-score at the lumbar spine, total hip, or femoral neck is ≤ -2.5.",
        "* **Diagnostic Principle:** The diagnosis is based on the *lowest* T-score from any of the three qualifying measurement sites. One does not average the scores from different skeletal regions (e.g., spine and hip).",
        "* **Interpretation (Lumbar Spine):** The standard region of interest is the average of vertebrae L1 through L4. However, if individual vertebrae show a T-score ≤ -2.5, this can be used for diagnosis, even if the L1-L4 average is in the osteopenic range.",
        "* **Interpretation (Exclusions):** Vertebrae with structural abnormalities or artifacts (e.g., compression fracture, severe degenerative changes) should be excluded from the analysis, as they can falsely elevate the BMD measurement.",
        "* **Interpretation (Hip):** The femoral neck and total hip are the valid diagnostic sites in the hip. The Ward's triangle region is highly variable and should not be used for formal diagnosis.",
        "* **Clinical Diagnosis:** A fragility fracture (a low-trauma fracture, e.g., from a fall from standing height) establishes a clinical diagnosis of severe osteoporosis, regardless of the DXA T-score.",
        "* **Management:** The presence of a fragility fracture is a firm indication to initiate pharmacologic treatment for osteoporosis.",
        "* **Pitfalls (general):**\n  - Diagnosing based on the better of two sites (e.g., calling it osteopenia because the hip is better than the spine).\n  - Using non-diagnostic sites like Ward's triangle.\n  - Failing to recommend treatment for a patient with a fragility fracture just because their T-score is in the osteopenic range."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "41",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "등쪽 척추근육은 피부근육분절(dermatomyotome) 잔류세포에서, 배곧은근은 복외측순(VLL) 세포의 이동으로 형성된다"
      },
      "why": [
        "* **Diagnosis:** This question tests knowledge of musculoskeletal embryology, specifically the differential development of axial muscles from the somitic mesoderm.",
        "* **Pathophysiology:** Skeletal muscles of the trunk and limbs originate from somites, which are blocks of paraxial mesoderm. Each somite differentiates into a sclerotome, dermatome, and myotome. The myotome gives rise to skeletal muscles.",
        "* **Myotome Differentiation:** The myotome is organized into two primary domains based on signaling cues from adjacent structures like the neural tube, notochord, and ectoderm.",
        "* **Primaxial Domain:** This domain includes the dorsomedial portion of the somite. Its cells remain close to the neural tube and form the epaxial muscles (intrinsic back muscles). These muscles are innervated by the dorsal rami of spinal nerves.",
        "* **Abaxial Domain:** This domain's precursor cells originate from the ventrolateral lip (VLL) of the dermatomyotome. These cells migrate away from the somite into the somatic layer of the lateral plate mesoderm.",
        "* **Muscle Development:**\n  - **Back Muscles (Epaxial):** The deep muscles of the back (e.g., erector spinae) develop from the primaxial domain, which is formed from the dorsomedial lip (DML) and residual cells of the dermatomyotome. They do not migrate extensively.\n  - **Rectus Abdominis (Hypaxial):** The muscles of the ventrolateral body wall (including the rectus abdominis) and limbs are hypaxial muscles. They develop from the abaxial domain, which is formed by the migration of cells from the ventrolateral lip (VLL) of the dermatomyotome.",
        "* **Conclusion:** The statement that back muscles form from residual dermatomyotome cells (primaxial precursors) and the rectus abdominis forms from migrating VLL cells (abaxial precursors) is the most accurate description.",
        "* **Innervation Pattern:** This developmental division also explains the innervation pattern. Primaxial (epaxial) muscles are supplied by dorsal rami, while abaxial (hypaxial) muscles are supplied by ventral rami of the spinal nerves corresponding to their somite of origin."
      ],
      "others": [
        {
          "label": "①",
          "text": "두 근육 모두 측판중배엽(lateral plate mesoderm)에서 직접 분화한다",
          "reason": "Incorrect. Both the back muscles and rectus abdominis are skeletal muscles that originate from the paraxial mesoderm (somites), not the lateral plate mesoderm. The lateral plate mesoderm gives rise to smooth muscle of the gut, cardiac muscle, and connective tissues of the limbs."
        },
        {
          "label": "③",
          "text": "등쪽 척추근육은 배축영역(abaxial domain)에서, 배곧은근은 초축영역(primaxial domain)에서 각각 발생한다",
          "reason": "Incorrect. This statement has the domains reversed. The intrinsic back muscles (등쪽 척추근육) develop from the primaxial domain (초축영역), while the rectus abdominis (배곧은근) develops from the abaxial domain (배축영역)."
        },
        {
          "label": "④",
          "text": "같은 몸분절에서 기원한 두 근육은 서로 다른 척수 분절에서 신경지배를 받는다",
          "reason": "Incorrect. Muscles derived from a specific somite are innervated by the spinal nerve of that same segment. While they are innervated by different branches (dorsal vs. ventral rami), the segmental level of innervation corresponds to the somite of origin."
        },
        {
          "label": "⑤",
          "text": "등쪽 척추근육은 축성(axial) 골격근이고, 배곧은근은 부속(appendicular)골격근이다.",
          "reason": "Incorrect. Both the intrinsic back muscles and the rectus abdominis are part of the trunk musculature and are therefore considered axial skeletal muscles. Appendicular skeletal muscles are the muscles of the limbs."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "등쪽 척추근육은 피부근육분절(dermatomyotome) 잔류세포에서, 배곧은근은 복외측순(VLL) 세포의 이동으로 형성된다"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** This question addresses the embryological origin of axial skeletal muscles, specifically the intrinsic back muscles versus the ventrolateral body wall muscles.",
        "* **Workup:** Understanding the differential development of muscles from somitic mesoderm is key. Somites, blocks of paraxial mesoderm, differentiate into sclerotome, dermatome, and myotome.",
        "* **Pathophysiology:** The myotome, the source of skeletal muscle, is organized into two domains: the primaxial and abaxial domains, based on signaling from adjacent structures.",
        "* **Primaxial Domain:** This domain consists of cells from the dorsomedial lip (DML) of the somite that remain near the neural tube. These cells develop into the epaxial muscles, which are the deep, intrinsic muscles of the back (e.g., erector spinae).",
        "* **Abaxial Domain:** This domain's precursor cells originate from the ventrolateral lip (VLL) of the somite. These cells migrate into the lateral plate mesoderm to form the hypaxial muscles.",
        "* **Hypaxial Muscles:** This group includes the muscles of the ventrolateral body wall (e.g., rectus abdominis, obliques) and all limb muscles.",
        "* **Innervation Pattern:** This developmental division dictates the innervation pattern. Primaxial (epaxial) muscles are innervated by the dorsal rami of spinal nerves, while abaxial (hypaxial) muscles are innervated by the ventral rami.",
        "* **Differential/Discriminators:** Skeletal muscles of the trunk and limbs derive from paraxial mesoderm (somites), not lateral plate mesoderm, which forms smooth muscle of the gut and cardiac muscle.",
        "* **Conclusion:** Intrinsic back muscles develop from the primaxial domain (dermatomyotome remnant cells), and the rectus abdominis develops from migrating VLL cells of the abaxial domain.",
        "* **Pitfalls (general):** A common error is confusing the origin of different mesodermal derivatives. Remember: Paraxial mesoderm gives rise to the axial skeleton and associated muscles, while lateral plate mesoderm contributes to limb connective tissue, serous membranes, and cardiovascular structures."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "42",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "Popliteal artery"
      },
      "why": [
        "* **Diagnosis:** The question asks for the most common site of vascular entrapment syndrome.",
        "* **Definition:** Vascular entrapment syndromes are a group of conditions where blood vessels are compressed by adjacent anatomical structures, such as muscles, tendons, or fibrous bands. This compression can lead to stenosis, occlusion, or aneurysm formation.",
        "* **Most Common Site:** The most well-described and common form of vascular entrapment syndrome in the limbs is Popliteal Artery Entrapment Syndrome (PAES).",
        "* **Pathophysiology of PAES:** In PAES, the popliteal artery is compressed in the popliteal fossa. The most common cause is an anomalous relationship between the artery and the medial head of the gastrocnemius muscle. Other causes include compression by the plantaris muscle, popliteus muscle, or fibrous bands.",
        "* **Clinical Presentation of PAES:** It typically affects young, athletic individuals without traditional risk factors for atherosclerosis. Symptoms include intermittent claudication (pain with exercise that resolves with rest), paresthesias, or coldness in the foot. In acute cases, it can present with limb-threatening ischemia due to thrombosis.",
        "* **Differential Diagnosis of Sites:**\n  - **Adductor Canal Syndrome:** Compression of the superficial femoral artery in the adductor (Hunter's) canal is a much rarer cause of claudication.\n  - **Thoracic Outlet Syndrome:** Involves compression of the subclavian artery, vein, or brachial plexus in the thoracic outlet, but PAES is more common as a primary vascular entrapment syndrome.\n  - **Median Arcuate Ligament Syndrome:** Compression of the celiac artery by the median arcuate ligament of the diaphragm.",
        "* **Conclusion:** Among the choices provided, which are all arteries of the lower limb, the popliteal artery is by far the most frequent site for a clinically significant entrapment syndrome.",
        "* **Diagnostic Workup:** Diagnosis is often made with duplex ultrasound with provocative maneuvers (plantarflexion/dorsiflexion), CTA, or MRA to demonstrate the compression."
      ],
      "others": [
        {
          "label": "①",
          "text": "Common femoral artery",
          "reason": "Incorrect. The common femoral artery is a relatively uncommon site for entrapment syndromes compared to the popliteal artery."
        },
        {
          "label": "②",
          "text": "Superficial femoral artery",
          "reason": "Incorrect. While the superficial femoral artery can be compressed in the adductor canal (adductor canal syndrome), this is significantly less common than popliteal artery entrapment syndrome."
        },
        {
          "label": "④",
          "text": "Dorsalis pedis artery",
          "reason": "Incorrect. The dorsalis pedis artery is a distal vessel on the dorsum of the foot and is not a typical location for entrapment syndromes."
        },
        {
          "label": "⑤",
          "text": "Anterior tibial artery",
          "reason": "Incorrect. The anterior tibial artery can be affected by anterior compartment syndrome, which is an issue of elevated pressure within a fascial compartment, rather than a classic entrapment by a single anomalous muscle or band."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "Popliteal artery"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Popliteal Artery Entrapment Syndrome (PAES) is the most common vascular entrapment syndrome of the limbs. It typically affects young, athletic individuals without traditional atherosclerotic risk factors.",
        "* **Presentation:** Patients often present with intermittent claudication (exertional calf pain relieved by rest), paresthesias, or coldness in the foot. Acute thrombosis can lead to limb-threatening ischemia.",
        "* **Pathophysiology:** PAES is most commonly caused by an anomalous anatomical relationship between the popliteal artery and the medial head of the gastrocnemius muscle. Compression can also occur from the plantaris muscle or fibrous bands.",
        "* **Workup:** The initial investigation is typically a duplex ultrasound with provocative maneuvers (active plantarflexion and dorsiflexion) to demonstrate dynamic compression of the artery.",
        "* **Confirmatory Imaging:** CT angiography (CTA) or MR angiography (MRA), also with provocative maneuvers, can confirm the diagnosis and delineate the specific anatomy causing the entrapment.",
        "* **Management:** Treatment is primarily surgical and involves releasing the compressing structure (e.g., myotomy of the gastrocnemius head) and, if necessary, arterial reconstruction with a vein graft if the artery is damaged.",
        "* **Differential/Discriminators:**\n  - **Adductor Canal Syndrome:** A much rarer condition involving compression of the superficial femoral artery in Hunter's canal.\n  - **Chronic Exertional Compartment Syndrome:** Causes exertional leg pain but is due to increased intra-compartmental pressure, not direct arterial compression.\n  - **Atherosclerosis:** Typically occurs in older patients with cardiovascular risk factors.",
        "* **Pitfalls (general):** Misattributing claudication in a young, healthy patient to musculoskeletal causes without considering PAES. Failure to perform provocative maneuvers during imaging can lead to a false-negative result."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "43",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "수동 관절 운동"
      },
      "why": [
        "* **Diagnosis:** The question asks to identify the type of range of motion (ROM) exercise suitable for a patient with the lowest level of muscle strength.",
        "* **Principle of Therapeutic Exercise:** The selection of exercise type is progressive and depends on the patient's ability to actively participate in movement. The goal is to maintain joint mobility, prevent contractures, and gradually increase strength.",
        "* **Hierarchy of ROM Exercises:** Exercises are graded based on the amount of patient effort required:\n  - **Passive ROM (PROM):** No patient effort. The joint is moved by an external force (therapist, machine).\n  - **Active-Assistive ROM (AAROM):** The patient initiates the movement, and an external force assists in completing it.\n  - **Active ROM (AROM):** The patient moves the joint through the full range of motion without assistance.\n  - **Resistive ROM:** The patient moves against an external resistance to build strength.",
        "* **Lowest Muscle Strength Scenario:** When muscle strength is minimal or absent (e.g., paralysis, coma, immediate post-operative period where active contraction is contraindicated), the patient cannot move the joint on their own. In this case, passive range of motion is the only appropriate option to maintain joint health.",
        "* **Manual Muscle Testing (MMT) Correlation:**\n  - **Grade 0/5 (Zero):** No palpable muscle contraction. Requires PROM.\n  - **Grade 1/5 (Trace):** Palpable contraction but no joint movement. Requires PROM.\n  - **Grade 2/5 (Poor):** Full ROM in a gravity-eliminated plane. Requires AAROM or AROM in a gravity-eliminated plane.\n  - **Grade 3/5 (Fair):** Full ROM against gravity. Can perform AROM.\n  - **Grade 4/5 (Good) & 5/5 (Normal):** Full ROM against gravity with moderate to maximal resistance. Can perform resistive exercises.",
        "* **Conclusion:** Passive range of motion (수동 관절 운동) is performed when the patient has the lowest muscle strength, as it requires no active muscle contraction from the patient.",
        "* **Goals of PROM:** The primary goals are to maintain joint flexibility, prevent contractures, improve circulation, and enhance proprioception, not to increase muscle strength."
      ],
      "others": [
        {
          "label": "②",
          "text": "능동 관절 운동",
          "reason": "Incorrect. Active range of motion (AROM) requires the patient to have sufficient muscle strength (at least Grade 3/5) to move the limb against gravity without assistance. This is not for patients with the lowest strength."
        },
        {
          "label": "③",
          "text": "능동 보조 관절 운동",
          "reason": "Incorrect. Active-assistive range of motion (AAROM) is for patients who have some muscle function but are too weak to complete the full range of motion independently. This requires more strength than a patient who can only tolerate passive motion."
        },
        {
          "label": "④",
          "text": "능동 저항 관절 운동",
          "reason": "Incorrect. Active-resistive exercise is a strengthening exercise used for patients who already have good muscle strength (at least Grade 3+/5) and can move against external resistance. This is for patients with relatively high strength."
        },
        {
          "label": "⑤",
          "text": "등속성 운동",
          "reason": "Incorrect. Isokinetic exercise is an advanced form of resistive training where movement speed is constant. It is used for muscle strengthening and rehabilitation in patients with significant baseline strength, not for those with the lowest strength."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "수동 관절 운동"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** The choice of therapeutic exercise is progressive, based on the patient's muscle strength and ability to participate in movement.",
        "* **Hierarchy of Exercise:** Range of motion (ROM) exercises are graded by the level of patient effort required, from none (passive) to maximal (resistive).",
        "* **Passive ROM (PROM):** The joint is moved entirely by an external force (therapist, machine) with no active muscle contraction from the patient. This is indicated for the lowest levels of muscle strength.",
        "* **Active-Assistive ROM (AAROM):** The patient initiates movement, but an external force is required to complete the full range of motion. This is for patients with some, but insufficient, strength.",
        "* **Active ROM (AROM):** The patient moves the joint through its full range of motion without any assistance.",
        "* **Resistive ROM:** The patient moves against an external resistance to build muscle strength.",
        "* **Criteria/Thresholds (MMT Correlation):** The choice of ROM exercise directly correlates with Manual Muscle Testing (MMT) grades:\n  - **Grade 0-1/5 (Zero/Trace):** Requires Passive ROM.\n  - **Grade 2/5 (Poor):** Can perform AROM in a gravity-eliminated plane; may need Active-Assistive ROM against gravity.\n  - **Grade 3/5 (Fair):** Can perform Active ROM against gravity.\n  - **Grade 4-5/5 (Good/Normal):** Can perform Resistive ROM.",
        "* **Goals of PROM:** The primary goals are to maintain joint mobility, prevent contractures, improve circulation, and decrease pain. It does not increase muscle strength.",
        "* **Pitfalls (general):** Applying active or resistive exercises to a patient with insufficient strength (MMT < 3/5) can cause injury, pain, or frustration. Confusing the goal of PROM (maintaining mobility) with the goal of active/resistive exercise (building strength)."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "44",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "상처 소독 및 멸균 드레싱으로 피복→ 혈역학적 안정화 → 1세대 세팔로스포린+ 아미노글리코사이드 정맥 투여→ 파상풍 톡소이드 투여→ 신속한 정형외과 협진"
      },
      "why": [
        "* **Diagnosis:** The patient has a Gustilo-Anderson type III open tibial fracture with gross contamination and signs of early hemorrhagic shock.",
        "* **Treatment Principle:** The management of a severe open fracture follows a strict protocol prioritizing life over limb, and then limb salvage with infection prevention as a paramount goal.",
        "* **Management Algorithm (ATLS & Open Fracture Protocol):**\n  1. **Primary Survey (ABCDE):** The first step is always to assess and manage airway, breathing, and circulation. The patient's tachycardia (110 bpm) and borderline hypotension (100/70 mmHg) indicate mild hemodynamic instability requiring stabilization, typically with IV crystalloids.\n  2. **Initial Wound Care:** Gross contaminants should be removed, and the wound should be covered with a sterile, saline-soaked dressing to prevent further contamination. Extensive cleaning or reduction in the ER is avoided.\n  3. **IV Antibiotics:** Prompt administration of broad-spectrum IV antibiotics (ideally within 1 hour of injury) is crucial to reduce the risk of osteomyelitis. For a Type III fracture with soil contamination, coverage for gram-positives (e.g., a first-generation cephalosporin like cefazolin) and gram-negatives (e.g., an aminoglycoside like gentamicin) is standard. Some protocols add penicillin for anaerobic coverage (especially Clostridium).\n  4. **Tetanus Prophylaxis:** The wound is tetanus-prone. The patient's last booster was 7 years ago. According to CDC guidelines, for a dirty/major wound, a tetanus toxoid booster is indicated if the last dose was >5 years ago. Tetanus immune globulin (TIG) is not needed if the patient has a history of a complete primary vaccination series.\n  5. **Surgical Debridement:** Urgent referral to orthopedics for surgical irrigation and debridement (I&D) in the operating room is the definitive treatment to remove nonviable tissue and contaminants.\n  6. **Fracture Stabilization:** This is done surgically, often with an external fixator for severe open fractures.",
        "* **Analysis of Correct Option (②):** This option correctly sequences the critical initial steps: initial wound care (sterile dressing), hemodynamic stabilization, prompt and appropriate IV antibiotics, tetanus prophylaxis, and urgent surgical consultation. This represents the most comprehensive and correct initial plan.",
        "* **Pitfalls (General):** A common error is to prioritize definitive fracture fixation before hemodynamic stabilization and infection prophylaxis. Another is inadequate antibiotic coverage or delaying its administration. Attempting fracture reduction in a contaminated wound in the ER is contraindicated."
      ],
      "others": [
        {
          "label": "①",
          "text": "즉시 수술실로 이송하여 변연절제술 및 내고정술 시행 → 수술 후 항생제 투여→ 파상풍 예방접종",
          "reason": "Incorrect sequence. Hemodynamic stabilization and administration of pre-operative antibiotics are critical first steps that must be performed before transferring the patient to the operating room."
        },
        {
          "label": "③",
          "text": "진통제 투여로 통증 조절→ 단순X-ray 촬영→ 항생제는 감염 징후 확인 후 투여→ 파상풍 예방접종은 입원 중 시행",
          "reason": "Incorrect. Delaying antibiotics until signs of infection appear in an open fracture is a serious medical error and significantly increases the risk of osteomyelitis and sepsis. Prophylactic antibiotics are mandatory and urgent."
        },
        {
          "label": "④",
          "text": "혈역학적 소생술만 우선 시행→ 뼈를 응급실에서 정복 → Triple antibiotic therapy 즉시 투여→ 파상풍 면역글로불린+ 톡소이드 동시 투여",
          "reason": "Incorrect. Reducing a grossly contaminated open fracture in the emergency room is contraindicated as it can drive contaminants deeper into the wound, increasing infection risk. Debridement must precede reduction."
        },
        {
          "label": "⑤",
          "text": "상처 부위 과산화수소 세척→ 항생제 연고 도포 후 거즈 피복→ 경구 세팔로스포린 투여→ 파상풍 톡소이드만 투여",
          "reason": "Incorrect. This represents grossly inadequate management. Hydrogen peroxide is cytotoxic, topical antibiotics are insufficient, and oral antibiotics are inappropriate for a severe systemic infection risk. This patient requires IV antibiotics and surgical debridement."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "상처 소독 및 멸균 드레싱으로 피복→ 혈역학적 안정화 → 1세대 세팔로스포린+ 아미노글리코사이드 정맥 투여→ 파상풍 톡소이드 투여→ 신속한 정형외과 협진"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A high-energy open fracture (e.g., Gustilo-Anderson type III) is a surgical emergency characterized by extensive soft-tissue damage and gross contamination.",
        "* **Management (algorithmic):** The initial management follows a strict sequence prioritizing life over limb, and then limb salvage with infection prevention.",
        "* **Step 1: Primary Survey (ATLS):** Assess and manage Airway, Breathing, and Circulation. Hemodynamic stabilization with IV crystalloids is the first priority.",
        "* **Step 2: Initial Wound Care:** Remove gross contaminants, irrigate superficially, and cover the wound with a sterile, saline-soaked dressing. Avoid deep probing or reduction in the emergency department.",
        "* **Step 3: IV Antibiotics:** Administer broad-spectrum IV antibiotics as soon as possible, ideally within 1 hour of injury, to reduce the risk of osteomyelitis.",
        "* **Criteria/Thresholds (Antibiotic Selection):**\n  - **Type I/II:** First-generation cephalosporin (e.g., cefazolin).\n  - **Type III:** Add an aminoglycoside for gram-negative coverage (e.g., gentamicin).\n  - **Farm/Soil Contamination:** Add penicillin for anaerobic coverage (e.g., Clostridium).",
        "* **Step 4: Tetanus Prophylaxis:** Assess vaccination status. For a contaminated wound, a tetanus toxoid booster is given if the last dose was >5 years ago. Tetanus immune globulin (TIG) is added if the primary series is incomplete or unknown.",
        "* **Step 5: Urgent Surgical Debridement:** The definitive step is urgent and thorough surgical irrigation and debridement (I&D) in the operating room to remove all nonviable tissue and contaminants.",
        "* **Step 6: Fracture Stabilization:** After debridement, the fracture is stabilized, often with an external fixator for severe open fractures to allow for continued wound care.",
        "* **Pitfalls (general):**\n  - Delaying antibiotic administration beyond 1-3 hours significantly increases infection risk.\n  - Attempting to reduce a contaminated fracture in the ER, which can drive debris deeper into the wound.\n  - Prioritizing definitive fixation over hemodynamic stabilization and infection prophylaxis."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "45",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "골수강내 정"
      },
      "why": [
        "* **Diagnosis:** The question asks for the optimal fixation method for a tibial shaft fracture that allows for early weight-bearing, assuming good soft tissue condition.",
        "* **Treatment Principle:** The goal of operative fixation for long bone diaphyseal fractures is to provide sufficient stability to allow for early joint motion and weight-bearing. This promotes bone healing (via micromotion and compression), prevents muscle atrophy and joint stiffness, and facilitates a faster return to function.",
        "* **Intramedullary (IM) Nailing:** This is the current standard of care for most tibial shaft fractures in adults. An IM nail is placed into the medullary canal of the bone. It acts as an internal splint.",
        "* **Biomechanical Advantage:** The key advantage of an IM nail is that it is a 'load-sharing' device. It is located at the mechanical axis of the bone, allowing it to effectively resist bending and torsional forces while allowing axial compression at the fracture site, which stimulates healing. This robust stability allows for early, often immediate, weight-bearing as tolerated.",
        "* **Comparison with Plate Fixation:** Plate and screw fixation is a 'load-bearing' or 'load-shielding' device. The plate carries the majority of the physiological load, bypassing the fracture site. This requires more extensive soft tissue dissection for placement and carries a higher risk of hardware failure if subjected to early, unprotected weight-bearing. Weight-bearing is typically restricted for a longer period after plating compared to nailing for diaphyseal fractures.",
        "* **Other Fixation Methods:**\n  - **Pins, Wires, Screws:** These are not used as standalone fixation for a tibial shaft fracture as they provide inadequate stability for weight-bearing. They are used as adjuncts to other fixation methods or for different fracture types (e.g., articular fractures).",
        "* **Conclusion:** For a tibial shaft fracture with adequate soft tissue, an intramedullary nail provides the most stable construct, allowing for the earliest and safest return to weight-bearing and ambulation."
      ],
      "others": [
        {
          "label": "①",
          "text": "핀",
          "reason": "Incorrect. Pins alone (e.g., Kirschner wires) do not provide sufficient mechanical stability to allow for weight-bearing on a tibial shaft fracture."
        },
        {
          "label": "②",
          "text": "금속줄(steel wire)",
          "reason": "Incorrect. Steel wires, typically used in tension band constructs for avulsion fractures (e.g., patella), are inadequate for providing the axial and rotational stability needed for a tibial shaft fracture."
        },
        {
          "label": "③",
          "text": "나사",
          "reason": "Incorrect. Screws are used to fix fragments together (lag screws) or to attach plates to bone, but they cannot be used as the sole method of fixation for a major long bone shaft fracture."
        },
        {
          "label": "④",
          "text": "금속판과 나사 고정",
          "reason": "Incorrect. While plate and screw fixation is a valid option, it is generally considered biomechanically inferior to intramedullary nailing for diaphyseal tibial fractures regarding early weight-bearing. IM nailing is the preferred method for this goal."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "골수강내 정"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** The goal of operative fixation for long bone diaphyseal fractures, such as the tibia, is to provide stability for early mobilization and weight-bearing.",
        "* **Treatment:** Intramedullary (IM) nailing is the gold standard and preferred method for fixation of most tibial shaft fractures in adults.",
        "* **Biomechanical Principle (Load-Sharing):** An IM nail is a 'load-sharing' device. It is placed within the medullary canal along the bone's mechanical axis, allowing it to resist bending and torsional forces while permitting axial compression at the fracture site, which stimulates healing.",
        "* **Clinical Advantage:** The robust stability provided by an IM nail allows for early, often immediate, weight-bearing as tolerated. This accelerates rehabilitation, prevents joint stiffness, and reduces muscle atrophy.",
        "* **Comparison to Plating (Load-Bearing):** Plate and screw fixation is a 'load-bearing' device. The plate carries the majority of the load, shielding the fracture. This construct is less suited for early weight-bearing and typically requires a period of protected or non-weight-bearing.",
        "* **Surgical Considerations:** IM nailing is typically performed through small incisions, minimizing soft tissue stripping and preserving the periosteal blood supply, which is crucial for healing.",
        "* **Indications for Plating:** Plate fixation may be preferred for fractures that are very proximal or distal (metaphyseal), have intra-articular extension, or in pediatric patients with open physes.",
        "* **Pitfalls (general):** Using less stable fixation methods (e.g., pins, wires alone) for a tibial shaft fracture is inadequate. Allowing early unprotected weight-bearing after plate fixation can lead to hardware failure or loss of reduction."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "46",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "초음파검사"
      },
      "why": [
        "* **Diagnosis:** The clinical presentation of a slow-growing, pea-sized, palpable mass on the dorsum of the hand is highly suggestive of a ganglion cyst, the most common soft tissue tumor of the hand.",
        "* **Diagnostic Principle:** When evaluating a superficial soft tissue mass, the initial imaging goal is to confirm its presence, determine if it is cystic or solid, and assess its relationship to adjacent structures. The ideal first-line test should be non-invasive, readily available, cost-effective, and provide this information.",
        "* **Ultrasound as First-Line Imaging:** Ultrasound is the most appropriate initial imaging modality for this presentation. It excels at differentiating cystic (fluid-filled) structures from solid masses. A ganglion cyst will appear as a well-defined, anechoic (black) or hypoechoic, compressible lesion, often with posterior acoustic enhancement.",
        "* **Advantages of Ultrasound:**\n  - **Cystic vs. Solid:** It is the best initial test to confirm the cystic nature of the mass.\n  - **Safety:** It uses no ionizing radiation.\n  - **Cost-Effectiveness:** It is significantly less expensive than MRI or CT.\n  - **Dynamic Assessment:** It allows for real-time evaluation of compressibility and relationship to moving tendons.\n  - **Vascularity:** Doppler ultrasound can assess for any associated blood vessels.",
        "* **Role of Other Imaging Modalities:**\n  - **Plain X-ray:** Useful for ruling out underlying bony pathology (e.g., arthritis, bone tumor) but does not visualize soft tissue masses like cysts.\n  - **MRI:** Provides superior soft tissue detail and is the gold standard for characterizing soft tissue tumors. However, it is reserved for cases where the diagnosis is unclear after ultrasound or for complex pre-operative planning, not as a first-line test for a simple, suspected ganglion cyst.\n  - **CT Scan:** Primarily used for detailed bone imaging and is not the preferred modality for soft tissue evaluation.\n  - **Bone Scan:** Used to detect areas of increased bone metabolism (e.g., infection, metastasis, occult fracture) and is not indicated for this clinical scenario.",
        "* **Conclusion:** Given the high clinical suspicion for a ganglion cyst, ultrasound is the most logical, efficient, and cost-effective first-line imaging test to confirm the diagnosis."
      ],
      "others": [
        {
          "label": "①",
          "text": "뼈스캔",
          "reason": "Incorrect. A bone scan is a nuclear medicine test that evaluates bone metabolism. It is not indicated for the primary evaluation of a superficial soft tissue mass."
        },
        {
          "label": "③",
          "text": "단순X선촬영",
          "reason": "Incorrect. A plain X-ray is used to visualize bone and will not show a soft tissue mass like a ganglion cyst unless there is associated bony erosion or calcification, which is rare. It cannot differentiate cystic from solid masses."
        },
        {
          "label": "④",
          "text": "자기공명영상",
          "reason": "Incorrect. While MRI provides excellent soft tissue detail, it is more expensive and less accessible than ultrasound. It is considered a second-line investigation if the diagnosis remains uncertain after clinical examination and ultrasound."
        },
        {
          "label": "⑤",
          "text": "전산화단층촬영",
          "reason": "Incorrect. CT scan is superior for bone detail but offers poorer soft tissue contrast compared to ultrasound or MRI for evaluating a suspected ganglion cyst. It also involves ionizing radiation."
        }
      ],
      "runner_up": "④",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "초음파검사"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A ganglion cyst is the most common benign soft tissue tumor of the hand and wrist, typically presenting as a smooth, firm, non-tender, slow-growing subcutaneous lump.",
        "* **Workup:** For a superficial, palpable soft tissue mass, the primary diagnostic goal is to confirm its presence and differentiate between a cystic and a solid lesion.",
        "* **First-line Imaging:** Ultrasound is the most appropriate, cost-effective, and efficient initial imaging modality for a suspected ganglion cyst.",
        "* **Ultrasound Findings:** A ganglion cyst classically appears as a well-defined, anechoic (fluid-filled), non-compressible or minimally compressible lesion, often with posterior acoustic enhancement. It can also demonstrate its connection to an underlying joint or tendon sheath.",
        "* **Role of MRI:** MRI provides superior soft tissue detail and is the gold standard for characterizing soft tissue masses. However, it is reserved as a second-line test for cases where the diagnosis is unclear after ultrasound, if internal complexity is seen, or for detailed preoperative planning.",
        "* **Role of X-ray:** Plain radiographs are useful to exclude underlying bony pathology, such as arthritis or a bone tumor, but they do not visualize the soft tissue cyst itself.",
        "* **Management:** Asymptomatic ganglion cysts do not require treatment. Symptomatic cysts can be managed with aspiration (with or without steroid injection) or surgical excision, which has the lowest recurrence rate.",
        "* **Pitfalls (general):** Ordering an MRI as the initial imaging test for a clinically straightforward ganglion cyst is not cost-effective. Mistaking a solid soft tissue tumor for a ganglion cyst; ultrasound is crucial for this differentiation."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "47",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "광범위 항생제 투여 및 수술적 변연절제"
      },
      "why": [
        "* **Diagnosis:** Necrotizing fasciitis (or gas gangrene/clostridial myonecrosis). This is a life-threatening, rapidly progressive soft tissue infection.",
        "* **Clinical Presentation:** The patient presents with classic signs of a necrotizing soft tissue infection (NSTI). Key features include a history of minor trauma, rapid progression over 24 hours, severe pain, systemic signs (fever, chills), and physical findings of skin discoloration, bullae (blisters), and significant tenderness.",
        "* **Image Findings:**\n  - **X-ray (그림 2):** The presence of gas shadows (subcutaneous emphysema) is a pathognomonic, though not universally present, sign of infection with gas-forming organisms, such as Clostridium species or certain coliforms. This finding confirms a severe, life-threatening infection.",
        "* **Lab Findings:**\n  - **WBC:** 18,900/mm³ (leukocytosis) indicates a severe infection.\n  - **CRP:** 28.2 mg/dL (markedly elevated) reflects intense systemic inflammation.\n  - **Hemoglobin:** 8.9 g/dL (anemia) can be seen due to hemolysis from bacterial toxins (e.g., alpha-toxin from C. perfringens) or sepsis-induced bone marrow suppression.",
        "* **Treatment Principle:** The management of NSTI is a surgical emergency. The two cornerstones of treatment are immediate, aggressive surgical debridement and broad-spectrum intravenous antibiotics.",
        "* **Surgical Debridement:** This is the most critical intervention. All necrotic fascia, subcutaneous tissue, muscle, and skin must be excised until healthy, bleeding tissue is reached. Delays in surgery are directly correlated with increased mortality. Repeat debridements are often necessary.",
        "* **Antibiotic Therapy:** Broad-spectrum antibiotics should be started empirically and immediately. A typical regimen includes coverage for gram-positives (including MRSA), gram-negatives, and anaerobes. A combination like vancomycin + piperacillin-tazobactam + clindamycin is often used. Clindamycin is included for its ability to suppress bacterial toxin synthesis.",
        "* **Supportive Care:** Patients are often in septic shock and require aggressive fluid resuscitation, vasopressor support, and management in an intensive care unit (ICU)."
      ],
      "others": [
        {
          "label": "①",
          "text": "경험적 항생제 투여 및 반복적 흡인술",
          "reason": "Incorrect. While antibiotics are necessary, aspiration is completely inadequate for source control in necrotizing fasciitis. The infection involves widespread tissue death that must be surgically removed."
        },
        {
          "label": "②",
          "text": "경험적 항생제 투여 및 외고정 장치",
          "reason": "Incorrect. An external fixation device is used to stabilize bone fractures. It has no role in the management of a primary soft tissue infection."
        },
        {
          "label": "④",
          "text": "광범위 항생제 및 스테로이드 동시 투여",
          "reason": "Incorrect. Steroids are generally contraindicated in active, uncontrolled bacterial infections like necrotizing fasciitis as they can impair the host immune response and worsen the outcome."
        },
        {
          "label": "⑤",
          "text": "스테로이드 투여 및 반복적 흡인술",
          "reason": "Incorrect. This combination is inappropriate and harmful. Steroids would worsen the infection, and aspiration is not a therapeutic option for necrotic tissue."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "광범위 항생제 투여 및 수술적 변연절제"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Necrotizing fasciitis is a life-and-limb-threatening, rapidly progressive infection of the deep soft tissues. Hallmarks include pain out of proportion to physical findings, skin discoloration, bullae, crepitus, and systemic toxicity (fever, tachycardia, hypotension).",
        "* **Workup:** Diagnosis is primarily clinical. Laboratory studies often show marked leukocytosis and elevated inflammatory markers (CRP). The LRINEC score can aid in risk stratification but should not delay treatment.",
        "* **Imaging:** Plain X-rays are useful to look for subcutaneous gas (emphysema), which is a specific but insensitive finding, often associated with clostridial or polymicrobial infections. CT can help delineate the extent of fascial involvement.",
        "* **Management (algorithmic):** Necrotizing fasciitis is a surgical emergency requiring immediate and aggressive intervention.",
        "* **Step 1: Hemodynamic Support:** Patients are often septic and require aggressive fluid resuscitation and vasopressor support in an ICU setting.",
        "* **Step 2: Urgent Surgical Debridement:** This is the cornerstone of therapy and must not be delayed. All necrotic fascia, subcutaneous tissue, and muscle must be excised until healthy, bleeding tissue is encountered.",
        "* **Step 3: Broad-Spectrum Antibiotics:** Initiate immediately after blood cultures are drawn. Empiric therapy should cover gram-positives (including MRSA), gram-negatives, and anaerobes.",
        "* **Treatment (Antibiotics):** A common regimen is Vancomycin OR Linezolid + Piperacillin-tazobactam OR a Carbapenem + Clindamycin. Clindamycin is included to suppress bacterial toxin production.",
        "* **Monitoring/Follow-up:** Patients frequently require planned second-look operations every 24-48 hours for repeat debridement until the infection is controlled.",
        "* **Pitfalls (general):**\n  - Delaying surgery to obtain imaging or await definitive clinical signs.\n  - Mistaking necrotizing fasciitis for simple cellulitis, leading to a delay in diagnosis.\n  - Relying on antibiotics alone without surgical source control."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "48",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "심방세동"
      },
      "why": [
        "* **Diagnosis:** Atrial fibrillation with a rapid ventricular response (RVR).",
        "* **Clinical Presentation:** A 64-year-old man with a history of hypertension presents with palpitations after heavy alcohol consumption (binge drinking). This clinical scenario is classic for \"holiday heart syndrome,\" where alcohol acts as a trigger for paroxysmal atrial fibrillation.",
        "* **ECG Findings:** The provided ECG strip demonstrates the hallmark features of atrial fibrillation:\n  - **Irregularly Irregular Rhythm:** The R-R intervals are variable with no discernible pattern.\n  - **Absence of P waves:** There are no consistent, identifiable P waves preceding each QRS complex.\n  - **Fibrillatory Waves:** The baseline shows chaotic, fine undulations, especially visible in leads like V1. These are the fibrillatory 'f' waves.\n  - **Narrow QRS Complexes:** The QRS duration is normal (<0.12 seconds), indicating that the electrical impulse originates above the ventricles (supraventricular).\n  - **Tachycardia:** The ventricular rate is fast (greater than 100 bpm), consistent with a rapid ventricular response (RVR), which causes the symptom of palpitations.",
        "* **Differential Diagnosis (ECG):**\n  - **Sinus Tachycardia:** Would be regular with one P wave for every QRS.\n  - **Atrial Flutter:** Typically shows characteristic 'sawtooth' flutter waves and can have a regular or irregular ventricular response, but the atrial activity is organized, unlike the chaotic baseline here.\n  - **PSVT:** A regular, narrow-complex tachycardia.\n  - **Ventricular Tachycardia:** A wide-complex tachycardia.",
        "* **Conclusion:** The combination of the clinical history (holiday heart) and the classic ECG findings makes atrial fibrillation the definitive diagnosis."
      ],
      "others": [
        {
          "label": "①",
          "text": "발작성심실상성빈맥",
          "reason": "Incorrect. Paroxysmal supraventricular tachycardia (PSVT) is characterized by a regular rhythm, whereas this patient's ECG shows an irregularly irregular rhythm."
        },
        {
          "label": "②",
          "text": "동성빈맥",
          "reason": "Incorrect. Sinus tachycardia is a regular rhythm originating from the sinus node, with a clear P wave preceding every QRS complex. This ECG is irregular and lacks consistent P waves."
        },
        {
          "label": "③",
          "text": "심방조동",
          "reason": "Incorrect. Atrial flutter is characterized by organized, sawtooth-like flutter waves. The baseline in this ECG is chaotic and disorganized, which is characteristic of fibrillation, not flutter."
        },
        {
          "label": "⑤",
          "text": "심실빈맥",
          "reason": "Incorrect. Ventricular tachycardia is a ventricular arrhythmia characterized by wide QRS complexes (>0.12 seconds). The QRS complexes in this ECG are narrow, indicating a supraventricular origin."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "심방세동"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Patients may present with palpitations, dyspnea, fatigue, or may be asymptomatic. Binge alcohol consumption can trigger paroxysmal AF, a phenomenon known as \"holiday heart syndrome.\"",
        "* **ECG Criteria/Thresholds:** The diagnosis of atrial fibrillation is made by identifying three key features on an ECG:",
        "  - **Irregularly irregular rhythm:** The R-R intervals are completely variable with no repeating pattern.",
        "  - **Absence of P waves:** No consistent, discernible P waves precede the QRS complexes.",
        "  - **Fibrillatory waves:** The baseline is chaotic and undulating, representing disorganized atrial activity. These 'f' waves are often best seen in lead V1.",
        "* **QRS Complex:** The QRS complexes are typically narrow (<0.12 seconds) because the impulses originate above the ventricles.",
        "* **Ventricular Rate:** The ventricular response can be slow (<60 bpm), controlled (60-100 bpm), or rapid (>100 bpm), termed AF with a rapid ventricular response (RVR).",
        "* **Differential/Discriminators (ECG):**\n  - **Atrial Flutter:** Features organized 'sawtooth' flutter waves and often has a regular (or regularly irregular) ventricular response.\n  - **Multifocal Atrial Tachycardia (MAT):** Is irregularly irregular but has at least 3 distinct P wave morphologies and varying PR intervals.\n  - **Sinus Arrhythmia:** Is irregular but has a clear P wave before every QRS.",
        "* **Management (algorithmic):** The management of AF focuses on three main goals: rate control, rhythm control, and prevention of thromboembolism.",
        "* **Stroke Prophylaxis:** Stroke risk is assessed using the CHA₂DS₂-VASc score, and anticoagulation is prescribed accordingly.",
        "* **Pitfalls (general):** Mistaking AF with a rapid rate and aberrant conduction (wide QRS) for ventricular tachycardia. Overlooking fine fibrillatory waves and misdiagnosing the rhythm as junctional."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "49",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "C4"
      },
      "why": [
        "* **Diagnosis:** The question asks for the clinical stage of chronic venous disease using the CEAP classification based on the patient's signs.",
        "* **Clinical Presentation:** The patient has two key findings described and shown in Photo 1:\n  1. **Prominent veins:** These are varicose veins.\n  2. **Skin changes:** The skin around the ankle is described as hardened (induration/lipodermatosclerosis) and has pigmentation (hemosiderin staining).",
        "* **CEAP Classification System:** This system is used to classify patients with chronic venous disorders. The 'C' component refers to the clinical signs.",
        "* **CEAP Clinical Stages:**\n  - **C0:** No visible or palpable signs of venous disease.\n  - **C1:** Telangiectasias or reticular veins.\n  - **C2:** Varicose veins.\n  - **C3:** Edema.\n  - **C4:** Changes in skin and subcutaneous tissue secondary to venous disease.\n    - **C4a:** Pigmentation or eczema.\n    - **C4b:** Lipodermatosclerosis or atrophie blanche.\n  - **C5:** Healed venous ulcer.\n  - **C6:** Active venous ulcer.",
        "* **Applying CEAP to the Patient:**\n  - The presence of varicose veins qualifies the patient for at least stage C2.\n  - The presence of skin pigmentation and hardening (lipodermatosclerosis) qualifies the patient for stage C4 (specifically C4a and C4b).\n  - According to the CEAP guidelines, the patient is classified by the most advanced clinical sign present.",
        "* **Conclusion:** Since the patient has skin changes (pigmentation and lipodermatosclerosis), which are characteristic of stage C4, this is the correct classification. The presence of varicose veins (C2) is also noted, but C4 represents a more advanced stage of the disease."
      ],
      "others": [
        {
          "label": "①",
          "text": "C2",
          "reason": "Incorrect. While the patient does have varicose veins (C2), they also have more advanced signs, specifically skin pigmentation and hardening (lipodermatosclerosis), which places them in a higher clinical class."
        },
        {
          "label": "②",
          "text": "C3",
          "reason": "Incorrect. C3 refers to edema. Although the patient may have edema, the presence of skin changes like pigmentation and lipodermatosclerosis defines a more severe stage (C4)."
        },
        {
          "label": "④",
          "text": "C5",
          "reason": "Incorrect. Stage C5 is defined by the presence of a healed venous ulcer. There is no history or evidence of a healed ulcer mentioned in the vignette."
        },
        {
          "label": "⑤",
          "text": "C6",
          "reason": "Incorrect. Stage C6 is defined by an active venous ulcer. The patient's skin shows chronic changes but no active ulceration is described."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "C4"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** The CEAP (Clinical, Etiologic, Anatomic, Pathophysiologic) classification system is the international standard for describing patients with chronic venous disorders.",
        "* **Pathophysiology:** Chronic venous insufficiency leads to venous hypertension, causing capillary leakage, inflammation, hemosiderin deposition from red blood cell breakdown (pigmentation), and fibrosis of subcutaneous fat and skin (lipodermatosclerosis).",
        "* **Criteria/Thresholds (CEAP Clinical Classification):** The 'C' component grades the severity of clinical signs. A patient is classified by their most advanced sign.",
        "  - **C0:** No visible or palpable signs of venous disease.",
        "  - **C1:** Telangiectasias or reticular veins.",
        "  - **C2:** Varicose veins.",
        "  - **C3:** Edema.",
        "  - **C4:** Skin changes secondary to venous disease.",
        "    - **C4a:** Pigmentation or eczema.",
        "    - **C4b:** Lipodermatosclerosis or atrophie blanche.",
        "  - **C5:** Healed venous ulcer.",
        "  - **C6:** Active venous ulcer.",
        "* **Application:** This patient has varicose veins (C2) but also has skin pigmentation and hardening (lipodermatosclerosis), which are C4 findings. Therefore, the correct classification is C4.",
        "* **Workup:** Duplex ultrasound is the primary diagnostic tool to confirm venous reflux and map the anatomy for treatment planning.",
        "* **Management:** Management is stage-dependent and includes lifestyle modification, compression therapy (cornerstone for C2-C6), and procedural interventions like endovenous ablation or sclerotherapy for refluxing veins.",
        "* **Pitfalls (general):** Under-classifying a patient by focusing only on varicose veins (C2) while ignoring more advanced skin changes (C4) or edema (C3). Attributing leg swelling and skin changes to other causes without considering venous insufficiency."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "50",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "Grade 3"
      },
      "why": [
        "* **Diagnosis:** The question requires grading the patient's dyspnea using the Modified Medical Research Council (mMRC) scale.",
        "* **Clinical Presentation:** A 71-year-old man reports that he gets short of breath while walking on level ground and must stop after approximately 100 meters.",
        "* **mMRC Dyspnea Scale:** This is a simple, 5-point (0-4) scale used to quantify the degree of disability due to breathlessness, commonly in patients with chronic respiratory diseases like COPD.",
        "* **mMRC Scale Definitions:**\n  - **Grade 0:** Breathless only with strenuous exercise.\n  - **Grade 1:** Short of breath when hurrying on level ground or walking up a slight hill.\n  - **Grade 2:** Walks slower than people of the same age on level ground due to breathlessness, or has to stop for breath when walking at own pace on the level.\n  - **Grade 3:** Stops for breath after walking about 100 meters (or after a few minutes) on level ground.\n  - **Grade 4:** Too breathless to leave the house, or breathless when dressing/undressing.",
        "* **Application to Case:** The patient's statement, \"he has to stop after walking only about 100 meters,\" directly and precisely matches the description for mMRC Grade 3.",
        "* **Clinical Significance:** The mMRC score is a key component in assessing COPD severity (e.g., in the GOLD guidelines), guiding treatment decisions, and predicting prognosis. An mMRC score of ≥2 indicates a higher level of symptoms."
      ],
      "others": [
        {
          "label": "①",
          "text": "Grade 0",
          "reason": "Incorrect. Grade 0 describes breathlessness only with strenuous exercise. This patient has severe limitations with minimal activity."
        },
        {
          "label": "②",
          "text": "Grade 1",
          "reason": "Incorrect. Grade 1 describes breathlessness when hurrying or walking up a slight hill. This patient's symptoms are far more severe, occurring with slow walking on level ground."
        },
        {
          "label": "③",
          "text": "Grade 2",
          "reason": "Incorrect. Grade 2 describes walking slower than peers or having to stop when walking at one's own pace. The patient's specific limitation of stopping after 100 meters is a more severe condition that fits Grade 3."
        },
        {
          "label": "⑤",
          "text": "Grade 4",
          "reason": "Incorrect. Grade 4 describes being too breathless to leave the house or becoming breathless with activities of daily living like dressing. This patient is still able to walk 100 meters outside."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "Grade 3"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** The Modified Medical Research Council (mMRC) dyspnea scale is a simple, validated tool used to grade the severity of breathlessness and its impact on daily activities.",
        "* **Purpose:** It is widely used in chronic respiratory diseases, particularly COPD, to quantify symptoms, guide therapy, and assess prognosis.",
        "* **Criteria/Thresholds (mMRC Scale):** The scale ranges from 0 to 4, based on the activity level that provokes dyspnea.",
        "  - **Grade 0:** Breathless only with strenuous exercise.",
        "  - **Grade 1:** Short of breath when hurrying on level ground or walking up a slight hill.",
        "  - **Grade 2:** Walks slower than people of the same age on level ground because of breathlessness, or has to stop for breath when walking at their own pace on the level.",
        "  - **Grade 3:** Stops for breath after walking about 100 meters or after a few minutes on level ground.",
        "  - **Grade 4:** Too breathless to leave the house or breathless when dressing or undressing.",
        "* **Application:** The patient's statement that he must stop after walking about 100 meters on level ground is the precise definition of mMRC Grade 3.",
        "* **Clinical Significance (COPD):** The mMRC score is a key component of the GOLD guidelines for COPD assessment. An mMRC score of 0-1 indicates fewer symptoms, while a score of ≥2 indicates more symptoms, which influences the patient's classification (e.g., GOLD Group B or D) and treatment recommendations.",
        "* **Differential/Discriminators:** It is important to distinguish between Grade 2 (slowing down or stopping at own pace) and Grade 3 (stopping after a specific, short distance).",
        "* **Pitfalls (general):** Subjectively estimating a patient's dyspnea without using a standardized scale like the mMRC. Confusing the definitions between adjacent grades on the scale."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "51",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "비침습양압환기"
      },
      "why": [
        "* **Diagnosis:** Acute-on-chronic hypercapnic respiratory failure, likely secondary to an infectious exacerbation of Chronic Obstructive Pulmonary Disease (COPD).",
        "* **Clinical Presentation:** The patient is a 68-year-old male with a long smoking history and prior use of inhalers (suggesting underlying COPD). He presents with acute respiratory distress (tachypnea RR 30/min, severe dyspnea) and symptoms of a respiratory infection (fever, chills, cough, sputum).",
        "* **Lab Findings (Arterial Blood Gas):**\n  - **pH 7.36:** Within the normal range (7.35-7.45), but on the acidotic side, indicating compensation.\n  - **PaCO2 54 mmHg:** Elevated (normal ~35-45 mmHg), indicating hypercapnic respiratory acidosis.\n  - **PaO2 48 mmHg:** Severely low (normal >80 mmHg), indicating significant hypoxemia.\n  - **HCO3- 30 mmol/L:** Elevated (normal 22-26 mmol/L), indicating metabolic compensation for chronic respiratory acidosis.",
        "* **Interpretation:** The ABG shows acute-on-chronic respiratory failure. The elevated bicarbonate indicates the patient is a chronic CO2 retainer, and the current illness has caused acute decompensation with worsening hypercapnia and severe hypoxemia. Despite the high PaCO2, the pH is compensated, suggesting the process is not yet critically severe.",
        "* **Treatment Principle:** The primary goal in a COPD exacerbation with hypercapnic respiratory failure is to improve alveolar ventilation to decrease PaCO2 and correct hypoxemia, while reducing the work of breathing.",
        "* **Management Guidelines:** For conscious and cooperative patients with acute hypercapnic respiratory failure due to a COPD exacerbation, non-invasive positive pressure ventilation (NIPPV), such as Bi-level Positive Airway Pressure (BiPAP), is the first-line treatment.",
        "* **Mechanism of NIPPV:** NIPPV provides inspiratory pressure support to augment the patient's tidal volume and expiratory pressure to stent airways open. This reduces the work of breathing, improves gas exchange (lowers PaCO2, raises PaO2), and has been shown to decrease the need for endotracheal intubation, hospital length of stay, and mortality.",
        "* **Patient Candidacy:** This patient is an ideal candidate for NIPPV as he is conscious, hemodynamically stable, and able to protect his airway."
      ],
      "others": [
        {
          "label": "①",
          "text": "항생제",
          "reason": "Antibiotics are indicated for a likely infectious exacerbation of COPD and should be given. However, they do not address the immediate, life-threatening problem of respiratory failure. Ventilatory support is the most urgent intervention."
        },
        {
          "label": "②",
          "text": "호흡재활",
          "reason": "Respiratory rehabilitation is a crucial component of long-term, stable COPD management. It is not an appropriate intervention for an acute exacerbation with respiratory failure."
        },
        {
          "label": "③",
          "text": "고농도 산소",
          "reason": "Administering high-concentration oxygen to a patient with chronic CO2 retention can suppress their hypoxic respiratory drive. This can lead to worsening hypercapnia, profound respiratory acidosis, and respiratory arrest."
        },
        {
          "label": "⑤",
          "text": "기관내 삽관 후 기계환기",
          "reason": "Invasive mechanical ventilation is indicated if NIPPV fails or if the patient presents with contraindications to NIPPV (e.g., altered mental status, inability to protect airway, hemodynamic instability, severe acidosis with pH < 7.25). This patient is conscious and his pH is compensated, so NIPPV should be tried first."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "비침습양압환기"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** This patient presents with an acute exacerbation of COPD, leading to acute-on-chronic hypercapnic respiratory failure.",
        "* **Workup (ABG Interpretation):** The arterial blood gas (ABG) is critical for diagnosis and management.",
        "  - **PaO₂ 48 mmHg:** Severe hypoxemia.",
        "  - **PaCO₂ 54 mmHg:** Acute hypercapnia (respiratory acidosis).",
        "  - **HCO₃⁻ 30 mmol/L:** Elevated, indicating chronic CO₂ retention with metabolic compensation.",
        "  - **pH 7.36:** Compensated acidosis, but the patient is tiring (RR 30/min) and at risk of decompensation.",
        "* **Management (algorithmic):** The primary goal is to improve alveolar ventilation, reduce the work of breathing, and correct gas exchange abnormalities.",
        "* **First-line Treatment:** For a conscious, cooperative patient with acute hypercapnic respiratory failure from a COPD exacerbation, Non-Invasive Positive Pressure Ventilation (NIPPV), such as BiPAP, is the standard of care.",
        "* **Mechanism of NIPPV:** NIPPV provides inspiratory pressure to augment tidal volume (improving ventilation and lowering PaCO₂) and expiratory pressure (PEEP) to prevent alveolar collapse and improve oxygenation. This reduces the work of breathing and prevents respiratory muscle fatigue.",
        "* **Benefits of NIPPV:** It is proven to decrease the need for endotracheal intubation, reduce hospital length of stay, and lower mortality.",
        "* **Criteria for Intubation:** NIPPV should be avoided or discontinued in favor of invasive mechanical ventilation if the patient has altered mental status, is unable to protect their airway, is hemodynamically unstable, has copious secretions, or fails to improve (e.g., worsening acidosis with pH < 7.25).",
        "* **Adjunctive Therapies:** Other essential treatments include controlled oxygen therapy (to target SpO₂ 88-92%), inhaled bronchodilators, systemic corticosteroids, and antibiotics for suspected infection.",
        "* **Pitfalls (general):**\n  - Administering uncontrolled high-flow oxygen, which can suppress the hypoxic drive and worsen hypercapnia.\n  - Delaying the initiation of NIPPV in a patient with respiratory muscle fatigue.\n  - Persisting with NIPPV in a patient who is clearly failing the trial."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "52",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "심실중격결손"
      },
      "why": [
        "* **Diagnosis:** Large Ventricular Septal Defect (VSD) causing congestive heart failure (CHF).",
        "* **Clinical Presentation:** The 4-month-old infant displays classic signs of CHF: tachypnea, feeding difficulties (fatigue during feeds), poor weight gain (failure to thrive), and decreased urine output. These symptoms arise from pulmonary overcirculation and inadequate systemic cardiac output.",
        "* **Image Findings (Phonocardiogram - fig 1):** The diagram shows a loud, harsh murmur that begins with the first heart sound (S1) and continues throughout systole, obscuring the second heart sound (S2). This is the classic pattern of a holosystolic (or pansystolic) murmur.",
        "* **Image Findings (Chest X-ray - fig 2):** The radiograph reveals cardiomegaly (enlarged cardiac silhouette) and increased pulmonary vascular markings (pulmonary plethora). These findings are characteristic of a significant left-to-right shunt, leading to volume overload of the pulmonary arteries, left atrium, and left ventricle.",
        "* **Pathophysiology:** A VSD is a hole in the septum between the left and right ventricles. In a large VSD, after the physiologic drop in pulmonary vascular resistance in the first few weeks of life, a large volume of oxygenated blood shunts from the high-pressure left ventricle to the low-pressure right ventricle. This leads to excessive blood flow to the lungs (pulmonary plethora) and volume overload of the left heart, resulting in CHF.",
        "* **Auscultatory Findings:** The holosystolic murmur is caused by the turbulent flow of blood across the VSD throughout systole. It is typically best heard at the lower left sternal border, as described in the vignette.",
        "* **Differential / Discriminators:** The combination of CHF symptoms, a holosystolic murmur at the left sternal border, and CXR findings of cardiomegaly and pulmonary plethora is textbook for a large VSD.",
        "* **Conclusion:** VSD is the most common congenital heart defect and the most likely diagnosis given the complete clinical, auscultatory, and radiographic picture."
      ],
      "others": [
        {
          "label": "①",
          "text": "동맥관개존증",
          "reason": "A large Patent Ductus Arteriosus (PDA) can cause similar CHF symptoms and radiographic findings. However, the classic murmur of a PDA is a continuous 'machinery' murmur heard best at the left infraclavicular area, which does not match the holosystolic murmur described."
        },
        {
          "label": "③",
          "text": "심방중격결손",
          "reason": "An Atrial Septal Defect (ASD) rarely causes heart failure in infancy. Its characteristic murmur is a soft systolic ejection murmur at the upper left sternal border with a fixed, widely split S2."
        },
        {
          "label": "④",
          "text": "승모판역류",
          "reason": "Mitral regurgitation can cause a holosystolic murmur, but it is typically best heard at the apex and radiates to the axilla. While it can cause CHF, a large VSD is a much more common cause of this presentation in infancy."
        },
        {
          "label": "⑤",
          "text": "대동맥판역류",
          "reason": "Aortic regurgitation causes a diastolic murmur, not a holosystolic one. It is not consistent with the findings."
        }
      ],
      "runner_up": "① 동맥관개존증",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 0.9,
      "rethink": {
        "mismatch": true,
        "first_guess": {
          "label": "②",
          "text": "심실중격결손"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "override_key",
        "note": "The key suggests PDA, but the phonocardiogram and murmur location (left sternal border) are classic for VSD. Both can cause CHF and similar CXR findings, but the auscultatory findings are the primary discriminator here and point strongly to VSD.",
        "override_key": true
      },
      "teaching_points": [
        "* **Clinical picture:** A large Ventricular Septal Defect (VSD) is the most common congenital heart defect. Infants typically become symptomatic at 4-8 weeks of age as pulmonary vascular resistance (PVR) falls.",
        "* **Presentation:** Classic signs are those of congestive heart failure (CHF) due to a large left-to-right shunt: tachypnea, tachycardia, poor feeding, diaphoresis with feeding, and failure to thrive.",
        "* **Auscultation:** The hallmark of a VSD is a loud, harsh, holosystolic (pansystolic) murmur heard best at the lower left sternal border. A palpable thrill is often present.",
        "* **Pathophysiology:** After PVR drops, oxygenated blood shunts from the high-pressure left ventricle to the low-pressure right ventricle. This leads to excessive pulmonary blood flow (pulmonary plethora) and volume overload of the left atrium and left ventricle, causing cardiomegaly and CHF.",
        "* **Workup:**\n  - **Chest X-ray:** Shows cardiomegaly and increased pulmonary vascular markings.\n  - **Echocardiogram:** The definitive diagnostic test. It visualizes the defect, determines its size and location, estimates the shunt magnitude, and assesses ventricular function.",
        "* **Management:**\n  - **Medical:** Initial management focuses on controlling CHF with diuretics (e.g., furosemide) and sometimes digoxin or afterload reduction.\n  - **Surgical:** Surgical closure is indicated for large VSDs causing refractory CHF, failure to thrive, or evidence of developing pulmonary hypertension.",
        "* **Differential/Discriminators:**\n  - **Patent Ductus Arteriosus (PDA):** Causes similar CHF symptoms but has a continuous 'machinery' murmur.\n  - **Atrial Septal Defect (ASD):** Rarely causes CHF in infancy and has a systolic ejection murmur with a fixed, widely split S2.",
        "* **Pitfalls (general):** A very large, non-restrictive VSD may have a softer or absent murmur due to pressure equalization between ventricles. The onset of symptoms is delayed until PVR falls, so a newborn may appear well."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "53",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "당뇨병"
      },
      "why": [
        "* **Diagnosis:** Type 2 Diabetes Mellitus.",
        "* **Diagnostic Criteria (ADA/KDA):** The diagnosis of diabetes mellitus can be made if any one of the following criteria is met and confirmed on a subsequent day, or if two criteria are met from the same or different samples:\n  - **Fasting Plasma Glucose (FPG):** ≥ 126 mg/dL (7.0 mmol/L)\n  - **Hemoglobin A1c (HbA1c):** ≥ 6.5% (48 mmol/mol)\n  - **2-hour plasma glucose during OGTT:** ≥ 200 mg/dL (11.1 mmol/L)\n  - **Random plasma glucose:** ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia.",
        "* **Patient's Lab Findings:** This patient meets two of the diagnostic criteria for diabetes:\n  - **Initial FPG:** The screening fasting glucose was 129 mg/dL, which is ≥ 126 mg/dL.\n  - **HbA1c:** The hospital-measured HbA1c was 6.6%, which is ≥ 6.5%.",
        "* **Interpretation:** Although the repeat fasting glucose at the hospital was 119 mg/dL (in the impaired fasting glucose range), the HbA1c value reflects the average blood glucose over the preceding 2-3 months and is definitively in the diabetic range. Having two different tests (initial FPG and HbA1c) meet the criteria is sufficient to make the diagnosis.",
        "* **Clinical Picture:** The patient is asymptomatic, which is a common presentation for newly diagnosed Type 2 diabetes. The presence of dyslipidemia (Total cholesterol 256 mg/dL, Triglycerides 345 mg/dL) is also a frequent comorbidity.",
        "* **Urinalysis:** The finding of glycosuria (Glucose 1+) supports the diagnosis of hyperglycemia, as glucose typically spills into the urine when blood glucose levels exceed the renal reabsorptive capacity (around 180 mg/dL).",
        "* **Conclusion:** Based on an HbA1c of 6.6% and a prior fasting glucose of 129 mg/dL, the diagnosis is diabetes mellitus. Further testing with an oral glucose tolerance test is not required."
      ],
      "others": [
        {
          "label": "①",
          "text": "정상혈당",
          "reason": "This is incorrect. A fasting glucose of 119 mg/dL and an HbA1c of 6.6% are both above the normal range."
        },
        {
          "label": "③",
          "text": "내당능장애",
          "reason": "Impaired glucose tolerance is diagnosed by a 2-hour post-OGTT glucose of 140-199 mg/dL. This test was not performed, and the patient's HbA1c already meets the criteria for diabetes."
        },
        {
          "label": "④",
          "text": "공복혈당장애",
          "reason": "Impaired fasting glucose (FPG 100-125 mg/dL) describes a prediabetic state. While the patient's second FPG falls in this range, her HbA1c of 6.6% is in the diabetic range, making diabetes the more accurate and complete diagnosis."
        },
        {
          "label": "⑤",
          "text": "진단불가, 경구포도당부하검사 필요함.",
          "reason": "The diagnosis is possible with the available information. The HbA1c value of ≥ 6.5% is a standalone diagnostic criterion for diabetes, making an OGTT unnecessary for diagnosis."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "당뇨병"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Type 2 Diabetes Mellitus (T2DM) is often diagnosed through screening in asymptomatic individuals. It is frequently associated with other metabolic conditions like dyslipidemia and hypertension.",
        "* **Criteria/Thresholds (Diagnosis of Diabetes):** The diagnosis can be made if any one of the following criteria is met, typically requiring confirmation with a repeat test.",
        "  - **Hemoglobin A1c (HbA1c) ≥ 6.5%**",
        "  - **Fasting Plasma Glucose (FPG) ≥ 126 mg/dL** (fasting is defined as no caloric intake for at least 8 hours)",
        "  - **2-hour plasma glucose ≥ 200 mg/dL** during a 75g oral glucose tolerance test (OGTT)",
        "  - **Random plasma glucose ≥ 200 mg/dL** in a patient with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss).",
        "* **Application:** This patient meets the diagnostic criteria for diabetes based on two separate tests: an initial screening FPG of 129 mg/dL (≥126) and a subsequent HbA1c of 6.6% (≥6.5).",
        "* **Role of HbA1c:** HbA1c reflects the average blood glucose concentration over the preceding 2-3 months and is a reliable measure for diagnosis and monitoring. It is less susceptible to day-to-day variations than plasma glucose.",
        "* **Prediabetes Categories:** It is important to recognize the categories for increased risk of diabetes (prediabetes):",
        "  - **Impaired Fasting Glucose (IFG):** FPG 100-125 mg/dL.",
        "  - **Impaired Glucose Tolerance (IGT):** 2-hour OGTT glucose 140-199 mg/dL.",
        "  - **HbA1c:** 5.7-6.4%.",
        "* **Workup:** An OGTT is not necessary for diagnosis in this case because the FPG and HbA1c results are already diagnostic.",
        "* **Urinalysis:** Glycosuria (glucose in the urine) occurs when the filtered load of glucose exceeds the reabsorptive capacity of the renal tubules, typically when blood glucose is >180 mg/dL. It supports the diagnosis of hyperglycemia but is not a primary diagnostic criterion.",
        "* **Pitfalls (general):** Not making a diagnosis when two different tests meet the criteria. Relying on a single abnormal value without confirmation. Delaying diagnosis by ordering an unnecessary OGTT when other criteria are already met."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "54",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "폐암이 의심되어 조직검사를 시행한다."
      },
      "why": [
        "* **Diagnosis:** High-risk solitary pulmonary nodule (SPN), highly suspicious for lung cancer.",
        "* **Clinical Presentation:** The patient is a 72-year-old male, a high-risk individual for lung cancer due to his advanced age and extensive smoking history (40 pack-years), even though he quit 11 years ago. The nodule was found incidentally, and he is asymptomatic, which is common for early-stage lung cancer.",
        "* **Image Findings:**\n  - **Chest X-ray:** Reveals a nodule in the right upper lobe.\n  - **Chest CT:** Confirms a solid, irregularly shaped nodule with spiculated margins in the right upper lobe. Spiculated or irregular margins are one of the strongest radiologic predictors of malignancy in an SPN.",
        "* **Risk Assessment:** The combination of patient risk factors (age, smoking history) and nodule characteristics (solid, spiculated) places this lesion at a high pre-test probability for being malignant.",
        "* **Diagnostic Algorithm:** According to guidelines for managing SPNs (e.g., Fleischner Society, ACCP), a solid nodule of this size and appearance in a high-risk patient warrants definitive diagnostic action.",
        "* **Next Step in Management:** The most appropriate next step is to obtain a tissue sample for histopathological diagnosis. This confirms the diagnosis, determines the cancer type (e.g., adenocarcinoma, squamous cell carcinoma), and allows for molecular testing, which guides treatment.",
        "* **Biopsy Methods:** For a peripheral nodule like this, a transthoracic needle biopsy (TTNB) under CT guidance is a common and effective method. Alternatively, bronchoscopy with navigational tools could be used.",
        "* **Conclusion:** Dismissing the nodule as a scar or pursuing investigations for less likely causes like TB would be inappropriate and potentially harmful. A tissue biopsy is the necessary next step to confirm the strong suspicion of lung cancer."
      ],
      "others": [
        {
          "label": "①",
          "text": "폐결핵이 의심되어 객담검사를 시행한다.",
          "reason": "While tuberculosis can present as a nodule, the spiculated appearance in an elderly heavy smoker makes lung cancer far more likely. Sputum tests for TB would be a low-yield first step."
        },
        {
          "label": "②",
          "text": "폐기종이 의심되어 폐기능 검사를 시행한다.",
          "reason": "The CT does show emphysema, but the critical finding is the suspicious nodule. Pulmonary function tests (PFTs) are important for pre-operative assessment but do not help diagnose the nodule itself."
        },
        {
          "label": "③",
          "text": "만성폐쇄성폐질환이 의심되어 폐기능 검사를 시행한다.",
          "reason": "Similar to option ②, diagnosing or evaluating COPD is not the priority. The urgent task is to diagnose the lung nodule which is highly suspicious for cancer."
        },
        {
          "label": "④",
          "text": "과거 폐결핵 흔적으로 추가검사는 불필요하다.",
          "reason": "This is a dangerous conclusion. A new or uncharacterized spiculated nodule in a high-risk patient must be presumed malignant until proven otherwise. Ignoring it could lead to a delay in diagnosing a curable cancer."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "폐암이 의심되어 조직검사를 시행한다."
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A solitary pulmonary nodule (SPN) is a single, well-circumscribed lesion ≤3 cm in diameter, completely surrounded by lung parenchyma. Most are found incidentally.",
        "* **Workup (Risk Stratification):** The most crucial step in managing an SPN is to assess the pre-test probability of malignancy based on patient and nodule characteristics.",
        "* **High-Risk Patient Factors:** Advanced age, significant smoking history (current or former), personal history of cancer.",
        "* **High-Risk Nodule Features:** Larger size (>8 mm), irregular or spiculated margins, upper lobe location, and documented growth on serial imaging.",
        "* **Application:** This 72-year-old patient with a 40 pack-year smoking history and a spiculated nodule on CT is at very high risk for lung cancer.",
        "* **Management (algorithmic):**\n  - **Low Risk:** Serial CT surveillance is appropriate.\n  - **Intermediate Risk:** May benefit from further non-invasive testing like a PET scan to assess metabolic activity before deciding on biopsy.\n  - **High Risk:** Proceed directly to obtaining a tissue diagnosis or surgical resection.",
        "* **Diagnostic Procedure:** For a peripheral nodule, the preferred method for tissue diagnosis is a CT-guided transthoracic needle biopsy (TTNB). For central lesions, bronchoscopy is often used.",
        "* **Differential/Discriminators:** While infectious granulomas (e.g., from TB or fungal infection) are a common cause of benign nodules, a spiculated appearance in a high-risk patient makes malignancy the primary concern.",
        "* **Pitfalls (general):**\n  - Dismissing a new or uncharacterized nodule in a high-risk patient as an old scar or infection without proper workup.\n  - Choosing prolonged surveillance ('watchful waiting') for a high-risk lesion, which can delay the diagnosis of a potentially curable cancer.\n  - Relying on low-yield tests like sputum cytology for peripheral nodules."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "55",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "폐렴구균 (S.pneumoniae) 에 대한 항균력이 있는 항생제를 선택한다."
      },
      "why": [
        "* **Diagnosis:** Community-acquired pneumonia (CAP) requiring hospitalization.",
        "* **Clinical Presentation:** A 65-year-old male with comorbidities (hypertension, diabetes) and risk factors (smoking) presents with a classic acute pneumonia syndrome: fever, cough, and dyspnea.",
        "* **Image Findings:** The chest X-ray shows a consolidation in the right lower lung field, confirming the diagnosis of pneumonia.",
        "* **Severity Assessment:** The patient requires hospitalization based on clinical judgment, considering his age, comorbidities, and vital signs (fever, tachypnea). His CURB-65 score is 1 (for age ≥ 65), which supports admission for observation and treatment.",
        "* **Treatment Principle:** The cornerstone of CAP management is prompt initiation of empirical antibiotic therapy. The choice of antibiotics is guided by the most likely causative pathogens and local resistance patterns.",
        "* **Most Common Pathogen:** *Streptococcus pneumoniae* (pneumococcus) is the most common bacterial cause of CAP in adults. Therefore, any empirical antibiotic regimen for CAP must provide reliable coverage against it.",
        "* **Guideline Recommendations:** For an inpatient, non-ICU setting, standard regimens like a beta-lactam (e.g., ceftriaxone) plus a macrolide (e.g., azithromycin) or monotherapy with a respiratory fluoroquinolone (e.g., levofloxacin) are recommended. Both of these options provide excellent coverage for *S. pneumoniae* and atypical pathogens.",
        "* **Conclusion:** Ensuring coverage for *S. pneumoniae* is the most fundamental and universally correct principle among the choices for the initial treatment of this patient's CAP."
      ],
      "others": [
        {
          "label": "①",
          "text": "원인균을 확인 후 항생제를 투여한다.",
          "reason": "This is incorrect. Delaying antibiotic therapy in pneumonia to await culture results is associated with increased mortality. Treatment should be started empirically as soon as possible."
        },
        {
          "label": "②",
          "text": "페니실린 단독요법은 모든 입원 환자에서 1차 선택이다.",
          "reason": "Penicillin monotherapy is inadequate for empirical treatment of CAP due to high rates of pneumococcal resistance and its lack of coverage for atypical pathogens (like *Mycoplasma* or *Legionella*)."
        },
        {
          "label": "③",
          "text": "입원환자에서는 반드시 macrolide 항생제 병용이 필요하다.",
          "reason": "This is not strictly true. While combination therapy with a macrolide is a primary recommended regimen, monotherapy with a respiratory fluoroquinolone is an acceptable alternative. The principle is to cover both typical and atypical pathogens."
        },
        {
          "label": "⑤",
          "text": "최소14일간 항생제를 유지한다.",
          "reason": "The recommended duration of therapy for uncomplicated CAP is typically 5 to 7 days, as long as the patient is afebrile and clinically stable for at least 48-72 hours. A 14-day course is unnecessarily long."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "폐렴구균 (S.pneumoniae) 에 대한 항균력이 있는 항생제를 선택한다."
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Community-acquired pneumonia (CAP) is an acute infection of the pulmonary parenchyma in a patient who has not been recently hospitalized. Classic symptoms include fever, cough, dyspnea, and pleuritic chest pain.",
        "* **Workup:** Diagnosis is confirmed by a new infiltrate on chest X-ray. Severity assessment scores like CURB-65 or PSI help determine the appropriate site of care (outpatient, inpatient ward, or ICU).",
        "* **Treatment Principle:** Prompt initiation of empirical antibiotic therapy is crucial and has been shown to improve outcomes. Treatment should not be delayed while awaiting microbiological results.",
        "* **Microbiology:** *Streptococcus pneumoniae* is the most common bacterial pathogen responsible for CAP across all settings. Therefore, any empirical antibiotic regimen must provide reliable coverage against it.",
        "* **Management (Inpatient, Non-ICU):** Guideline-recommended regimens are designed to cover both *S. pneumoniae* and atypical pathogens (e.g., *Mycoplasma*, *Legionella*).",
        "  - **Option 1:** A beta-lactam (e.g., ceftriaxone, ampicillin-sulbactam) PLUS a macrolide (e.g., azithromycin).",
        "  - **Option 2:** Monotherapy with a respiratory fluoroquinolone (e.g., levofloxacin, moxifloxacin).",
        "* **Monitoring/Follow-up:** The typical duration of therapy for uncomplicated CAP is a minimum of 5 days, and the patient should be afebrile for 48-72 hours and clinically stable before discontinuation.",
        "* **Pitfalls (general):**\n  - Delaying the first dose of antibiotics.\n  - Using penicillin monotherapy, which is inadequate due to resistance and lack of atypical coverage.\n  - Prescribing an unnecessarily long course of antibiotics (e.g., 14 days) for uncomplicated CAP."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "56",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "anti-TSH-Receptor Ab"
      },
      "why": [
        "* **Diagnosis:** Overt primary hyperthyroidism (thyrotoxicosis) in the postpartum period.",
        "* **Clinical Presentation:** The 36-year-old woman presents with classic signs and symptoms of thyrotoxicosis (weight loss, palpitations, sweating, tremor, fatigue) that began 6 months after childbirth.",
        "* **Lab Findings:** The thyroid function tests confirm primary hyperthyroidism:\n  - **TSH <0.01 mIU/L:** Suppressed, indicating the pituitary is responding correctly to high thyroid hormone levels.\n  - **fT4 3.24 ng/dL & T3 320 ng/dL:** Both are significantly elevated, confirming the thyroid gland is the source of the excess hormone.",
        "* **Differential Diagnosis:** In the postpartum setting, the two most likely causes of thyrotoxicosis are:\n  - **Graves' disease:** An autoimmune disorder where stimulating antibodies target the TSH receptor, causing the thyroid to overproduce hormone. It is the most common cause of hyperthyroidism overall.\n  - **Postpartum thyroiditis:** A destructive (inflammatory) process that releases pre-formed thyroid hormone from the damaged gland. It is typically transient.",
        "* **Diagnostic Challenge:** It is crucial to differentiate between these two conditions as their management differs. The standard test to do this is a radioactive iodine uptake (RAIU) scan, which would show high uptake in Graves' disease and low uptake in thyroiditis.",
        "* **Contraindication:** The patient is breastfeeding. Radioisotopes like ¹³¹I or ⁹⁹ᵐTc are excreted in breast milk and are therefore contraindicated, as they would expose the infant to radiation.",
        "* **Best Alternative Test:** When an RAIU scan is contraindicated, measuring TSH-receptor antibodies (TRAb) is the best alternative test. A positive TRAb test is highly specific and diagnostic for Graves' disease.",
        "* **Conclusion:** To determine the etiology of this patient's postpartum thyrotoxicosis without using a contraindicated radioisotope scan, measuring anti-TSH-Receptor antibodies is the most appropriate and necessary next diagnostic step."
      ],
      "others": [
        {
          "label": "①",
          "text": "1311 thyroid scan",
          "reason": "This is incorrect. Radioactive iodine-131 is absolutely contraindicated during breastfeeding due to its secretion into breast milk."
        },
        {
          "label": "②",
          "text": "99mTc thyroid scan",
          "reason": "This is incorrect. Technetium-99m is also secreted in breast milk and is contraindicated or requires a significant interruption of breastfeeding, making it an unsuitable first-line test in this patient."
        },
        {
          "label": "③",
          "text": "anti-Thyroglobulin Ab",
          "reason": "Anti-thyroglobulin antibodies are non-specific markers of thyroid autoimmunity. They can be elevated in both Graves' disease and postpartum thyroiditis and therefore cannot differentiate between the two."
        },
        {
          "label": "⑤",
          "text": "anti-Thyroperoxidase Ab",
          "reason": "Anti-thyroperoxidase (TPO) antibodies are also non-specific. While often present in both Graves' disease and postpartum thyroiditis, they do not help distinguish the cause of the hyperthyroidism."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "anti-TSH-Receptor Ab"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** New-onset thyrotoxicosis in the postpartum period presents a key diagnostic challenge: differentiating Graves' disease from postpartum thyroiditis.",
        "* **Differential Diagnosis:**\n  - **Graves' Disease:** An autoimmune disorder caused by TSH-receptor stimulating antibodies (TRAb), leading to true hyperthyroidism (hormone overproduction). Requires treatment with anti-thyroid drugs.",
        "  - **Postpartum Thyroiditis:** An autoimmune destructive process that causes a transient release of pre-formed thyroid hormone. It is managed symptomatically with beta-blockers and does not respond to anti-thyroid drugs.",
        "* **Workup:** The thyroid function tests (suppressed TSH, elevated fT4/T3) confirm thyrotoxicosis but do not reveal the etiology.",
        "* **Standard Diagnostic Test:** A radioactive iodine uptake (RAIU) scan is the standard test to differentiate the two conditions. Uptake is high in Graves' disease and low or absent in thyroiditis.",
        "* **Criteria/Thresholds (Contraindication):** Radioactive iodine (¹³¹I or ¹²³I) and technetium (⁹⁹ᵐTc) are excreted in breast milk and are therefore **contraindicated** in breastfeeding mothers.",
        "* **Best Alternative Test:** When an RAIU scan is contraindicated, measuring the TSH-receptor antibody (TRAb) level is the most appropriate next step.",
        "* **Interpretation of TRAb:** A positive TRAb test is highly specific for and confirms the diagnosis of Graves' disease. A negative test in this context strongly suggests postpartum thyroiditis.",
        "* **Role of Other Antibodies:** Anti-thyroperoxidase (TPO) and anti-thyroglobulin (Tg) antibodies are often elevated in both conditions and are therefore not useful for distinguishing between them.",
        "* **Pitfalls (general):** Ordering a radioisotope scan in a breastfeeding patient. Incorrectly treating the thyrotoxic phase of postpartum thyroiditis with anti-thyroid medications."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "57",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "CT Colonography는 대장 용종의 발견에 유용하다."
      },
      "why": [
        "* **Correct Statement Analysis:** CT Colonography (CTC), also known as virtual colonoscopy, is a well-established imaging technique for colorectal cancer screening.",
        "* **Technique:** CTC involves acquiring thin-slice CT images of a cleansed and air-distended colon. Sophisticated software then creates 2D and 3D reconstructions that allow a radiologist to navigate through the colon lumen virtually.",
        "* **Clinical Utility:** The primary purpose of CTC is to detect colorectal polyps and cancers. It is a non-invasive alternative to conventional optical colonoscopy.",
        "* **Performance:** Numerous studies have shown that CTC has high sensitivity and specificity for detecting clinically significant adenomatous polyps, particularly those 10 mm or larger in size. Its performance is comparable to optical colonoscopy for large polyps.",
        "* **Advantages:** Advantages include its non-invasive nature, lower risk of perforation compared to optical colonoscopy, and the ability to visualize the entire colon even in cases of obstructing lesions.",
        "* **Limitations:** Limitations include radiation exposure, inability to remove polyps during the same procedure (requiring a subsequent colonoscopy), and lower sensitivity for small (<6 mm) or flat polyps.",
        "* **Conclusion:** Despite its limitations, the statement that CT Colonography is useful for detecting colon polyps is accurate and reflects its current role in clinical practice."
      ],
      "others": [
        {
          "label": "①",
          "text": "Plain radiography 는 위장관의 종양을 진단하는데 매우 민감하다",
          "reason": "This is false. Plain radiography is very insensitive for detecting most GI tumors. It is primarily used to evaluate for complications like bowel obstruction or perforation, not for primary tumor diagnosis."
        },
        {
          "label": "②",
          "text": "UGIS는 위 종양의 국소 침윤 평가에 적합하다.",
          "reason": "This is false. An Upper GI Series (UGIS) is a barium study that visualizes the mucosal lining. It cannot assess the depth of tumor invasion into the stomach wall or spread to lymph nodes; CT and endoscopic ultrasound (EUS) are used for local staging."
        },
        {
          "label": "③",
          "text": "초음파는 대장암 병기 결정 시CT보다 정확하다.",
          "reason": "This is false. Abdominal CT is the standard modality for staging colon cancer, as it evaluates the primary tumor, lymph nodes, and distant metastatic sites like the liver and lungs. Transabdominal ultrasound is significantly less accurate for this purpose."
        },
        {
          "label": "④",
          "text": "CT Enterography에서 점막 표면의 미세 변화를 관찰할 수 있다.",
          "reason": "This is false. CT Enterography is excellent for assessing bowel wall thickness, enhancement, and extra-luminal disease (e.g., in Crohn's disease), but it cannot resolve fine mucosal details like small erosions or villi. Endoscopy is the gold standard for mucosal evaluation."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "CT Colonography는 대장 용종의 발견에 유용하다."
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** CT Colonography (CTC), also known as virtual colonoscopy, is a minimally invasive imaging technique used for colorectal cancer screening.",
        "* **Technique:** CTC requires a full bowel preparation similar to conventional colonoscopy. The colon is then distended with air or carbon dioxide, and thin-slice CT images are acquired. These images are processed to create 2D and 3D views of the colon's interior.",
        "* **Performance:** CTC has high sensitivity and specificity for detecting adenomatous polyps, with performance comparable to optical colonoscopy for polyps ≥10 mm in size.",
        "* **Advantages:** Key advantages include its lower risk of complications (e.g., perforation) compared to optical colonoscopy, the ability to visualize the entire colon even in cases of obstructing lesions, and the detection of extracolonic findings.",
        "* **Limitations:** The main limitations are radiation exposure, lower sensitivity for small (<6 mm) or flat polyps, and the inability to perform a biopsy or polypectomy during the procedure. A positive finding on CTC requires a subsequent conventional colonoscopy for removal.",
        "* **Indications:** CTC is an accepted screening option for average-risk individuals and can be used as a completion study when a conventional colonoscopy is incomplete.",
        "* **Discriminators (Other Modalities):**\n  - **Plain Radiography:** Insensitive for GI tumors; used for obstruction or perforation.\n  - **UGIS (Barium Study):** Visualizes mucosa but cannot assess tumor invasion depth (staging); CT and endoscopic ultrasound (EUS) are used for this.\n  - **CT Enterography:** Excellent for evaluating small bowel wall inflammation (e.g., Crohn's disease) but cannot resolve fine mucosal detail like endoscopy.",
        "* **Pitfalls (general):** Overestimating the ability of certain imaging modalities; for example, assuming a barium study can stage a tumor or that a standard CT can visualize fine mucosal changes."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "58",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "Enteroenteric fistula"
      },
      "why": [
        "* **Diagnosis:** Crohn's disease.",
        "* **Clinical Presentation:** The patient is a young man with a chronic history of abdominal pain, weight loss, diarrhea, and low-grade fever. Laboratory tests confirm anemia and inflammation. This constellation of findings is classic for inflammatory bowel disease (IBD), particularly Crohn's disease.",
        "* **Image Findings:** The provided CT images (likely CT enterography) show characteristic features of Crohn's disease:\n  - **Mural Thickening:** There is marked thickening and enhancement of the bowel wall, likely in the terminal ileum, a common site of involvement.\n  - **Mesenteric Inflammation:** There is associated inflammation in the adjacent mesentery, including fat stranding and prominent vasa recta (the \"comb sign\").",
        "* **Pathophysiology of Crohn's Disease:** Crohn's disease is defined by transmural inflammation, meaning the inflammation extends through the entire thickness of the bowel wall, from the mucosa to the serosa. This is a key feature that distinguishes it from ulcerative colitis, where inflammation is typically limited to the mucosa.",
        "* **Complications of Transmural Inflammation:** The transmural nature of the inflammation predisposes patients to developing penetrating complications, including:\n  - **Fistulas:** Abnormal tracts connecting the bowel to other structures. Enteroenteric fistulas (between loops of bowel) are common.\n  - **Strictures:** Narrowing of the bowel lumen due to fibrosis and scarring from chronic inflammation.\n  - **Abscesses:** Contained collections of pus.",
        "* **Characteristic Finding:** Therefore, the development of an enteroenteric fistula is a hallmark and characteristic feature of Crohn's disease, directly resulting from its underlying pathophysiology.",
        "* **Conclusion:** Among the given options, an enteroenteric fistula is the most characteristic finding associated with the patient's likely diagnosis of Crohn's disease."
      ],
      "others": [
        {
          "label": "①",
          "text": "Apple-core appearance",
          "reason": "The 'apple-core' sign describes a short, annular, constricting lesion with overhanging edges, which is the classic appearance of a colorectal carcinoma on barium enema or CT."
        },
        {
          "label": "②",
          "text": "Bird beak sign",
          "reason": "The 'bird beak' sign refers to the smooth, tapered narrowing of the distal esophagus seen on a barium swallow, which is characteristic of achalasia."
        },
        {
          "label": "③",
          "text": "Pseudoobstruction",
          "reason": "Pseudoobstruction is a functional disorder characterized by signs and symptoms of bowel obstruction without a mechanical blockage. It is a syndrome, not a specific imaging finding characteristic of Crohn's disease."
        },
        {
          "label": "⑤",
          "text": "Rectal involvement",
          "reason": "While Crohn's disease can affect the rectum, rectal sparing is common (occurring in up to 50% of cases). In contrast, ulcerative colitis almost always involves the rectum, making rectal involvement more characteristic of UC than Crohn's."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "Enteroenteric fistula"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by abdominal pain, diarrhea, weight loss, and systemic inflammation. It typically affects young adults.",
        "* **Pathophysiology:** The hallmark of Crohn's disease is **transmural inflammation**, meaning the inflammation extends through the entire thickness of the bowel wall, from mucosa to serosa. It can affect any part of the GI tract in a discontinuous 'skip lesion' pattern.",
        "* **Characteristic Complications:** The transmural nature of the inflammation predisposes patients to penetrating complications, which are characteristic of the disease.",
        "  - **Fistulas:** Abnormal tracts connecting the bowel to other structures (e.g., enteroenteric, enterovesical, enterocutaneous).",
        "  - **Strictures:** Fibrotic narrowing of the bowel lumen, which can lead to obstruction.",
        "  - **Abscesses:** Contained collections of pus, often arising from a microperforation.",
        "* **Workup (Imaging):** CT enterography or MR enterography are the primary imaging modalities. They can show bowel wall thickening, mucosal enhancement, mesenteric inflammation ('creeping fat', 'comb sign'), and the characteristic complications listed above.",
        "* **Differential/Discriminators (vs. Ulcerative Colitis):** Ulcerative colitis involves only the mucosal layer, is continuous, and almost always involves the rectum. Fistulas and strictures are rare in UC.",
        "* **Discriminators (Other Imaging Signs):**\n  - **'Apple-core' sign:** Classic appearance of an annular constricting colorectal carcinoma.\n  - **'Bird beak' sign:** Tapered narrowing of the distal esophagus, characteristic of achalasia.",
        "* **Pitfalls (general):** Mistaking Crohn's disease for infectious colitis or appendicitis initially. Underestimating the extent of disease, as symptoms may not correlate perfectly with inflammatory burden."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "59",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "객담배양"
      },
      "why": [
        "* **Diagnosis:** Suspected miliary tuberculosis (TB).",
        "* **Clinical Presentation:** The patient presents with a subacute cough (2 months) and low-grade fever that did not respond to a course of antibiotics. This history is suggestive of an atypical or chronic infection like tuberculosis.",
        "* **Image Findings:**\n  - **Chest X-ray & CT:** Both imaging studies show a classic miliary pattern. This is defined by innumerable, tiny (1-3 mm), discrete nodules distributed randomly and uniformly throughout both lungs, resembling millet seeds.",
        "* **Pathophysiology:** A miliary pattern is the hallmark of hematogenous (bloodstream) dissemination of an infection or malignancy. The most classic cause is miliary tuberculosis, resulting from the widespread dissemination of *Mycobacterium tuberculosis*.",
        "* **Differential Diagnosis:** While miliary TB is the most likely diagnosis, other considerations for a miliary pattern include disseminated fungal infections (e.g., histoplasmosis), certain metastatic cancers (e.g., thyroid, renal cell), and sarcoidosis.",
        "* **Diagnostic Algorithm:** When pulmonary tuberculosis is suspected, the primary goal is to obtain a microbiological diagnosis.",
        "* **First-Line Investigation:** The standard, least invasive, and most appropriate initial test is to collect sputum samples for acid-fast bacilli (AFB) smear and mycobacterial culture. Sputum induction may be necessary if the patient is not producing sputum spontaneously.",
        "* **Rationale:** A positive sputum smear or culture provides a definitive diagnosis of tuberculosis and allows for drug susceptibility testing to guide therapy. While the sensitivity of sputum smears can be lower in miliary TB compared to cavitary disease, it remains the essential first step before proceeding to more invasive procedures.",
        "* **Conclusion:** Sputum culture is the necessary and standard first-line test for diagnosing the suspected disease."
      ],
      "others": [
        {
          "label": "②",
          "text": "폐기능검사",
          "reason": "Pulmonary function tests would likely show a restrictive pattern due to the diffuse interstitial disease but would not provide an etiological diagnosis."
        },
        {
          "label": "③",
          "text": "폐조직검사",
          "reason": "A lung biopsy is a more invasive procedure. It is the gold standard for diagnosis if less invasive methods like sputum analysis and bronchoscopy with bronchoalveolar lavage are non-diagnostic."
        },
        {
          "label": "④",
          "text": "흉부 자기공명영상",
          "reason": "Chest MRI is generally inferior to CT for evaluating diffuse parenchymal lung disease and is not used for this purpose."
        },
        {
          "label": "⑤",
          "text": "양전자방출단층촬영",
          "reason": "A PET scan would show metabolic activity but cannot reliably distinguish between infection/inflammation (like TB) and malignancy, which are both in the differential diagnosis."
        }
      ],
      "runner_up": "③ 폐조직검사",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "객담배양"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Miliary tuberculosis (TB) results from the massive hematogenous (bloodstream) dissemination of *Mycobacterium tuberculosis*. Patients often present with non-specific constitutional symptoms like fever, night sweats, and weight loss, along with a dry cough.",
        "* **Imaging:** The chest X-ray and CT show a classic miliary pattern, characterized by innumerable, tiny (1-3 mm), discrete nodules distributed uniformly throughout both lungs, resembling millet seeds.",
        "* **Differential Diagnosis:** While miliary TB is the most likely diagnosis for this pattern, other considerations include disseminated fungal infections (e.g., histoplasmosis), certain metastatic cancers (e.g., thyroid, renal cell), and sarcoidosis.",
        "* **Workup (algorithmic):** The primary goal is to obtain a microbiological diagnosis. The workup should proceed from least to most invasive.",
        "* **First-line Investigation:** The most appropriate initial test is to collect multiple sputum samples for acid-fast bacilli (AFB) smear and mycobacterial culture. Sputum induction may be necessary if the patient has a non-productive cough.",
        "* **Second-line Investigation:** If sputum studies are negative, the next step is typically bronchoscopy with bronchoalveolar lavage (BAL) and/or transbronchial biopsy.",
        "* **Third-line Investigation:** If less invasive methods are non-diagnostic, a more invasive procedure like a surgical lung biopsy may be required to obtain tissue for histology and culture.",
        "* **Management:** Treatment is with a standard multi-drug anti-tuberculous regimen (e.g., RIPE: Rifampin, Isoniazid, Pyrazinamide, Ethambutol).",
        "* **Pitfalls (general):** Delaying diagnosis by attributing non-specific symptoms to other causes. Proceeding directly to an invasive lung biopsy before attempting less invasive methods like sputum collection and bronchoscopy."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "60",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "Empagliflozin (SGLT2-inhibitor)"
      },
      "why": [
        "* **Diagnosis:** Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF).",
        "* **Clinical Status:** The patient has a significantly reduced LVEF of 33% and remains symptomatic (dyspnea on exertion) despite being on a robust, three-drug regimen for HFrEF.",
        "* **Guideline-Directed Medical Therapy (GDMT):** Current international guidelines (ACC/AHA/ESC) recommend a four-drug foundational therapy, known as the \"four pillars,\" for all eligible patients with HFrEF to improve survival and reduce hospitalizations.",
        "* **The Four Pillars of HFrEF Therapy:**\n  - **1. ARNI/ACEi/ARB:** The patient is on sacubitril/valsartan (an ARNI).\n  - **2. Evidence-Based Beta-Blocker:** The patient is on carvedilol.\n  - **3. MRA (Mineralocorticoid Receptor Antagonist):** The patient is on spironolactone.\n  - **4. SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitor:** This is the missing class of medication.",
        "* **Patient's Current Regimen:** The patient is already on three of the four pillars (ARNI, beta-blocker, MRA), along with a diuretic for symptom control. This represents excellent but incomplete GDMT.",
        "* **Role of SGLT2 Inhibitors:** Landmark clinical trials (e.g., DAPA-HF, EMPEROR-Reduced) have conclusively shown that SGLT2 inhibitors, such as empagliflozin and dapagliflozin, provide significant morbidity and mortality benefits in patients with HFrEF, irrespective of diabetes status.",
        "* **Patient Candidacy:** This patient's renal function (Creatinine 0.9 mg/dL) and potassium level (K 3.5 mmol/L) are well within the acceptable range for initiating an SGLT2 inhibitor.",
        "* **Conclusion:** To optimize the patient's treatment according to the current standard of care and to further improve his symptoms and prognosis, adding an SGLT2 inhibitor like empagliflozin is the most appropriate next step."
      ],
      "others": [
        {
          "label": "①",
          "text": "Amlodipine (CCB)",
          "reason": "Calcium channel blockers like amlodipine have no mortality benefit in HFrEF and are not part of foundational therapy. They are used for other indications like hypertension or angina if necessary, but would not be added to improve heart failure outcomes."
        },
        {
          "label": "②",
          "text": "Digoxin (digitalis)",
          "reason": "Digoxin is a second-line agent in HFrEF. It can be added to reduce hospitalizations in patients who remain symptomatic despite optimal GDMT, but it does not improve survival and should only be considered after all four pillars are in place."
        },
        {
          "label": "③",
          "text": "Dobutamine (inotrope)",
          "reason": "Dobutamine is an intravenous inotrope used for short-term management of acute decompensated heart failure or cardiogenic shock, not for chronic outpatient therapy."
        },
        {
          "label": "⑤",
          "text": "Finerenoe (non-steroidal MRA)",
          "reason": "The patient is already on spironolactone, a mineralocorticoid receptor antagonist (MRA). Adding another MRA, even a non-steroidal one like finerenone, would be duplicative and is contraindicated due to the high risk of life-threatening hyperkalemia."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "Empagliflozin (SGLT2-inhibitor)"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Diagnosis:** Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF), defined as a left ventricular ejection fraction (LVEF) of ≤40%.",
        "* **Management (algorithmic):** The standard of care for HFrEF is Guideline-Directed Medical Therapy (GDMT) with four classes of medications, known as the 'four pillars,' which have been proven to reduce morbidity and mortality.",
        "* **Criteria/Thresholds (The Four Pillars of HFrEF Therapy):** All four classes should be initiated and titrated in all eligible patients.",
        "  - **1. ARNI/ACEi/ARB:** An Angiotensin Receptor-Neprilysin Inhibitor (ARNI, e.g., sacubitril/valsartan) is preferred over an ACE inhibitor or ARB.",
        "  - **2. Evidence-Based Beta-Blocker:** Specifically carvedilol, metoprolol succinate, or bisoprolol.",
        "  - **3. Mineralocorticoid Receptor Antagonist (MRA):** Spironolactone or eplerenone.",
        "  - **4. SGLT2 Inhibitor:** A Sodium-Glucose Cotransporter-2 inhibitor (e.g., empagliflozin, dapagliflozin).",
        "* **Application:** This patient is already on an ARNI, a beta-blocker, and an MRA. The missing foundational therapy is an SGLT2 inhibitor.",
        "* **Role of SGLT2 Inhibitors:** These agents reduce the risk of cardiovascular death and hospitalization for heart failure in patients with HFrEF, regardless of whether they have type 2 diabetes.",
        "* **Role of Other Medications:**\n  - **Diuretics (e.g., furosemide):** Used for symptom and volume control but do not provide a mortality benefit.\n  - **Digoxin:** A second-line agent that can reduce hospitalizations but does not improve survival. It is considered for patients who remain symptomatic despite optimal GDMT.",
        "* **Contraindicated/Non-Beneficial Medications:**\n  - **Amlodipine (CCB):** Dihydropyridine calcium channel blockers have a neutral effect but are not part of foundational HFrEF therapy. Non-dihydropyridines (verapamil, diltiazem) are generally contraindicated.",
        "  - **Dobutamine:** An intravenous inotrope for acute decompensated heart failure, not for chronic outpatient management.",
        "* **Pitfalls (general):** Failure to initiate all four pillars of GDMT in eligible patients. Using medications that lack benefit or may cause harm in HFrEF. Adding a second MRA (e.g., finerenone to spironolactone) is contraindicated due to the high risk of severe hyperkalemia."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "61",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "터너증후군"
      },
      "why": [
        "* **Diagnosis:** Turner syndrome, presenting with short stature and primary ovarian failure (hypergonadotropic hypogonadism).",
        "* **Clinical Presentation:** A 13-year-old girl with significant short stature (height <3rd percentile) but relatively normal weight (50-75th percentile). She has delayed puberty, with prepubertal breasts (Tanner stage 1) but evidence of adrenarche (pubic hair Tanner stage 2).",
        "* **Lab Findings:** The key findings are markedly elevated gonadotropins with low estrogen, confirming primary ovarian failure.\n  - **LH:** 31.6 uIU/mL (high; ref 2-15)\n  - **FSH:** 62.5 IU/L (high; ref 3-20)\n  - **Estradiol:** 2.1 ng/mL (low; ref 3-17)",
        "* **Pathophysiology:** Turner syndrome is caused by a complete or partial absence of one X chromosome (e.g., 45,X karyotype). This leads to gonadal dysgenesis, resulting in 'streak ovaries' that cannot produce estrogen or ova, causing primary amenorrhea and infertility. The lack of negative feedback from estrogen leads to compensatory high levels of pituitary gonadotropins (FSH and LH).",
        "* **Associated Findings:**\n  - **Short Stature:** A cardinal feature of Turner syndrome, due to haploinsufficiency of the SHOX gene on the X chromosome.\n  - **Hypothyroidism:** The patient has an elevated TSH (15.4 uIU/L) with a low-normal free T4 (0.85 ng/dL), indicating primary hypothyroidism. Autoimmune thyroiditis is a common comorbidity in Turner syndrome.\n  - **Metabolic:** Impaired fasting glucose (115 mg/dL) is also more common in individuals with Turner syndrome due to increased insulin resistance.",
        "* **Growth and Development:** The bone age (12 years) is delayed relative to the chronological age (13 years), which is consistent with both untreated hypothyroidism and hypogonadism, both of which are present.",
        "* **Differential / Discriminators:**\n  - **Growth Hormone Deficiency:** Would be characterized by low or low-normal IGF-1 levels; here, IGF-1 is normal (190 ng/mL).\n  - **Constitutional Delay:** Would present with delayed bone age and low gonadotropins (hypogonadotropic hypogonadism), which would rise with time. This patient has hypergonadotropic hypogonadism.\n  - **Central Hypothyroidism:** Would show low or inappropriately normal TSH with low free T4. This patient has a high TSH, indicating a primary thyroid problem."
      ],
      "others": [
        {
          "label": "①",
          "text": "성장호르몬 결핍증",
          "reason": "This is unlikely because the insulin-like growth factor-I (IGF-I) level is normal for her age (190 ng/mL). Growth hormone deficiency would typically present with low IGF-I."
        },
        {
          "label": "②",
          "text": "중추 갑상샘저하증",
          "reason": "This diagnosis is incorrect because the TSH level is high (15.4 uIU/L). Central hypothyroidism is characterized by low or inappropriately normal TSH in the setting of low free T4."
        },
        {
          "label": "④",
          "text": "쿠싱증후군",
          "reason": "This is not supported by the clinical picture or labs. The patient lacks features of hypercortisolism (e.g., central obesity, striae, hypertension), and the serum cortisol level is normal (16 ug/dL)."
        },
        {
          "label": "⑤",
          "text": "안드로겐 불감 증후군(androgen insensitivity syndrome)",
          "reason": "This is incorrect. Patients with complete androgen insensitivity syndrome (46,XY) have female external genitalia but develop breasts at puberty and have scant pubic hair. This patient has Tanner 1 breasts and Tanner 2 pubic hair, and the hormonal profile points to ovarian, not testicular, failure."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "터너증후군"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Turner syndrome (45,X) classically presents with short stature, primary amenorrhea due to ovarian dysgenesis ('streak ovaries'), and characteristic physical features like a webbed neck, shield chest, and low posterior hairline.",
        "* **Workup:** The definitive diagnosis is made by karyotype analysis. Initial laboratory evaluation reveals hypergonadotropic hypogonadism, characterized by elevated FSH and LH levels with low estradiol, confirming primary ovarian failure.",
        "* **Criteria/Thresholds:** Markedly elevated gonadotropins (FSH: 62.5 IU/L, LH: 31.6 uIU/mL) in the setting of low estrogen (estradiol: 2.1 ng/mL) in a prepubertal or pubertal female with short stature is highly suggestive.",
        "* **Pathophysiology:** The absence of one X chromosome (or part of it) leads to gonadal dysgenesis. The resulting lack of estrogen production from the ovaries removes negative feedback on the pituitary, causing a compensatory rise in FSH and LH.",
        "* **Management (algorithmic):** Management is multidisciplinary and focuses on addressing the key features.\n  - **Short Stature:** Growth hormone therapy is initiated in childhood to improve final height.\n  - **Pubertal Failure:** Estrogen replacement therapy is started at an appropriate age (around 12-13 years) to induce puberty, followed by the addition of progestin to establish menstrual cycles and protect the endometrium.",
        "* **Associated Conditions:** Patients require lifelong screening for common comorbidities, including autoimmune hypothyroidism (as seen in this patient with high TSH), bicuspid aortic valve, coarctation of the aorta, horseshoe kidney, sensorineural hearing loss, and glucose intolerance.",
        "* **Differential/Discriminators:** It must be distinguished from other causes of short stature and delayed puberty.\n  - **Constitutional Delay:** Characterized by delayed bone age but low or normal gonadotropins (hypogonadotropic hypogonadism).\n  - **Growth Hormone Deficiency:** Presents with low IGF-1 levels; this patient's IGF-1 was normal.",
        "* **Pitfalls (general):** A common pitfall is failing to perform a comprehensive screening for associated cardiac (echo/MRI) and renal (ultrasound) anomalies at the time of diagnosis. Another is attributing delayed puberty to constitutional delay without checking gonadotropin levels."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "62",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "수두대상포진바이러스"
      },
      "why": [
        "* **Diagnosis:** Varicella (chickenpox), caused by the Varicella-zoster virus (VZV).",
        "* **Clinical Presentation:** The patient is a 5-year-old boy with a 3-day history of fever and a pruritic (itchy) rash. The rash started on the scalp and face and spread to the trunk and limbs (centrifugal spread), which is a classic distribution for varicella.",
        "* **Epidemiology:** There is a clear history of exposure, as his sister had a similar rash two weeks ago. The incubation period for varicella is typically 10 to 21 days, which fits this timeline perfectly.",
        "* **Image Findings:** The photograph of the chest shows a polymorphic rash. There are lesions in various stages of development simultaneously: erythematous papules, vesicles (some appearing as a 'dewdrop on a rose petal'), and crusted lesions. This polymorphism is pathognomonic for chickenpox.",
        "* **Pathophysiology:** Primary infection with VZV results in varicella. The virus enters through the respiratory tract, undergoes replication in regional lymph nodes, and then disseminates via viremia to the skin, causing the characteristic vesicular rash.",
        "* **Differential / Discriminators:**\n  - **Measles (Rubeola):** Presents with a maculopapular, confluent rash preceded by cough, coryza, and conjunctivitis. The rash is not vesicular.\n  - **Rubella (German Measles):** A milder illness with a maculopapular rash that is not vesicular and typically associated with postauricular lymphadenopathy.\n  - **Roseola Infantum (HHV-6):** Characterized by several days of high fever that resolves abruptly, followed by the appearance of a maculopapular rash. The rash is not vesicular.\n  - **Hand-Foot-Mouth Disease (Coxsackievirus):** Causes vesicles, but they are typically located on the hands, feet, and in the oral cavity, and the rash is not typically polymorphic."
      ],
      "others": [
        {
          "label": "①",
          "text": "에코바이러스",
          "reason": "Echovirus typically causes a nonspecific maculopapular rash. It does not cause the classic polymorphic vesicular rash seen in this patient."
        },
        {
          "label": "②",
          "text": "풍진바이러스",
          "reason": "Rubella (German measles) causes a maculopapular rash that is not vesicular. The clinical picture of a highly pruritic, polymorphic rash is not consistent with rubella."
        },
        {
          "label": "③",
          "text": "홍역바이러스",
          "reason": "Measles (rubeola) is characterized by a prodrome of cough, coryza, and conjunctivitis, followed by a confluent maculopapular rash. The rash is not vesicular, and the polymorphism seen in the image is absent."
        },
        {
          "label": "⑤",
          "text": "사람헤르페스바이러스6형",
          "reason": "HHV-6 causes roseola infantum (exanthem subitum), which presents with high fever followed by a maculopapular rash after the fever defervesces. The rash is not vesicular or polymorphic."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "수두대상포진바이러스"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Varicella (chickenpox) is caused by the Varicella-Zoster Virus (VZV). It presents with a prodrome of fever and malaise, followed by a highly pruritic vesicular rash.",
        "* **Hallmark Finding:** The rash is pathognomonically polymorphic, meaning lesions in various stages of development (macules, papules, vesicles, and crusted lesions) are present simultaneously in the same area.",
        "* **Rash Distribution:** The rash classically begins on the scalp, face, or trunk and spreads centrifugally to the extremities.",
        "* **Epidemiology:** Varicella is highly contagious, with a typical incubation period of 10-21 days. A history of exposure to an infected individual is a key diagnostic clue.",
        "* **Workup:** Diagnosis is almost always made clinically based on the characteristic history and rash. If confirmation is needed, PCR of vesicular fluid is the most sensitive and specific test.",
        "* **Management:** In healthy children, treatment is supportive with antipyretics (acetaminophen, not aspirin), antihistamines, and soothing baths. Antiviral therapy (e.g., acyclovir) is recommended for adolescents, adults, and immunocompromised individuals to reduce severity and risk of complications.",
        "* **Complications:** The most common complication is secondary bacterial skin infection (e.g., *Staphylococcus aureus*, *Streptococcus pyogenes*). More severe complications include pneumonia (more common in adults), encephalitis, and Reye syndrome if aspirin is used.",
        "* **Prevention:** The live attenuated varicella vaccine is highly effective for prevention.",
        "* **Differential/Discriminators:** The polymorphic nature distinguishes it from other rashes.\n  - **Measles:** Maculopapular rash preceded by cough, coryza, conjunctivitis.\n  - **Hand-Foot-Mouth Disease:** Vesicles are primarily on hands, feet, and in the mouth; not typically polymorphic on the trunk.",
        "* **Pitfalls (general):** A critical pitfall is administering aspirin to a child with a viral illness, which carries a risk of Reye syndrome. Another is underestimating the severity of varicella in adults, who are at higher risk for pneumonia."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "63",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "반코마이신"
      },
      "why": [
        "* **Diagnosis:** Catheter-related bloodstream infection (CRBSI) due to Methicillin-resistant *Staphylococcus aureus* (MRSA).",
        "* **Clinical Context:** The patient has multiple risk factors for CRBSI: an indwelling central venous catheter and receipt of total parenteral nutrition (TPN). The development of fever in this context is highly suspicious for CRBSI.",
        "* **Microbiology Report:** Blood and catheter tip cultures grew *Staphylococcus aureus*. The key finding in the susceptibility report is resistance to oxacillin. Oxacillin resistance is the defining characteristic of MRSA.",
        "* **Treatment Principle:** The standard-of-care, first-line antibiotic for treating bloodstream infections caused by MRSA is intravenous vancomycin. The susceptibility report confirms that the isolate is sensitive to vancomycin.",
        "* **Guideline-Based Management:** For complicated MRSA bacteremia (such as that associated with an infected catheter), guidelines recommend a prolonged course of IV vancomycin (typically 2-6 weeks, depending on the source and presence of metastatic infection) and removal of the infected catheter.",
        "* **Evaluating Other Options:**\n  - **Oxacillin/Cefazolin:** These are beta-lactam antibiotics effective against methicillin-sensitive *S. aureus* (MSSA), but they are ineffective against MRSA.\n  - **Meropenem:** This is a carbapenem with broad-spectrum activity against many gram-negative and anaerobic organisms, but it lacks activity against MRSA.\n  - **Rifampin:** It should not be used as monotherapy for MRSA bacteremia due to the rapid development of resistance. It is sometimes used as adjunctive therapy for infections involving prosthetic material."
      ],
      "others": [
        {
          "label": "①",
          "text": "리팜핀",
          "reason": "Rifampin should not be used as monotherapy for MRSA bacteremia because resistance develops rapidly. It is sometimes used as an add-on agent for infections involving foreign bodies, but vancomycin is the primary bactericidal agent."
        },
        {
          "label": "②",
          "text": "세파졸린",
          "reason": "Cefazolin is a first-line treatment for methicillin-SENSITIVE *Staphylococcus aureus* (MSSA). This organism is resistant to oxacillin, defining it as MRSA, for which cefazolin is ineffective."
        },
        {
          "label": "③",
          "text": "메로페넴",
          "reason": "Meropenem is a broad-spectrum carbapenem antibiotic that does not have activity against MRSA. Its spectrum is primarily focused on gram-negative organisms, anaerobes, and some gram-positives like streptococci."
        },
        {
          "label": "⑤",
          "text": "레보플록사신",
          "reason": "Although the report shows susceptibility to ciprofloxacin (another fluoroquinolone), vancomycin is the standard of care and preferred agent for treating MRSA bacteremia. Fluoroquinolones are generally considered inferior for this indication."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "반코마이신"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Catheter-related bloodstream infection (CRBSI) should be suspected in any patient with a central venous catheter who develops fever, chills, or signs of sepsis.",
        "* **Risk Factors:** Major risk factors include prolonged catheterization, total parenteral nutrition (TPN), immunosuppression, and breaks in sterile technique.",
        "* **Workup:** The diagnostic workup includes drawing paired blood cultures (one from the catheter hub and one from a peripheral vein). A positive culture from the catheter tip after removal is also diagnostic.",
        "* **Microbiology:** *Staphylococcus aureus* is a common cause. Resistance to oxacillin on susceptibility testing defines the organism as Methicillin-resistant *S. aureus* (MRSA).",
        "* **Management (algorithmic):** The two cornerstones of management are appropriate antibiotic therapy and source control.\n  - **Source Control:** Prompt removal of the infected catheter is essential for cure and to prevent metastatic infection.\n  - **Antibiotics:** Initiate empiric therapy covering MRSA (e.g., vancomycin) in septic patients with risk factors. Tailor therapy once susceptibilities are known.",
        "* **Treatment:** Intravenous vancomycin is the first-line antibiotic for MRSA bacteremia. Daptomycin is an alternative for patients with vancomycin intolerance, nephrotoxicity, or high vancomycin MICs.",
        "* **Monitoring/Follow-up:** Repeat blood cultures every 24-48 hours to document clearance. The duration of therapy for complicated MRSA bacteremia (like CRBSI) is typically 2-6 weeks, and an echocardiogram is often performed to rule out endocarditis.",
        "* **Differential/Discriminators:** Beta-lactams like cefazolin are first-line for methicillin-SENSITIVE *S. aureus* (MSSA) but are ineffective against MRSA. Carbapenems like meropenem lack activity against MRSA.",
        "* **Pitfalls (general):** A major pitfall is delaying catheter removal, which significantly increases the risk of treatment failure and complications. Using rifampin as monotherapy is inappropriate due to rapid resistance development."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "64",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "Vibrio vulnificus"
      },
      "why": [
        "* **Diagnosis:** *Vibrio vulnificus* septicemia with necrotizing fasciitis.",
        "* **Clinical Picture:** The patient presents with septic shock (hypotension 90/58 mmHg, tachycardia 114/min, fever 38.9°C, altered mental status) and a rapidly progressing soft tissue infection.",
        "* **Epidemiology:** The history is classic for *Vibrio vulnificus* infection. Key risk factors include:\n  - **Underlying Liver Disease:** The patient has known liver cirrhosis.\n  - **Exposure:** Recent consumption of raw seafood (raw fish) and contact with a marine environment (sea fishing).",
        "* **Image Findings:** The photograph of the leg shows marked edema, erythema, and large, tense hemorrhagic bullae. This is a characteristic skin manifestation of *Vibrio vulnificus* necrotizing soft tissue infection.",
        "* **Lab Findings:** The labs show multi-organ failure, consistent with severe sepsis.\n  - **Hematologic:** Leukopenia (3,920/mm³) and severe thrombocytopenia (29,000/mm³).\n  - **Renal:** Acute kidney injury (BUN/Cr 59/3.1 mg/dL).\n  - **Hepatic:** Worsening liver function (AST 488 U/L, total bilirubin 3.6 mg/dL) on top of chronic disease.\n  - **Muscle:** Rhabdomyolysis (CK >8,000 U/L).\n  - **Metabolic:** Poorly controlled diabetes (glucose 297 mg/dL), another risk factor.",
        "* **Pathophysiology:** *Vibrio vulnificus* is a halophilic (salt-loving) bacterium found in warm coastal waters. In patients with liver disease (especially with high iron levels), ingestion can lead to primary septicemia with a high mortality rate. Direct inoculation into a wound can cause severe necrotizing fasciitis.",
        "* **Differential / Discriminators:** While other organisms can cause necrotizing fasciitis (e.g., *Streptococcus pyogenes*, *Clostridium perfringens*), the specific constellation of underlying liver disease, raw seafood/seawater exposure, and hemorrhagic bullae is pathognomonic for *Vibrio vulnificus*."
      ],
      "others": [
        {
          "label": "①",
          "text": "Closteridium perfrigens",
          "reason": "This organism causes gas gangrene, typically associated with deep, contaminated traumatic wounds. It is not associated with seawater exposure or raw seafood consumption, and hemorrhagic bullae are less characteristic than crepitus from gas production."
        },
        {
          "label": "②",
          "text": "Pseudomonas aeruginosa",
          "reason": "While it can cause severe infections in immunocompromised hosts, it is not the classic cause of this syndrome. The epidemiological link to seawater and raw fish strongly points away from *Pseudomonas*."
        },
        {
          "label": "③",
          "text": "Staphylocuccus aureus",
          "reason": "MRSA can cause necrotizing fasciitis, but it lacks the specific epidemiological risk factors of liver disease and marine exposure. Hemorrhagic bullae are also less common than with *Vibrio*."
        },
        {
          "label": "④",
          "text": "Streptococcus pyogenes",
          "reason": "This is a classic cause of necrotizing fasciitis ('flesh-eating bacteria'), but the presentation is not linked to marine exposure or underlying liver disease. The presence of hemorrhagic bullae makes *Vibrio* more likely."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "Vibrio vulnificus"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** *Vibrio vulnificus* infection presents as a rapidly progressive, life-threatening illness, typically with two main syndromes: primary septicemia or necrotizing soft tissue infection.",
        "* **Hallmark Finding:** The development of large, tense, hemorrhagic bullae in the setting of a rapidly advancing cellulitis or fasciitis is highly characteristic.",
        "* **Epidemiology (Classic Triad):** The diagnosis should be strongly suspected in a patient with: 1) septic shock, 2) underlying chronic liver disease (especially cirrhosis or hemochromatosis), and 3) recent exposure to warm seawater or consumption of raw seafood (particularly oysters).",
        "* **Workup:** Blood and wound cultures are essential and are often positive. Imaging (CT/MRI) can help delineate the extent of necrotizing fasciitis. Labs typically show evidence of multi-organ failure, including leukopenia, severe thrombocytopenia, and rhabdomyolysis.",
        "* **Management (algorithmic):** This is a medical and surgical emergency with very high mortality.\n  - **Initial:** Immediate, aggressive fluid resuscitation for septic shock and prompt initiation of empiric antibiotics.\n  - **Definitive:** Urgent surgical exploration and extensive debridement of all necrotic tissue is life-saving and mandatory for source control.",
        "* **Treatment:** Combination antibiotic therapy is standard.\n  - **First-line:** A third-generation cephalosporin (e.g., ceftriaxone) PLUS doxycycline.",
        "* **Differential/Discriminators:** While other organisms cause necrotizing fasciitis (*Streptococcus pyogenes*, *Clostridium perfringens*), the specific epidemiological link to liver disease and marine exposure, combined with hemorrhagic bullae, is pathognomonic for *Vibrio vulnificus*.",
        "* **Pitfalls (general):** The most critical pitfall is delaying surgical debridement, which is the single most important factor determining survival. Another is failing to obtain a detailed exposure history (seafood, seawater) in a septic patient with liver disease."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "65",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "중증열성혈소판감소증후군"
      },
      "why": [
        "* **Diagnosis:** Severe Fever with Thrombocytopenia Syndrome (SFTS).",
        "* **Clinical Presentation:** The patient presents with a 3-day history of fever and diarrhea. This occurred approximately one week after hiking in an endemic area (Jeju Island), where he sustained an arthropod bite.",
        "* **Epidemiology:** SFTS is a tick-borne viral illness caused by the SFTS virus (a phlebovirus). It is endemic in East Asia, including Korea (especially Jeju Island). The typical exposure is hiking or farming in rural areas during warmer months.",
        "* **Lab Findings:** The laboratory results are highly characteristic of SFTS.\n  - **Leukopenia:** WBC 2,500/mm³.\n  - **Thrombocytopenia:** Platelets 70,000/mm³.\n  - **Elevated Liver Enzymes:** AST 84 IU/L and ALT 90 IU/L are mildly elevated.",
        "* **Image Findings:** The image shows a skin lesion at the site of the bite. While it has a central dark area resembling an eschar (more classic for scrub typhus), such eschar-like lesions can be seen at the tick bite site in SFTS.",
        "* **Differential / Discriminators:** The main differential is scrub typhus (Tsutsugamushi disease). While the eschar-like lesion is suggestive of scrub typhus, several features in this case point more strongly towards SFTS:\n  - **Prominent GI Symptoms:** Diarrhea is mentioned, which is a very common feature of SFTS.\n  - **Low C-Reactive Protein:** The CRP is 10 mg/L, which is at the upper limit of normal. Viral infections like SFTS typically cause a less pronounced CRP elevation compared to bacterial/rickettsial infections like scrub typhus, where CRP is often markedly elevated.",
        "* **Conclusion:** The combination of fever, diarrhea, leukopenia, thrombocytopenia, and a low CRP following a tick bite in an endemic region makes SFTS the most probable diagnosis, despite the eschar-like appearance of the bite."
      ],
      "others": [
        {
          "label": "①",
          "text": "말라리아",
          "reason": "Malaria is transmitted by mosquitoes and causes cyclical fevers. It does not cause an eschar, leukopenia, or significant thrombocytopenia in this pattern."
        },
        {
          "label": "②",
          "text": "렙토스피라증",
          "reason": "Leptospirosis is associated with exposure to contaminated water or soil. It typically presents with fever, myalgia, and conjunctival suffusion, but not an eschar, leukopenia, or thrombocytopenia."
        },
        {
          "label": "③",
          "text": "쯔쯔가무시증",
          "reason": "This is a strong runner-up, as the eschar is classic for scrub typhus. However, the presence of prominent diarrhea and a low C-reactive protein level are more suggestive of SFTS in this specific clinical context."
        },
        {
          "label": "④",
          "text": "신증후군출혈열",
          "reason": "Hantavirus infection (Hemorrhagic Fever with Renal Syndrome) is transmitted by rodents and is characterized by fever, hemorrhage, and acute kidney injury. It does not cause an eschar."
        }
      ],
      "runner_up": "③ 쯔쯔가무시증",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 0.8,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "쯔쯔가무시증"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "The eschar is classic for scrub typhus, but the prominent diarrhea and low CRP are more suggestive of SFTS. This is a subtle distinction, but SFTS is the better fit for the complete clinical and lab picture.",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Severe Fever with Thrombocytopenia Syndrome (SFTS) is an acute viral illness characterized by high fever, myalgia, and prominent gastrointestinal symptoms like diarrhea, nausea, and vomiting.",
        "* **Epidemiology:** SFTS is a tick-borne illness caused by a phlebovirus, endemic to East Asia. A history of hiking, farming, or other outdoor activities in a rural, endemic area is a key risk factor.",
        "* **Workup:** Diagnosis is confirmed by detecting viral RNA via RT-PCR in blood during the acute phase. Serology can be used for retrospective diagnosis.",
        "* **Criteria/Thresholds (Lab Hallmarks):** The classic laboratory triad is fever, marked thrombocytopenia (platelets often <100,000/mm³), and leukopenia. Mild to moderate elevation of liver enzymes (AST, ALT) is also common.",
        "* **Management:** Treatment is primarily supportive, focusing on maintaining fluid and electrolyte balance, and monitoring for complications. The efficacy of antiviral agents like ribavirin is not well established.",
        "* **Complications:** Severe cases can lead to hemorrhagic manifestations, coagulopathy (DIC), multi-organ failure, and central nervous system involvement.",
        "* **Differential/Discriminators:** The primary differential is scrub typhus (Tsutsugamushi disease), which can also present with fever, rash, and an eschar. Key discriminators include:\n  - **SFTS:** More prominent GI symptoms, leukopenia, and typically a lower CRP.\n  - **Scrub Typhus:** More prominent rash, often a higher CRP, and leukopenia is less common.",
        "* **Pitfalls (general):** Mistaking an eschar-like tick bite lesion as being exclusive to scrub typhus. Attributing fever, thrombocytopenia, and leukopenia to bacterial sepsis without considering tick-borne illnesses in patients with relevant exposures."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "66",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "caspofungin"
      },
      "why": [
        "* **Diagnosis:** Candidemia (a form of invasive candidiasis) in a patient with febrile neutropenia.",
        "* **Clinical Context:** The patient is severely immunocompromised due to acute leukemia and recent chemotherapy, resulting in profound neutropenia (WBC 120/mm³). He has persistent/recurrent fever despite broad-spectrum antibacterial therapy (piperacillin-tazobactam) and is now hemodynamically unstable (hypotension, tachycardia).",
        "* **Microbiology:** The crucial finding is the interim blood culture report showing \"presumptive fungal growth, Yeast-like cell\" from multiple sets. This confirms a fungemia, most commonly caused by *Candida* species in this setting.",
        "* **Treatment Principle:** According to major infectious disease guidelines (e.g., IDSA), the first-line empirical treatment for suspected invasive candidiasis in neutropenic and/or critically ill patients is an echinocandin.",
        "* **Drug Class - Echinocandins:** Caspofungin, micafungin, and anidulafungin belong to this class. They are fungicidal against most *Candida* species, including fluconazole-resistant strains like *C. glabrata* and *C. krusei*, which are more prevalent in hematology-oncology patients.",
        "* **Rationale for Choice:** Given the patient's neutropenia, hemodynamic instability, and confirmed fungemia, an echinocandin like caspofungin is the most appropriate choice for initial therapy. It provides broad anti-Candida coverage and is recommended over azoles in this high-risk scenario.",
        "* **Pitfalls (general):** Delaying appropriate antifungal therapy in patients with candidemia is associated with increased mortality. It is critical to start effective treatment promptly based on clinical suspicion and preliminary microbiology data."
      ],
      "others": [
        {
          "label": "②",
          "text": "fluconazole",
          "reason": "Fluconazole is not the preferred first-line agent for candidemia in neutropenic or hemodynamically unstable patients. There is a higher risk of infection with fluconazole-resistant species (*C. glabrata*, *C. krusei*), and echinocandins have demonstrated better outcomes in this population."
        },
        {
          "label": "③",
          "text": "flucytosine",
          "reason": "Flucytosine is never used as monotherapy for invasive candidiasis due to the rapid development of resistance. It is primarily used in combination therapy for cryptococcal meningitis."
        },
        {
          "label": "④",
          "text": "itraconazole",
          "reason": "Itraconazole has limited activity against many *Candida* species, poor bioavailability, and is not recommended for the treatment of candidemia. Its primary use is for endemic mycoses and aspergillosis."
        },
        {
          "label": "⑤",
          "text": "vancomycin",
          "reason": "Vancomycin is an antibacterial agent with activity against gram-positive bacteria like MRSA. It has no antifungal activity and is inappropriate for treating a yeast infection."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "caspofungin"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Candidemia should be suspected in high-risk patients, such as those with profound neutropenia, central venous catheters, recent abdominal surgery, or on TPN, who have persistent fever despite broad-spectrum antibiotics or develop signs of sepsis.",
        "* **Workup:** Blood cultures are the gold standard for diagnosis. A preliminary report of 'yeast' from a blood culture in a high-risk patient is sufficient to initiate targeted therapy. Non-culture methods like the beta-D-glucan assay can be supportive.",
        "* **Management (algorithmic):** Prompt initiation of antifungal therapy is critical for survival.\n  - **Empiric:** In high-risk, febrile neutropenic patients unresponsive to antibiotics, start empiric antifungal therapy.\n  - **Targeted:** Once candidemia is confirmed, continue therapy based on species identification and patient stability.",
        "* **Treatment (First-line):** An echinocandin (e.g., caspofungin, micafungin) is the recommended first-line therapy for most adult patients with candidemia, especially those who are neutropenic, critically ill, or have had recent azole exposure.",
        "* **Rationale for Echinocandins:** They are fungicidal and have excellent activity against most *Candida* species, including the often fluconazole-resistant *C. glabrata* and *C. krusei*.",
        "* **Alternative Treatments:** Fluconazole is an acceptable alternative for hemodynamically stable, non-neutropenic patients who are unlikely to have a fluconazole-resistant species. Amphotericin B is a broad-spectrum option but has significant toxicity.",
        "* **Monitoring/Follow-up:** A dilated ophthalmologic exam should be performed in all patients with candidemia to screen for endophthalmitis. Follow-up blood cultures are needed to document clearance. Therapy should continue for 14 days after the first negative blood culture.",
        "* **Pitfalls (general):** A major pitfall is delaying the initiation of appropriate antifungal therapy, which is associated with increased mortality. Using fluconazole empirically in a critically ill or neutropenic patient is another common error due to the risk of resistance."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "67",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "류마티스 관절염"
      },
      "why": [
        "* **Diagnosis:** Rheumatoid Arthritis (RA).",
        "* **Clinical Presentation:** The patient, a 40-year-old woman, presents with a classic history for RA: a chronic (1-year duration), symmetric, inflammatory polyarthritis affecting the small joints of the hands (fingers, wrists). The prolonged morning stiffness (>1 hour, here 2 hours) is a hallmark feature.",
        "* **Physical Examination:** Findings of tenderness and swelling in the wrists and metacarpophalangeal (MCP) joints confirm active synovitis in the characteristic distribution for RA.",
        "* **Lab Findings:** The laboratory results are strongly supportive of the diagnosis.\n  - **Inflammatory Markers:** Both ESR (82 mm/hr) and CRP (32.0 mg/L) are significantly elevated, indicating systemic inflammation.\n  - **Serology:** The patient is positive for both Rheumatoid Factor (RF: 97 IU/mL) and anti-cyclic citrullinated peptide (anti-CCP) antibodies (90 IU/mL). Anti-CCP antibodies are highly specific for RA.",
        "* **Image Findings:** The provided hand X-rays (though not explicitly part of the text stem, they are shown in the PDF for this question number) demonstrate classic RA changes, including periarticular osteopenia, joint space narrowing, and bony erosions, particularly at the MCP and wrist joints.",
        "* **Diagnostic Criteria:** The patient fulfills the 2010 ACR/EULAR classification criteria for RA based on the number and site of involved joints (small joints), positive high-titer serology (RF and anti-CCP), elevated acute-phase reactants (ESR and CRP), and duration of symptoms (>6 weeks).",
        "* **Differential / Discriminators:**\n  - **Systemic Lupus Erythematosus (SLE):** While SLE can cause arthritis, it is typically non-erosive. Furthermore, the ANA is negative in this patient, making SLE highly unlikely.\n  - **Spondyloarthropathies:** These typically involve the axial skeleton, which is explicitly spared in this patient. Peripheral arthritis can occur but is often asymmetric.\n  - **Gout/Pseudogout:** These are crystal arthropathies that usually present with acute, episodic monoarthritis rather than chronic, symmetric polyarthritis."
      ],
      "others": [
        {
          "label": "①",
          "text": "통풍",
          "reason": "Gout typically presents as an acute monoarthritis, most commonly affecting the first metatarsophalangeal joint. This patient's chronic, symmetric polyarthritis and positive RA-specific serologies are not consistent with gout."
        },
        {
          "label": "②",
          "text": "가성통풍",
          "reason": "Pseudogout (CPPD) typically affects larger joints like the knees and wrists and does not usually cause the symmetric small joint polyarthritis pattern seen here. It is also not associated with positive RF or anti-CCP antibodies."
        },
        {
          "label": "③",
          "text": "강직척추염",
          "reason": "Ankylosing spondylitis is an axial spondyloarthropathy, primarily affecting the spine and sacroiliac joints. The patient specifically denies back and hip pain, and her presentation is classic for peripheral arthritis."
        },
        {
          "label": "④",
          "text": "전신홍반루푸스",
          "reason": "Systemic lupus erythematosus is unlikely because the antinuclear antibody (ANA) test is negative, which has a high negative predictive value. Also, arthritis in lupus is typically non-erosive."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "류마티스 관절염"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune disease characterized by symmetric, inflammatory polyarthritis. It typically affects the small joints of the hands (MCP, PIP) and wrists.",
        "* **Hallmark Symptom:** Prolonged morning stiffness, usually lasting more than one hour, that improves with activity is a key feature.",
        "* **Workup:** The diagnosis is supported by elevated inflammatory markers (ESR, CRP) and the presence of specific autoantibodies.",
        "* **Criteria/Thresholds:** Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific for RA. Rheumatoid factor (RF) is sensitive but less specific. The 2010 ACR/EULAR criteria are used for classification.",
        "* **Imaging:** Early X-ray findings include periarticular osteopenia and soft tissue swelling. The hallmark of established RA is the presence of marginal bony erosions and joint space narrowing.",
        "* **Management (algorithmic):** The goal is to achieve remission or low disease activity. Early initiation of a disease-modifying antirheumatic drug (DMARD) is crucial.\n  - **First-line:** Methotrexate is the anchor drug for most patients.\n  - **Adjuncts:** NSAIDs or short-term, low-dose corticosteroids can be used as 'bridging therapy' for symptom control while waiting for DMARDs to take effect.\n  - **Escalation:** If methotrexate monotherapy is insufficient, treatment is escalated to combination conventional DMARDs or the addition of a biologic or targeted synthetic DMARD.",
        "* **Differential/Discriminators:** RA must be distinguished from other arthritides.\n  - **Systemic Lupus Erythematosus (SLE):** Arthritis is typically non-erosive; ANA is usually positive.\n  - **Ankylosing Spondylitis:** Primarily affects the axial skeleton.\n  - **Gout:** Typically an acute, episodic monoarthritis.",
        "* **Pitfalls (general):** Relying on a negative RF to rule out RA, as seronegative RA exists. Delaying DMARD therapy, which allows for irreversible joint damage. Using chronic corticosteroids as monotherapy is inappropriate due to side effects."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "68",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "전신홍반루푸스"
      },
      "why": [
        "* **Diagnosis:** Systemic Lupus Erythematosus (SLE).",
        "* **Clinical Presentation:** The patient, a young woman, presents with a constellation of symptoms affecting multiple organ systems, which is characteristic of SLE.\n  - **Musculoskeletal:** Inflammatory polyarthritis of the hands, worse in the morning.\n  - **Mucocutaneous:** A photosensitive skin rash.\n  - **Serositis:** Pleuritic chest pain (sharp pain on deep inspiration), suggesting pleurisy.",
        "* **Image Findings:** The photograph shows a classic erythematous malar rash (or 'butterfly rash') across the cheeks and bridge of the nose, with sparing of the nasolabial folds. This is a highly characteristic finding in SLE.",
        "* **Lab Findings:** The laboratory results provide strong evidence for SLE.\n  - **Hematologic:** Cytopenias are present, including leukopenia (WBC 2,800/mm³) and thrombocytopenia (Platelets 100,000/mm³).\n  - **Immunologic:** The serology is pathognomonic. A positive antinuclear antibody (ANA) at a high titer (1:320) is sensitive for SLE, and a positive anti-double-stranded DNA (anti-dsDNA) antibody (80.0 IU/mL) is highly specific for the diagnosis.",
        "* **Inflammatory Markers:** The pattern of a high ESR (42 mm/hr) with a normal or low CRP (0.23 mg/L) is a classic finding in active SLE (unless there is co-existing infection or significant serositis).",
        "* **Diagnostic Criteria:** The patient meets multiple 2019 EULAR/ACR classification criteria for SLE, including the entry criterion of a positive ANA, plus clinical criteria (arthritis, serositis, cutaneous lupus) and immunologic criteria (anti-dsDNA, cytopenias)."
      ],
      "others": [
        {
          "label": "①",
          "text": "통풍",
          "reason": "Gout does not explain the multisystem involvement, including the photosensitive rash, pleuritis, cytopenias, or the specific positive autoantibodies (ANA, anti-dsDNA)."
        },
        {
          "label": "②",
          "text": "피부근염",
          "reason": "Dermatomyositis is characterized by proximal muscle weakness (not mentioned here) and specific rashes like the heliotrope rash or Gottron's papules. While it can have a photosensitive rash and positive ANA, the presence of anti-dsDNA antibodies and pleuritis makes SLE a much better fit."
        },
        {
          "label": "④",
          "text": "타가야수혈관염",
          "reason": "Takayasu arteritis is a large-vessel vasculitis that presents with constitutional symptoms, limb claudication, and blood pressure discrepancies. It does not cause this clinical or serological picture."
        },
        {
          "label": "⑤",
          "text": "류마티스 관절염",
          "reason": "While the patient has inflammatory arthritis, RA does not typically cause a malar rash, photosensitivity, pleuritis, or cytopenias. Furthermore, the serology (negative RF, positive ANA and anti-dsDNA) is classic for SLE, not RA."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "전신홍반루푸스"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that predominantly affects young women. Presentations are highly variable but often include constitutional symptoms, arthritis, and skin manifestations.",
        "* **Hallmark Findings:** The classic photosensitive malar ('butterfly') rash spares the nasolabial folds. Other key features include inflammatory, non-erosive polyarthritis, serositis (pleuritis, pericarditis), and cytopenias.",
        "* **Workup:** The antinuclear antibody (ANA) test is a highly sensitive screening test. If positive, more specific autoantibodies should be checked.",
        "* **Criteria/Thresholds:** A positive anti-double-stranded DNA (anti-dsDNA) antibody is highly specific for SLE and often correlates with disease activity, particularly lupus nephritis. Anti-Smith (anti-Sm) antibody is also highly specific but less sensitive.",
        "* **Lab Patterns:** Active SLE is often associated with hematologic abnormalities (leukopenia, thrombocytopenia, autoimmune hemolytic anemia) and low serum complement levels (C3, C4). A high ESR with a normal CRP is also a characteristic finding.",
        "* **Management (algorithmic):** Treatment is guided by the severity and type of organ involvement.\n  - **All patients:** Hydroxychloroquine is recommended for all patients unless contraindicated, as it reduces flare rates and improves long-term outcomes.\n  - **Mild disease (skin/joints):** NSAIDs and low-dose corticosteroids.\n  - **Severe/organ-threatening disease (nephritis, CNS):** High-dose corticosteroids plus an immunosuppressive agent (e.g., mycophenolate mofetil, cyclophosphamide).",
        "* **Differential/Discriminators:** SLE must be distinguished from other connective tissue diseases.\n  - **Rheumatoid Arthritis:** Arthritis is erosive; anti-CCP is often positive.\n  - **Dermatomyositis:** Characterized by proximal muscle weakness and specific rashes (heliotrope, Gottron's papules).",
        "* **Pitfalls (general):** A critical pitfall is failing to screen for lupus nephritis with a urinalysis in all SLE patients. Another is not prescribing hydroxychloroquine, which is a cornerstone of maintenance therapy."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "69",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "Febuxostat"
      },
      "why": [
        "* **Diagnosis:** Acute gouty arthritis (gout).",
        "* **Clinical Presentation:** The patient has a history of recurrent, episodic, acute inflammatory arthritis, with the current attack affecting the first metatarsophalangeal (MTP) joint (podagra) and ankle. This clinical history is highly suggestive of gout.",
        "* **Lab Findings:** The patient has hyperuricemia (serum uric acid 9.7 mg/dL) and evidence of acute inflammation (WBC 14,000/mm³, CRP 88.6 mg/L).",
        "* **Image Findings:** The polarized light microscopy image of the synovial fluid is diagnostic. It shows needle-shaped, negatively birefringent crystals, which are pathognomonic for monosodium urate (MSU) crystals, confirming the diagnosis of gout.",
        "* **Treatment Principle:** The question asks for therapy to prevent future recurrence. This requires long-term urate-lowering therapy (ULT). The goal of ULT is to lower serum uric acid levels to below a target (typically <6 mg/dL) to prevent crystal formation and dissolve existing crystals.",
        "* **Indications for ULT:** This patient has had multiple (at least four) attacks, which is a clear indication to start ULT.",
        "* **First-Line ULT:** Xanthine oxidase inhibitors, such as allopurinol or febuxostat, are the first-line agents for ULT. They work by reducing the production of uric acid.",
        "* **Rationale for Choice:** Febuxostat is a xanthine oxidase inhibitor and a correct first-line choice for preventing gout recurrence. Allopurinol would also be a correct choice.",
        "* **Distinguishing Acute vs. Prophylactic Treatment:** It is crucial to distinguish between treatment for an acute flare (NSAIDs, colchicine, corticosteroids) and long-term preventative therapy (ULT like febuxostat). This question specifically asks about preventing recurrence."
      ],
      "others": [
        {
          "label": "①",
          "text": "Colchicine",
          "reason": "Colchicine is used to treat acute gout flares and as short-term prophylaxis when initiating urate-lowering therapy to prevent mobilization flares. It does not lower serum uric acid levels and is not a long-term monotherapy for preventing recurrence."
        },
        {
          "label": "③",
          "text": "Methotrexate",
          "reason": "Methotrexate is a disease-modifying antirheumatic drug (DMARD) used for inflammatory conditions like rheumatoid arthritis. It has no role in the management of gout."
        },
        {
          "label": "④",
          "text": "Naxozol",
          "reason": "This is likely a brand name for a non-steroidal anti-inflammatory drug (NSAID), possibly combined with a proton pump inhibitor. NSAIDs are used to treat the pain and inflammation of an *acute* gout attack, not to prevent future attacks by lowering uric acid."
        },
        {
          "label": "⑤",
          "text": "Sulfasalazine",
          "reason": "Sulfasalazine is a DMARD used for rheumatoid arthritis and inflammatory bowel disease. It is not used in the treatment of gout."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "Febuxostat"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Gout is a crystal arthropathy characterized by recurrent episodes of acute, intensely painful inflammatory monoarthritis. The first metatarsophalangeal (MTP) joint is the most common site (podagra).",
        "* **Workup (Gold Standard):** The definitive diagnosis is made by synovial fluid analysis showing needle-shaped, negatively birefringent monosodium urate (MSU) crystals under polarized light microscopy.",
        "* **Lab Findings:** Hyperuricemia (serum uric acid >7.0 mg/dL) is the primary risk factor, although levels can be normal during an acute flare. Inflammatory markers (WBC, CRP) are typically elevated.",
        "* **Management (Acute Flare):** The goal is rapid pain and inflammation relief. First-line options include:\n  - Non-steroidal anti-inflammatory drugs (NSAIDs).\n  - Colchicine.\n  - Corticosteroids (oral, intra-articular, or systemic).",
        "* **Management (Chronic Prevention):** Long-term urate-lowering therapy (ULT) is used to prevent recurrences. This question asks for a preventative therapy.",
        "* **Indications for ULT:** Indications include ≥2 gout attacks per year, presence of tophi, or evidence of radiographic damage from gout.",
        "* **Treatment (ULT):** Xanthine oxidase inhibitors, such as allopurinol or febuxostat, are the first-line agents. They reduce the production of uric acid.",
        "* **Criteria/Thresholds:** The goal of ULT is to maintain a serum uric acid level below 6.0 mg/dL (or <5.0 mg/dL in patients with tophi).",
        "* **Pitfalls (general):** A common error is initiating ULT during an acute flare without concurrent anti-inflammatory prophylaxis, which can precipitate a worsening of the flare. Another is relying on a single normal serum uric acid level to rule out gout during an acute attack."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "70",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "피부바늘따끔검사(skin prick test)"
      },
      "why": [
        "* **Diagnosis:** Anaphylaxis, likely secondary to intravenous contrast media.",
        "* **Clinical Presentation:** The patient experienced a rapid-onset, life-threatening reaction immediately following a potential trigger (abdominal CT scan, which uses IV contrast). The symptoms are classic for anaphylaxis: cutaneous (generalized pruritus), respiratory (rapidly progressive dyspnea), and cardiovascular (syncope/loss of consciousness).",
        "* **Pathophysiology:** Anaphylaxis is a severe, systemic Type I hypersensitivity reaction mediated by IgE antibodies. Upon re-exposure to an allergen, IgE on the surface of mast cells and basophils is cross-linked, triggering massive degranulation and release of inflammatory mediators like histamine and tryptase.",
        "* **Diagnostic Workup:** The question asks for the test to diagnose the cause for future avoidance. After the patient is stabilized, an allergy workup is necessary to confirm the trigger.",
        "* **First Step in Allergy Testing:** For suspected IgE-mediated (Type I) reactions, skin prick testing is the standard initial test. It is safe, sensitive, and relatively inexpensive. A small amount of the suspected allergen (in this case, the specific contrast agent used) is introduced into the epidermis. A positive reaction (wheal and flare) indicates the presence of specific IgE antibodies.",
        "* **Purpose of Testing:** Identifying the specific causative agent is crucial for patient safety. The patient must be counseled to avoid that specific agent and any cross-reacting substances in the future. This information should be clearly documented in their medical record.",
        "* **Alternative Testing:** If skin testing is negative but clinical suspicion is high, intradermal testing (more sensitive but slightly higher risk) or a graded drug challenge (gold standard but highest risk) may be considered in a specialized setting."
      ],
      "others": [
        {
          "label": "①",
          "text": "피부생검",
          "reason": "A skin biopsy is used to diagnose primary dermatologic conditions by examining tissue histology. It is not used to identify the trigger of a systemic allergic reaction like anaphylaxis."
        },
        {
          "label": "③",
          "text": "주사유발검사",
          "reason": "A drug provocation test (challenge test) is the definitive gold standard but carries a significant risk of inducing another severe reaction. It is reserved for situations where skin testing is inconclusive and the information is essential, and it is performed only under strict medical supervision."
        },
        {
          "label": "④",
          "text": "혈청 보체",
          "reason": "Complement levels are measured to investigate complement-mediated diseases like hereditary angioedema or certain autoimmune conditions. While some contrast reactions can be non-IgE mediated ('anaphylactoid'), complement testing is not the primary method to identify the specific trigger for future avoidance."
        },
        {
          "label": "⑤",
          "text": "첩포 검사(patch test)",
          "reason": "Patch testing is used to diagnose Type IV (delayed-type) hypersensitivity reactions, such as allergic contact dermatitis, which typically manifest 48-72 hours after exposure. Anaphylaxis is a Type I (immediate) hypersensitivity reaction."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "피부바늘따끔검사(skin prick test)"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Anaphylaxis is a severe, life-threatening, systemic hypersensitivity reaction. It is characterized by rapid onset and involvement of at least two organ systems (e.g., cutaneous, respiratory, cardiovascular, gastrointestinal).",
        "* **Pathophysiology:** Most cases are IgE-mediated (Type I hypersensitivity). An allergen cross-links IgE on mast cells and basophils, triggering massive degranulation and release of inflammatory mediators like histamine.",
        "* **Management (Acute):** The immediate, first-line treatment is intramuscular epinephrine. This should be followed by securing the airway, providing oxygen, IV fluids, and administering adjunct therapies like antihistamines and corticosteroids.",
        "* **Workup (Identifying the Cause):** After the patient is stabilized, an allergy workup is essential to identify the trigger and prevent future episodes. This question asks for the diagnostic test to find the cause.",
        "* **Diagnostic Testing:**\n  - **First-line:** Skin prick testing is the standard initial method to test for IgE-mediated allergies. It is sensitive, rapid, and cost-effective.\n  - **Second-line:** Serum specific IgE tests (e.g., ImmunoCAP) are an alternative, especially if skin testing is contraindicated.\n  - **Gold Standard:** A graded drug provocation test is the most definitive test but carries the risk of inducing another reaction and is reserved for specific circumstances.",
        "* **Differential Testing:** It is crucial to select the correct test for the suspected hypersensitivity type.\n  - **Patch Test:** Used to diagnose Type IV (delayed-type) hypersensitivity, such as allergic contact dermatitis.\n  - **Skin Biopsy:** Used to diagnose primary dermatologic conditions, not to identify an allergic trigger.",
        "* **Pitfalls (general):** The most critical pitfall in acute management is delaying the administration of epinephrine. In diagnostics, a common error is performing skin testing too soon after an anaphylactic event (within 4-6 weeks), as this can lead to false-negative results due to mast cell mediator depletion."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "71",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "비만세포(Mast cell)"
      },
      "why": [
        "* **Diagnosis:** The patient is experiencing an early-phase allergic asthma exacerbation, which is a classic example of a Type I hypersensitivity reaction.",
        "* **Clinical Presentation:** The key features are the rapid onset of symptoms (wheezing, dyspnea) within 10 minutes following exposure to a known allergen (pet cat). This timeline is characteristic of an immediate hypersensitivity reaction.",
        "* **Pathophysiology:** Type I hypersensitivity reactions are mediated by IgE antibodies. In a sensitized individual, re-exposure to an allergen leads to cross-linking of IgE molecules bound to the surface of mast cells and basophils.",
        "* **Central Effector Cell:** This cross-linking triggers the immediate degranulation of mast cells, releasing pre-formed inflammatory mediators.",
        "* **Key Mediators (Early Phase):** The primary mediators released from mast cells include histamine, tryptase, leukotrienes (LTC4, LTD4), and prostaglandins (PGD2).",
        "* **Mechanism of Symptoms:** Histamine and leukotrienes are potent bronchoconstrictors, directly causing the contraction of bronchial smooth muscle. This leads to the acute symptoms of wheezing and dyspnea.",
        "* **Role of Other Cells:** While other cells are involved in the overall allergic inflammatory cascade, they are not central to the immediate reaction.",
        "  - **Eosinophils:** These are recruited later and are the primary effectors of the late-phase reaction, which occurs 4-8 hours after allergen exposure.",
        "  - **Lymphocytes (T and B cells):** T-helper 2 (Th2) cells and B cells are crucial for the initial sensitization phase, where allergen-specific IgE is produced, but they do not directly cause the acute bronchoconstriction.",
        "  - **Dendritic cells:** As antigen-presenting cells, they initiate the immune response by presenting the allergen to T cells, but they are not the effector cells of the immediate reaction.",
        "* **Conclusion:** The mast cell is the central immune cell responsible for initiating the immediate cascade of events leading to bronchial smooth muscle contraction in an allergic asthma attack."
      ],
      "others": [
        {
          "label": "①",
          "text": "호산구(Eosinophil)",
          "reason": "Eosinophils are the primary effector cells of the late-phase allergic reaction, which occurs hours after the initial exposure, not the immediate reaction within 10 minutes."
        },
        {
          "label": "②",
          "text": "호중구(Neutrophil)",
          "reason": "Neutrophils are primarily involved in the innate immune response to bacterial infections and are not the central cell in IgE-mediated allergic reactions like asthma."
        },
        {
          "label": "④",
          "text": "림프구(Lymphocyte)",
          "reason": "Lymphocytes (T and B cells) are essential for the sensitization phase and production of IgE, but they do not directly release the mediators that cause acute bronchoconstriction."
        },
        {
          "label": "⑤",
          "text": "수지상세포(Dendritic cell)",
          "reason": "Dendritic cells are antigen-presenting cells that initiate the allergic sensitization process but are not the effector cells that degranulate to cause immediate symptoms."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "비만세포(Mast cell)"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Core Concept:** Allergic asthma is a classic example of a Type I (immediate) hypersensitivity reaction.",
        "* **Pathophysiology (Sensitization):** On first exposure, an allergen is processed by antigen-presenting cells (dendritic cells) and presented to T-helper 2 (Th2) lymphocytes. Th2 cells then stimulate B lymphocytes to produce allergen-specific IgE antibodies.",
        "* **Pathophysiology (Re-exposure):** The allergen-specific IgE antibodies bind to high-affinity FcεRI receptors on the surface of mast cells and basophils, sensitizing them.",
        "* **Central Effector Cell (Early Phase):** Upon re-exposure, the allergen cross-links the surface-bound IgE on **mast cells**, triggering their immediate degranulation. This makes the mast cell the central cell in the early-phase reaction.",
        "* **Early-Phase Reaction (Minutes):** Mast cell degranulation releases pre-formed mediators (histamine, tryptase) and newly synthesized lipid mediators (leukotrienes, prostaglandins).",
        "* **Mechanism of Symptoms:** Histamine and leukotrienes are potent bronchoconstrictors that cause smooth muscle contraction, increased vascular permeability, and mucus secretion, leading to the acute symptoms of wheezing and dyspnea within minutes.",
        "* **Late-Phase Reaction (Hours):** Cytokines released by mast cells recruit other inflammatory cells, most notably **eosinophils**, to the airways. Eosinophils are the primary effector cells of the late-phase reaction (4-8 hours later), which causes sustained inflammation and airway hyperresponsiveness.",
        "* **Differential Cell Roles:**\n  - **Mast Cell:** Initiates the immediate reaction.\n  - **Eosinophil:** Mediates the late-phase reaction.\n  - **Lymphocyte (T/B cells):** Crucial for the initial sensitization and IgE production.",
        "* **Pitfalls (general):** A common point of confusion is misattributing the immediate bronchoconstriction to eosinophils. It is critical to distinguish the mast cell's role in the early phase from the eosinophil's role in the late phase."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "72",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "식품의존성 운동유발 아나필락시스"
      },
      "why": [
        "* **Diagnosis:** Food-dependent exercise-induced anaphylaxis (FDEIA).",
        "* **Clinical Presentation:** The patient experienced a severe anaphylactic reaction (dizziness, loss of consciousness, hypotension at 66/38 mmHg) associated with urticaria and angioedema.",
        "* **Diagnostic Criteria:** The diagnosis of FDEIA is made based on the characteristic history where anaphylaxis occurs only when exercise is performed within a few hours after ingesting a specific food. The vignette explicitly states this pattern.",
        "* **Provocation Test Findings:** The provocation tests are classic for FDEIA: symptoms were absent with the food (bread) alone and with exercise alone, but were triggered when exercise followed food ingestion.",
        "* **Lab Findings:** The positive ImmunoCAP test for omega-5-gliadin specific IgE (class 3) confirms sensitization to a major wheat allergen. Omega-5-gliadin is the most common causative antigen in wheat-dependent FDEIA.",
        "* **Pathophysiology:** The exact mechanism is not fully understood, but it's thought that exercise increases gut permeability, allowing more undigested food allergens to enter the bloodstream. Exercise may also lower the threshold for mast cell degranulation in sensitized individuals.",
        "* **Differential / Discriminators:** This pattern distinguishes FDEIA from other conditions.",
        "  - **Simple Food Allergy:** Symptoms would occur after ingesting the food, even without exercise.",
        "  - **Exercise-Induced Anaphylaxis (EIA):** Symptoms would occur with exercise alone, regardless of food intake.",
        "  - **Cholinergic Urticaria:** Triggered by increased body temperature, typically causing small punctate hives, and rarely progressing to severe anaphylaxis.",
        "* **Management:** The primary management is strict avoidance of the culprit food for at least 4-6 hours before planned exercise. Patients should also carry an epinephrine auto-injector."
      ],
      "others": [
        {
          "label": "①",
          "text": "밀가루 알레르기",
          "reason": "This is incorrect because a simple wheat allergy would cause symptoms upon ingestion of bread alone, but the provocation test with bread was negative."
        },
        {
          "label": "②",
          "text": "콜린성 두드러기",
          "reason": "Cholinergic urticaria is not food-dependent and typically presents with small, punctate wheals rather than the severe anaphylaxis with hypotension seen in this patient."
        },
        {
          "label": "③",
          "text": "자율신경계 실조증",
          "reason": "While autonomic dysfunction can cause syncope with exertion, it does not explain the associated urticaria and angioedema, which are hallmarks of an allergic reaction."
        },
        {
          "label": "⑤",
          "text": "운동 유발 두드러기",
          "reason": "This is incorrect because exercise-induced urticaria/anaphylaxis would be triggered by exercise alone, but the provocation test with exercise was negative in this patient."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "식품의존성 운동유발 아나필락시스"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Food-dependent exercise-induced anaphylaxis (FDEIA) is a distinct syndrome where anaphylaxis occurs only when physical exertion follows the ingestion of a specific food.",
        "* **Diagnostic Criteria:** The diagnosis is based on a characteristic history where symptoms are absent when the food is eaten without exercise, and also absent when exercise is performed without eating the food. The combination of the two triggers the reaction.",
        "* **Workup:** The diagnosis is confirmed with a provocation test under medical supervision, where the patient ingests the food and then exercises. Allergy testing (skin prick or serum specific IgE) can identify sensitization to the culprit food.",
        "* **Common Triggers:** Wheat is the most common food trigger worldwide, and the specific allergen is often omega-5-gliadin. Shellfish is another common trigger.",
        "* **Pathophysiology:** The mechanism is not fully understood but may involve exercise-induced increases in gut permeability, allowing more allergen to enter the circulation, or exercise lowering the threshold for mast cell degranulation in sensitized individuals.",
        "* **Management:** The cornerstone of management is avoidance. Patients must avoid eating the specific culprit food for at least 4-6 hours before and immediately after planned exercise.",
        "* **Emergency Preparedness:** All patients diagnosed with FDEIA must be prescribed and trained to use an epinephrine auto-injector.",
        "* **Differential/Discriminators:** It is crucial to differentiate FDEIA from similar conditions:\n  - **Simple Food Allergy:** Symptoms occur after food ingestion, regardless of exercise.\n  - **Exercise-Induced Anaphylaxis (non-food dependent):** Symptoms occur with exercise alone.\n  - **Cholinergic Urticaria:** Triggered by increased body temperature; typically causes small, punctate hives and rarely progresses to anaphylaxis.",
        "* **Pitfalls (general):** Misdiagnosing FDEIA as a simple food allergy, leading to unnecessary complete dietary avoidance. Failing to recognize the role of exercise as a necessary co-factor."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "73",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "코르티코스테로이드"
      },
      "why": [
        "* **Diagnosis:** Severe immune-related adverse event (irAE), specifically a high-grade dermatitis, likely Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), secondary to pembrolizumab (a PD-1 inhibitor).",
        "* **Clinical Presentation:** A 68-year-old man on pembrolizumab for metastatic NSCLC presents with a new, widespread skin rash, low-grade fever (37.8°C), and systemic inflammation.",
        "* **Image Findings:** The photograph shows a diffuse, erythematous, maculopapular rash covering the patient's trunk, consistent with a severe drug-induced exanthem.",
        "* **Lab Findings:** Key findings include leukocytosis (15,000/mm³) with marked peripheral eosinophilia (25%, absolute count of 3,750/mm³) and an elevated C-reactive protein (14.5 mg/L).",
        "* **Diagnostic Criteria (DRESS):** The combination of a morbilliform rash, fever, and significant eosinophilia (>1,500/mm³) in the context of a new drug exposure strongly suggests DRESS syndrome.",
        "* **Pathophysiology of irAEs:** Immune checkpoint inhibitors like pembrolizumab enhance T-cell activity against tumors but can also lead to loss of self-tolerance, causing T-cell mediated damage to healthy organs. The skin is one of the most commonly affected sites.",
        "* **Treatment Principle / Guidelines:** The management of irAEs is graded by severity. For severe (Grade 3 or 4) reactions, which this case represents due to the extensive rash and systemic symptoms, the first-line treatment is high-dose systemic corticosteroids.",
        "* **Management:** The checkpoint inhibitor (pembrolizumab) should be held, and treatment with systemic corticosteroids (e.g., prednisone 1-2 mg/kg/day or equivalent IV methylprednisolone) should be initiated promptly. The steroids are then tapered slowly over several weeks once symptoms improve.",
        "* **Differential / Discriminators:** While other immunosuppressants are used, they are typically reserved for steroid-refractory cases. Corticosteroids are the standard initial therapy for severe irAEs."
      ],
      "others": [
        {
          "label": "①",
          "text": "CTLA-4 억제 단클론항체",
          "reason": "This is another type of immune checkpoint inhibitor (e.g., ipilimumab). Administering another checkpoint inhibitor would likely worsen the immune-related adverse event."
        },
        {
          "label": "②",
          "text": "JAK 억제제",
          "reason": "While JAK inhibitors have immunosuppressive properties, they are not the standard first-line treatment for severe cutaneous irAEs like DRESS syndrome. High-dose corticosteroids are the established initial therapy."
        },
        {
          "label": "③",
          "text": "TNF-a억제제",
          "reason": "TNF-α inhibitors like infliximab are typically used for steroid-refractory irAEs, particularly immune-mediated colitis, not as a first-line treatment for cutaneous reactions."
        },
        {
          "label": "④",
          "text": "미코페놀레이트",
          "reason": "Mycophenolate is a second-line immunosuppressive agent used for steroid-refractory irAEs. Systemic corticosteroids are the appropriate first-line treatment."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "코르티코스테로이드"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Core Concept:** Immune checkpoint inhibitors (e.g., pembrolizumab, a PD-1 inhibitor) can cause a wide spectrum of immune-related adverse events (irAEs) by disrupting self-tolerance.",
        "* **Clinical picture:** This patient presents with a severe cutaneous irAE consistent with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The key features are a widespread morbilliform rash, fever, and marked peripheral eosinophilia.",
        "* **Workup:** Evaluation includes a complete blood count with differential to look for eosinophilia, a comprehensive metabolic panel to assess for liver or kidney involvement, and inflammatory markers like CRP.",
        "* **Criteria/Thresholds:** DRESS syndrome is suggested by the triad of rash, fever, and eosinophilia (typically absolute count >1,500/mm³). This patient's absolute eosinophil count is 3,750/mm³.",
        "* **Management (algorithmic):** The management of irAEs is based on severity, graded using the Common Terminology Criteria for Adverse Events (CTCAE).\n  - **Grade 1 (Mild):** Continue immunotherapy, manage with topical therapies.\n  - **Grade 2 (Moderate):** Hold immunotherapy, start oral corticosteroids (e.g., prednisone 0.5-1 mg/kg/day).\n  - **Grade 3/4 (Severe/Life-threatening):** Permanently discontinue immunotherapy and initiate high-dose intravenous corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day).",
        "* **Treatment (First-line):** High-dose systemic corticosteroids are the cornerstone and first-line treatment for any severe (Grade 3 or 4) irAE.",
        "* **Second-line Treatment:** For steroid-refractory irAEs, other immunosuppressive agents such as infliximab (especially for colitis) or mycophenolate may be considered.",
        "* **Monitoring:** After initiating high-dose steroids, a slow taper over at least 4-6 weeks is required to prevent the recurrence of the irAE.",
        "* **Pitfalls (general):** A critical pitfall is failing to recognize a new symptom in a patient on immunotherapy as a potential irAE. Another is not grading the severity correctly, leading to undertreatment. Tapering corticosteroids too quickly can lead to a flare of the irAE."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "74",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "Streptococcus pneumoniae"
      },
      "why": [
        "* **Core Concept:** The question describes the immunological principle behind conjugate vaccines. Pure polysaccharide antigens are T-cell independent, leading to a weak immune response (mainly IgM) and poor memory, especially in infants.",
        "* **Conjugation Technology:** By covalently linking (conjugating) the polysaccharide antigen to a carrier protein (e.g., diphtheria or tetanus toxoid), the vaccine is converted into a T-cell dependent antigen.",
        "* **Mechanism of Action:** B-cells recognize the polysaccharide, internalize the entire conjugate, and then present peptides from the carrier protein on MHC class II molecules to T-helper cells. This T-cell help drives B-cell proliferation, class switching to produce high-affinity IgG, and the formation of long-lived memory B-cells.",
        "* **Application:** This technology is crucial for protecting infants against encapsulated bacteria, whose polysaccharide capsules are major virulence factors.",
        "* **Analysis of Options:** The question asks to identify the bacterium for which a conjugate vaccine has been developed.",
        "  - **Streptococcus pneumoniae:** This is a classic example. The pneumococcal conjugate vaccines (PCV13, PCV15, PCV20) are standard in infant immunization schedules and are highly effective at preventing invasive pneumococcal disease.",
        "  - **Other examples:** Other major conjugate vaccines target *Haemophilus influenzae* type b (Hib) and *Neisseria meningitidis*.",
        "* **Distractor Rationale:** The other options are incorrect types of vaccines.",
        "  - **Bordetella pertussis:** The vaccine is acellular, containing purified protein antigens (pertussis toxoid, etc.).",
        "  - **Clostridium tetani & Corynebacterium diphtheriae:** The vaccines are toxoids, which are inactivated protein toxins.",
        "  - **Pseudomonas aeruginosa:** While it is an encapsulated bacterium, there is no widely used conjugate vaccine for it in routine immunization schedules."
      ],
      "others": [
        {
          "label": "①",
          "text": "Bordetella pertussis",
          "reason": "The pertussis vaccine is an acellular vaccine containing purified protein components, not a polysaccharide-protein conjugate vaccine."
        },
        {
          "label": "②",
          "text": "Clostridium tetani",
          "reason": "The tetanus vaccine is a toxoid vaccine, which uses an inactivated protein toxin, not a polysaccharide antigen."
        },
        {
          "label": "③",
          "text": "Corynebacterium diphtheriae",
          "reason": "The diphtheria vaccine is a toxoid vaccine, based on an inactivated protein toxin, not a polysaccharide conjugate."
        },
        {
          "label": "④",
          "text": "Pseudomonas aerugionsa",
          "reason": "While vaccines for *Pseudomonas aeruginosa* are in development, there is no standard, routinely administered conjugate vaccine for this organism."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "Streptococcus pneumoniae"
        },
        "provided_key": {
          "label": "5",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Core Concept:** Polysaccharide antigens, such as the capsules of bacteria like *Streptococcus pneumoniae*, are T-cell independent antigens.",
        "* **T-cell Independent Response:** This type of immune response is weak, especially in infants and young children. It primarily generates low-affinity IgM antibodies and fails to produce immunologic memory.",
        "* **Conjugate Vaccine Technology:** To overcome this limitation, the polysaccharide antigen is covalently linked (conjugated) to a carrier protein (e.g., an inactivated diphtheria or tetanus toxoid).",
        "* **Mechanism of Action:** The B-cell recognizes the polysaccharide, but the attached protein is processed and its peptides are presented on MHC class II molecules to T-helper cells. This T-cell help is crucial for inducing a robust immune response.",
        "* **Benefits of Conjugation:** This process converts a T-cell independent response into a T-cell dependent response, which leads to:\n  - **Class switching:** Production of high-affinity IgG antibodies.\n  - **Immunologic memory:** Formation of long-lived memory B-cells.\n  - **Efficacy in infants:** Strong, protective immunity even in children under 2 years of age.",
        "* **Examples of Conjugate Vaccines:** The three most important conjugate vaccines in routine pediatric immunization are for:\n  - *Streptococcus pneumoniae* (PCV)\n  - *Haemophilus influenzae* type b (Hib)\n  - *Neisseria meningitidis* (meningococcal conjugate vaccine)",
        "* **Differential (Other Vaccine Types):**\n  - **Toxoid vaccines:** Use an inactivated bacterial toxin (e.g., Tetanus, Diphtheria).\n  - **Acellular vaccines:** Use purified protein components of the bacterium (e.g., Pertussis).",
        "* **Pitfalls (general):** Confusing conjugate vaccines (like PCV13/PCV20) with pure polysaccharide vaccines (like PPSV23). PPSV23 is T-cell independent and is primarily used in adults, as it is poorly immunogenic in young children."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "75",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "항생제는 세균의 단백질 합성을 억제하여 세균의 사멸을 유도한다."
      },
      "why": [
        "* **Core Concept:** This question tests fundamental knowledge of antibiotic mechanisms of action and resistance.",
        "* **Analysis of Correct Option (②):** Inhibition of protein synthesis is a major mechanism of action for several important classes of antibiotics. These drugs target the bacterial ribosome, which differs from eukaryotic ribosomes, allowing for selective toxicity.",
        "  - **Examples:** Aminoglycosides (e.g., gentamicin) and tetracyclines (e.g., doxycycline) bind to the 30S ribosomal subunit. Macrolides (e.g., azithromycin), clindamycin, and linezolid bind to the 50S ribosomal subunit.",
        "  - **Effect:** By disrupting protein synthesis, these antibiotics halt essential cellular processes, leading to either inhibition of growth (bacteriostatic) or cell death (bactericidal).",
        "* **Analysis of Incorrect Options:**",
        "  - **Option ①:** Antibiotics like beta-lactams and vancomycin *inhibit* cell wall synthesis, they do not promote it. This inhibition weakens the cell wall, leading to lysis and death.",
        "  - **Option ③:** Antibiotics *inhibit* essential metabolic pathways. For example, sulfonamides and trimethoprim block the synthesis of folic acid, a crucial metabolite.",
        "  - **Option ④:** Increased accumulation of antibiotics inside the bacterium would enhance their effect. A common resistance mechanism is the opposite: *decreased* accumulation via efflux pumps that actively remove the antibiotic from the cell.",
        "  - **Option ⑤:** While target modification is a resistance mechanism, simply increasing the synthesis of the normal target is generally not an effective strategy. More common mechanisms include enzymatic inactivation of the drug (e.g., beta-lactamases) or alteration of the target site to reduce drug binding (e.g., mutated penicillin-binding proteins)."
      ],
      "others": [
        {
          "label": "①",
          "text": "항생제는 세균의 세포벽 생성을 촉진하여 세균의 사멸을 유도한다.",
          "reason": "This is incorrect. Antibiotics such as beta-lactams and vancomycin work by *inhibiting* cell wall synthesis, which leads to bacterial cell death."
        },
        {
          "label": "③",
          "text": "항생제는 세균의 대사 기능을 촉진하여 세균의 사멸을 유도한다.",
          "reason": "This is incorrect. Antibiotics typically *inhibit* essential metabolic pathways, such as folate synthesis, rather than promoting them."
        },
        {
          "label": "④",
          "text": "세균 내 항생제 축적이 증가하여 항생제 내성이 발생한다.",
          "reason": "This is the opposite of a common resistance mechanism. Resistance often arises from *decreased* intracellular antibiotic concentration, frequently due to efflux pumps."
        },
        {
          "label": "⑤",
          "text": "세균 내 항생제 표적 합성 증가로 항생제 내성이 발생한다.",
          "reason": "This is not a primary mechanism of resistance. Common mechanisms include enzymatic inactivation of the antibiotic, modification of the target site, or decreased drug accumulation."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "항생제는 세균의 단백질 합성을 억제하여 세균의 사멸을 유도한다."
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Core Concept:** Antibiotics exert their effects by selectively targeting structures or metabolic pathways that are present in bacteria but absent or different in eukaryotic (human) cells.",
        "* **Mechanism: Protein Synthesis Inhibition:** A major class of antibiotics works by inhibiting bacterial protein synthesis. They bind to the bacterial ribosome (which is a 70S ribosome, different from the eukaryotic 80S ribosome), halting the production of essential proteins. This is the correct statement.",
        "* **Examples (Protein Synthesis Inhibitors):**\n  - **30S subunit:** Aminoglycosides, Tetracyclines.\n  - **50S subunit:** Macrolides, Clindamycin, Linezolid, Chloramphenicol.",
        "* **Mechanism: Cell Wall Synthesis Inhibition:** Beta-lactams (penicillins, cephalosporins) and glycopeptides (vancomycin) *inhibit* the synthesis of the peptidoglycan cell wall, they do not promote it. This leads to a weakened cell wall and bacterial lysis.",
        "* **Mechanism: Metabolic Pathway Inhibition:** Antimetabolite antibiotics, such as sulfonamides and trimethoprim, *inhibit* essential pathways. They block the synthesis of folic acid, which is necessary for nucleotide production.",
        "* **Mechanism of Resistance: Decreased Accumulation:** A common resistance mechanism is *decreased* accumulation of the antibiotic inside the bacterium. This is often achieved by efflux pumps that actively transport the drug out of the cell.",
        "* **Mechanism of Resistance: Target Modification:** Another key resistance mechanism involves altering the molecular target of the antibiotic (e.g., a mutation in the penicillin-binding protein or ribosomal RNA) so that the drug can no longer bind effectively.",
        "* **Pitfalls (general):** Common misconceptions include believing antibiotics 'promote' bacterial functions (they inhibit them) or that increased drug accumulation leads to resistance (the opposite is true)."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "76",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "항생제 사용 최소화"
      },
      "why": [
        "* **Diagnosis:** *Clostridioides difficile* infection (CDI), presenting as pseudomembranous colitis.",
        "* **Clinical Presentation:** An elderly patient (70 years old) on prolonged (3 weeks) antibiotic therapy for pneumonia develops new-onset fever and frequent, mucoid diarrhea (6-7 times/day). This is a classic history for CDI.",
        "* **Image Findings:** The sigmoidoscopy image shows multiple, adherent, yellow-white plaques (pseudomembranes) on an inflamed colonic mucosa. This finding is pathognomonic for pseudomembranous colitis caused by *C. difficile*.",
        "* **Pathophysiology:** Broad-spectrum antibiotics disrupt the normal, protective gut microbiota. This allows the spore-forming, anaerobic bacterium *C. difficile* to proliferate and produce toxins A and B, which cause severe colonic inflammation and mucosal damage.",
        "* **Primary Risk Factor:** The single most important and modifiable risk factor for developing CDI is exposure to antibiotics. The risk increases with the duration of therapy and the use of broad-spectrum agents (e.g., clindamycin, fluoroquinolones, third-generation cephalosporins).",
        "* **Prevention Principle:** The most effective strategy to prevent CDI is to address its primary cause. This involves implementing antimicrobial stewardship programs.",
        "* **Antimicrobial Stewardship:** This includes using antibiotics only when necessary, choosing the narrowest spectrum agent possible, and limiting the duration of therapy to the shortest effective course. By minimizing unnecessary antibiotic exposure, the risk of disrupting the gut flora and subsequent CDI is significantly reduced.",
        "* **Other Risk Factors:** Other risk factors include advanced age, hospitalization, and use of proton pump inhibitors, but antibiotic use is the most critical modifiable factor."
      ],
      "others": [
        {
          "label": "①",
          "text": "예방접종",
          "reason": "While a vaccine for *C. difficile* is under development, it is not currently available for routine clinical use and is not the most effective preventive measure."
        },
        {
          "label": "②",
          "text": "위산 억제제 사용",
          "reason": "The use of proton pump inhibitors (PPIs) is a known risk factor for developing *C. difficile* infection, so this would increase, not decrease, the risk."
        },
        {
          "label": "③",
          "text": "철저한 혈당 조절",
          "reason": "While important for general health and reducing the risk of many infections, strict glycemic control is not the primary or most effective measure for preventing CDI."
        },
        {
          "label": "⑤",
          "text": "충분한 식이섬유 섭취",
          "reason": "A high-fiber diet is beneficial for overall gut health but is not a specific or primary preventive measure against antibiotic-associated *C. difficile* infection."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "항생제 사용 최소화"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** *Clostridioides difficile* infection (CDI) typically presents with watery diarrhea, abdominal pain, fever, and leukocytosis, most commonly in patients with recent antibiotic exposure or hospitalization.",
        "* **Pathophysiology:** The primary cause is the disruption of the normal, protective gut microbiota by antibiotics. This allows the spore-forming *C. difficile* to proliferate and produce toxins (Toxin A and Toxin B) that cause colonic inflammation and mucosal damage.",
        "* **Hallmark Finding:** In severe cases, CDI can cause pseudomembranous colitis, which is characterized by adherent yellow-white plaques (pseudomembranes) on the colonic mucosa, as seen in the sigmoidoscopy image.",
        "* **Primary Risk Factor:** The single most important and modifiable risk factor for CDI is the use of antibiotics. The risk is highest with broad-spectrum agents like clindamycin, fluoroquinolones, and third/fourth-generation cephalosporins.",
        "* **Prevention (Most Effective Strategy):** The most effective way to prevent CDI is through robust antimicrobial stewardship. This involves using antibiotics only when necessary, choosing the narrowest spectrum agent, and limiting the duration of therapy.",
        "* **Other Risk Factors:** Other significant risk factors include advanced age (>65 years), prolonged hospitalization, and the use of gastric acid-suppressing medications like proton pump inhibitors (PPIs).",
        "* **Infection Control:** To prevent transmission, strict contact precautions (gown and gloves) are required. Crucially, hands must be washed with soap and water, as alcohol-based hand sanitizers do not effectively kill *C. difficile* spores.",
        "* **Pitfalls (general):** A major pitfall in prevention is the failure to implement antimicrobial stewardship programs. In infection control, relying on alcohol-based hand sanitizers instead of soap and water after caring for a CDI patient is a critical error."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "77",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "C3 glomerulonephritis"
      },
      "why": [
        "* **Diagnosis:** C3 glomerulonephritis (C3G), specifically the subtype Dense Deposit Disease (DDD).",
        "* **Clinical Presentation:** A 65-year-old man with a mixed nephritic-nephrotic syndrome, characterized by nephrotic-range proteinuria (2.1 g/g), microscopic hematuria (RBC 5-10/HPF), edema, and acute kidney injury (Creatinine 1.7 mg/dL).",
        "* **Lab Findings:** The key serological finding is a markedly low serum C3 level (54 mg/dL) with a normal C4 level (21 mg/dL). This pattern strongly suggests activation of the alternative complement pathway.",
        "* **Image Findings (Kidney Biopsy):**",
        "  - **Light Microscopy (LM):** The glomeruli show a membranoproliferative (MPGN) pattern of injury, with mesangial and endocapillary hypercellularity, lobular accentuation, and thickened capillary walls with double contours ('tram-tracking').",
        "  - **Immunofluorescence (IF):** There is dominant, bright staining for C3 along the capillary walls and in the mesangium. The staining for IgG is negative or trace, which rules out immune-complex mediated diseases like lupus nephritis or infection-related GN.",
        "  - **Electron Microscopy (EM):** The EM image shows highly characteristic, electron-dense, sausage-shaped deposits located within the lamina densa of the glomerular basement membrane. This finding is pathognomonic for Dense Deposit Disease (DDD).",
        "* **Pathophysiology:** C3G is caused by dysregulation of the alternative complement pathway, leading to uncontrolled C3 activation and deposition of complement products in the glomeruli. DDD is a specific subtype defined by the unique intramembranous deposits on EM.",
        "* **Classification:** The diagnosis of C3 glomerulonephritis is based on the IF finding of C3-dominant staining with minimal or no immunoglobulin. The LM pattern is typically MPGN, and the EM findings further subclassify the disease (e.g., into DDD or C3 glomerulonephritis NOS).",
        "* **Conclusion:** The combination of the clinical picture, low serum C3, MPGN pattern on LM, C3-dominant IF, and pathognomonic EM findings confirms the diagnosis of C3 glomerulonephritis (Dense Deposit Disease).",
        "* **Historical Note:** This entity was previously known as MPGN Type II."
      ],
      "others": [
        {
          "label": "①",
          "text": "IgA nephropathy",
          "reason": "This is incorrect because IgA nephropathy is characterized by dominant IgA deposition on immunofluorescence, and serum complement levels are typically normal."
        },
        {
          "label": "③",
          "text": "Minimal change disease",
          "reason": "This is incorrect. Minimal change disease presents with pure nephrotic syndrome, normal light microscopy, negative immunofluorescence, and no hematuria or low C3."
        },
        {
          "label": "④",
          "text": "Membranous nephropathy",
          "reason": "This is incorrect. Membranous nephropathy shows subepithelial deposits on EM and granular IgG and C3 staining on IF, without significant hypercellularity or low serum C3."
        },
        {
          "label": "⑤",
          "text": "Membraoproliferative glomerulonephritis",
          "reason": "While the light microscopy shows an MPGN pattern, this is a descriptive term for a pattern of injury, not the final diagnosis. C3 glomerulonephritis is the specific disease entity based on the pathognomonic immunofluorescence and electron microscopy findings."
        }
      ],
      "runner_up": "⑤ Membraoproliferative glomerulonephritis",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "C3 glomerulonephritis"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** C3 Glomerulonephritis (C3G) is a rare kidney disease that can present with a wide spectrum of findings, from asymptomatic hematuria and proteinuria to a mixed nephritic-nephrotic syndrome or rapidly progressive glomerulonephritis.",
        "* **Pathophysiology:** C3G is caused by dysregulation of the alternative complement pathway, leading to abnormal deposition of C3 complement components in the glomeruli.",
        "* **Workup:** The key initial serologic finding is a low serum C3 level with a normal C4 level, which points specifically to alternative pathway activation. The definitive diagnosis requires a kidney biopsy.",
        "* **Kidney Biopsy (Diagnostic Triad):** The diagnosis is established by a specific combination of findings:\n  - **Light Microscopy (LM):** Often shows a membranoproliferative (MPGN) pattern of injury.\n  - **Immunofluorescence (IF):** The pathognomonic finding is dominant C3 staining (at least 2+ intensity stronger than any immunoglobulin staining).\n  - **Electron Microscopy (EM):** Confirms the diagnosis and sub-classifies the disease.",
        "* **Subtype: Dense Deposit Disease (DDD):** The EM image in this case is classic for DDD, a subtype of C3G. It shows highly characteristic, intensely electron-dense, sausage-shaped deposits within the lamina densa of the glomerular basement membrane.",
        "* **Management:** Treatment is challenging and often supportive, including blood pressure control with ACE inhibitors or ARBs. In more severe cases, immunosuppressants (corticosteroids, mycophenolate) or complement-inhibiting drugs may be used.",
        "* **Differential/Discriminators:** C3G is distinguished from immune-complex mediated glomerulonephritis (like lupus nephritis or infection-related GN) by the lack of significant immunoglobulin deposition on immunofluorescence.",
        "* **Pitfalls (general):** A common error is to stop at the descriptive diagnosis of 'MPGN' on light microscopy. The definitive diagnosis requires integration of IF and EM findings to identify the underlying disease, such as C3G."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "78",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "부종에 대한 치료를 위해 저염식이 처방 및 고리 이뇨제를 주사로 투약한다."
      },
      "why": [
        "* **Diagnosis:** The patient presents with a classic, full-blown nephrotic syndrome.",
        "* **Diagnostic Criteria / Thresholds:** The diagnosis is established by the presence of:",
        "  - **Massive proteinuria:** Urine protein/creatinine ratio of 7.1 g/g (well above the threshold of >3.5 g/day).",
        "  - **Hypoalbuminemia:** Serum albumin of 2.8 g/dL (below the threshold of <3.0 g/dL).",
        "  - **Edema:** Severe peripheral edema with an 11 kg weight gain.",
        "  - **Hyperlipidemia:** Total cholesterol of 364 mg/dL.",
        "* **Initial Management Principle:** Before a definitive diagnosis is made by kidney biopsy, management focuses on treating the severe complications of the nephrotic state. The most pressing clinical problem is the massive volume overload.",
        "* **Treatment of Edema:** The cornerstone of managing severe edema in nephrotic syndrome is twofold:",
        "  - **Sodium Restriction:** A low-salt diet (typically <2 grams of sodium per day) is essential to prevent further fluid retention.",
        "  - **Diuresis:** High-dose loop diuretics (e.g., furosemide) are required to promote excretion of the excess sodium and water. IV administration is often preferred in hospitalized patients with severe edema due to potentially impaired oral absorption from gut edema.",
        "* **Rationale for Correct Option:** This option directly and appropriately addresses the patient's most significant and symptomatic problem—the massive fluid overload—using the standard-of-care approach.",
        "* **Rationale for Rejecting Others:** Other options are either second-line, inappropriate, or less urgent.",
        "  - **Anticoagulation:** While considered for hypercoagulability, it is not the most urgent initial step compared to managing life-threatening volume overload.",
        "  - **Albumin infusion:** Used only in specific situations like diuretic resistance, not as routine daily therapy.",
        "  - **Diet:** A high-protein diet is not recommended; moderate protein intake is preferred. Salt restriction is the key dietary intervention."
      ],
      "others": [
        {
          "label": "①",
          "text": "혈압 조절을 위하여 칼슘채널차단제를 투약한다.",
          "reason": "While blood pressure control is important, ACE inhibitors or ARBs are preferred for their antiproteinuric effects. More importantly, managing the severe volume overload with diuretics is the most urgent priority."
        },
        {
          "label": "②",
          "text": "저알부민혈증에 대한 치료로 매일20% 알부민100cc를 투약한다.",
          "reason": "Routine albumin infusions are not recommended as the infused albumin is rapidly excreted in the urine. This is reserved for cases of severe diuretic resistance or symptomatic intravascular volume depletion."
        },
        {
          "label": "④",
          "text": "심부정맥혈전증의 합병증 발생을 예방하기 위해 와파린과 같은 항응고제를 투약한다.",
          "reason": "Although nephrotic syndrome is a hypercoagulable state, prophylactic anticoagulation is a considered intervention, not an immediate, universal requirement. Managing the severe, symptomatic edema is a higher priority."
        },
        {
          "label": "⑤",
          "text": "급격한 체중 증가에 대한 식이 조절을 위해 탄수화물 제한 및 고단백 식이를 권고한다.",
          "reason": "A high-protein diet is not recommended as it may worsen proteinuria. The most critical dietary intervention is strict sodium restriction, not carbohydrate or protein manipulation."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "부종에 대한 치료를 위해 저염식이 처방 및 고리 이뇨제를 주사로 투약한다."
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Nephrotic syndrome is a clinical state characterized by a tetrad of findings: massive proteinuria, hypoalbuminemia, edema, and hyperlipidemia.",
        "* **Criteria/Thresholds:** The key diagnostic criterion is nephrotic-range proteinuria, defined as >3.5 grams of protein excretion per day or a spot urine protein/creatinine ratio >3.5 g/g. This is accompanied by hypoalbuminemia (serum albumin <3.0 g/dL).",
        "* **Initial Management Principle:** While awaiting a definitive diagnosis from a kidney biopsy, the initial management focuses on treating the severe symptoms and complications of the nephrotic state.",
        "* **Management of Edema:** The most pressing initial problem is typically massive volume overload. The cornerstone of treatment is a two-pronged approach:\n  - **Diet:** Strict dietary sodium restriction (typically <2 g/day).\n  - **Diuresis:** High-dose intravenous loop diuretics (e.g., furosemide) to promote excretion of excess sodium and water.",
        "* **Management of Other Complications:**\n  - **Hypertension & Proteinuria:** ACE inhibitors or ARBs are the preferred antihypertensives due to their antiproteinuric effects.\n  - **Hyperlipidemia:** Statins are used to manage the associated dyslipidemia.\n  - **Hypercoagulability:** Prophylactic anticoagulation is considered for patients at high risk of thrombosis (e.g., serum albumin <2.0-2.5 g/dL).",
        "* **Role of Albumin Infusion:** Routine infusion of albumin is not recommended, as the infused albumin is rapidly lost in the urine. It is reserved for specific situations like diuretic resistance or hemodynamic instability.",
        "* **Role of Diet:** The most important dietary modification is sodium restriction. A high-protein diet is not recommended as it can exacerbate proteinuria.",
        "* **Pitfalls (general):** A common pitfall is providing inadequate diuretic doses or failing to enforce strict salt restriction. Another is the routine use of albumin infusions, which is generally ineffective and costly."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "79",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "혈액 투석"
      },
      "why": [
        "* **Diagnosis:** Acute-on-chronic kidney failure with severe, life-threatening complications.",
        "* **Clinical Presentation:** An 85-year-old man with oliguria (300 mL/day), dyspnea, and pitting edema, who has been taking potentially nephrotoxic herbal medicines.",
        "* **Lab Findings:** The labs show severe renal failure (BUN 120 mg/dL, Creatinine 10.2 mg/dL) and life-threatening hyperkalemia (K 6.2 mmol/L).",
        "* **Image Findings:** The chest X-ray reveals severe pulmonary edema, evidenced by cardiomegaly, bilateral opacities, and vascular congestion, which explains his dyspnea and hypoxia (SpO2 90%).",
        "* **Urgent Dialysis Indications:** The patient meets multiple absolute indications for emergency renal replacement therapy (hemodialysis). The classic mnemonic is AEIOU:",
        "  - **A**cidosis: Not given, but likely present.",
        "  - **E**lectrolytes: Refractory hyperkalemia. His K+ of 6.2 mmol/L is a life-threatening emergency.",
        "  - **I**ngestion: Possible herbal toxin.",
        "  - **O**verload: Refractory volume overload. He has severe pulmonary edema and is oliguric and unresponsive to IV diuretics.",
        "  - **U**remia: Symptomatic uremia. BUN of 120 is extremely high, and his dyspnea is likely exacerbated by uremia.",
        "* **Treatment Principle:** When life-threatening complications of acute kidney injury are present and are refractory to medical management, urgent dialysis is indicated to correct volume status, electrolyte abnormalities, and remove uremic toxins.",
        "* **Surgical Consideration:** The patient also has suspected appendicitis requiring surgery. Hemodialysis is crucial for metabolic and hemodynamic stabilization before he can safely undergo anesthesia and an operation.",
        "* **Conclusion:** The combination of refractory pulmonary edema and severe hyperkalemia makes hemodialysis the only appropriate and life-saving intervention."
      ],
      "others": [
        {
          "label": "②",
          "text": "Isotonic saline 정맥 투여",
          "reason": "This is strongly contraindicated. The patient has severe volume overload with pulmonary edema; administering more fluid would be fatal."
        },
        {
          "label": "③",
          "text": "근육이완제 투여",
          "reason": "This is irrelevant to the management of acute renal failure and its complications."
        },
        {
          "label": "④",
          "text": "신장 이식",
          "reason": "Kidney transplantation is a treatment for end-stage renal disease, not an emergency procedure for acute kidney failure, especially in an unstable patient with a potential active infection (appendicitis)."
        },
        {
          "label": "⑤",
          "text": "방광내시경",
          "reason": "Cystoscopy is a diagnostic tool for bladder pathology and has no role in treating intrinsic renal failure with systemic complications like hyperkalemia and pulmonary edema."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "혈액 투석"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Core Concept:** Urgent hemodialysis is a life-saving intervention for patients with acute kidney injury (AKI) who develop severe, life-threatening complications that are refractory to medical management.",
        "* **Indications for Urgent Dialysis (AEIOU):** The classic mnemonic for absolute dialysis indications is AEIOU:\n  - **A**cidosis: Severe metabolic acidosis (e.g., pH <7.1) unresponsive to bicarbonate.\n  - **E**lectrolytes: Refractory, life-threatening hyperkalemia (e.g., K >6.5 mmol/L or with EKG changes).\n  - **I**ngestions: Dialysis can remove certain toxins (e.g., salicylates, lithium, ethylene glycol).\n  - **O**verload: Volume overload causing severe pulmonary edema that is unresponsive to diuretics.\n  - **U**remia: Symptomatic uremia, such as uremic pericarditis or encephalopathy.",
        "* **Vignette Analysis:** This patient has at least two clear, absolute indications for urgent hemodialysis: refractory volume overload causing severe pulmonary edema (hypoxia, CXR findings) and life-threatening hyperkalemia (K 6.2 mmol/L).",
        "* **Management:** The only appropriate and immediate life-saving intervention is to initiate renal replacement therapy, most commonly intermittent hemodialysis.",
        "* **Pre-Operative Stabilization:** In a patient with AKI requiring urgent surgery (like for suspected appendicitis), pre-operative dialysis is crucial to correct metabolic derangements and volume status to make them a safer candidate for anesthesia.",
        "* **Contraindicated Actions:** Administering intravenous fluids (e.g., isotonic saline) is absolutely contraindicated in a patient with severe pulmonary edema and would likely be fatal.",
        "* **Differential/Discriminators:** Medical management of hyperkalemia (calcium, insulin/glucose, beta-agonists) and pulmonary edema (diuretics) are first-line steps, but this patient is described as oliguric and unresponsive, making dialysis the necessary next step.",
        "* **Pitfalls (general):** The most critical pitfall is delaying the initiation of dialysis when absolute indications are present. This can lead to cardiac arrest from hyperkalemia or respiratory failure from pulmonary edema."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "80",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "loop diuretics 투여"
      },
      "why": [
        "* **Diagnosis:** Acute decompensated heart failure (ADHF) with volume overload, leading to cardiorenal syndrome.",
        "* **Clinical Presentation:** A patient with a history of hypertension, diabetes, and recent mitral valve replacement presents with classic signs of heart failure: dyspnea, generalized pitting edema, and elevated blood pressure.",
        "* **Image Findings:** The chest X-ray shows cardiomegaly, pulmonary vascular congestion, and pleural effusions, confirming congestive heart failure.",
        "* **Lab Findings:**",
        "  - **Renal Dysfunction:** Elevated BUN (56 mg/dL) and creatinine (1.9 mg/dL) indicate acute kidney injury, likely due to decreased renal perfusion from low cardiac output (cardiorenal syndrome).",
        "  - **Hyponatremia:** Serum sodium of 129 meq/L is a dilutional hyponatremia, a marker of severe heart failure and neurohormonal activation (e.g., high ADH levels).",
        "  - **Urine Sodium:** A very low urine sodium (10 meq/L) indicates avid renal sodium retention, which is a key pathophysiologic feature of heart failure.",
        "* **FENa Calculation:** The fractional excretion of sodium (FENa) is approximately 0.21%, which is <1%. This confirms a prerenal state, consistent with cardiorenal syndrome where the kidneys are trying to conserve sodium and water due to perceived low effective arterial volume.",
        "* **Treatment Principle:** The primary goal in a patient with ADHF presenting with signs of congestion ('wet' profile) is to remove the excess fluid (diuresis).",
        "* **First-line Therapy:** Intravenous loop diuretics (e.g., furosemide, bumetanide) are the cornerstone of treatment for volume overload in ADHF. They potently inhibit sodium reabsorption in the loop of Henle, leading to significant natriuresis and diuresis, which reduces preload and relieves congestion.",
        "* **Conclusion:** Given the clear evidence of volume overload (edema, CXR findings), loop diuretics are the most appropriate and immediate therapy."
      ],
      "others": [
        {
          "label": "①",
          "text": "혈액투석",
          "reason": "Hemodialysis or ultrafiltration is reserved for patients with severe renal failure or diuretic-refractory volume overload, neither of which is established here. Loop diuretics are the first-line therapy."
        },
        {
          "label": "③",
          "text": "thiazide diuretics 투여",
          "reason": "Thiazide diuretics are less potent than loop diuretics and are ineffective in patients with significant renal impairment (GFR < 30 mL/min). They are not the primary choice for acute, severe congestion."
        },
        {
          "label": "④",
          "text": "0.9% 생리식염수 투여",
          "reason": "Administering saline is strongly contraindicated as it would add to the sodium and water overload, worsening the heart failure and pulmonary edema."
        },
        {
          "label": "⑤",
          "text": "3% 생리식염수 투여",
          "reason": "Hypertonic saline is used for severe, symptomatic hyponatremia. This patient's hyponatremia is mild (129 meq/L) and due to dilution; the correct treatment is fluid removal with diuretics and fluid restriction, not sodium administration."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "loop diuretics 투여"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** This patient presents with acute decompensated heart failure (ADHF) characterized by signs of volume overload (congestion), including dyspnea, pitting edema, and pulmonary congestion on chest X-ray.",
        "* **Diagnosis: Cardiorenal Syndrome:** The presence of acute kidney injury (elevated BUN/creatinine) in the setting of ADHF is known as cardiorenal syndrome (Type 1). It is caused by a combination of decreased renal perfusion and increased renal venous congestion.",
        "* **Workup:** Key laboratory findings support the diagnosis. The very low urine sodium (10 meq/L) and calculated fractional excretion of sodium (FENa <1%) indicate avid renal sodium retention, a hallmark of the neurohormonal activation seen in heart failure.",
        "* **Pathophysiology:** In heart failure, the kidneys perceive low effective arterial blood volume, leading to activation of the RAAS and sympathetic nervous system. This drives intense sodium and water reabsorption, worsening the volume overload and creating a vicious cycle.",
        "* **Management Principle:** The primary therapeutic goal in a patient with ADHF who is 'wet' (congested) is decongestion through diuresis.",
        "* **Treatment (First-line):** Intravenous loop diuretics (e.g., furosemide, bumetanide) are the cornerstone of treatment. They potently block sodium reabsorption in the loop of Henle, promoting natriuresis and relieving the symptoms of congestion.",
        "* **Hyponatremia in Heart Failure:** The mild hyponatremia (129 meq/L) is a dilutional hyponatremia, caused by excess water retention stimulated by high levels of ADH. It is a marker of advanced heart failure, and the treatment is fluid removal (diuresis) and fluid restriction, not sodium administration.",
        "* **Contraindicated Treatments:** Administering saline (either 0.9% or 3%) is absolutely contraindicated as it would worsen the sodium and water overload, exacerbating the heart failure.",
        "* **Pitfalls (general):** A critical pitfall is misinterpreting the AKI and low urine sodium as a sign of true volume depletion and incorrectly administering IV fluids. In cardiorenal syndrome, these findings are a signal to diurese, not to hydrate."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "81",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "간경변증"
      },
      "why": [
        "* **Diagnosis:** The question asks for a risk factor for black pigment gallstones. Liver cirrhosis is a classic and significant risk factor.",
        "* **Pathophysiology:** Gallstones are broadly classified into cholesterol, black pigment, and brown pigment stones. Each type has distinct risk factors and formation mechanisms.",
        "* **Black Pigment Stones:** These stones are primarily composed of calcium bilirubinate polymers. They form when there is an excess of unconjugated bilirubin in the bile, which precipitates with calcium.",
        "* **Role of Liver Cirrhosis:** Liver cirrhosis leads to conditions that promote black pigment stone formation.\n  - **Hypersplenism:** Portal hypertension in cirrhosis often causes splenomegaly and hypersplenism, leading to increased destruction of red blood cells (chronic hemolysis).\n  - **Increased Bilirubin Load:** The breakdown of heme from red blood cells produces bilirubin. Chronic hemolysis increases the load of bilirubin that the liver must process.\n  - **Impaired Conjugation:** A cirrhotic liver has reduced functional capacity, including a decreased ability to conjugate bilirubin with glucuronic acid. This results in a higher proportion of unconjugated bilirubin being excreted into the bile.",
        "* **Differential / Discriminators:** It is crucial to distinguish the risk factors for the three main types of gallstones.\n  - **Cholesterol Stones:** Associated with obesity, female sex, multiparity, oral contraceptive use, and rapid weight loss. These factors lead to bile that is supersaturated with cholesterol.\n  - **Brown Pigment Stones:** Associated with biliary stasis and chronic bacterial or parasitic infections of the biliary tree. Bacterial enzymes (like beta-glucuronidase) deconjugate bilirubin, which then precipitates with calcium and fatty acids.",
        "* **Clinical Correlation:** Patients with liver cirrhosis and chronic hemolytic anemias (e.g., sickle cell disease, hereditary spherocytosis) are at high risk for developing black pigment gallstones."
      ],
      "others": [
        {
          "label": "①",
          "text": "비만",
          "reason": "Obesity is a major risk factor for cholesterol gallstones, not black pigment stones. It increases hepatic cholesterol synthesis and secretion, leading to cholesterol supersaturation in bile."
        },
        {
          "label": "②",
          "text": "고령",
          "reason": "While advancing age is a general risk factor for all types of gallstones due to increased biliary cholesterol secretion and decreased bile acid synthesis, it is not as specific a risk factor for black pigment stones as liver cirrhosis."
        },
        {
          "label": "④",
          "text": "경구피임제 복용",
          "reason": "Oral contraceptive use, due to its estrogen content, is a well-established risk factor for cholesterol gallstones by increasing cholesterol secretion and decreasing bile acid synthesis. It is not associated with black pigment stones."
        },
        {
          "label": "⑤",
          "text": "담즙의 혐기성 감염",
          "reason": "Anaerobic (and aerobic) bacterial infection of the bile is the primary risk factor for the formation of brown pigment gallstones, not black pigment stones. Bacterial enzymes deconjugate bilirubin, leading to the formation of soft, earthy, brown stones."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "간경변증"
        },
        "provided_key": {
          "label": "3",
          "text": "간경변증"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Gallstones can be asymptomatic or cause biliary colic (RUQ pain after fatty meals). Complications include cholecystitis, choledocholithiasis, cholangitis, and gallstone pancreatitis.",
        "* **Pathophysiology:** Gallstones are classified into three main types based on composition, each with a distinct pathophysiology.",
        "* **Cholesterol Stones (80%):** Form when bile is supersaturated with cholesterol. Risk factors are summarized by the '4 Fs': Female, Fat (obesity), Fertile (multiparity, pregnancy), and Forty (age >40). Other risks include rapid weight loss and oral contraceptive use.",
        "* **Black Pigment Stones (15%):** Composed of calcium bilirubinate polymers. They form in sterile bile due to conditions causing excess unconjugated bilirubin.",
        "* **Risk Factors for Black Pigment Stones:** The primary risk factors are chronic hemolytic states (e.g., sickle cell disease, hereditary spherocytosis) and liver cirrhosis.",
        "* **Mechanism in Liver Cirrhosis:** Cirrhosis promotes black pigment stone formation through two main mechanisms:\n  - **Hypersplenism:** Portal hypertension leads to an enlarged spleen that sequesters and destroys red blood cells, causing chronic low-grade hemolysis.\n  - **Impaired Bilirubin Conjugation:** The damaged liver has a reduced capacity to conjugate bilirubin, leading to a higher concentration of unconjugated bilirubin in the bile.",
        "* **Brown Pigment Stones (5%):** Composed of calcium salts of unconjugated bilirubin with cholesterol and fatty acids. They are soft and earthy.",
        "* **Risk Factors for Brown Pigment Stones:** These stones are associated with biliary stasis and chronic infection of the biliary tree (bacterial or parasitic, e.g., Clonorchis sinensis). Bacterial enzymes (beta-glucuronidase) deconjugate bilirubin, which then precipitates.",
        "* **Workup:** Abdominal ultrasound is the initial imaging modality of choice for suspected gallstones, with a sensitivity >95% for cholelithiasis.",
        "* **Management:** Asymptomatic stones are generally not treated. Symptomatic stones are treated with elective cholecystectomy. Complicated disease requires urgent intervention.",
        "* **Differential/Discriminators:** The patient's underlying medical conditions are key to predicting the stone type. A patient with obesity is likely to have cholesterol stones, while a patient with cirrhosis or sickle cell disease is likely to have black pigment stones.",
        "* **Pitfalls (general):** Do not assume all gallstones are cholesterol stones. Always consider the patient's full clinical context, especially hematologic disorders and liver disease, to anticipate the stone type and associated risks."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": "간경변증"
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "82",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "아급성갑상선염"
      },
      "why": [
        "* **Diagnosis:** Subacute (de Quervain's) thyroiditis.",
        "* **Clinical Presentation:** The patient presents with a classic triad for subacute thyroiditis: anterior neck pain, symptoms of thyrotoxicosis (palpitations, tremors), and systemic inflammation.",
        "* **Lab Findings:** The laboratory results strongly support the diagnosis.\n  - **Thyrotoxicosis:** Elevated free T4 (3.54 ng/dL) with a suppressed TSH (<0.01 mIU/L) confirms hyperthyroidism.\n  - **Inflammation:** A markedly elevated Erythrocyte Sedimentation Rate (ESR) of 75 mm/hr is a hallmark of the inflammatory process in subacute thyroiditis.",
        "* **Image Findings:** The Tc-99m thyroid scan is decisive.\n  - **Low Radioactive Iodine Uptake (RAIU):** The scan shows globally decreased or absent uptake of the radiotracer. This indicates that the thyrotoxicosis is due to the release of pre-formed thyroid hormone from damaged follicles (destructive thyroiditis), not from de novo hormone synthesis.",
        "* **Pathophysiology:** Subacute thyroiditis is a self-limited inflammatory condition of the thyroid gland, often preceded by a viral upper respiratory infection. The inflammation destroys thyroid follicles, leading to an unregulated release of stored T4 and T3 into the circulation.",
        "* **Diagnostic Algorithm:** In a patient with thyrotoxicosis, the RAIU scan is a key step to differentiate causes. High uptake suggests Graves' disease or a toxic nodule, while low uptake points towards thyroiditis or exogenous hormone intake.",
        "* **Differential / Discriminators:** The combination of a painful thyroid, high ESR, and low RAIU is pathognomonic for subacute thyroiditis. This constellation of findings effectively rules out other causes of thyrotoxicosis."
      ],
      "others": [
        {
          "label": "①",
          "text": "갑상선호르몬에 대한 뇌하수체 내성",
          "reason": "This is a rare condition characterized by high T4/T3 levels with a normal or elevated TSH, as the pituitary is resistant to negative feedback. This patient has a suppressed TSH."
        },
        {
          "label": "②",
          "text": "갑상선종양(중독성 결절)",
          "reason": "A toxic nodule or toxic multinodular goiter would cause hyperthyroidism but would show high uptake ('hot' nodule) on a thyroid scan, not the near-absent uptake seen in this patient."
        },
        {
          "label": "④",
          "text": "무통성갑상선염",
          "reason": "Painless (silent) thyroiditis also presents with thyrotoxicosis and low uptake on a scan, but it is, by definition, painless. This patient's primary complaint is significant anterior neck pain."
        },
        {
          "label": "⑤",
          "text": "그레이브스병",
          "reason": "Graves' disease is the most common cause of hyperthyroidism and is characterized by diffuse, high uptake on a thyroid scan due to TSH receptor-stimulating antibodies. This is the opposite of the scan finding in this case."
        }
      ],
      "runner_up": "④ 무통성갑상선염",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "아급성갑상선염"
        },
        "provided_key": {
          "label": "3",
          "text": "아급성갑상선염"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Subacute (de Quervain's) thyroiditis typically presents with an acute onset of anterior neck pain (often radiating to the jaw or ears), a tender, firm goiter, and symptoms of thyrotoxicosis. It is often preceded by a viral upper respiratory infection.",
        "* **Pathophysiology:** This is an inflammatory condition that destroys thyroid follicles, causing a massive release of pre-formed thyroid hormone (T4 and T3) into the circulation. This leads to a transient thyrotoxic phase.",
        "* **Clinical Course:** The disease follows a classic triphasic or quadraphasic course over several months:\n  - **Thyrotoxic phase (3-6 weeks):** Release of stored hormone.\n  - **Euthyroid phase (transient):** Hormone stores are depleted.\n  - **Hypothyroid phase (weeks to months):** Follicles recover but hormone synthesis is not yet sufficient.\n  - **Euthyroid phase (recovery):** Most patients return to normal function.",
        "* **Workup:** The diagnosis is based on the combination of clinical findings and specific laboratory and imaging results.",
        "* **Criteria/Thresholds:** Key diagnostic findings include:\n  - Suppressed TSH (<0.01 mIU/L) with elevated free T4 and T3.\n  - Markedly elevated inflammatory markers, especially ESR (often >50 mm/hr, sometimes >100 mm/hr).\n  - Near-absent uptake on a radioactive iodine uptake (RAIU) scan or Tc-99m thyroid scan.",
        "* **Differential/Discriminators:** The RAIU scan is crucial for differentiating causes of thyrotoxicosis.\n  - **High Uptake:** Graves' disease (diffuse), toxic multinodular goiter (patchy), toxic adenoma (focal).\n  - **Low Uptake:** Subacute thyroiditis, painless (silent) thyroiditis, postpartum thyroiditis, amiodarone-induced thyroiditis, or exogenous thyroid hormone intake.",
        "* **Distinguishing Low-Uptake Causes:** Subacute thyroiditis is distinguished from painless or postpartum thyroiditis by the presence of significant neck pain and a very high ESR.",
        "* **Management:** Treatment is supportive and aimed at symptom control.\n  - **Pain/Inflammation:** NSAIDs are first-line for mild to moderate pain. Corticosteroids (e.g., prednisone) are used for severe pain.\n  - **Thyrotoxic Symptoms:** Beta-blockers (e.g., propranolol) are used to control palpitations, tremor, and anxiety.",
        "* **Treatment (Specifics):** Anti-thyroid drugs (methimazole, PTU) have no role in the thyrotoxic phase, as the problem is hormone release, not overproduction.",
        "* **Monitoring/Follow-up:** Thyroid function should be monitored every 2-8 weeks to track the clinical course. Levothyroxine may be needed during the hypothyroid phase if symptomatic, but is often temporary.",
        "* **Pitfalls (general):** Misdiagnosing subacute thyroiditis as a bacterial infection and treating with antibiotics is a common error. The key is recognizing the inflammatory, not infectious, nature of the disease."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": "아급성갑상선염"
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "83",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "미세아교세포(microglia)가infarction된 부위 주위로 모여 탐식하는 기능이 활성화된다."
      },
      "why": [
        "* **Diagnosis:** The question asks for the characteristic cellular response to acute CNS infarction.",
        "* **Pathophysiology of Ischemic Stroke:** When blood flow to a brain region is cut off, neurons undergo ischemic cell death. This triggers a well-defined inflammatory and repair process.",
        "* **Timeline of Histologic Changes:**\n  - **0-12 hours:** Minimal changes, followed by the appearance of 'red neurons' (eosinophilic cytoplasm, pyknotic nuclei).\n  - **12-48 hours:** Neutrophilic infiltration begins, peaking around 24-48 hours.\n  - **2-3 days to weeks:** Microglia, the resident macrophages of the CNS, become activated. They migrate to the site of injury, proliferate, and transform into phagocytic cells (often called gitter cells or lipid-laden macrophages) to clear necrotic debris.",
        "* **Microglial Activation:** This activation and phagocytic function of microglia is a central and critical part of the CNS response to infarction. They remove dead cells and myelin breakdown products, preparing the area for repair.",
        "* **Later Stages:** Following the microglial response, astrocytes proliferate (astrogliosis) at the margins of the infarct, forming a glial scar that walls off the area of liquefactive necrosis, eventually resulting in a cystic cavity.",
        "* **Conclusion:** The activation of microglia to perform phagocytosis is a hallmark of the subacute phase of cerebral infarction."
      ],
      "others": [
        {
          "label": "①",
          "text": "Alzheimer type II 별아교세포의 증식이 관찰된다.",
          "reason": "Alzheimer type II astrocytes are characteristic of metabolic encephalopathies, particularly hepatic encephalopathy, due to hyperammonemia. They are not a feature of acute ischemic infarction."
        },
        {
          "label": "③",
          "text": "별아교세포(astrocyte)의 사멸이 관찰되면서 세포수가 감소한다.",
          "reason": "This is incorrect. While astrocytes in the core of the infarct die, the surrounding astrocytes undergo reactive astrogliosis, where they proliferate and hypertrophy to form a glial scar. The overall response is proliferation, not a net decrease."
        },
        {
          "label": "④",
          "text": "신경세포의 세포질에tau 단백질의 침착이 관찰된다.",
          "reason": "Tau protein aggregates (neurofibrillary tangles) are a hallmark of tauopathies like Alzheimer's disease and frontotemporal dementia, not a response to acute infarction."
        },
        {
          "label": "⑤",
          "text": "별아교세포 돌기부분을 중심으로rosenthal fiber의 침착이 관찰된다.",
          "reason": "Rosenthal fibers are eosinophilic protein aggregates found in astrocytic processes, characteristic of long-standing gliosis, Alexander disease, and pilocytic astrocytomas. They are not seen in acute infarction."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "미세아교세포(microglia)가infarction된 부위 주위로 모여 탐식하는 기능이 활성화된다."
        },
        "provided_key": {
          "label": "2",
          "text": "미세아교세포(microglia)가infarction된 부위 주위로 모여 탐식하는 기능이 활성화된다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Acute cerebral infarction presents with the sudden onset of focal neurologic deficits corresponding to a specific vascular territory.",
        "* **Pathophysiology:** Ischemic stroke leads to liquefactive necrosis in the brain parenchyma. This triggers a predictable, time-dependent inflammatory and cellular response.",
        "* **Histologic Timeline (Acute to Subacute):** The cellular response to CNS infarction evolves over time:\n  - **0-12 hours:** Minimal changes, followed by eosinophilic 'red neurons' with pyknotic nuclei.\n  - **12-48 hours:** Neutrophilic infiltration begins, peaking around 24-48 hours, accompanied by vasogenic edema.\n  - **2-3 days to 3 weeks:** Microglia become activated and migrate to the infarct. This is the key cellular response in the subacute phase.",
        "* **Microglial Function:** Activated microglia transform into phagocytic macrophages (gitter cells or lipid-laden macrophages). Their primary role is to clear necrotic cellular debris, including dead neurons and myelin breakdown products.",
        "* **Astrocyte Response (Gliosis):** Following the microglial response (from about 1 week onwards), reactive astrocytes at the periphery of the infarct proliferate and form a dense glial scar. This process, known as astrogliosis, walls off the necrotic area.",
        "* **Histologic Timeline (Chronic):** Over weeks to months, the area of liquefactive necrosis is resorbed, leaving a fluid-filled cystic cavity surrounded by the glial scar.",
        "* **Differential/Discriminators (Cellular Pathology):** It is crucial to distinguish the cellular response in infarction from other CNS pathologies.\n  - **Alzheimer Type II Astrocytes:** Seen in metabolic encephalopathies (especially hepatic), not infarction.\n  - **Tau Protein Aggregates:** Hallmark of tauopathies like Alzheimer's disease.\n  - **Rosenthal Fibers:** Found in long-standing gliosis, pilocytic astrocytomas, or Alexander disease, not acute infarction.",
        "* **Pitfalls (general):** The cellular infiltrate changes over time. Confusing the early neutrophilic infiltrate with the later microglial/macrophage response is a common error. Microglia are the dominant phagocytic cells of the CNS parenchyma."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": "미세아교세포(microglia)가infarction된 부위 주위로 모여 탐식하는 기능이 활성화된다."
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "84",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "부신 수질의 chromaffin 세포에서 기원한 종양이다."
      },
      "why": [
        "* **Diagnosis:** Pheochromocytoma.",
        "* **Clinical Presentation:** The patient's symptoms of paroxysmal palpitations, headache, and sweating form the classic triad for pheochromocytoma. These episodes are caused by the sudden release of catecholamines (epinephrine and norepinephrine) from the tumor.",
        "* **Image Findings:** The gross pathology image shows a well-circumscribed mass in the adrenal gland with areas of hemorrhage and necrosis, which is a typical appearance for a pheochromocytoma.",
        "* **Pathophysiology:** Pheochromocytomas are neuroendocrine tumors that arise from the chromaffin cells of the adrenal medulla. These cells are responsible for synthesizing and secreting catecholamines as part of the sympathetic nervous system.",
        "* **Biochemical Diagnosis:** The diagnosis is confirmed by measuring elevated levels of catecholamines and their metabolites (metanephrines and normetanephrines) in a 24-hour urine collection or in plasma.",
        "* **Genetic Associations:** About 25-30% of pheochromocytomas are associated with hereditary syndromes, such as Multiple Endocrine Neoplasia type 2 (MEN2A and MEN2B), von Hippel-Lindau (VHL) disease, and Neurofibromatosis type 1 (NF1).",
        "* **Conclusion:** The defining characteristic of a pheochromocytoma is its origin from the chromaffin cells of the adrenal medulla. This statement is the most accurate and fundamental description of the tumor among the choices provided."
      ],
      "others": [
        {
          "label": "①",
          "text": "유사분열이 많이 관찰되고 괴사를 보이는 경우 악성으로 진단할 수 있다.",
          "reason": "This is incorrect. While features like high mitotic activity, necrosis, and vascular invasion are concerning, the only definitive criterion for malignant pheochromocytoma is the presence of metastases in non-chromaffin tissues (e.g., bone, liver, distant lymph nodes). Histology alone is notoriously unreliable for predicting malignant behavior."
        },
        {
          "label": "②",
          "text": "24시간 소변에서cortisol 검출이 특징적이다.",
          "reason": "Elevated 24-hour urine cortisol is the hallmark of Cushing's syndrome, which is caused by a cortisol-producing tumor of the adrenal cortex or by excess ACTH. Pheochromocytoma is diagnosed with metanephrines."
        },
        {
          "label": "③",
          "text": "대부분 기능성이고, 가장 흔한 증상은 hyperaldosteronism이다.",
          "reason": "Hyperaldosteronism (Conn's syndrome) is caused by an aldosterone-producing adenoma of the adrenal cortex. While pheochromocytomas are functional, their symptoms are due to catecholamine excess, not hyperaldosteronism."
        },
        {
          "label": "④",
          "text": "가족력이 있을 경우 산발적으로 발생한 내분비종양에 비해 젊은 연령에 발생하여 예후가 좋다.",
          "reason": "Familial pheochromocytomas do present at a younger age, but they are often bilateral or multifocal, which can complicate management. The prognosis is not necessarily better than sporadic cases and depends on the specific genetic syndrome and presence of malignancy."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "부신 수질의 chromaffin 세포에서 기원한 종양이다."
        },
        "provided_key": {
          "label": "5",
          "text": "부신 수질의 chromaffin 세포에서 기원한 종양이다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Pheochromocytoma presents with the classic triad of paroxysmal symptoms: episodic headaches, sweating (diaphoresis), and palpitations (tachycardia). Sustained or paroxysmal hypertension is common.",
        "* **Pathophysiology:** These are neuroendocrine tumors arising from the chromaffin cells of the adrenal medulla. They synthesize and secrete excess catecholamines (epinephrine, norepinephrine).",
        "* **Workup:** The initial step is biochemical confirmation of catecholamine excess. The preferred tests are measurement of fractionated metanephrines and normetanephrines in plasma or a 24-hour urine collection.",
        "* **Imaging:** Once biochemical diagnosis is confirmed, imaging is used for localization. CT or MRI of the abdomen and pelvis is the first-line imaging modality. Functional imaging (e.g., MIBG scan, PET scan) may be used if the primary tumor is not found or to look for metastases.",
        "* **Genetic Associations:** Approximately 25-30% of cases are hereditary. Associated syndromes include:\n  - **MEN 2A/2B:** Multiple Endocrine Neoplasia type 2 (RET proto-oncogene).\n  - **Von Hippel-Lindau (VHL) disease:** VHL gene.\n  - **Neurofibromatosis type 1 (NF1):** NF1 gene.",
        "* **Management (Preoperative):** Preoperative medical management is critical to prevent intraoperative hypertensive crisis. This involves:\n  - **Alpha-blockade:** First, using a non-selective alpha-blocker like phenoxybenzamine or a selective alpha-1 blocker like doxazosin. This should be started 7-14 days before surgery.\n  - **Beta-blockade:** Added *after* adequate alpha-blockade is achieved, to control tachycardia. Starting a beta-blocker first can lead to unopposed alpha-stimulation and a hypertensive crisis.",
        "* **Treatment:** The definitive treatment is surgical resection of the tumor (adrenalectomy).",
        "* **Criteria/Thresholds (Malignancy):** The diagnosis of malignant pheochromocytoma is not based on histology. The only definitive criterion for malignancy is the presence of metastases at sites where chromaffin tissue is not normally found (e.g., lymph nodes, bone, liver, lung).",
        "* **Differential/Discriminators:** The differential diagnosis includes panic attacks, anxiety disorders, hyperthyroidism, and carcinoid syndrome. Biochemical testing is key to differentiation.",
        "* **Pitfalls (general):**\n  - **Beta-blocker first:** Never initiate beta-blockade before alpha-blockade.\n  - **Biopsy:** Percutaneous biopsy of a suspected pheochromocytoma is contraindicated as it can provoke a massive catecholamine release and hypertensive crisis.\n  - **Histology for malignancy:** Relying on histologic features like necrosis or mitoses to diagnose malignancy is unreliable."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": "부신 수질의 chromaffin 세포에서 기원한 종양이다."
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "85",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "감별진단에 피검사가 도움이 되고 관상동맥조영술이 필요하다."
      },
      "why": [
        "* **Diagnosis:** Acute inferior wall ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock.",
        "* **Clinical Presentation:** The patient is a 75-year-old male with multiple cardiovascular risk factors (age, diabetes, hyperlipidemia) presenting with a crescendo pattern of angina (stable to unstable) culminating in rest pain. He is now in shock (BP 90/50 mmHg).",
        "* **ECG Findings:** The ECG is pathognomonic for an acute inferior STEMI.\n  - **ST-segment Elevation:** There is clear ST elevation in leads II, III, and aVF, which look at the inferior wall of the left ventricle.\n  - **Reciprocal Changes:** There is ST-segment depression in leads I and aVL, which are reciprocal to the inferior leads. This pattern confirms an acute coronary occlusion.",
        "* **Management Principle:** The cornerstone of management for STEMI is rapid reperfusion of the occluded coronary artery. The preferred method is primary percutaneous coronary intervention (PCI).",
        "* **Diagnostic Algorithm:** The diagnosis of STEMI is made based on clinical symptoms and characteristic ECG changes. Blood tests for cardiac biomarkers (e.g., troponin) are sent to confirm myocardial necrosis, but treatment should not be delayed while waiting for these results.",
        "* **Next Step:** Given the diagnosis of STEMI, the patient requires emergent cardiac catheterization for coronary angiography to identify the occluded vessel and perform PCI (stenting). This is the definitive treatment.",
        "* **Conclusion:** The combination of clinical, hemodynamic, and ECG findings points to an acute STEMI. Blood tests will confirm the diagnosis, and emergent coronary angiography is the necessary and life-saving intervention."
      ],
      "others": [
        {
          "label": "①",
          "text": "심인성과 패혈성 쇼크 가능성이 있으며 감별을 위해 백혈구 상승여부를 확인해야 한다.",
          "reason": "While an MI can cause a stress-induced leukocytosis, the clinical picture and diagnostic ECG make cardiogenic shock the overwhelming diagnosis. Delaying cardiac intervention to rule out septic shock would be inappropriate."
        },
        {
          "label": "②",
          "text": "급성심근경색의 가능성은 배재되며 불안정형 협심증 가능성이 높다.",
          "reason": "This is incorrect. The presence of ST-segment elevation on the ECG defines the event as an ST-elevation myocardial infarction (STEMI), which is a more severe condition than unstable angina."
        },
        {
          "label": "③",
          "text": "정상 심전도이며 이형협심증이 의심된다.",
          "reason": "The ECG is grossly abnormal with clear ST elevations and reciprocal depressions. It is not a normal ECG. Variant (Prinzmetal) angina is much less likely in this clinical context."
        },
        {
          "label": "④",
          "text": "쇼크 상태로 생리식염수의 빠른 주입이 필요하다.",
          "reason": "This is potentially dangerous. The patient is in cardiogenic shock, likely due to left ventricular failure and possible right ventricular involvement (common in inferior MI). Aggressive fluid administration without assessing volume status and for signs of pulmonary edema could worsen heart failure."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "감별진단에 피검사가 도움이 되고 관상동맥조영술이 필요하다."
        },
        "provided_key": {
          "label": "5",
          "text": "감별진단에 피검사가 도움이 되고 관상동맥조영술이 필요하다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Acute ST-elevation myocardial infarction (STEMI) presents with prolonged, severe retrosternal chest pain, often radiating to the arm or jaw, and may be associated with diaphoresis, nausea, and dyspnea. The patient in this vignette is also in cardiogenic shock (hypotension).",
        "* **Workup:** The diagnosis of STEMI is made emergently based on the clinical presentation and a 12-lead ECG. Cardiac biomarkers (troponin) are sent to confirm myocardial necrosis but should not delay reperfusion therapy.",
        "* **Criteria/Thresholds (ECG):** STEMI is defined by ST-segment elevation in ≥2 contiguous leads. For this inferior STEMI, the key findings are:\n  - **ST elevation** in leads II, III, and aVF.\n  - **Reciprocal ST depression** in leads I and aVL.",
        "* **Management (Algorithmic):** The immediate goal in STEMI is rapid reperfusion of the occluded coronary artery. The mantra is \"time is muscle.\"",
        "* **Reperfusion Therapy:** Primary percutaneous coronary intervention (PCI) is the preferred method if it can be performed in a timely manner (door-to-balloon time <90 minutes). Fibrinolytic therapy is an alternative if PCI is not available.",
        "* **Treatment (Initial Medical):** While preparing for reperfusion, initial medical management includes:\n  - **Antiplatelet therapy:** Aspirin and a P2Y12 inhibitor (e.g., clopidogrel, ticagrelor).\n  - **Anticoagulation:** Heparin or bivalirudin.\n  - **Oxygen:** Only if patient is hypoxic (SpO₂ <90%).\n  - **Nitrates:** For ongoing pain, unless hypotensive or suspected right ventricular MI.\n  - **Morphine:** For refractory pain.",
        "* **Management of Cardiogenic Shock:** This patient's hypotension (90/50 mmHg) indicates cardiogenic shock. Management involves hemodynamic support with vasopressors or inotropes and potentially mechanical circulatory support (e.g., intra-aortic balloon pump). Emergent reperfusion with PCI is critical.",
        "* **Differential/Discriminators:** Other causes of chest pain include unstable angina, NSTEMI, aortic dissection, pulmonary embolism, and pericarditis. The ECG is the key initial tool to differentiate STEMI.",
        "* **Pitfalls (general):**\n  - **Delaying reperfusion:** Waiting for troponin results before activating the cath lab for a clear STEMI is a critical error.\n  - **Fluid bolus in cardiogenic shock:** Aggressive IV fluid administration can worsen pulmonary edema and heart failure in cardiogenic shock, especially with left ventricular failure. This is different from hypovolemic or septic shock.\n  - **Missing RV infarction:** In an inferior STEMI, always obtain a right-sided ECG (V4R) to assess for right ventricular involvement, which would contraindicate nitrates and require fluid resuscitation."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": "감별진단에 피검사가 도움이 되고 관상동맥조영술이 필요하다."
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "86",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "저위전방절제술"
      },
      "why": [
        "* **Diagnosis:** Early-stage (pT1) rectal adenocarcinoma treated with endoscopic resection.",
        "* **Treatment Principle:** The decision for further treatment after endoscopic resection of a T1 colorectal cancer depends on the histopathologic risk of lymph node metastasis. If the risk is low, endoscopic resection is considered curative. If the risk is high, radical oncologic surgery is required.",
        "* **High-Risk Features for Nodal Metastasis:** The pathology report shows multiple features that indicate a high risk of lymph node involvement, making the local excision inadequate for a cure.\n  - **Deep Submucosal Invasion:** Invasion depth of 1400 µm is greater than the commonly accepted cutoff of 1000 µm (1 mm) for low-risk lesions.\n  - **Lymphatic Invasion:** The presence of cancer cells within lymphatic channels is a direct indicator of metastatic potential and a strong indication for radical surgery.\n  - **Tumor Budding:** The presence of ≥10 tumor buds is a significant independent predictor of lymph node metastasis and poor prognosis.",
        "* **Surgical Management:** Because of these high-risk features, the patient requires a formal oncologic resection to remove the primary tumor site along with its draining lymph nodes (total mesorectal excision). For a tumor located 6 cm from the anal verge, the standard procedure is a low anterior resection (LAR).",
        "* **Conclusion:** The endoscopic resection is non-curative due to multiple high-risk pathologic features. The standard of care is to proceed with radical surgery, which in this case is a low anterior resection."
      ],
      "others": [
        {
          "label": "①",
          "text": "방사선치료",
          "reason": "Radiation therapy is typically used in the neoadjuvant or adjuvant setting for more advanced rectal cancers (T3/T4 or node-positive), not as the primary treatment for a high-risk T1 lesion after polypectomy."
        },
        {
          "label": "②",
          "text": "항암화학치료",
          "reason": "Chemotherapy is indicated for node-positive (Stage III) disease or sometimes for high-risk Stage II disease after radical surgery. It is not the next step after a non-curative endoscopic resection of a T1 tumor."
        },
        {
          "label": "④",
          "text": "주기적인 추적 관찰",
          "reason": "Observation alone is inappropriate given the high risk of residual disease or lymph node metastasis, which would lead to a preventable recurrence. The risk of nodal metastasis with these features can be 15-25% or higher."
        },
        {
          "label": "⑤",
          "text": "경향문내시경미세수술(Transanal Endoscopic Microsurgery)",
          "reason": "Transanal Endoscopic Microsurgery (TEMS) is a form of local excision. The patient has already undergone a local excision (endoscopic resection), and the pathology indicates that any form of local excision is insufficient. A radical resection with lymphadenectomy is required."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "저위전방절제술"
        },
        "provided_key": {
          "label": "3",
          "text": "저위전방절제술"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A T1 colorectal cancer is one that invades the submucosa but not the muscularis propria. It can often be completely removed endoscopically (e.g., polypectomy, EMR, ESD).",
        "* **Management (Algorithmic):** After endoscopic resection of a T1 adenocarcinoma, the decision for further treatment hinges on the histopathologic risk of lymph node metastasis. The specimen must be carefully evaluated for high-risk features.",
        "* **Criteria/Thresholds (High-Risk Features):** Features indicating a high risk of nodal metastasis and requiring formal oncologic surgery include:\n  - **Deep submucosal invasion:** Typically defined as invasion depth >1000 µm (1 mm).\n  - **Poor differentiation** (high-grade tumor).\n  - **Lymphovascular invasion:** Presence of tumor cells in lymphatic or blood vessels.\n  - **Tumor budding:** Presence of isolated cancer cells or small clusters (≥5-10 buds) at the invasive front.\n  - **Positive or indeterminate resection margin.**",
        "* **Vignette Analysis:** This patient's pathology report shows multiple high-risk features: deep submucosal invasion (1400 µm), lymphatic invasion, and significant tumor budding (≥10).",
        "* **Treatment:** The presence of any high-risk feature makes the endoscopic resection non-curative. The standard of care is to proceed with a radical surgical resection, which includes removal of the primary tumor site and its regional draining lymph nodes.",
        "* **Surgical Options for Rectal Cancer:** The type of surgery depends on the tumor's location relative to the anal verge.\n  - **Low Anterior Resection (LAR):** For tumors in the upper and middle rectum. The colon is re-anastomosed to the remaining rectum.\n  - **Abdominoperineal Resection (APR):** For very low tumors involving the sphincter complex, requiring a permanent colostomy.",
        "* **Procedure for this Patient:** For a tumor at 6 cm from the anal verge, a low anterior resection with total mesorectal excision (TME) is the appropriate radical surgery.",
        "* **Differential/Discriminators (Treatment Options):**\n  - **Observation:** Inappropriate due to the high risk (15-25%) of occult nodal metastases.\n  - **Local Excision (e.g., TEMS):** Insufficient, as it does not address the risk of lymph node disease.\n  - **Chemo/Radiation:** Used as neoadjuvant or adjuvant therapy for more advanced disease (T3/T4 or N+), not as the primary next step for a high-risk T1 lesion.",
        "* **Pitfalls (general):** Under-treating a high-risk T1 colorectal cancer by accepting endoscopic resection as definitive therapy is a major pitfall that can lead to preventable local or distant recurrence."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": "저위전방절제술"
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "87",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "대장 절제술 및 장루 조성술"
      },
      "why": [
        "* **Diagnosis:** Acute bowel ischemia leading to infarction and peritonitis.",
        "* **Clinical Presentation:** The patient is an elderly man with significant cardiovascular risk factors presenting with an acute abdomen (sudden pain, hematochezia). Key findings point to a surgical emergency.\n  - **Hemodynamic Instability:** Tachycardia (118/min) and borderline hypotension (100/60 mmHg) suggest shock.\n  - **Peritonitis:** Generalized abdominal tenderness and rebound tenderness are classic signs of peritoneal inflammation, indicating a process like perforation or transmural bowel necrosis.\n  - **Systemic Inflammatory Response:** Fever (38.2°C) and marked leukocytosis (WBC 18,000/mm³) confirm a severe inflammatory or infectious process.",
        "* **Image Findings:** The CT scan findings are crucial.\n  - **Bowel Ischemia/Infarction:** The description of \"partially decreased contrast enhancement\" of the bowel wall is a specific sign of compromised blood flow, indicating ischemia or infarction.\n  - **Inflammation:** The images show bowel wall thickening and surrounding fat stranding, consistent with severe inflammation.",
        "* **Treatment Principle:** Bowel infarction with peritonitis is a life-threatening condition that requires emergent surgical intervention. The goals are to control the source of sepsis, resect the non-viable bowel, and restore intestinal continuity if safe, or create an ostomy.",
        "* **Management:** The patient requires initial resuscitation with fluids and broad-spectrum antibiotics, followed immediately by an exploratory laparotomy. During surgery, the infarcted segment of the colon will be resected. Given the patient's instability and peritoneal contamination, a primary anastomosis is often unsafe, so a colostomy (장루 조성술) is typically performed.",
        "* **Conclusion:** The combination of clinical signs of peritonitis and CT findings of bowel infarction mandates emergency surgery."
      ],
      "others": [
        {
          "label": "①",
          "text": "대장내시경적 지혈술",
          "reason": "Colonoscopy is contraindicated in patients with suspected bowel perforation or peritonitis. Furthermore, the cause of bleeding is infarction, not a discrete bleeding vessel amenable to endoscopic therapy."
        },
        {
          "label": "②",
          "text": "고농도 스테로이드",
          "reason": "Steroids are used for inflammatory conditions like IBD, not ischemic bowel. They would be harmful here as they impair healing and increase the risk of infection in a patient with peritonitis."
        },
        {
          "label": "④",
          "text": "경피적 배농술",
          "reason": "Percutaneous drainage is a treatment for a localized, contained abscess. This patient has diffuse peritonitis from bowel infarction, which is not amenable to this approach."
        },
        {
          "label": "⑤",
          "text": "적혈구 수혈",
          "reason": "While the patient may require blood products as part of resuscitation (current Hb is 11.5 g/dl), transfusion is a supportive measure, not the definitive treatment. The underlying cause—the necrotic bowel—must be surgically removed to save the patient's life."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "대장 절제술 및 장루 조성술"
        },
        "provided_key": {
          "label": "3",
          "text": "대장 절제술 및 장루 조성술"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Acute mesenteric ischemia (leading to bowel infarction) classically presents with severe abdominal pain that is out of proportion to the physical exam findings in its early stages. As infarction and necrosis develop, signs of peritonitis (rebound tenderness, rigidity) and systemic toxicity (fever, tachycardia, hypotension, leukocytosis) emerge.",
        "* **Workup:** CT angiography (CTA) of the abdomen and pelvis is the diagnostic imaging modality of choice. It can identify arterial occlusion or thrombosis and assess for signs of bowel ischemia.",
        "* **Criteria/Thresholds (CT Findings):** Key CT findings suggesting bowel ischemia and infarction include:\n  - **Bowel wall thickening** (edema).\n  - **Decreased or absent bowel wall enhancement** with IV contrast (most specific sign).\n  - **Pneumatosis intestinalis** (air in the bowel wall).\n  - **Portal venous gas.**\n  - **Mesenteric fat stranding.**",
        "* **Vignette Analysis:** This patient presents with an acute abdomen, signs of peritonitis (rebound tenderness), and systemic inflammation (fever, leukocytosis). The CT confirms bowel ischemia with decreased contrast enhancement.",
        "* **Management (Algorithmic):** The management of bowel infarction with peritonitis is a surgical emergency.\n  - **Initial:** Resuscitation with IV fluids, correction of electrolyte abnormalities, and initiation of broad-spectrum antibiotics.\n  - **Definitive:** Emergent exploratory laparotomy.",
        "* **Treatment (Surgical):** The surgical goals are to resect all non-viable, infarcted bowel and control peritoneal contamination. A primary anastomosis is often avoided in an unstable patient with a contaminated abdomen; instead, an ostomy (e.g., colostomy, ileostomy) is created.",
        "* **Differential/Discriminators:** The differential for an acute abdomen includes perforated viscus (e.g., peptic ulcer, diverticulitis), acute pancreatitis, and ruptured abdominal aortic aneurysm. The CT findings are crucial for diagnosis.",
        "* **Pitfalls (general):**\n  - **Delaying surgery:** Bowel infarction is a rapidly progressive and highly lethal condition. Any delay in surgical intervention significantly increases mortality.\n  - **Contraindicated procedures:** Colonoscopy is contraindicated in the setting of peritonitis and suspected perforation.\n  - **Inappropriate medical management:** Steroids are harmful, and percutaneous drainage is not a treatment for diffuse peritonitis from infarcted bowel."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": "대장 절제술 및 장루 조성술"
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "88",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "지혈 후 심혈관계 위험을 고려하여 아스피린을 가능한 조기에 재개한다."
      },
      "why": [
        "* **Diagnosis:** Peptic ulcer bleeding in a patient on aspirin for secondary cardiovascular prevention.",
        "* **Clinical Dilemma:** The core issue is balancing the risk of gastrointestinal re-bleeding against the risk of a major adverse cardiovascular event (MACE), such as myocardial infarction or stent thrombosis, if antiplatelet therapy is withheld.",
        "* **Patient Risk Profile:** This patient has a high cardiovascular risk due to a prior MI and coronary stent. Discontinuing aspirin significantly increases his risk of a life-threatening thrombotic event.",
        "* **Guideline Recommendations (ACC/AHA/ACG):** For patients with an indication for secondary prevention, aspirin should be restarted as soon as the cardiovascular benefits are thought to outweigh the gastrointestinal risks. After successful endoscopic hemostasis for peptic ulcer bleeding, aspirin should be resumed promptly, typically within 1-7 days and before hospital discharge.",
        "* **Risk Mitigation:** The risk of aspirin-induced re-bleeding is substantially reduced by co-prescribing a high-dose proton pump inhibitor (PPI), which should be started immediately and continued long-term.",
        "* **Evidence:** Multiple studies and meta-analyses have shown that in patients with high cardiovascular risk, early resumption of aspirin after a GI bleed is associated with a net clinical benefit, reducing all-cause mortality despite a small increase in the risk of re-bleeding.",
        "* **Conclusion:** The standard of care is to restart aspirin as soon as possible after endoscopic control of bleeding is confirmed, in conjunction with high-dose PPI therapy."
      ],
      "others": [
        {
          "label": "①",
          "text": "아스피린은 앞으로 복용할 수 없다.",
          "reason": "Incorrect. Permanently stopping aspirin in a patient with a coronary stent and history of MI would place them at an unacceptably high risk of a fatal cardiovascular event."
        },
        {
          "label": "③",
          "text": "궤양 치유가 확인될 때까지 약4주간 아스피린을 중단한다.",
          "reason": "This is an outdated and dangerous approach. A 4-week delay in restarting aspirin is too long and significantly increases the risk of MACE. The highest risk period for stent thrombosis is when antiplatelet therapy is interrupted."
        },
        {
          "label": "④",
          "text": "아스피린 대신 클로피도그렐로 대체한다.",
          "reason": "Substituting clopidogrel for aspirin is not beneficial. Clopidogrel monotherapy carries a similar risk of GI bleeding as aspirin, and combining it with a PPI may reduce its efficacy. The standard is to use aspirin plus a PPI."
        },
        {
          "label": "⑤",
          "text": "아스피린 대신 항응고제를 투여한다.",
          "reason": "Anticoagulants (e.g., warfarin, DOACs) are not indicated for secondary prevention after MI/stenting (unless there's another indication like atrial fibrillation). They also carry a much higher risk of major bleeding than aspirin."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "지혈 후 심혈관계 위험을 고려하여 아스피린을 가능한 조기에 재개한다."
        },
        "provided_key": {
          "label": "2",
          "text": "지혈 후 심혈관계 위험을 고려하여 아스피린을 가능한 조기에 재개한다."
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A patient with known coronary artery disease (history of MI and stent) on aspirin for secondary prevention presents with an upper GI bleed from a peptic ulcer.",
        "* **Management (Algorithmic):** The immediate management involves hemodynamic resuscitation, initiation of an IV proton pump inhibitor (PPI), and urgent upper endoscopy for diagnosis and hemostatic therapy.",
        "* **Clinical Dilemma:** The core management decision after endoscopic control of bleeding is when to resume antiplatelet therapy. This requires balancing the risk of GI re-bleeding against the risk of a major adverse cardiovascular event (MACE), such as stent thrombosis or MI.",
        "* **Risk Stratification:** This patient has a very high cardiovascular risk due to his history of MI and a coronary stent. Discontinuation of aspirin places him at significant risk for a life-threatening thrombotic event.",
        "* **Treatment (Guideline Consensus):** For patients on low-dose aspirin for secondary cardiovascular prevention who have a GI bleed, aspirin should be restarted as soon as possible after endoscopic hemostasis is achieved.",
        "* **Criteria/Thresholds (Timing):** Aspirin should ideally be resumed within 1-7 days of the bleeding event, and almost always before hospital discharge, once the patient is hemodynamically stable and there is no evidence of active bleeding.",
        "* **Risk Mitigation:** To reduce the risk of re-bleeding, aspirin should be resumed in conjunction with high-dose PPI therapy, which should be continued long-term.",
        "* **Evidence:** Randomized trials have shown that resuming aspirin early in high-risk cardiac patients is associated with a reduction in all-cause mortality that outweighs the small increased risk of recurrent GI bleeding.",
        "* **Differential/Discriminators (Antiplatelet vs. Anticoagulant):** Clopidogrel is not a safer alternative to aspirin regarding GI bleeding risk. Anticoagulants (e.g., warfarin, DOACs) are not indicated for this patient's secondary prevention and carry an even higher bleeding risk.",
        "* **Pitfalls (general):**\n  - **Prolonged discontinuation:** Withholding aspirin for several weeks until the ulcer is fully healed is an outdated and dangerous practice that significantly increases cardiovascular risk.\n  - **Permanent discontinuation:** Permanently stopping aspirin in a patient with a high-risk indication is associated with a major increase in MACE and mortality."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": "지혈 후 심혈관계 위험을 고려하여 아스피린을 가능한 조기에 재개한다."
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "89",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "방향화효소 억제제 (letrozole)"
      },
      "why": [
        "* **Diagnosis:** Polycystic Ovary Syndrome (PCOS) causing anovulatory infertility.",
        "* **Diagnostic Criteria (Rotterdam):** The patient meets all three criteria for PCOS:\n  1. **Oligo- and/or anovulation:** Documented by irregular menstrual cycles of 40-50 days.\n  2. **Clinical and/or biochemical signs of hyperandrogenism:** Biochemical evidence with elevated total testosterone (120 ng/dL; ref 20-80).\n  3. **Polycystic ovaries on ultrasound:** The image shows the characteristic \"string of pearls\" appearance of multiple small antral follicles.",
        "* **Lab Findings:** The elevated LH:FSH ratio (11.2 / 5.6 = 2.0) is also a classic, though not required, finding in PCOS. Normal TSH and prolactin levels rule out other common causes of irregular menses.",
        "* **Treatment Goal:** The patient desires pregnancy, so the primary goal is ovulation induction.",
        "* **Treatment Principle / Guidelines:** According to current guidelines from major societies like the American College of Obstetricians and Gynecologists (ACOG) and the Endocrine Society, letrozole is the recommended first-line pharmacologic treatment for ovulation induction in women with PCOS.",
        "* **Mechanism of Letrozole:** As an aromatase inhibitor, letrozole blocks the conversion of androgens to estrogens. The resulting low estrogen state reduces negative feedback on the hypothalamus and pituitary, leading to an increase in FSH secretion, which stimulates follicular development and ovulation.",
        "* **Superiority over Clomiphene:** Letrozole has been shown in multiple large trials to result in higher live-birth rates and ovulation rates compared to clomiphene citrate, with a lower risk of multiple gestation."
      ],
      "others": [
        {
          "label": "①",
          "text": "클로미펜 (clomiphene citrate)",
          "reason": "Clomiphene citrate was historically the first-line agent but is now considered a second-line or alternative option to letrozole due to lower efficacy and higher rates of multiple births and anti-estrogenic side effects on the endometrium."
        },
        {
          "label": "②",
          "text": "항안드로겐 제재 (spironolactone)",
          "reason": "Spironolactone is used to treat the dermatologic effects of hyperandrogenism (hirsutism, acne) in PCOS. It does not induce ovulation and is teratogenic, making it contraindicated in women attempting to conceive."
        },
        {
          "label": "④",
          "text": "인슐린 저항성 개선제 (metformin)",
          "reason": "Metformin can help regulate menstrual cycles and improve metabolic parameters in women with PCOS, especially those who are overweight or have glucose intolerance. However, it is less effective than letrozole or clomiphene for inducing ovulation and is typically used as an adjunct therapy."
        },
        {
          "label": "⑤",
          "text": "생식샘자극호르몬제재(human menopausal gonadotropin)",
          "reason": "Injectable gonadotropins are a highly effective but more complex, expensive, and higher-risk (ovarian hyperstimulation syndrome, high-order multiple pregnancies) treatment. They are reserved as a second- or third-line therapy after oral agents have failed."
        }
      ],
      "runner_up": "① 클로미펜 (clomiphene citrate)",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "방향화효소 억제제 (letrozole)"
        },
        "provided_key": {
          "label": "3",
          "text": "방향화효소 억제제 (letrozole)"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder in reproductive-aged women, characterized by irregular menses, hyperandrogenism (hirsutism, acne, alopecia), and often obesity and insulin resistance.",
        "* **Criteria/Thresholds (Rotterdam Criteria):** Diagnosis requires at least two of the following three criteria, after excluding other causes:\n  1. **Oligo- or anovulation:** Manifested as irregular menstrual cycles.\n  2. **Clinical or biochemical hyperandrogenism:** e.g., hirsutism or elevated testosterone levels.\n  3. **Polycystic morphology on ultrasound:** ≥12-20 follicles per ovary measuring 2-9 mm, and/or increased ovarian volume (>10 mL).",
        "* **Workup:** Initial workup includes a pregnancy test, TSH, prolactin, and testosterone levels to rule out other causes of irregular menses. An ultrasound is performed to assess ovarian morphology. An elevated LH:FSH ratio (>2:1) is a classic but not required finding.",
        "* **Management (Goal-Directed):** Treatment for PCOS is tailored to the patient's primary concern (e.g., menstrual regulation, hirsutism, infertility).",
        "* **Treatment (Infertility):** The primary goal for a patient desiring pregnancy is ovulation induction.",
        "* **First-Line Ovulation Induction:** Letrozole (an aromatase inhibitor) is the recommended first-line pharmacologic agent for ovulation induction in women with PCOS.",
        "* **Mechanism of Letrozole:** It inhibits the aromatase enzyme, blocking the conversion of androgens to estrogens. The resulting low estrogen levels reduce negative feedback on the pituitary, leading to increased FSH secretion, which stimulates follicular growth and ovulation.",
        "* **Comparison to Clomiphene:** Letrozole has demonstrated higher live-birth rates and ovulation rates compared to clomiphene citrate, which was the historical first-line agent. Letrozole also has a lower risk of multiple gestation and fewer anti-estrogenic effects on the endometrium.",
        "* **Second/Third-Line Treatments for Infertility:** If oral agents fail, options include injectable gonadotropins or in vitro fertilization (IVF).",
        "* **Other PCOS Treatments (Not for fertility):**\n  - **Menstrual Regulation:** Combination oral contraceptives.\n  - **Hirsutism/Acne:** Oral contraceptives, spironolactone (anti-androgen).\n  - **Metabolic Issues:** Metformin, lifestyle modification (weight loss).",
        "* **Pitfalls (general):** Spironolactone is teratogenic and must be avoided in women attempting to conceive. Metformin is less effective than letrozole for inducing ovulation and is considered an adjunct therapy."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": "방향화효소 억제제 (letrozole)"
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "90",
      "depth": "expanded",
      "answer": {
        "label": "⑤",
        "text": "접형동경유 절제술"
      },
      "why": [
        "* **Diagnosis:** Cushing's disease (ACTH-secreting pituitary adenoma).",
        "* **Diagnostic Workup Step 1 (Confirm Hypercortisolism):** The patient has classic clinical features (central obesity, moon facies, purple striae, hypertension). This is confirmed biochemically by a high baseline serum cortisol (31 µg/dL), high 24-hour urine free cortisol (450 µg), and failure of cortisol suppression after a low-dose dexamethasone suppression test (cortisol remains 29 µg/dL).",
        "* **Diagnostic Workup Step 2 (Determine ACTH-Dependence):** The plasma ACTH level is in the high-normal to elevated range (79 pg/mL). This indicates an ACTH-dependent cause, ruling out a primary adrenal tumor (which would cause suppressed ACTH). The differential is between a pituitary adenoma (Cushing's disease) and an ectopic ACTH-producing tumor.",
        "* **Diagnostic Workup Step 3 (Localize the Source):** The high-dose dexamethasone suppression test is used to differentiate a pituitary from an ectopic source. This patient shows significant suppression of both serum cortisol (to 3 µg/dL) and urine cortisol (to 38 µg). This suppression is characteristic of a pituitary adenoma, which typically retains some negative feedback sensitivity to high levels of glucocorticoids.",
        "* **Image Findings:** The pituitary MRI (shown in the image area) confirms the presence of a pituitary microadenoma, solidifying the diagnosis of Cushing's disease.",
        "* **Treatment Principle:** The definitive treatment for Cushing's disease is the selective removal of the ACTH-secreting pituitary adenoma.",
        "* **Management:** Transsphenoidal surgery is the first-line treatment of choice for Cushing's disease. It has a high success rate (70-90% for microadenomas) and aims to cure the hypercortisolism while preserving normal pituitary function."
      ],
      "others": [
        {
          "label": "①",
          "text": "카베골린",
          "reason": "Cabergoline is a dopamine agonist, the first-line treatment for prolactinomas. While it has some limited, off-label efficacy in a subset of patients with Cushing's disease, it is not the primary or definitive therapy."
        },
        {
          "label": "②",
          "text": "케토코나졸",
          "reason": "Ketoconazole is a medical therapy that inhibits adrenal steroidogenesis. It is used to control hypercortisolism in preparation for surgery, as a bridge to radiation therapy, or in cases where surgery is not successful or feasible, but it is not a curative treatment."
        },
        {
          "label": "③",
          "text": "양측부신절제술",
          "reason": "Bilateral adrenalectomy is a definitive but second- or third-line treatment for Cushing's disease. It is reserved for cases where pituitary surgery fails or an ectopic source cannot be found. It results in permanent adrenal insufficiency and risks Nelson's syndrome."
        },
        {
          "label": "④",
          "text": "코티코스테로이드",
          "reason": "Administering corticosteroids would exacerbate the patient's condition of cortisol excess. Corticosteroid replacement therapy is only required *after* successful curative surgery leads to temporary or permanent adrenal insufficiency."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "⑤",
          "text": "접형동경유 절제술"
        },
        "provided_key": {
          "label": "5",
          "text": "접형동경유 절제술"
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Cushing's syndrome is a state of chronic hypercortisolism. Features include central obesity, moon facies, buffalo hump, purple striae, proximal muscle weakness, hypertension, and glucose intolerance.",
        "* **Workup (Step 1: Confirm Hypercortisolism):** The first step is to confirm cortisol excess using one of three tests:\n  - 24-hour urinary free cortisol (at least two measurements).\n  - Late-night salivary cortisol (at least two measurements).\n  - Low-dose (1 mg) overnight dexamethasone suppression test.",
        "* **Workup (Step 2: Determine ACTH-Dependence):** Once hypercortisolism is confirmed, a plasma ACTH level is measured. \n  - **Low ACTH (<5 pg/mL):** ACTH-independent cause (primary adrenal tumor).\n  - **Normal to High ACTH (>20 pg/mL):** ACTH-dependent cause (pituitary adenoma or ectopic ACTH production).",
        "* **Workup (Step 3: Differentiate Pituitary vs. Ectopic):** For ACTH-dependent cases, the next step is to distinguish between a pituitary source (Cushing's disease) and an ectopic source. This is done with:\n  - **High-dose (8 mg) dexamethasone suppression test:** Suppression of cortisol (>50%) suggests a pituitary source.\n  - **Pituitary MRI:** To visualize a potential adenoma.",
        "* **Vignette Analysis:** This patient has confirmed hypercortisolism, an ACTH-dependent process, and cortisol suppression on the high-dose dexamethasone test. The MRI confirms a pituitary adenoma. This is a classic workup for Cushing's disease.",
        "* **Treatment:** The definitive, first-line treatment for Cushing's disease (ACTH-secreting pituitary adenoma) is surgical resection of the tumor.",
        "* **Management:** Transsphenoidal surgery is the procedure of choice. It aims to selectively remove the adenoma while preserving normal pituitary function, offering a high cure rate for microadenomas.",
        "* **Alternative Treatments:** If surgery fails or is not possible, options include medical therapy to inhibit steroidogenesis (e.g., ketoconazole, metyrapone), pituitary radiation therapy, or bilateral adrenalectomy as a last resort.",
        "* **Monitoring/Follow-up:** Post-operatively, patients are monitored for remission (low cortisol levels) and may require temporary glucocorticoid replacement due to suppression of the normal HPA axis.",
        "* **Pitfalls (general):** Misinterpreting the results of suppression tests can lead to incorrect localization of the cortisol source. Bilateral adrenalectomy is a salvage therapy, not first-line, as it induces permanent adrenal insufficiency and carries the risk of Nelson's syndrome (aggressive growth of the pituitary tumor)."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "5",
            "text": "접형동경유 절제술"
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "91",
      "depth": "expanded",
      "answer": {
        "label": "①",
        "text": "제세동"
      },
      "why": [
        "* **Diagnosis:** The patient is in cardiac arrest with ventricular fibrillation (VF).",
        "* **Clinical Presentation:** A 64-year-old man with chest pain suddenly loses consciousness. This is a presentation of sudden cardiac arrest.",
        "* **ECG Findings:** The monitor strip shows a chaotic, disorganized electrical activity with no identifiable P waves, QRS complexes, or T waves. The baseline is coarse and fibrillatory. This is the classic appearance of ventricular fibrillation (VF).",
        "* **Pathophysiology:** In VF, the ventricular muscle fibers contract in a rapid, uncoordinated, and ineffective manner. This results in no effective cardiac output, leading to loss of consciousness, pulselessness, and death if not treated immediately.",
        "* **Diagnostic Algorithm (ACLS):** For a patient with sudden collapse, the first steps are to check for responsiveness and breathing, activate the emergency response system, and start high-quality CPR. As soon as a monitor/defibrillator is available, the rhythm should be checked. The rhythm shown is VF, which is a shockable rhythm.",
        "* **Treatment Principle / Guidelines:** According to Advanced Cardiac Life Support (ACLS) guidelines, the immediate and definitive treatment for ventricular fibrillation is electrical defibrillation. This delivers a high-energy, unsynchronized shock to depolarize the entire myocardium simultaneously, allowing the heart's natural pacemaker to potentially re-establish an organized rhythm.",
        "* **Management Sequence:**\n  - **Immediate:** Continue high-quality chest compressions while the defibrillator is being charged.\n  - **Definitive:** As soon as the defibrillator is ready, pause compressions briefly, ensure everyone is clear, and deliver a shock.\n  - **Post-shock:** Immediately resume chest compressions for 2 minutes before the next rhythm check. Epinephrine is administered after the first or second shock, but defibrillation is the priority.",
        "* **Differential / Discriminators:** The other shockable rhythm is pulseless ventricular tachycardia (pVT). Non-shockable rhythms are asystole and pulseless electrical activity (PEA), for which defibrillation is not indicated."
      ],
      "others": [
        {
          "label": "②",
          "text": "심율동전환",
          "reason": "Cardioversion is a synchronized shock used for unstable tachycardias with a pulse (e.g., atrial fibrillation with RVR, SVT, VT with a pulse). It is not used for pulseless, disorganized rhythms like ventricular fibrillation."
        },
        {
          "label": "③",
          "text": "가슴압박만 지속",
          "reason": "Continuing chest compressions is crucial but insufficient alone for a shockable rhythm like VF. The definitive treatment is defibrillation, which must be performed as soon as possible to terminate the arrhythmia."
        },
        {
          "label": "④",
          "text": "심장박동기 삽입",
          "reason": "A pacemaker is a treatment for symptomatic bradycardia or high-degree heart block. It is not indicated for a tachyarrhythmia like ventricular fibrillation or in the acute setting of cardiac arrest."
        },
        {
          "label": "⑤",
          "text": "에피네프린 투약",
          "reason": "Epinephrine is part of the ACLS algorithm for VF, but it is administered after the initial defibrillation attempts. The first and most critical intervention for VF is the electrical shock."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "①",
          "text": "제세동"
        },
        "provided_key": {
          "label": "1",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Sudden cardiac arrest is the abrupt loss of heart function, breathing, and consciousness. The patient is unresponsive, pulseless, and apneic.",
        "* **Workup (Rhythm Analysis):** In cardiac arrest, the immediate priority is to start high-quality CPR and identify the underlying cardiac rhythm using a monitor/defibrillator. Rhythms are categorized as shockable or non-shockable.",
        "* **ECG Findings:** The rhythm strip shows ventricular fibrillation (VF), a chaotic, disorganized electrical pattern with no identifiable QRS complexes. This results in no effective cardiac output.",
        "* **Shockable Rhythms:** The two shockable rhythms in cardiac arrest are:\n  - **Ventricular Fibrillation (VF):** Disorganized ventricular activity.\n  - **Pulseless Ventricular Tachycardia (pVT):** Organized wide-complex tachycardia without a pulse.",
        "* **Non-Shockable Rhythms:** The two non-shockable rhythms are:\n  - **Asystole:** Flat line; no electrical activity.\n  - **Pulseless Electrical Activity (PEA):** Organized electrical activity on the monitor, but no palpable pulse.",
        "* **Management (ACLS Algorithm for VF/pVT):** The cornerstone of treatment for a shockable rhythm is immediate electrical defibrillation.\n  - **Step 1:** Start high-quality CPR (compressions and ventilations).\n  - **Step 2:** When defibrillator arrives, apply pads and check rhythm. If VF/pVT, charge the defibrillator while another provider continues CPR.\n  - **Step 3:** Pause CPR, ensure all are clear, and deliver an unsynchronized high-energy shock (defibrillation).\n  - **Step 4:** Immediately resume CPR for 2 minutes.",
        "* **Treatment (Pharmacologic):** Medications are secondary to high-quality CPR and defibrillation.\n  - **Epinephrine:** 1 mg IV/IO every 3-5 minutes.\n  - **Antiarrhythmics:** Amiodarone or lidocaine may be considered after initial shocks and epinephrine.",
        "* **Differential/Discriminators (Defibrillation vs. Cardioversion):**\n  - **Defibrillation:** An unsynchronized shock used for pulseless arrest (VF/pVT).\n  - **Cardioversion:** A synchronized shock (timed to the R-wave) used for unstable tachyarrhythmias *with a pulse* (e.g., atrial fibrillation with RVR, SVT, VT with a pulse).",
        "* **Pitfalls (general):**\n  - **Delaying defibrillation:** For every minute defibrillation is delayed in VF, survival decreases by about 10%. It is the single most important intervention.\n  - **Prolonged interruptions in CPR:** Minimize pauses in chest compressions, especially during rhythm checks and before/after shocks."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "1",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "92",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "뇌하수체에서 갑상샘 자극호르몬TSH 증가"
      },
      "why": [
        "* **Topic:** Hormonal changes associated with aging.",
        "* **Correct Statement:** Pituitary TSH levels tend to increase slightly with age. This is often due to a mild decrease in thyroid gland function, leading to a compensatory rise in TSH to maintain euthyroidism. The prevalence of subclinical hypothyroidism (elevated TSH with normal free T4) increases with age.",
        "* **Insulin Dynamics:** Aging is associated with increased insulin resistance in peripheral tissues and a relative decline in pancreatic beta-cell function, leading to impaired glucose tolerance. Therefore, insulin resistance *increases*, and secretion may not be able to compensate, or may even decrease over time.",
        "* **Adrenal Androgens:** The production of dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) by the adrenal glands declines progressively and significantly from early adulthood. This phenomenon is termed 'adrenopause'.",
        "* **Growth Hormone Axis:** The secretion of growth hormone (GH) from the pituitary becomes less pulsatile and overall production decreases with age. This leads to a corresponding decline in the liver's production of insulin-like growth factor-1 (IGF-1). This is known as 'somatopause'.",
        "* **Glucocorticoids:** While total cortisol levels may not change significantly or may even slightly increase, the diurnal rhythm is often blunted. This means the morning peak is lower and the evening nadir is higher, leading to a flatter secretion profile, not maintenance of the rhythm with decreased levels.",
        "* **Summary of Age-Related Hormonal Changes:**\n  - **GH/IGF-1:** Decrease\n  - **DHEA/DHEA-S:** Decrease\n  - **Testosterone (men) / Estrogen (women):** Decrease\n  - **Insulin:** Increased resistance, variable secretion\n  - **TSH:** Slight increase\n  - **Cortisol:** Blunted diurnal rhythm, levels stable or slightly increased",
        "* **Conclusion:** Among the given options, the most accurate description of a hormonal change with aging is the tendency for TSH to increase."
      ],
      "others": [
        {
          "label": "①",
          "text": "인슐린 분비의 증가 및 저항성 감소",
          "reason": "This is incorrect. Aging is characterized by an *increase* in insulin resistance and often a relative *decrease* or inadequate compensatory increase in insulin secretion."
        },
        {
          "label": "③",
          "text": "부신 Dehydroepiandrosterone (DHEA)생성 증가",
          "reason": "This is incorrect. Adrenal DHEA production significantly *decreases* with age, a process known as adrenopause."
        },
        {
          "label": "④",
          "text": "성장호르몬 및 인슐린양성장인자(IGF-1) 증가",
          "reason": "This is incorrect. Both growth hormone and IGF-1 levels *decrease* with age, a process known as somatopause."
        },
        {
          "label": "⑤",
          "text": "부신 Glucocorticoid 의 일중변화 유지 및 수치 감소",
          "reason": "This is incorrect. The diurnal variation of glucocorticoids is typically *blunted* (not maintained), and overall levels tend to remain stable or slightly increase, not decrease."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "뇌하수체에서 갑상샘 자극호르몬TSH 증가"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Topic:** The aging process is associated with a gradual decline in the function of multiple endocrine systems, leading to predictable hormonal changes.",
        "* **Growth Hormone Axis (Somatopause):** Secretion of Growth Hormone (GH) from the pituitary decreases, becoming less pulsatile. This leads to a secondary decline in Insulin-like Growth Factor-1 (IGF-1) production by the liver. This contributes to decreased muscle mass and bone density.",
        "* **Adrenal Androgen Axis (Adrenopause):** There is a progressive and marked decline in the adrenal production of dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S) starting from early adulthood.",
        "* **Gonadal Axis (Menopause/Andropause):** Women experience a sharp decline in estrogen production at menopause. Men experience a more gradual decline in testosterone levels with age.",
        "* **Thyroid Axis:** The thyroid gland's response to TSH may slightly decrease with age. To compensate and maintain a euthyroid state, TSH levels often show a slight, gradual increase. The prevalence of subclinical hypothyroidism (high TSH, normal fT4) rises with age.",
        "* **Glucose Homeostasis:** Aging is characterized by increased insulin resistance in peripheral tissues (muscle, fat). While beta-cells may initially increase insulin secretion to compensate, their function can decline over time, leading to impaired glucose tolerance and an increased risk of type 2 diabetes.",
        "* **Adrenal Glucocorticoid Axis:** While overall 24-hour cortisol production may remain stable or slightly increase, the diurnal rhythm is often blunted. This means the morning peak is lower and the evening nadir is higher, resulting in a flatter secretion profile.",
        "* **Summary of Hormonal Changes with Age:**\n  - **Decrease:** GH, IGF-1, DHEA, DHEA-S, Testosterone (men), Estrogen (women).\n  - **Increase:** TSH (slight), Insulin resistance, FSH/LH (post-menopause).\n  - **Blunted Rhythm:** Cortisol.",
        "* **Pitfalls (general):** Do not confuse age-related changes with specific disease states, although they can overlap (e.g., age-related TSH rise vs. true subclinical hypothyroidism requiring treatment). Reference ranges for some hormones may need to be age-adjusted."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "93",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "근감소증은 근육량, 근력, 근기능이 모두 감소한다"
      },
      "why": [
        "* **Diagnosis:** Sarcopenia.",
        "* **Definition:** Sarcopenia is a progressive and generalized skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increased adverse outcomes including falls, functional decline, frailty, and mortality.",
        "* **Diagnostic Criteria (EWGSOP2):** The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) defines sarcopenia based on three components:\n  - **Low muscle strength:** This is the primary parameter. It is considered the most reliable measure of muscle function.\n  - **Low muscle quantity or quality:** This confirms the diagnosis of sarcopenia.\n  - **Low physical performance:** The presence of all three components indicates severe sarcopenia.",
        "* **Pathophysiology:** The loss of muscle mass (quantity) is a key feature, primarily due to a decrease in the number and size of muscle fibers, especially type II (fast-twitch) fibers. This is accompanied by a decline in muscle strength (quality) and physical performance (function), such as walking speed or ability to rise from a chair.",
        "* **Body Composition Changes:** Sarcopenia is often accompanied by an increase in fat mass, a condition known as sarcopenic obesity. Fat can also infiltrate the muscle itself (myosteatosis), which further impairs muscle quality and function. Therefore, visceral fat is not typically lost; it may increase.",
        "* **Diagnosis Methods:** Sarcopenia is not diagnosed by height and weight alone. Diagnosis involves specific measurements like handgrip strength (for muscle strength), DEXA or BIA (for muscle mass), and tests like the Short Physical Performance Battery (SPPB) or gait speed (for physical function).",
        "* **Management:** The primary management strategies are resistance exercise and adequate protein intake, not a high-fat diet and rest. Rest and inactivity accelerate muscle loss.",
        "* **Conclusion:** The statement that sarcopenia involves a decrease in muscle mass, muscle strength, and muscle function is the most accurate and comprehensive description of the condition."
      ],
      "others": [
        {
          "label": "①",
          "text": "근감소증은 주로 키와 체중감소로 진단한다",
          "reason": "This is incorrect. While weight loss can occur, diagnosis is based on specific measurements of muscle strength, mass, and physical performance, not just changes in height or weight."
        },
        {
          "label": "②",
          "text": "MRI 검사에서 골격근 내부의 지방침착은 감소한다",
          "reason": "This is incorrect. Sarcopenia is associated with an *increase* in intramuscular fat infiltration (myosteatosis), which contributes to poor muscle quality."
        },
        {
          "label": "④",
          "text": "노인에서의 골격근 소실은 보통 내장지방의 소실과 동반된다",
          "reason": "This is incorrect. Sarcopenia is often associated with an *increase* in total and visceral fat mass, a condition known as sarcopenic obesity."
        },
        {
          "label": "⑤",
          "text": "근감소증은 고지방식이 및 안정과 휴식이 중요하다",
          "reason": "This is incorrect. The cornerstones of managing sarcopenia are resistance exercise and adequate protein intake. A high-fat diet and inactivity would worsen the condition."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "근감소증은 근육량, 근력, 근기능이 모두 감소한다"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death.",
        "* **Definition:** Sarcopenia is fundamentally a disorder of muscle quantity and quality. It involves a reduction in muscle mass (atrophy), a decline in muscle strength (dynapenia), and impaired physical performance.",
        "* **Criteria/Thresholds (EWGSOP2 Definition):** The European Working Group on Sarcopenia in Older People defines sarcopenia based on three components:\n  1. **Low muscle strength** (e.g., low handgrip strength) is the primary parameter. If low, sarcopenia is probable.\n  2. **Low muscle quantity or quality** (e.g., by DEXA or BIA) confirms the diagnosis.\n  3. **Low physical performance** (e.g., slow gait speed, poor SPPB score) indicates severe sarcopenia.",
        "* **Pathophysiology:** The process involves a decrease in the number and size of muscle fibers, particularly type II (fast-twitch) fibers. This is often accompanied by an increase in fat mass and infiltration of fat into the muscle itself (myosteatosis), which further impairs muscle quality.",
        "* **Sarcopenic Obesity:** Sarcopenia can coexist with obesity. This combination of low muscle mass and high fat mass is particularly detrimental, as it synergistically increases the risk of metabolic disease and functional decline. Visceral fat is typically increased, not lost.",
        "* **Workup:** Diagnosis is not based on simple metrics like height and weight. It requires specific functional and body composition assessments.\n  - **Strength:** Handgrip dynamometry.\n  - **Mass:** Dual-energy X-ray absorptiometry (DEXA) or Bioelectrical Impedance Analysis (BIA).\n  - **Performance:** Short Physical Performance Battery (SPPB), Timed Up and Go (TUG) test, or gait speed.",
        "* **Management:** The cornerstones of management are resistance exercise and nutritional optimization, particularly adequate protein intake.",
        "* **Pitfalls (general):**\n  - **Confusing sarcopenia with cachexia:** Cachexia is muscle loss driven by a severe underlying inflammatory illness (e.g., cancer, heart failure), while sarcopenia is primarily age-related.\n  - **Focusing only on weight:** An older adult can have a stable or even increased weight due to fat gain while simultaneously losing muscle mass (sarcopenic obesity)."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "94",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "저항성근력운동과 충분한 양질의 단백질 섭취를 권고한다"
      },
      "why": [
        "* **Topic:** Treatment and management of sarcopenia.",
        "* **Primary Intervention:** The most effective and evidence-based interventions for managing sarcopenia are physical activity, particularly resistance training, and nutritional support, specifically adequate protein intake.",
        "* **Resistance Exercise:** Progressive resistance training is the cornerstone of therapy. It directly stimulates muscle protein synthesis, leading to improvements in muscle mass, strength, and physical function. It is more effective than aerobic exercise for combating sarcopenia.",
        "* **Nutritional Support:** Older adults often have higher protein requirements to overcome 'anabolic resistance'. Guidelines recommend a protein intake of 1.0-1.2 g/kg body weight/day, with an even distribution across meals. High-quality protein sources rich in essential amino acids, especially leucine (e.g., whey, dairy, meat), are beneficial.",
        "* **Ineffective/Inappropriate Interventions:**\n  - **High-fat diet:** This is not recommended and can contribute to sarcopenic obesity without improving muscle mass or function.\n  - **Hormone therapy:** Testosterone or estrogen replacement has not been proven to be consistently effective for improving function and carries significant risks. It is not a primary treatment.\n  - **Growth hormone:** While GH can increase muscle mass, it does not typically improve muscle strength or function and has a high rate of adverse effects. It is not recommended for treating sarcopenia.",
        "* **Evaluation:** Contrary to one of the distractors, standardized methods for evaluating sarcopenia do exist, as established by international consensus groups (e.g., EWGSOP, AWGS, FNIH).",
        "* **Conclusion:** The combination of resistance exercise and sufficient high-quality protein intake is the most appropriate and recommended management strategy for sarcopenia."
      ],
      "others": [
        {
          "label": "①",
          "text": "고지방식이를 통한 체중증가가 필요하다",
          "reason": "This is incorrect. Management focuses on increasing muscle mass, not just body weight. A high-fat diet is not recommended; the focus should be on adequate protein intake."
        },
        {
          "label": "②",
          "text": "근감소증을 평가하는 표준적인 방법이 존재하지 않는다",
          "reason": "This is incorrect. Standardized diagnostic criteria and assessment tools for sarcopenia have been developed and are widely used (e.g., EWGSOP2 guidelines)."
        },
        {
          "label": "③",
          "text": "여성호르몬, 남성호르몬 보충치료가 주된 약물치료이다",
          "reason": "This is incorrect. Hormone replacement therapies are not considered primary or standard drug treatments for sarcopenia due to limited efficacy on function and potential adverse effects."
        },
        {
          "label": "⑤",
          "text": "인슐린양 성장인자의 촉진을 위해 성장호르몬 치료를 시행한다",
          "reason": "This is incorrect. Growth hormone therapy is not recommended for sarcopenia as it fails to improve muscle strength and function and is associated with significant side effects."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "저항성근력운동과 충분한 양질의 단백질 섭취를 권고한다"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Topic:** Management of sarcopenia in older adults.",
        "* **Management (Core Principles):** The most effective, evidence-based interventions for preventing and treating sarcopenia are a combination of targeted physical activity and optimized nutrition.",
        "* **Treatment (Exercise):** Progressive resistance training is the most effective form of exercise for increasing muscle mass and strength. It directly stimulates muscle protein synthesis. Aerobic exercise is beneficial for cardiovascular health but is less effective for building muscle.",
        "* **Treatment (Nutrition):** Adequate protein intake is crucial to provide the building blocks for muscle synthesis. Older adults have higher protein needs due to 'anabolic resistance'.",
        "* **Criteria/Thresholds (Protein Intake):** Current recommendations for older adults are to consume 1.0-1.2 g of protein per kg of body weight per day. For those with severe illness or injury, this may increase to 1.2-1.5 g/kg/day.",
        "* **Protein Quality and Timing:** High-quality protein sources rich in the essential amino acid leucine (e.g., whey, dairy, meat, soy) are particularly effective. Spreading protein intake evenly throughout the day (e.g., 25-30g per meal) may be more beneficial than consuming most of it in one meal.",
        "* **Ineffective or Harmful Interventions:**\n  - **High-fat diet and rest:** Inactivity is a primary driver of muscle loss. A high-fat diet without adequate protein will promote fat gain, not muscle gain, worsening sarcopenic obesity.",
        "* **Pharmacologic Therapy:** There are currently no FDA-approved drugs specifically for the treatment of sarcopenia. Research is ongoing, but hormonal therapies are not standard care.",
        "* **Hormone Replacement:** Testosterone or growth hormone can increase muscle mass but have not been shown to consistently improve muscle strength or physical function and carry significant risks and side effects. They are not recommended for routine treatment of sarcopenia.",
        "* **Evaluation:** Standardized methods and diagnostic criteria for sarcopenia exist and have been published by international consensus groups (e.g., EWGSOP2, FNIH), allowing for objective assessment and monitoring of the condition.",
        "* **Pitfalls (general):** Prescribing rest and focusing on weight gain through high-calorie, low-protein diets is counterproductive and will accelerate functional decline in a sarcopenic individual."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "95",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "장중첩증(Intussusception)"
      },
      "why": [
        "* **Diagnosis:** Intussusception.",
        "* **Clinical Presentation:** The patient is a 10-month-old infant, which is the peak age range for intussusception (typically 3 months to 3 years). The presentation is classic: sudden onset of intermittent, severe, colicky abdominal pain (manifesting as recurrent fussiness/screaming spells), followed by periods of lethargy or normal behavior. Vomiting and poor feeding are also common. A preceding viral illness or gastroenteritis (as suggested by the history of watery diarrhea) is a known risk factor, likely due to hypertrophy of Peyer's patches in the terminal ileum acting as a lead point.",
        "* **Physical Exam:** The finding of a non-tender abdomen between episodes of pain is characteristic. In some cases, a sausage-shaped mass may be palpated in the right upper quadrant.",
        "* **Image Findings:** The abdominal ultrasound is the diagnostic modality of choice. The image provided shows a classic **\"target sign\"** or **\"doughnut sign\"** on a transverse view. This pathognomonic finding represents layers of the telescoped bowel and mesentery.",
        "* **Pathophysiology:** Intussusception is the telescoping or invagination of a proximal segment of the bowel (the intussusceptum) into the adjacent distal segment (the intussuscipiens). The most common type is ileocolic.",
        "* **Differential / Discriminators:**\n  - **Malrotation with volvulus:** Presents with bilious vomiting and signs of shock. Ultrasound would show a \"whirlpool sign.\"\n  - **Incarcerated hernia:** A firm, tender, non-reducible mass would be present in the inguinal or scrotal region.\n  - **Ischemic colitis:** Rare in this age group and usually associated with a specific cause like necrotizing enterocolitis in premature infants or severe shock.",
        "* **Management:** The initial treatment is typically non-operative reduction with a therapeutic air or contrast enema under fluoroscopic or ultrasound guidance. Surgery is reserved for cases where non-operative reduction fails or if there are signs of peritonitis or bowel perforation."
      ],
      "others": [
        {
          "label": "①",
          "text": "장회전이상(Malrotation)",
          "reason": "Malrotation typically presents with bilious vomiting. The ultrasound finding for malrotation would be an abnormal relationship between the superior mesenteric artery and vein, not a target sign."
        },
        {
          "label": "②",
          "text": "감돈 탈장(Incacerated hernia)",
          "reason": "An incarcerated hernia would present with a palpable, irreducible mass in the groin or scrotum, which was not described in the physical exam."
        },
        {
          "label": "④",
          "text": "장염전(volvulus)",
          "reason": "Volvulus, a complication of malrotation, causes acute bowel obstruction and ischemia, presenting with bilious emesis and rapid clinical deterioration. The ultrasound would show a \"whirlpool sign,\" not a target sign."
        },
        {
          "label": "⑤",
          "text": "허혈성 장염(Ischemic colitis)",
          "reason": "Ischemic colitis is very rare in a healthy 10-month-old. The presentation and pathognomonic ultrasound finding are classic for intussusception."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "장중첩증(Intussusception)"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Intussusception is the most common cause of intestinal obstruction in infants between 3 months and 3 years of age. The classic triad is intermittent, severe, colicky abdominal pain; a palpable, sausage-shaped abdominal mass; and currant jelly stool (a mix of blood and mucus).",
        "* **Presentation in Infants:** The colicky pain often manifests as sudden, loud crying and drawing the legs up to the chest. These episodes are followed by periods of lethargy or normal behavior.",
        "* **Pathophysiology:** Intussusception occurs when a proximal segment of bowel (intussusceptum) telescopes into the adjacent distal segment (intussuscipiens). This drags the mesentery along with it, leading to venous compression, edema, and eventual arterial compromise, ischemia, and necrosis.",
        "* **Lead Points:** In most infants, intussusception is idiopathic, thought to be caused by hypertrophied Peyer's patches following a viral illness. In older children, a pathologic lead point (e.g., Meckel's diverticulum, polyp, lymphoma) is more common.",
        "* **Workup:** Abdominal ultrasound is the diagnostic modality of choice, with high sensitivity and specificity. It does not involve radiation.",
        "* **Criteria/Thresholds (Ultrasound Findings):** The pathognomonic finding on ultrasound is the **\"target sign\"** or **\"doughnut sign\"** on a transverse view, representing the concentric rings of the telescoped bowel.",
        "* **Management (Non-operative):** For a stable child without signs of peritonitis or perforation, the first-line treatment is non-operative reduction via a therapeutic enema (air or contrast) performed under fluoroscopic or ultrasound guidance.",
        "* **Management (Surgical):** Surgery is indicated if:\n  - Non-operative reduction is unsuccessful.\n  - The patient shows signs of peritonitis, perforation, or shock.\n  - A pathologic lead point is identified.",
        "* **Differential/Discriminators:** Key differentials include:\n  - **Malrotation with midgut volvulus:** Presents with bilious vomiting and requires emergent surgery. Ultrasound shows a \"whirlpool sign.\"\n  - **Incarcerated hernia:** A tender, non-reducible mass in the groin.\n  - **Gastroenteritis:** Pain is typically less severe and constant, not colicky and intermittent.",
        "* **Pitfalls (general):** Misattributing the periods of lethargy between painful episodes to simple fatigue can delay diagnosis. Lethargy can be a sign of significant underlying pathology."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "96",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "대장 조영술"
      },
      "why": [
        "* **Diagnosis:** High suspicion for Hirschsprung disease (congenital aganglionic megacolon).",
        "* **Clinical Presentation:** The 2-month-old infant presents with a classic history for Hirschsprung disease: constipation since birth, progressive abdominal distension, poor feeding, and fussiness.",
        "* **Pathognomonic Sign:** The digital rectal exam (DRE) finding is highly suggestive. The rectal vault is empty, but withdrawal of the finger results in an explosive discharge of foul-smelling gas and liquid stool. This is known as the \"squirt sign\" or \"blast sign\" and is caused by the temporary relief of the functional obstruction at the aganglionic segment.",
        "* **Pathophysiology:** Hirschsprung disease is caused by the failure of neural crest cells to migrate to the distal colon during embryonic development. This results in an aganglionic segment of bowel that cannot relax, leading to a functional obstruction.",
        "* **Diagnostic Algorithm:**\n  - **First Step (Imaging):** For a stable infant with high clinical suspicion, the initial diagnostic study is a contrast enema (using barium or water-soluble contrast). This is preferred over other imaging modalities.\n  - **Expected Findings:** The contrast enema will typically demonstrate a narrow, spastic aganglionic segment (usually the rectosigmoid) with a dilated, normally innervated colon proximally. The area between these two is called the \"transition zone.\"\n  - **Confirmation:** The gold standard for diagnosis is a rectal suction biopsy, which demonstrates the absence of ganglion cells in the submucosal (Meissner's) and myenteric (Auerbach's) plexuses. However, the contrast enema is the appropriate *initial* investigation.",
        "* **Differential Diagnosis:** Other causes of constipation in infancy include functional constipation (rare in the first month), hypothyroidism, and anal stenosis, but the clinical picture and DRE findings strongly point towards Hirschsprung disease."
      ],
      "others": [
        {
          "label": "①",
          "text": "복부초음파",
          "reason": "Abdominal ultrasound is not the primary imaging modality for diagnosing Hirschsprung disease, although it might show a dilated proximal colon. A contrast enema is the standard initial radiologic test."
        },
        {
          "label": "②",
          "text": "갑상선 기능 검사",
          "reason": "While congenital hypothyroidism can cause constipation, the explosive release of stool on rectal exam is a classic sign of Hirschsprung disease, making it the primary suspicion. A contrast enema is the most direct way to investigate this suspicion."
        },
        {
          "label": "④",
          "text": "결장 내시경",
          "reason": "Colonoscopy is not typically used for the initial diagnosis of Hirschsprung disease. It is more invasive than a contrast enema and does not provide the same information about the transition zone."
        },
        {
          "label": "⑤",
          "text": "직장 흡인 생검",
          "reason": "A rectal suction biopsy is the definitive gold standard for diagnosis. However, a contrast enema is the less invasive, first-line *imaging* study performed to identify a transition zone and guide the level of biopsy."
        }
      ],
      "runner_up": "⑤",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": false
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "대장 조영술"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Hirschsprung disease is a congenital disorder that should be suspected in any full-term infant with delayed passage of meconium (>48 hours), constipation since birth, abdominal distension, and poor feeding.",
        "* **Pathophysiology:** It is caused by the congenital absence of ganglion cells (aganglionosis) in the submucosal (Meissner's) and myenteric (Auerbach's) plexuses of the distal bowel. This results in a segment of bowel that cannot relax, leading to a functional obstruction.",
        "* **Anatomic Distribution:** The aganglionosis always starts at the anus and extends proximally for a variable distance. The rectosigmoid colon is the most commonly affected segment (short-segment disease).",
        "* **Physical Exam:** A key finding is an empty rectal vault on digital rectal exam (DRE). Withdrawal of the finger may produce an explosive discharge of gas and liquid stool (the \"squirt sign\" or \"blast sign\"), which is highly suggestive of the diagnosis.",
        "* **Workup (Algorithmic):**\n  - **Initial Imaging:** A contrast enema is the first-line radiologic study in a stable infant.\n  - **Definitive Diagnosis:** Rectal suction biopsy is the gold standard.",
        "* **Criteria/Thresholds (Contrast Enema):** The classic finding on a contrast enema is a narrow, spastic aganglionic segment distally, with a dilated, normally innervated colon proximally. The junction between these two areas is called the \"transition zone.\"",
        "* **Criteria/Thresholds (Biopsy):** The definitive diagnosis is confirmed by histopathology showing the absence of ganglion cells in the biopsy specimen. The specimen must be deep enough to include the submucosa.",
        "* **Management:** Treatment is surgical. It involves resecting the aganglionic segment and performing a pull-through procedure to bring the normally innervated bowel down to the anus.",
        "* **Complications:** The most serious complication is Hirschsprung-associated enterocolitis (HAEC), a life-threatening condition with fever, explosive diarrhea, and abdominal distension, which can lead to sepsis and death.",
        "* **Pitfalls (general):** Attributing neonatal constipation to functional causes or formula intolerance can dangerously delay the diagnosis of Hirschsprung disease. Constipation starting from the first days of life is a major red flag."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "97",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "총담관"
      },
      "why": [
        "* **Diagnosis:** Obstructive jaundice, likely due to a malignant obstruction of the distal common bile duct.",
        "* **Clinical Presentation:** The triad of painless jaundice, significant weight loss, and a palpable, non-tender gallbladder in an elderly patient is highly suggestive of a malignancy causing distal biliary obstruction. The palpable gallbladder is known as Courvoisier's sign.",
        "* **Pathophysiology of Courvoisier's Sign:** A palpable, non-tender, distended gallbladder in the presence of jaundice suggests that the obstruction is distal to the junction of the cystic duct and the common hepatic duct. Chronic obstruction from a slow-growing tumor (like pancreatic head cancer or cholangiocarcinoma) allows the gallbladder wall to stretch and become distended. In contrast, obstruction by a gallstone is usually acute and occurs in a chronically inflamed, fibrotic gallbladder that cannot distend.",
        "* **Lab Findings:** The laboratory results show a classic cholestatic pattern:\n  - **Hyperbilirubinemia:** Markedly elevated total bilirubin (15.1 mg/dL) with a predominance of direct (conjugated) bilirubin (12.2 mg/dL), confirming post-hepatic obstruction.\n  - **Elevated Cholestatic Enzymes:** Markedly elevated alkaline phosphatase (ALP) at 415 IU/L and gamma-glutamyl transferase (GGT) at 450 IU/L are characteristic of biliary obstruction.\n  - **Mildly Elevated Transaminases:** AST/ALT are only mildly elevated, which is typical for obstructive jaundice rather than primary hepatocellular injury.",
        "* **Image Findings:** The ultrasound finding of intrahepatic bile duct dilation confirms that there is an obstruction somewhere in the biliary tree downstream.",
        "* **Localization of Obstruction:** Since both the intrahepatic ducts are dilated AND the gallbladder is palpable (distended), the obstruction must be in the common bile duct, distal to the insertion of the cystic duct. An obstruction at the hilum (Klatskin tumor) or in the common hepatic duct would cause intrahepatic dilation but the gallbladder would be collapsed, not distended.",
        "* **Conclusion:** The combination of clinical, laboratory, and imaging findings points to an obstruction in the common bile duct."
      ],
      "others": [
        {
          "label": "①",
          "text": "담낭",
          "reason": "A lesion in the gallbladder itself (e.g., gallbladder cancer) would not typically cause obstruction of the entire biliary tree unless it invaded the common bile duct. The primary finding is obstructive jaundice."
        },
        {
          "label": "②",
          "text": "간문부",
          "reason": "An obstruction at the hepatic hilum (e.g., a Klatskin tumor) would cause intrahepatic ductal dilation but would result in a collapsed, non-palpable gallbladder. This contradicts the finding of a palpable mass (Courvoisier's sign)."
        },
        {
          "label": "③",
          "text": "총간관",
          "reason": "An obstruction in the common hepatic duct, which is proximal to the cystic duct insertion, would cause intrahepatic ductal dilation but a collapsed gallbladder, contradicting Courvoisier's sign."
        },
        {
          "label": "⑤",
          "text": "간내담관",
          "reason": "A lesion in an intrahepatic bile duct would cause segmental, not diffuse, intrahepatic biliary dilation and would not explain the palpable gallbladder or the degree of jaundice."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "총담관"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** The presentation of painless jaundice, significant weight loss, and a palpable, non-tender gallbladder in an elderly patient is classic for a malignant obstruction of the distal biliary tree.",
        "* **Courvoisier's Sign:** A palpable, non-tender, distended gallbladder in the presence of jaundice is known as Courvoisier's sign. It implies that the obstruction is slow and progressive, allowing the gallbladder to distend, which is typical of a malignancy (e.g., pancreatic head cancer, distal cholangiocarcinoma).",
        "* **Pathophysiology of Courvoisier's Sign:** Obstruction by a gallstone is typically acute and occurs in a chronically inflamed, fibrotic gallbladder that is incapable of distension. In contrast, a slow-growing tumor allows the non-diseased gallbladder wall to stretch.",
        "* **Workup (Labs):** The laboratory pattern is cholestatic or obstructive:\n  - **Elevated total bilirubin** with a predominance of **conjugated (direct) bilirubin**.\n  - **Markedly elevated alkaline phosphatase (ALP)** and **gamma-glutamyl transferase (GGT)**.\n  - **Mildly elevated transaminases (AST/ALT).",
        "* **Workup (Imaging):** The initial imaging study is typically an abdominal ultrasound. It can detect biliary ductal dilation and may identify the level of obstruction or a mass.",
        "* **Localization of Obstruction:** The combination of findings helps localize the lesion:\n  - **Intrahepatic ductal dilation only:** Obstruction is at the hepatic hilum (e.g., Klatskin tumor). The gallbladder will be collapsed.\n  - **Intra- and extrahepatic ductal dilation + distended gallbladder:** Obstruction is distal to the cystic duct insertion, in the common bile duct.",
        "* **Vignette Analysis:** This patient has intrahepatic ductal dilation (from ultrasound) and a palpable gallbladder (Courvoisier's sign), which localizes the obstruction to the common bile duct.",
        "* **Management (Algorithmic):** After ultrasound, the next step is usually a high-resolution cross-sectional imaging study like a multiphasic CT scan or an MRCP to better define the anatomy and identify a potential mass. Endoscopic retrograde cholangiopancreatography (ERCP) can be both diagnostic (visualizing the duct, obtaining brushings/biopsy) and therapeutic (placing a stent to relieve the obstruction).",
        "* **Differential/Discriminators:** The main differential is between malignant causes (pancreatic cancer, cholangiocarcinoma, ampullary cancer) and benign causes (choledocholithiasis, benign stricture). The painless nature and Courvoisier's sign strongly favor malignancy.",
        "* **Pitfalls (general):** A palpable gallbladder in a jaundiced patient should not be dismissed as simple cholecystitis; it is a significant sign pointing towards malignancy until proven otherwise."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "98",
      "depth": "expanded",
      "answer": {
        "label": "②",
        "text": "선천성 담도폐쇄증"
      },
      "why": [
        "* **Diagnosis:** Biliary atresia.",
        "* **Clinical Presentation:** The infant is 5 weeks old and presents with the classic triad for biliary atresia: persistent and worsening jaundice, acholic (pale, clay-colored) stools, and dark urine (due to renal excretion of conjugated bilirubin). The presence of hepatosplenomegaly indicates significant cholestasis leading to liver damage and portal hypertension.",
        "* **Lab Findings:** The blood tests confirm neonatal cholestasis with conjugated hyperbilirubinemia (Direct bilirubin 7.8 mg/dL out of Total 9.2 mg/dL). The most specific laboratory clue is the markedly elevated gamma-glutamyl transferase (GGT > 300 IU/L, here it is 980 IU/L), which is highly suggestive of biliary atresia in this clinical context.",
        "* **Image Findings:** The provided ultrasound image is consistent with biliary atresia. Key findings on ultrasound for biliary atresia include an absent or very small (<1.5 cm) gallbladder, or the \"triangular cord sign,\" which is a triangular or tubular echogenic density seen just cranial to the portal vein bifurcation, representing the fibrotic remnant of the extrahepatic bile duct. While the image is not perfectly clear, it does not show a normal, fluid-filled gallbladder.",
        "* **Pathophysiology:** Biliary atresia is a progressive, idiopathic, fibro-obliterative disease of the extrahepatic biliary tree that presents in early infancy. It leads to obstruction of bile flow, cholestasis, and progressive liver damage, cirrhosis, and death if not treated.",
        "* **Management:** Early diagnosis is critical. The Kasai portoenterostomy procedure must be performed, ideally before 60 days of life, to re-establish bile flow. Even with a successful Kasai procedure, most patients will eventually require a liver transplant.",
        "* **Differential / Discriminators:**\n  - **Crigler-Najjar syndrome:** Causes *unconjugated* hyperbilirubinemia.\n  - **Choledochal cyst:** Would show a cystic dilation of the bile duct on ultrasound.\n  - **Alagille syndrome:** Also presents with cholestasis and high GGT, but is associated with other features like butterfly vertebrae, posterior embryotoxon, characteristic facies, and peripheral pulmonary stenosis. The acholic stools and ultrasound findings are more classic for atresia."
      ],
      "others": [
        {
          "label": "①",
          "text": "신생아 감염",
          "reason": "Neonatal sepsis or TORCH infections can cause cholestasis, but the GGT is typically not as markedly elevated as seen here, and the combination of acholic stools and ultrasound findings makes biliary atresia more likely."
        },
        {
          "label": "③",
          "text": "총담관낭종",
          "reason": "A choledochal cyst would be identified on ultrasound as a cystic dilation of the common bile duct, which is not seen here. Instead, the gallbladder appears atretic or absent."
        },
        {
          "label": "④",
          "text": "Alagille 증후군",
          "reason": "While Alagille syndrome causes cholestasis, it is a multisystem genetic disorder with other characteristic findings (facial, skeletal, cardiac) not mentioned here. The presentation is more classic for biliary atresia."
        },
        {
          "label": "⑤",
          "text": "Crigler-Najjar 증후군",
          "reason": "This is a disorder of bilirubin conjugation, resulting in severe *unconjugated* hyperbilirubinemia. This patient has predominantly *conjugated* hyperbilirubinemia."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "②",
          "text": "선천성 담도폐쇄증"
        },
        "provided_key": {
          "label": "2",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** Biliary atresia is the most common cause of pathologic jaundice in the first few weeks of life. It presents with persistent jaundice, acholic (pale, clay-colored) stools, and dark urine.",
        "* **Pathophysiology:** It is a progressive, fibro-obliterative disease of the extrahepatic biliary tree, leading to complete obstruction of bile flow. This results in cholestasis, conjugated hyperbilirubinemia, and rapid progression to cirrhosis and liver failure if untreated.",
        "* **Workup (Labs):** The key laboratory finding is **conjugated (direct) hyperbilirubinemia**. A direct bilirubin >1 mg/dL or >20% of the total bilirubin is always pathologic in an infant and requires urgent investigation. A markedly elevated GGT is highly characteristic of biliary atresia.",
        "* **Workup (Imaging):**\n  - **Abdominal Ultrasound:** The initial imaging study. Findings suggestive of biliary atresia include an absent or small/atretic gallbladder (<1.5 cm) or the \"triangular cord sign\" (a fibrotic remnant of the bile duct).\n  - **HIDA Scan:** A hepatobiliary iminodiacetic acid scan performed after 5-7 days of phenobarbital pre-treatment. Failure of the radiotracer to be excreted into the small intestine is suggestive of biliary atresia.",
        "* **Definitive Diagnosis:** The gold standard for diagnosis is an intraoperative cholangiogram, which directly visualizes the biliary tree. This is typically performed just prior to the definitive surgical procedure.",
        "* **Management:** Biliary atresia is a surgical emergency. The treatment is the Kasai portoenterostomy, where a loop of small intestine is anastomosed to the porta hepatis to re-establish bile drainage.",
        "* **Criteria/Thresholds (Timing):** The success of the Kasai procedure is highly dependent on the infant's age at the time of surgery. The best outcomes are achieved when surgery is performed before 60 days of life. Early diagnosis is critical.",
        "* **Prognosis:** Even with a successful Kasai procedure, progressive liver disease is common, and the majority of patients will ultimately require a liver transplant during childhood or adolescence.",
        "* **Differential/Discriminators:** The differential for neonatal cholestasis is broad (e.g., infections, Alagille syndrome, alpha-1 antitrypsin deficiency), but the combination of acholic stools and a very high GGT makes biliary atresia the primary concern. Crigler-Najjar syndrome causes *unconjugated* hyperbilirubinemia.",
        "* **Pitfalls (general):** Dismissing neonatal jaundice as benign \"physiologic jaundice\" or \"breast milk jaundice\" in the presence of conjugated hyperbilirubinemia or acholic stools is a critical error that can lead to irreversible liver damage."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "2",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "99",
      "depth": "expanded",
      "answer": {
        "label": "③",
        "text": "체-폐동맥간 단락술 (Blalock-Taussig shunt)"
      },
      "why": [
        "* **Diagnosis:** Large, hemodynamically significant Ventricular Septal Defect (VSD) with congestive heart failure (CHF).",
        "* **Clinical Presentation:** The infant presents with signs of CHF: tachypnea (respiratory rate 50/min), increased work of breathing (intercostal retractions), and likely poor feeding/failure to thrive (implied by referral from check-up). The murmur is the classic finding that leads to investigation. This is an acyanotic congenital heart defect with a large left-to-right shunt.",
        "* **Image Findings:**\n  - **Chest X-ray (left):** Shows cardiomegaly (enlarged heart silhouette) and increased pulmonary vascular markings (pulmonary plethora). This is due to the large volume of blood being shunted from the left ventricle to the right ventricle and then to the pulmonary circulation.\n  - **Echocardiogram (right):** The images clearly show a large defect in the ventricular septum, with color Doppler confirming a significant left-to-right shunt. This is the definitive diagnostic finding.",
        "* **Treatment Principles for Large VSD with CHF:** The goal is to manage the heart failure symptoms and protect the pulmonary vasculature from irreversible damage (pulmonary hypertension) caused by excessive blood flow and pressure. Treatment can be medical or surgical.",
        "* **Possible Treatments:**\n  - **Diuretics:** Medical therapy to reduce fluid overload and pulmonary congestion is a first-line treatment for CHF symptoms.\n  - **Pulmonary artery banding (PAB):** A palliative surgical procedure that places a band around the main pulmonary artery to restrict blood flow to the lungs. It is used in small infants or those with contraindications to immediate full repair to control CHF and prevent pulmonary hypertension.\n  - **Total correction:** Definitive surgical repair via open-heart surgery to close the VSD with a patch. This is the ultimate treatment.",
        "* **Contraindicated Treatment:**\n  - **Blalock-Taussig (BT) shunt:** This is a palliative procedure designed for **cyanotic** heart defects with **decreased pulmonary blood flow** (e.g., Tetralogy of Fallot, pulmonary atresia). It creates a shunt from a systemic artery (like the subclavian) to the pulmonary artery to *increase* blood flow to the lungs. In this patient with a VSD, pulmonary blood flow is already excessive. A BT shunt would worsen the pulmonary overcirculation, exacerbate heart failure, and be life-threatening."
      ],
      "others": [
        {
          "label": "①",
          "text": "이뇨제 투약 (diuretics)",
          "reason": "This is a standard medical treatment for managing the symptoms of congestive heart failure (pulmonary overcirculation) caused by a large VSD."
        },
        {
          "label": "②",
          "text": "폐동맥 교약술 (pulmonary artery banding)",
          "reason": "This is a valid palliative surgical option for an infant with a large VSD and severe heart failure who is too small or unstable for definitive repair. It reduces excessive pulmonary blood flow."
        },
        {
          "label": "④",
          "text": "개심술을 통한 전체 교정술 (total correction)",
          "reason": "This is the definitive treatment for a large VSD, involving surgical closure of the defect. It is a standard and necessary procedure for this condition."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "incomplete_options": true,
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "③",
          "text": "체-폐동맥간 단락술 (Blalock-Taussig shunt)"
        },
        "provided_key": {
          "label": "3",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A large Ventricular Septal Defect (VSD) is an acyanotic congenital heart defect. The large left-to-right shunt causes excessive pulmonary blood flow (pulmonary overcirculation), leading to signs of congestive heart failure (CHF) in infancy: tachypnea, poor feeding, failure to thrive, and hepatomegaly.",
        "* **Pathophysiology:** In a large, unrestrictive VSD, blood flows from the high-pressure left ventricle to the low-pressure right ventricle during systole. This volume overload on the right ventricle and pulmonary circulation leads to pulmonary edema and CHF.",
        "* **Workup:**\n  - **Chest X-ray:** Shows cardiomegaly and increased pulmonary vascular markings (pulmonary plethora).\n  - **Echocardiogram:** The definitive diagnostic tool. It visualizes the VSD, determines its size and location, and assesses the magnitude of the shunt and its hemodynamic consequences.",
        "* **Management (Goal):** The goals are to manage CHF symptoms and prevent long-term complications, primarily the development of irreversible pulmonary hypertension (Eisenmenger syndrome).",
        "* **Management (Medical):** Initial management of CHF symptoms includes diuretics (to reduce fluid overload) and sometimes digoxin or ACE inhibitors.",
        "* **Management (Surgical):** Definitive treatment is surgical closure of the VSD. This is indicated for infants with large VSDs who have uncontrolled CHF or failure to thrive.",
        "* **Palliative Surgery (Pulmonary Artery Banding):** For small infants or those with contraindications to full repair, a pulmonary artery (PA) band can be placed. This procedure restricts blood flow to the lungs, alleviating CHF and protecting the pulmonary vasculature until the infant is larger and can undergo definitive repair.",
        "* **Contraindicated Procedure (Systemic-to-Pulmonary Shunt):** A Blalock-Taussig (BT) shunt, or any systemic-to-pulmonary artery shunt, is a procedure designed to *increase* pulmonary blood flow.",
        "* **Indications for BT Shunt:** These shunts are used for **cyanotic** congenital heart defects characterized by **decreased pulmonary blood flow**, such as Tetralogy of Fallot or pulmonary atresia.",
        "* **Pitfalls (general):** Applying a treatment for decreased pulmonary blood flow (like a BT shunt) to a condition of increased pulmonary blood flow (like a large VSD) is a life-threatening error. It would flood the lungs, severely worsening heart failure and pulmonary edema."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": true,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "3",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    },
    {
      "question_no": "100",
      "depth": "expanded",
      "answer": {
        "label": "④",
        "text": "요소호기검사"
      },
      "why": [
        "* **Diagnosis:** Bleeding duodenal ulcer with a history of treated but unconfirmed H. pylori eradication.",
        "* **Clinical Goal:** The primary goal is to determine if the patient has an active H. pylori infection, as this would be the most likely cause of the recurrent ulcer and would require further eradication therapy to prevent future recurrence.",
        "* **Diagnostic Algorithm:** After initial treatment for a peptic ulcer (especially a complicated one like bleeding), it is crucial to test for and eradicate H. pylori. Since this patient's eradication status is unknown, testing for *active* infection is the next logical step.",
        "* **Urea Breath Test (UBT):** The UBT is a highly accurate, non-invasive test for detecting active H. pylori infection. The patient ingests urea labeled with a non-radioactive isotope (13C) or radioactive isotope (14C). If H. pylori is present, its urease enzyme will break down the urea into ammonia and labeled carbon dioxide, which is then exhaled and measured. It is the preferred non-invasive method for confirming eradication (a \"test of cure\").",
        "* **Timing of Test:** For highest accuracy, the UBT should be performed after the patient has been off proton pump inhibitors (PPIs) for at least 1-2 weeks and off antibiotics or bismuth compounds for at least 4 weeks, as these can cause false-negative results.",
        "* **Alternative Test:** A stool antigen test is another excellent non-invasive option for detecting active infection and for test-of-cure.",
        "* **Why other options are incorrect:**\n  - **Serology (IgG):** Cannot distinguish between active and past infection. Since the patient is known to have been infected, a positive result is expected and unhelpful.\n  - **Culture/Sequencing:** These are invasive (require biopsy) and are typically reserved for cases of treatment failure to assess for antibiotic resistance, not for routine diagnosis or test-of-cure.\n  - **Serum gastrin:** This tests for Zollinger-Ellison syndrome, a much rarer cause of ulcers. H. pylori status should be clarified first."
      ],
      "others": [
        {
          "label": "①",
          "text": "헬리코박터 배양검사",
          "reason": "H. pylori culture requires an endoscopic biopsy and is typically reserved for determining antibiotic susceptibility in cases of refractory infection. It is not a routine or first-line test for confirming eradication."
        },
        {
          "label": "②",
          "text": "혈청 가스트린 검사",
          "reason": "A serum gastrin test is used to screen for Zollinger-Ellison syndrome, a rare cause of peptic ulcers. The most common cause is H. pylori, which must be evaluated first, especially given the patient's history."
        },
        {
          "label": "③",
          "text": "혈청 항헬리코박터 IgG 항체검사",
          "reason": "Serology (IgG antibody test) indicates past exposure but cannot differentiate between a current, active infection and a successfully treated past infection. It is not useful for confirming eradication."
        },
        {
          "label": "⑤",
          "text": "헬리코박터 16S rRNA 유전자 염기서열분석",
          "reason": "This is a specialized molecular test, primarily used in research or for complex cases to identify resistance mutations. It is not a standard clinical test for this scenario."
        }
      ],
      "runner_up": "",
      "flags": {
        "illegible": false,
        "assumptions": "",
        "mixed_lang": true
      },
      "confidence": 1.0,
      "rethink": {
        "mismatch": false,
        "first_guess": {
          "label": "④",
          "text": "요소호기검사"
        },
        "provided_key": {
          "label": "4",
          "text": null
        },
        "final_decision": "agree_with_key",
        "note": "",
        "override_key": false
      },
      "teaching_points": [
        "* **Clinical picture:** A patient with a history of a bleeding peptic ulcer, previously treated for H. pylori, but without confirmation of eradication.",
        "* **Management (Initial):** The first step in managing any complicated peptic ulcer (e.g., bleeding, perforation) is to test for H. pylori infection.",
        "* **Management (Eradication):** If H. pylori is present, it must be eradicated with appropriate antibiotic therapy to significantly reduce the risk of ulcer recurrence.",
        "* **Management (Test of Cure):** After completing eradication therapy, it is mandatory to perform a \"test of cure\" to confirm that the infection has been successfully cleared. This should be done at least 4 weeks after the completion of antibiotics.",
        "* **Diagnostic Tests for Active Infection:** Tests used for initial diagnosis and for confirming eradication must be able to detect *active* infection. The best options are:\n  - **Urea Breath Test (UBT):** A highly accurate, non-invasive test. It detects the urease enzyme produced by active H. pylori.\n  - **Stool Antigen Test:** Another highly accurate, non-invasive test that detects H. pylori antigens in the stool.",
        "* **Invasive Testing:** Endoscopy with biopsy can be used for a rapid urease test (e.g., CLO test), histology, or culture. Biopsy is required for initial diagnosis if endoscopy is performed, but non-invasive tests are preferred for test-of-cure.",
        "* **Contraindicated Test for Test-of-Cure:**\n  - **Serology (IgG antibody test):** This test detects antibodies to H. pylori. IgG antibodies can remain positive for years after the infection has been eradicated. Therefore, serology cannot distinguish between an active and a past infection and is useless for confirming eradication.",
        "* **Prerequisites for Accurate Testing:** To avoid false-negative results on UBT, stool antigen test, or biopsy-based tests, the patient must be off proton pump inhibitors (PPIs) for 1-2 weeks and off antibiotics or bismuth compounds for at least 4 weeks before testing.",
        "* **Vignette Analysis:** Since this patient's eradication status is unknown, the most appropriate next step is to test for active infection. The urea breath test is an excellent non-invasive choice for this purpose.",
        "* **Pitfalls (general):**\n  - **Failing to test for H. pylori:** Not testing for H. pylori in a patient with a peptic ulcer is a major omission.\n  - **Failing to confirm eradication:** Assuming eradication was successful without a test of cure can lead to recurrent ulcers.\n  - **Using serology for test of cure:** A positive serology result after treatment is uninformative and a common point of confusion."
      ],
      "metadata": {
        "input_metadata": {
          "has_images": false,
          "explanation_depth": "expanded",
          "answer_key": {
            "label": "4",
            "text": null
          }
        },
        "version": "mcq.batch.v1.7",
        "erratum_note": ""
      }
    }
  ]
}